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ABSTRACT 
 
α-synuclein is a small presynaptic neuronal protein, encoded by the SNCA gene, that is 
implicated genetically and neuropathologically in Parkinson’s disease (PD). A large 
body of evidence has established that PD pathogenesis is closely linked to increased 
levels of SNCA; however to date, the biochemical pathways and transcriptional 
elements that control SNCA expression are still obscure. Previous experiments in our 
laboratory in the PC12 cell line demonstrated that the transcription factor ZSCAN21 
binds to the intron 1 region of the Snca gene and is strongly involved in its 
transcriptional regulation. Therefore, in the current experiments, we wished to 
characterize further the role of ZSCAN21 in Snca transcriptional regulation in primary 
cultures and in vivo. We find that in vivo ZSCAN21 is expressed in neurons and its 
levels are developmentally regulated in different brain regions where ASYN is also 
detected. Further, we confirmed through Chromatin Immunoprecipitation its presence 
in a binding complex in the intron 1 region of the Snca gene in rat cortical neuronal 
cultures. Importantly, lentiviral-mediated silencing of Zscan21 increased significantly 
the promoter activity of Snca as well as its mRNA and protein levels in such cultures. 
In contrast, Zscan21 mediated silencing in differentiated neurosphere cultures reduced 
Snca levels. Stereotaxic delivery of adeno-associated virus against Zscan21 in the 
postnatal and adult hippocampus, an area linked with the non-motor symptoms of PD, 
revealed no significant alterations in Snca levels, despite efficient Zscan21 knock-
down. Interestingly, Zscan21 overexpression in cortical neurons with adenoviruses led 
to robust mRNA but negligible protein expression, suggesting that ZSCAN21 protein 
levels are tightly regulated post-transcriptionally and / or post-translationally. 
Therefore, overall, our study demonstrates that ZSCAN21, a transcription factor whose 
levels are under strict posttranscriptional / posttranslational control in neurons, is 
diversely implicated in the transcriptional regulation of Snca in respect to the 
developmental stage, at least in in vitro primary neuronal settings. In vivo, however, 
the unaltered Snca levels observed following Zscan21 downregulation, imply the 
presence of alternative or perhaps compensatory mechanisms that regulate Snca 
transcription in such settings. Furthermore, in a genetic case control study of the 
ZSCAN21 binding site in SNCA intron 1, we did not find polymorphisms between PD 
patients and controls, suggesting that genetic diversity within this region does not 
contribute to disease pathogenesis. Overall, given the diverse effects in cell culture, 
and the lack of discernible in vivo effects, and although further studies are needed, our 
work does not provide sufficient support for the idea of targeting ZSCAN21 in order 
to manipulate SNCA levels in synucleinopathy models.      
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ΠΕΡΙΛΗΨΗ 
 
Η νόσος του Πάρκινσον (ΝΠ) αποτελεί μια χρόνια νευροεκφυλιστική νόσο με 
άγνωστη μέχρι σήμερα αιτιολογική θεραπεία. Ένα από τα σημαντικότερα γονίδια που 
εμπλέκονται στη παθολογία της ΝΠ είναι η α-συνουκλεΐνη (SNCA), η οποία 
κωδικοποιεί για μια μικρή, νευρωνική, προσυναπτική πρωτεΐνη. Πλήθος μελετών 
υποστηρίζουν ότι η υπερέκφραση της SNCA οδηγεί σε φαινότυπους που 
προσομοιάζουν με τη ΝΠ σε διάφορα κυτταρικά και ζωικά μοντέλα. Παρόλα αυτά τα 
βιοχημικά μονοπάτια καθώς και τα ρυθμιστικά στοιχεία που ελέγχουν τα επίπεδα 
έκφρασής της παραμένουν σε μεγάλο βαθμό αδιευκρίνιστα. Προηγούμενα πειράματα 
στο εργαστήριο μας, στην κυτταρική σειρά PC12, έχουν δείξει ότι ο μεταγραφικός 
παράγοντας ZSCAN21 προσδένεται στη ρυθμιστική περιοχή του πρώτου εσωνίου της 
Snca και συμμετέχει ενεργά στη μεταγραφική της ρύθμιση. Βασιζόμενοι σε αυτό το 
εύρημα, στη παρούσα μελέτη διερευνήσαμε περαιτέρω τη δράση του ZSCAN21 στη 
ρύθμιση των επιπέδων της Snca σε πρωτογενείς καλλιέργειες νευρώνων  καθώς και σε 
εγκεφάλους από επίμυες in vivo. Διαπιστώσαμε τη νευρωνική έκφραση του ZSCAN21 
καθώς και τη διαφορική του ρύθμιση σε διακριτά αναπτυξιακά στάδια σε περιοχές του 
εγκεφάλου (από επίμυ) όπου εντοπίζεται και η ASYN. Επιπλέον, μέσω πειραμάτων 
ανοσοκατακρήμνισης χρωματίνης (CHIP), επιβεβαιώσαμε τη συμμετοχή του 
ZSCAN21 στο ρυθμιστικό σύμπλοκο-πρόσδεσης στη περιοχή του πρώτου εσωνίου της 
Snca σε καλλιέργειες  φλοιού από επίμυ. Στοχευμένη σίγαση της έκφρασης του 
Zscan21 σε πρωτογενείς καλλιέργειες νευρώνων μέσω λεντι-ιών οδήγησε σε 
σημαντική αύξηση της Snca τόσο σε επίπεδο ενεργότητας του υποκινητή της όσο και 
σε επίπεδο mRNA και πρωτεΐνης. Αντίθετα, σίγαση του Zscan21 σε καλλιέργειες 
νευρικών βλαστικών κυττάρων (νευροσφαιρών, neurosphere cultures) είχε σαν 
αποτέλεσμα τη μείωση των επιπέδων της Snca. Στερεοταξική έγχυση 
αδενοσχετιζόμενων ιών (AAVs) έναντι του Zscan21 σε μετεμβρυϊκούς (postnatal) και 
ενήλικες επίμυες στην περιοχή του ιππόκαμπου, η οποία συνδέεται κύρια με τα μη 
κινητικά συμπτώματα της ΝΠ, δε μετέβαλε σημαντικά τα επίπεδα της Snca. 
Πειράματα υπερέκφρασης του Zscan21 σε πρωτογενείς φλοιϊκές καλλιέργειες από 
επίμυ μέσω αδενο-ιών (AVs) δεν αύξησαν σημαντικά τα επίπεδα της πρωτεΐνης του 
ZSCAN21, παρά τη σημαντική αύξηση στο επίπεδο του mRNA του Zscan21, 
υποδηλώνοντας ότι τα επίπεδα του ZSCAN21 πρέπει να υπόκεινται σε αυστηρό μετα-
μεταγραφικό ή / και μετα-μεταφραστικό έλεγχο. Λαμβάνοντας υπόψιν τα παραπάνω 
αποτελέσματα διαπιστώνεται ότι ο ZSCAN21, ένας μεταγραφικός παράγοντας του 
οποίου τα πρωτεϊνικά επίπεδα ρυθμίζονται αυστηρά, εμπλέκεται ποικιλοτρόπως στη 
μεταγραφική ρύθμιση της Snca ανάλογα με το αναπτυξιακό στάδιο, τουλάχιστον στα 
in vitro συστήματα πρωτογενών καλλιεργειών που μελετήσαμε. Παρόλα αυτά, το 
γεγονός ότι δε παρατηρήθηκαν σημαντικές αλλαγές στα επίπεδα της Snca έπειτα από 
σίγαση του Zscan21 σε επίμυες ιn vivo, υποδηλώνει τη παρουσία αντιρροπιστικών 
μηχανισμών που συμμετέχουν στη ρύθμιση της. Επιπλέον, ανάλυση δειγμάτων 
ασθενών με ΝΠ  και ατόμων ελέγχου, σχετικά με την εύρεση πιθανών πολυμορφισμών 
τόσο στη θέση πρόσδεσης του ZSCAN21 όσο και στο ευρύτερο τμήμα στη περιοχής 
του πρώτου εσωνίου της SNCA που περιέχει επιπλέον ρυθμιστικά στοιχεία δεν 
αποκάλυψε σημαντικές διαφορές μεταξύ των δύο ομάδων. Το εύρημα αυτό 
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υποδηλώνει ότι η γενετική πολυμορφία μέσα στη συγκεκριμένη περιοχή δε φαίνεται 
να συνεισφέρει στη παθογένεια της νόσου. Συνολικά, η πολυπλοκότητα της δράσης 
του ZSCAN21 στη ρύθμιση της Snca σε διαφορετικά συστήματα πρωτογενών 
καλλιεργειών νευρώνων, σε συνδυασμό με την απουσία επίδρασης του ZSCAN21 στα 
επίπεδα της SNCA στα in vivo πειράματα, συνηγορούν στο ότι η στόχευση του 
ZSCAN21 ως πιθανό θεραπευτικό μέσο δε φαίνεται να αποτελεί τη κατάλληλη 
επιλογή για τη ρύθμιση των επιπέδων της SNCA.  
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1. INTRODUCTION 
 
1.1 Neurodegenerative diseases 
 
Neurodegenerative diseases is an umbrella term for a range of conditions that primarily 
affect the neurons in the human brain. Examples of neurodegenerative diseases include 
Parkinson’s, Alzheimer’s, Huntington’s, amyotrophic lateral sclerosis, spinal muscular 
atrophy, prion, and spinocerebellar ataxia. Neurodegenerative diseases are incurable 
and debilitating conditions that result in progressive degeneration and / or death of 
nerve cells. This broadly causes problems with movement or mental functioning or 
both. The discovery of causative genetic mutations in affected family members has 
historically dominated our understanding of neurodegenerative diseases. However, to 
date, it is becoming increasingly clear that most cases of neurodegenerative diseases 
cannot be explained only by Mendelian inheritance of known genetic variants, but 
instead have a complex etiology with numerous genetic and environmental factors 
contributing to susceptibility (Bertram and Tanzi 2005, McCarthy, Abecasis et al. 2008, 
Noorbakhsh, Overall et al. 2009, Gandhi and Wood 2010, Ku, Loy et al. 2010). 
However, despite their innate genetic variability, neurodegenerative diseases share 
common cellular and molecular mechanisms, with the most prominent being protein 
misfolding / aggregation and neuronal cell death (Bredesen, Rao et al. 2006, 
Rubinsztein 2006), which offers hope for therapeutic advances that could ameliorate 
many diseases simultaneously. 
 
                                                                                                                   (Ramanan and Saykin 2013) 
 
Figure 1. Conceptual model of candidate pathways contributing to neurodegeneration. Candidate 
pathways influencing the balance of neuronal survival and degeneration are displayed within broader 
functional groups based on their major site or mode of action (intracellular mechanisms, local tissue 
environment influences, systemic influences, and mechanisms related to neurodevelopment and 
aging). The pathways and overarching functional groups in this model are highly related and can have 
overlapping or interacting components that can collectively modulate neurodegenerative processes.  
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1.2 Parkinson’s Disease (PD) 
 
Parkinson’s disease (PD) is the second most common age-related chronic 
neurodegenerative disorder after Alzheimer’s disease (AD) that affects globally 2–3% 
of people aged 55 years and above (Trenkwalder, Schwarz et al. 1995, von 
Campenhausen, Bornschein et al. 2005). It was first described in 1817 by the British 
doctor James Parkinson in a monograph termed ‘‘An Essay of the Shaking Palsy.’’ 
Clinical diagnosis is based on the presence of the motor symptoms bradykinesia, 
resting tremor, rigidity and postural instability (Fahn 2003), while definite diagnosis 
can only be made post mortem (Hughes, Daniel et al. 1992). Secondary non motor 
symptoms include cognitive impairment, hallucinations, illusions, depression, 
freezing, sleep disorders, odor loss, hypotension, frequent urination, sweating and 
constipation (Dauer and Przedborski 2003), thus reflecting the multisystemic nature of 
PD. 
Neuropathologically, PD is characterized by the loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) and the abnormal deposition of proteinaceous 
inclusions termed Lewy bodies (LBs) and Lewy neurites (LNs) in the surviving 
neurons and axons, respectively (Forno 1996). These aberrant inclusions are robustly 
immunoreactive for α-synuclein protein (ASYN) (mainly in the halo of these 
inclusions) (Spillantini, Schmidt et al. 1997, Baba, Nakajo et al. 1998, Spillantini, 
Crowther et al. 1998) but also for other proteins such us ubiquitin and neurofilament 
(Surguchov 2008). Nonetheless, neurodegeneration and LB deposition are not only 
evident in the dopaminergic system but also extends to other neuronal systems such as 
the noradrenergic (locus coeruleus), serotonergic (raphe) and cholinergic (nucleus 
basalis of Meynert and dorsal motor nucleus of the vagus) systems, as well as to the 
cerebral cortex (especially cingulate and entorhinal cortices), olfactory bulb, and 
autonomic nervous system. The degeneration of hippocampal structures and 
cholinergic cortical inputs contributes to the high rate of dementia that accompanies 
PD, particularly in older patients.  
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A)                                            B) 
 
Figure 2. Neuropathological features of PD: A) Depigmentation of SNpc as a result of dopaminergic cell 
loss in post-mortem material from a PD patient in contrast to the intact substantia nigra of a healthy 
control. B) LBs and LNs immunolabeled for ASYN in the substantia nigra from a PD brain.  
 
Interestingly, (Braak, Del Tredici et al. 2003) described that LB formation follows an 
‘‘ascending course’’ in anatomically distinct brain areas and suggested a six-stage 
scheme in which the pathology appears first in the dorsal vagal nucleus and olfactory 
bulb (OB stage 1). This corresponds to the premotor symptoms hyposmia and 
autonomic dysfunction, including constipation (Abbott, Petrovitch et al. 2001, Hawkes 
2008, Ross, Petrovitch et al. 2008, Savica, Carlin et al. 2009). At stage 2, pathology 
appears in the pontine area of the locus coeruleus, raphe nuclei and reticular formation. 
This brainstem affection may cause rapid eye movement sleep behavior disorder which 
is one of the most specific indicators for the future development of PD and occurs in 
30–50% of PD patients (Gagnon, Postuma et al. 2006, Iranzo, Molinuevo et al. 2006). 
Stage 3 marks the involvement of the SN and the anterior olfactory nucleus, whereas 
significant rates of degenerating neurons in the pars compacta are detectable at stage 
4. The motor symptoms of PD emerge at stage 4 or later. Stages 5 and 6 are 
characterized by the involvement of the basal forebrain and cortical regions, including 
the entorhinal cortex and cornu ammonis regions of the hippocampus. This advanced 
stage of PD is clinically dominated by complicated control of motor symptoms (e.g., 
fluctuations, dyskinesias and dysphagia) and severe non motor symptoms like 
Parkinson’s disease dementia (PDD), psychosis and sleep-wake disorders. Dementia 
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with Lewy bodies (DLB) is clinically accompanied by a predominant dementia 
syndrome preceding motor symptoms and pathologically by neocortical accentuation 
of LB pathology (McKeith, Dickson et al. 2005, Halliday, Holton et al. 2011, Irwin, 
Lee et al. 2013). Although there have been criticisms of this hypothesis (Burke, Dauer 
et al. 2008) since it does not explain the absence of symptoms in subjects who on 
autopsy have widespread ASYN pathology, it appears to account for the majority of 
cases examined in large cohorts of LB cases (Dickson, Uchikado et al. 2010).  
Genetically PD is a rather heterogeneous and complex disorder. Epidimiological 
studies have revealed that approximately 10% of PD cases are familial (Thomas and 
Beal 2007) and the remaining 90% are sporadic. A plethora of studies and more 
recently large scale genome-wide association studies (GWAS) (Pankratz, Wilk et al. 
2009, Satake, Nakabayashi et al. 2009, Simon-Sanchez, Schulte et al. 2009, Edwards, 
Scott et al. 2010) have identified genes and gene loci that correlate with PD. These can 
be classified as rare causal genes, moderate risk common variants and low risk common 
variants (Houlden and Singleton 2012), which are presented below, in Fig. 3.  
   
 
Figure 3. Genetics of PD (Houlden and Singleton 2012). 
 
Additionally, besides mutations in specific genes that can cause rare familial PD, 
complex interactions between several genes encoded by nuclear or mitochondrial DNA 
(or both), modifying effects of susceptibility alleles and epigenetic factors, impaired 
proteolytic function, oxidative stress and effects on PD-linked-gene expression that are 
attributable to environmental agents and aging have also been proposed as risk factors 
for PD. Their interrelationship in normal aging and PD state is presented below, in 
Fig.4. 
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                                                                                                                               (Klein and Schlossmacher 
2006) 
Figure 4. PD as a complex disorder. A model of known pathogenetic events in PD shows a principal 
imbalance between factors that promote PD (e.g. increased total metal content in the substantia nigra, 
altered steady-state levels of ASYN protein, including its phosphorylation, rise in dopamine 
metabolism-related stress, and exposure to neurotoxins) and factors that prevent PD (e.g. cigarette 
smoking, caffeine consumption, expression of wild-type Parkin, DJ1, and PINK1, and normal levels of 
glutathione). LRRK2, leucine-rich repeat kinase 2; mt, mutant; phosphor., phosphorylation of ASYN at 
residue Ser129; PINK1, phosphatase and tensin homolog-induced putative kinase 1; Ser18, serine at 
residue 18; Tyr, tyrosine at residue 18; UCHL1, ubiquitin carboxyl-terminal esterase L1; wt, wild-type.  
 
Regarding current treatments for PD enormous progress has been made over the past 
half century due to advances in experimental therapeutics, yet levodopa (L-DOPA), a 
precursor of dopamine synthesis, still remains the most potent drug for controlling PD 
symptoms (Jankovic and Aguilar 2008). Nonetheless, it is associated with a variety of 
side-affects such as a ‘‘wearing off’’ effect, levodopa-induced dyskinesias and other 
motor complications (Stern 2004, Weiner 2004). Fortunately, other drugs are available, 
amongst these are dopamine agonists as the initial or early form of dopaminergic 
therapy, catechol-o-methyl-transferase inhibitors to prolong responses to dopamine 
agonists, and non-dopaminergic agents such as anticholinergics and amantadine, which 
usually provide satisfactory symptomatic relief in the early phases of anti-PD therapy. 
Additionally, adjunctive therapies have been developed, but these must be 
implemented early (Schapira 2004). For example, ‘‘deprenyl and tocopherol 
antioxidative therapy of Parkinsonism” together with L-DOPA has been accompanied 
with significantly slower decline, less wearing off, on-off motor fluctuations, and less 
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freezing, but more dyskinesias (Shoulson, Oakes et al. 2002). Rasagiline, a selective, 
irreversible monoamine oxidase inhibitor, provides a modest benefit as an adjunctive 
therapy in PD patients experiencing levodopa related motor fluctuations (Stern, Marek 
et al. 2004). 
Regarding neurosurgical approaches for treating PD, neuroablative surgeries include 
thalamotomy, pallidotomy and subthalotomy. Thalamotomy involves the ablation of a 
part of the thalamus, generally the ventralis intermedius, to relieve tremor with 
excellent short- and long-term tremor suppression in 80–90% of patients with PD. 
Pallidotomy involves destruction of a part of the globus pallidus interna (GPi) leading 
to significant improvements in each of the cardinal symptoms of PD (tremor, rigidity 
and bradykinesia), as well as a significant reduction in dyskinesia. Last, 
subthalamotomy involves destruction of a part of the subthalamic nucleus (STN) 
leading to significant improvements in the cardinal features of PD, as well as the 
reduction of motor fluctuations and dyskinesia. Currently, the aforementioned ablative 
surgeries for PD have largely been replaced by deep brain stimulation (DBS). DBS is a 
form of stereotactic surgery via electrodes implanted in the ventralis intermedius 
nucleus of the thalamus, GPi, STN, or other subcortical nuclei. Thalamic stimulation 
appears to be particularly effective in the treatment of parkinsonian and essential 
tremor (Ondo et al. 1998). Several studies have demonstrated that DBS of the GPi and 
STN improves parkinsonian symptoms and prolongs the “on” time (Linazasoro, Van 
Blercom et al. 2003), as well as other aspects of quality of life (Diamond and Jankovic 
2005). 
 
Figure 5. Treatment guidelines for the progressive stages of PD (Jankovic 2008 REVIEW). 
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Promising future therapies include A2α antagonists, such as Istradefylline, Preladenant 
and SYN115. L-DOPA formulations like levodopa/carbidopa intestinal gel (Duodopa), 
an aqueous gel that contains 20 mg/mL L-DOPA and 5 mg/mL carbidopais effective to 
reduce motor fluctuations and dyskinesia in advanced PD (Nyholm 2006, Fernandez 
and Odin 2011) and PX066, an extended-release oral formulation of 
carbidopa/levodopa. Other antiparkinsonian medications include XP21279, ND0611, 
Safinamide and Cogane (PMY50028). Antidyskinesia medications include AFQ056 
and Fipamezole. Gene therapy involving the use of CERE-120 (AAV2-NRTN), an 
adeno-associated virus serotype 2 vector encoding human neurturin is under a phase1/2 
clinical trial. Additionally, gene therapy including glutamic acid decarboxylase gene 
(GAD) transfer in a phase 2, double-blind, randomized trial (LeWitt, Rezai et al. 2011), 
practically defined OFF UPDRS motor scores improved by 8.1 points in the GAD 
group and 4.7 points in the sham surgery group at 6 months. Last but not least, speech 
therapy, exercise and physical therapy and dietary considerations are also an important 
part of PD therapeutic approaches. 
 
1.3 SNCA: a major risk factor for PD   
 
A mutation in the α-synuclein gene (SNCA) was the first genetic aberration linked to 
PD to be reported by Polymeropoulos et al. (1997). The mutation corresponded to a 
G209A substitution in the SNCA gene resulting in an A53T amino acid change in rare 
families with autosomal dominant inheritance. Following this initial report, two more 
point mutations were identified and linked to PD, A30P and E46K (Kruger, Kuhn et al. 
1998, Zarranz, Alegre et al. 2004). Recently, five additional SNCA substitutions (A18T, 
A29S, H50Q, G51D, and A53E) have been identified (Appel-Cresswell, Vilarino-Guell 
et al. 2013, Hoffman-Zacharska, Koziorowski et al. 2013, Lesage, Anheim et al. 2013, 
Proukakis, Dudzik et al. 2013, Pasanen, Myllykangas et al. 2014). 
 In addition to point mutations, duplications and triplications (Singleton, Farrer et al. 
2003, Chartier-Harlin, Kachergus et al. 2004, Miller, Hague et al. 2004) of the SNCA 
gene locus have been reported in familial PD. Interestingly, a gene dosage effect 
seemed to govern the multiplication cases since subjects carrying a triplication had an 
earlier onset and more severe symptoms than the duplication carriers. Therefore, 
increased levels of SNCA were directly linked to PD pathogenesis. Consistent with this 
notion, overexpression of mutant but most importantly wild-type (WT) ASYN in 
various animal models was able to recapitulate different aspects of PD. Specifically, 
ASYN-dependent neurodegeneration has been demonstrated in SNCA transgenic (Tg) 
flies (Feany and Bender 2000), SNCA Tg mice (Masliah, Rockenstein et al. 2000, van 
der Putten, Wiederhold et al. 2000, Giasson, Duda et al. 2002, Neumann, Kahle et al. 
2002) SNCA virus infected rats (Kirik, Rosenblad et al. 2002, Lo Bianco, Ridet et al. 
2002), and primates (Kirik, Annett et al. 2003).  
Besides familial PD, several lines of evidence have established the presence of a 
genetic link between SNCA and sporadic PD. For instance, a number of polymorphic 
variants in the 5' and 3' regions of the SNCA gene locus reportedly confer susceptibility 
to developing PD in case/control studies (Farrer, Maraganore et al. 2001, Pals, Lincoln 
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et al. 2004, Mueller, Fuchs et al. 2005, Mizuta, Satake et al. 2006). One of the most 
studied SNCA polymorphic variants, the Rep-1 dinucleotide repeat site located 10.7 kb 
upstream from the transcriptional start site of SNCA (Xia, Rohan de Silva et al. 1996, 
Touchman, Dehejia et al. 2001), and certain alleles of this variant have been associated 
with an increased risk of sporadic PD (Kruger, Vieira-Saecker et al. 1999, Tan, 
Matsuura et al. 2000, Farrer, Maraganore et al. 2001, Mizuta, Nishimura et al. 2002, 
Tan, Tan et al. 2003, Tan, Chai et al. 2004). It has to be noted that there were also 
studies that failed to replicate such an association (Parsian, Racette et al. 1998, Izumi, 
Morino et al. 2001, Khan, Graham et al. 2001, Spadafora, Annesi et al. 2003, Tan, Tan 
et al. 2003). However, a large meta-analysis (Maraganore, de Andrade et al. 2006) 
confirmed that Rep-1 allele-length variability was associated with an increased risk of 
PD. Nevertheless, it is not still clear whether the Rep-1 variant is responsible for this 
increased risk or if it is in linkage disequilibrium with the actual causative element 
within the SNCA promoter. Besides, Rep-1 polymorphic variants reportedly act as 
modulators of SNCA transcription (Chiba-Falek and Nussbaum 2001, Chiba-Falek, 
Touchman et al. 2003, Chiba-Falek, Kowalak et al. 2005), a finding that was further 
replicated in mice (Cronin, Ge et al. 2009) and even in the human brain (Linnertz, 
Saucier et al. 2009). Polymorphisms in the 3' region have also been correlated with 
SNCA levels and PD risk (Mueller, Fuchs et al. 2005, Mizuta, Satake et al. 2006, Fuchs, 
Tichopad et al. 2008, Simon-Sanchez, Schulte et al. 2009, Mata, Shi et al. 2010) in the 
European and Japanese populations. Four polymorphisms, i.e., rs356219, rs356220, 
rs35616, and rs356203, were associated prominently with PD in both populations 
(Mizuta, Takafuji et al. 2013). Intriguingly, risk conferring alleles at the 3' untranslated 
region (3'-UTR) were associated with the increased expression of an alternatively 
spliced form of SNCA (McCarthy, Linnertz et al. 2011, Rhinn, Qiang et al. 2012), 
suggesting an alternative mechanism via which gene variations may be linked to 
disease. Moreover, recent studies have identified the presence of functional non-coding 
conserved regions in the SNCA gene locus (Sterling, Walter et al. 2014) as well as a 
CT-rich haplotype in intron 4 of SNCA that confers risk for LB pathology in AD and 
affects SNCA (Lutz, Saul et al. 2015). 
Last and of most importance, large unbiased GWAS established single nucleotide 
polymorphisms (SNPs) in the SNCA region as one of the most common risk factors for 
sporadic PD (Pankratz, Wilk et al. 2009, Satake, Nakabayashi et al. 2009, Simon-
Sanchez, Schulte et al. 2009, Edwards, Scott et al. 2010, International Parkinson 
Disease Genomics, Nalls et al. 2011). The likely impact of disease-associated SNCA 
variants identified by GWAS includes altered control of the level of transcription, 
regulation of alternative splicing, or altered stability of mRNA through post-
transcriptional mechanisms. 
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1.4 Structure and function of ASYN   
 
ASYN is a small presynaptic predominately neuronal protein that is linked genetically 
and neuropathologically to PD. Nonetheless, ASYN pathology is not confined only to 
PD but occurs also in other neurodegenerative disorders such as multiple system 
atrophy, DLB, LB variant of AD (LBV/AD), neurodegeneration with brain iron 
accumulation type I, pure autonomic failure and even a subtype of essential tremor 
disease, which are collectively termed synucleinopathies.  
The first member of the family of proteins for which  ASYN is named was cloned from 
the neuromuscular junction of the electric eel (Maroteaux, Campanelli et al. 1988). 
Antibodies against that protein labeled both synapses and nuclei, leading to the name 
‘‘synuclein.’’ A related protein was cloned from zebra finch as a protein upregulated 
during song learning, a period of enormous synaptic plasticity (George, Jin et al. 1995). 
ASYN is a highly conserved protein of 140 amino acids belonging to a multigene 
family that includes β-synuclein and γ-synuclein (George 2002). In solution it lacks a 
defined structure, thus it is described as “natively unfolded.” However, ASYN can 
adopt an α-helical conformation upon binding to negatively charged lipids and can also 
form β-sheet structures on prolonged periods of incubation. Briefly, the protein is 
composed of three distinct structures: 1) the N-terminus region (residues 1-60) which 
contains apolipoprotein binding motifs (KTKEGV), responsible for the formation of 
α-helical structures; 2) the central hydrophobic region (residues 61-95), termed the 
NAC domain, which confers β-sheet potential; and 3) the C-terminus domain (residues 
96-140), which is highly negatively charged and primarily unstructured (George 2002). 
Post-translational modifications (PTMs) in the C-terminal region of ASYN, such as 
oxidation, nitration and phosphorylation, influence the propensity of ASYN to 
aggregate (Hashimoto, Hsu et al. 1999, Hashimoto, Takeda et al. 1999, Giasson, Duda 
et al. 2000). For example, phosphorylation at serine 129 may increase the propensity 
of ASYN to fibrillize, whereas phosphorylation at tyrosine 125 may prevent ASYN 
fibrillation (Uversky 2007). Similarly, C-terminal truncation of ASYN accelerates 
aggregation of the protein in vitro (Crowther, Jakes et al. 1998, Murray, Giasson et al. 
2003). Truncated ASYN has been detected in LB in PD and DLB (Baba, Nakajo et al. 
1998, Anderson, Walker et al. 2006). Tg mice overexpressing C-terminally truncated 
ASYN (1–130) have substantial cell loss in the SNpc but not in the ventral tegmental 
area (Wakamatsu, Ishii et al. 2008), suggesting a toxic function of truncated ASYN in 
SNpc dopaminergic neurons. 
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                                                                                                                                     (Venda, Cragg et al. 2010) 
Figure 6. Schematic representation of human ASYN domains. Structurally, ASYN is a 140 amino acid 
protein and its sequence can be divided into three regions with distinct structural characteristics. The 
highly conserved N-terminal domain encodes for a series of imperfect 11 amino acid repeats with a 
consensus motif of KTKEGV reminiscent of the lipid-binding domain of apolipoproteins, which in certain 
conditions forms amphipathic helices. The eight missense mutations known to cause familial PD (A30P, 
E46K, A53T, A53E, H50Q, G51D, A18T, and A29S) lie in the amphipathic region, suggesting an important 
function for this region of the protein. The central hydrophobic region (non-amyloid-b component or 
NAC domain) of ASYN is associated with an increased propensity of the protein to form fibrils. The 
acidic C-terminal tail contains mostly negatively charged residues and is largely unfolded. Most 
common post translational modifications in the C-terminal region of SNCA that influence ASYN 
propensity to aggregate in vivo are phosphorylation at serine 129 (Ser 129) and phosphorylation at 
tyrosine 125 (Tyr 125) are indicated by the red arrows. 
 
ASYN is expressed abundantly in the nervous system (1% of total cytosolic protein) 
but its expression has also been detected in peripheral tissues including heart, muscle 
and blood. Regarding its normal function although ASYN has been implicated in 
numerous cellular processes, its exact physiological function remains elusive. 
However, studies have identified various mechanisms in which ASYN interacts with 
neurotransmitters, lipids, carbohydrates, membrane bound receptors, and other 
proteins in the brain. Specifically, ASYN has been shown to interact with tubulin 
(Alim, Hossain et al. 2002) and that ASYN may have activity as a potential 
microtubule-associated protein, such as Tau (Alim, Ma et al. 2004). Importantly, recent 
evidence strongly suggests that ASYN functions as a molecular chaperone in the 
formation of SNARE complexes (Bonini and Giasson 2005, Chandra, Gallardo et al. 
2005, Burre, Sharma et al. 2010, Burre, Sharma et al. 2014). In particular, it 
simultaneously binds to phospholipids of the plasma membrane via its N-terminus 
domain and to synaptobrevin-2 via its C-terminus domain, with increased importance 
during synaptic activity (Burre, Sharma et al. 2010). Importantly, a recent study 
demonstrated that soluble monomeric ASYN assembles into higher-order multimers 
upon membrane binding and that membrane binding of ASYN is required for its 
physiological activity in promoting SNARE complex assembly at the synapse (Burre, 
Sharma et al. 2014). In addition, ASYN has also been shown to be essential for normal 
cognition, since ASYN knock-out mice showed impaired spatial learning and working 
memory (Kokhan, Afanasyeva et al. 2012).  
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1.5 SNCA gene 
 
SNCA was first identified as the gene encoding a protein of which a subfragment, 
termed the non-β-amyloid component of AD amyloid (NAC), was thought to be a 
component of the AD plaques (Ueda, Fukushima et al. 1993). Human SNCA is located 
on human chromosome 4q21.3–q22. Human SNCA spans a region of 111 kb and 
consists of 6 exons ranging in size from 42 to 1110 base pairs (bp) (Xia, Saitoh et al. 
2001), 5 of which correspond to a coding region that is highly conserved between 
vertebrates. The translation start codon (ATG) is encoded by exon 2 and the stop codon 
(TAA) is encoded by exon 6. The NAC component is encoded by exon 4. Exon 1 was 
found to have different splicing sites, producing different 5'-untranslated sequences in 
the cDNAs (Xia, Saitoh et al. 2001). Several studies reviewed in  Beyer et al. (Beyer 
2006) reported alternative isoforms of SNCA caused by alternative splicing of exons 3 
and 5 to produce 4 variants of different amino acid (aa) length: exons 3+5+ (140 aa; 
SNCA 140), exons 3-5+ (126 aa; SNCA 126), exons 3+5- (112 aa; SNCA 112) and exons 
3-5- (98 aa; SNCA 98). SNCA 112 is reportedly only found in the brains of patients 
with LB disease and is upregulated in cell culture models by the parkinsonian 
neurotoxins MPP+ and rotenone (Kalivendi, Yedlapudi et al. 2010). Each intron is 
flanked by the canonical GT-AG splice-site nucleotides and introns’ sizes range from 
1.270 bp (intron 1) to 93.050 bp (intron 4). A 400 bp fragment upstream of the 
transcriptional start site was found to be sufficient for transcription in a luciferase assay 
in the human neuroblastoma cell line SHSY5Y and the mouse hypothalamus cell line 
GT1-7 (Xia, Saitoh et al. 2001) and in the SHSY5Y and 293T cell lines (Chiba-Falek 
and Nussbaum 2001) and is likely to include the core promoter of SNCA. This finding 
was also confirmed in our laboratory in primary cortical neuronal cultures (Clough, 
Dermentzaki et al. 2011). Additionally, a highly TC-rich sequence in intron 4 was 
found to be polymorphic by length and four alleles, A0, A1, A2, and B were identified 
in a Caucasian population (Xia, Saitoh et al. 2001). A dinucleotide repeat 
polymorphism located ~10 kb upstream from the SNCA gene called the NACP-Rep-1 
repeat, has been shown to regulate SNCA expression in neuronal cell culture (Chiba-
Falek and Nussbaum 2001) and in a Tg model (Cronin et al. 2009).  In the European 
population, three of the four associated SNPs with the most significant P-values for PD 
in GWAS were clustered around the 3'-UTR of SNCA (rs2736990, rs3857059 and 
rs11931074) (Simon-Sanchez, Schulte et al. 2009). Additionally, the 3'-UTR of SNCA 
is known to contain target binding sites for two micro RNAs (miRNAs), mir-7 and mir-
153, which are expressed predominately in neurons and downregulate SNCA 
expression (Junn, Lee et al. 2009, Doxakis 2010). 
 
 
 25 
 
 
 
                                                                                                                                        (Venda, Cragg et al. 2010) 
Figure 7. Human SNCA gene and transcript variants. Human SNCA is located at chromosome 4, 
position 4q21.3-q22. Exons are depicted as numbered boxes and introns as lines. ATG and TAA 
represent the start and stop codons, respectively. 1a and 1b boxes represent different splicing products 
of exon 1. Alternative splicing of exons 3 and 5 generates four SNCA isoforms of different lengths (140 
aa, 126 aa, 112 aa, and 98 aa). The REP 1 repeat in the promoter region is indicated by the red arrow. 
The three SNPs that were found to be most highly associated with PD (rs2736990, rs3857059 and 
rs11931074) are indicated by the green arrows. The miRNAs mir-7 and mir-153 which bind to the 3'-
UTR of SNCA are indicated by the blue arrow. A TC-rich region is located 0.9 kb downstream of the 
exon 4/intron 4 boundary.   
Review 
 
The mouse α-synuclein gene (Snca) spans a genomic region of 98 kb, slightly smaller 
than its human counterpart. Comparison of the genomic and cDNA sequence using the 
VISTA program (Touchman, Dehejia et al. 2001) revealed that the intron / exon 
structures of the mouse and human genes are highly conserved, which was expected 
since the human and rodent proteins are 95.3% identical (Lavedan 1998). This 
comparison highlighted sequence conservation coinciding with the SNCA / Snca 
coding exons 2–5 and the 5' coding portion of exon 6. The 5'-UTR, which is contained 
almost entirely within the first exon, is not well conserved between human and mouse. 
In contrast, the 3'-UTR is 80.4% identical up to the first polyadenylation site shared by 
both species. Nineteen regions within intron 4 achieve an average cross-species identity 
of at least 75%. These evolutionary conserved regions, do not represent exons but are 
likely enhancer elements (Sterling, Walter et al. 2014, Lutz, Saul et al. 2015). The 
segment extending ∼10 kb upstream of exon 1, the region likely to contain the minimal 
promotor as well as putative regulatory sequences, also shows high sequence similarity. 
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1.6 Transcriptional gene regulation 
 
1.6a Layers of transcriptional gene regulation 
 
Gene regulation is a fundamental process in every biological system. Reflective of its 
importance to cell survival and function, the regulatory mechanisms governing gene 
expression are exquisitely sophisticated. The key concepts of transcriptional control 
were established in the early 1960s in bacterial systems by Francois Jacob and Jacques 
Monod (Jacob and Monod 1961). Their pioneering work and many subsequent studies 
established that regulatory proteins called transcription factors (TFs) act in trans to 
promote or inhibit gene expression by binding to specific DNA sequences in cis-
regulatory modules (CRMs) or enhancers. Currently new data and high-throughput 
technologies have expanded our knowledge regarding the cellular gene expression 
programs and the mechanisms involved in the global regulation of transcription. 
In order to facilitate our understanding of this extremely complex process of eukaryotic 
transcriptional gene regulation has been dissected into many layers. The first layer of 
transcriptional regulation can be appreciated at the level of naked DNA. The most basic 
model dictates that TFs bind to specific DNA binding sites (CRMs or enhancers) to 
drive or repress gene expression by recruiting cofactors and RNA polymerase II to 
target genes (Ong and Corces 2011, Lelli, Slattery et al. 2012, Spitz and Furlong 2012). 
TFs can be separated into two classes based on their regulatory responsibilities: control 
of initiation versus control of elongation (Yankulov, Blau et al. 1994, Fuda, Ardehali et 
al. 2009, Rahl, Lin et al. 2010, Adelman and Lis 2012, Zhou, Li et al. 2012). 
Nonetheless, this distinction is not always clear since some TFs may participate in the 
control of both initiation and elongation. Cofactors on the other hand, are protein 
complexes that contribute to activation (coactivators) or repression (corepressors), but 
do not have DNA-binding properties of their own. These coactivators include the 
Mediator complex, P300, and general transcription factors, among others (Sikorski and 
Buratowski 2009, Juven-Gershon and Kadonaga 2010, Malik and Roeder 2010, Taatjes 
2010). 
Briefly, once the recruited RNA polymerase II molecules initiate transcription, they 
generally transcribe for a short distance, typically 20–50 bp, and then pause (Adelman 
and Lis 2012). This process is controlled by the pause control factors DSIF and NELF, 
which are physically associated with the paused RNA polymerase II molecules. The 
paused polymerases may transition to active elongation through pause release, or they 
may ultimately terminate transcription with release of the small RNA species. Pause 
release and subsequent elongation occur through the recruitment and activation of 
positive transcription elongation factor b (P-TEFb), which phosphorylates the paused 
polymerase and its associated pause control factors. P-TEFb can be brought to these 
sites in the form of a large complex called the super elongation complex (Smith, Lin et 
al. 2011, Luo, Lin et al. 2012). Additional complexes, such as PAFc, also contribute to 
the regulation of elongation (Jaehning 2010). TFs such as c-Myc stimulate the P-TEFb-
mediated release of RNA polymerase II from these pause sites and thus contribute to 
the control of transcription elongation (Rahl, Lin et al. 2010).  
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Recent studies have provided new insights into cofactors that play important roles in 
DNA loop formation and maintenance, which are key to proper gene control. During 
transcription initiation, the DNA loop formed between enhancers and core promoter 
elements is stabilized by cohesin, which is recruited by the NIPBL cohesin-loading 
protein that is associated with mediator complex (Kagey, Newman et al. 2010). The 
cohesin complex has circular dimensions capable of encircling two nucleosome-bound 
molecules of DNA. Although cohesion is recruited to active promoters, it also becomes 
associated with the DNA-binding factor CTCF, which has been implicated in the 
formation of insulator elements. Thus, cohesin is thought to have roles in transcription 
activation at some genes and in silencing at others (Parelho, Hadjur et al. 2008, Wendt, 
Yoshida et al. 2008, Hadjur, Williams et al. 2009, Phillips and Corces 2009, Schmidt, 
Schwalie et al. 2010, Dorsett 2011). 
The above stripped-down view of DNA, although important for understanding the 
biophysical properties that govern TF-DNA interactions, ignores all of the complexities 
of the nuclear environment. DNA in eukaryotic genomes is compacted into chromatin; 
the basic unit of chromatin, the nucleosome, consists of 147 bp of DNA wrapped 
around a histone octamer containing 2 copies of each of the core histones H2A, H2B, 
H3, and H4 (Luger, Mader et al. 1997, Li and Reinberg 2011). DNA associated with 
histones is less accessible to TFs and RNA polymerase than is naked DNA, making 
chromatin transcriptionally more repressed than naked DNA. This fundamental unit of 
chromatin, the nucleosome is regulated by protein complexes that can mobilize the 
nucleosome or modify its histone compartments. Gene activation is accompanied by 
the recruitment of ATP-dependent chromatin remodeling complexes of the SWI/SNF 
family, which mobilize nucleosomes to facilitate access of the transcription apparatus 
and its regulators to DNA (Clapier and Cairns 2009, Hargreaves and Crabtree 2011).  
In addition, there is recruitment, by TFs and the transcription apparatus, of an array of 
histone-modifying enzymes that acetylate, methylate, ubiquitinylate, and otherwise 
chemically modify nucleosomes in a stereotypical fashion across the span of each 
active gene (Campos and Reinberg 2009, Bannister and Kouzarides 2011, Gardner, 
Allis et al. 2011, Li and Reinberg 2011, Rando 2012, Zhu, Adli et al. 2013). These 
modifications provide interaction surfaces for protein complexes that contribute to 
transcriptional control. Enzymes that remove these modifications are also typically 
present at the active genes, producing a highly dynamic process of chromatin 
modification as RNA polymerase is recruited and goes through the various steps of 
initiation and elongation of the RNA species.  
Repressed genes are embedded in chromatin with modifications that are characteristic 
of specific repression mechanisms (Moazed 2009, Beisel and Paro 2011, Cedar and 
Bergman 2012, Jones 2012, Reyes-Turcu and Grewal 2012). One type of repressed 
chromatin, which contains nucleosome modifications generated by the polycomb 
complex (e.g., histone H3K27me3), is found at genes that are silent but poised for 
activation at some later stage of development or differentiation (Orkin and 
Hochedlinger 2011). Another type of repressed chromatin is found in regions of the 
genome that are fully silenced, such as those containing retrotransposons and other 
repetitive elements (Feng, Jacobsen et al. 2010, Lejeune and Allshire 2011). The 
mechanisms that silence this latter set of genes can involve both nucleosome 
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modification (e.g., histone H3K9me3) and DNA methylation. Below, transcriptional 
regulation at the level of naked DNA and the nucleosome is presented schematically in 
Fig. 8.  
 
 
  
                                                                                                                       (Lee and Young 2013) 
 
Figure 8. Transcriptional Regulation process. (A) Formation of a preinitiation complex. TFs bind to 
specific DNA elements (enhancers) and coactivators, which bind to RNA polymerase II, which in turn 
binds to general TFs at the transcription start site (arrow). The DNA loop formed between the enhancer 
and the start site is stabilized by cofactors such as the mediator complex and cohesin. (B) Initiation and 
pausing by RNA polymerase II. RNA polymerase II begins transcription from the initiation site, but pause 
control factors cause it to stall some tens of bp downstream. (C) Pause release and elongation. Various 
TFs and cofactors recruit elongation factors such as P-TEFb, which phosphorylates the pause release 
factors and polymerase, allowing elongation to proceed. (D) Chromatin structure is regulated by ATP-
dependent remodeling complexes that can mobilize the nucleosome, allowing regulators and the 
transcription apparatus increased access to DNA sequences. (E) Transcriptional activity is influenced 
by proteins that modify and bind the histone components of nucleosomes. Some proteins add 
modifications (writers), some remove modifications (erasers), and others bind via these modifications 
(readers). The modifications include acetylation (Ac), methylation (Me), phosphorylation (P), 
SUMOylation (Su), and ubiquitination (Ub). (F) Histone modifications occur in characteristic patterns 
associated with different transcriptional activities. As an example, the characteristic patterns observed 
at actively transcribed genes are shown for histone H3 lysine 27 acetylation (H3K27Ac), histone H3 
lysine 4 trimethylation (H3K4me3), histone H3 lysine 79 dimethylation (H3K79me2), and histone H3 
lysine 36 trimethylation (H3K36me3). 
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Until this point we have unfolded a two-dimensional, linear view of DNA and 
chromatin. Another higher level of transcriptional control can be achieved by high-
order chromatin structure and three dimensional organization of chromosomes in the 
nuclei. Our knowledge of how nuclear architecture and chromosomal conformation are 
implicated in eukaryotic gene expression has increased dramatically over the past 
decade due to immense technological advances in chromosome conformation capture 
(3C) and 3C-bases high-throughput technologies (Dekker, Rippe et al. 2002, de Wit 
and de Laat 2012) as well as microscopy-based techniques for studying subnuclear 
DNA or RNA localization (Lieberman-Aiden, van Berkum et al. 2009, Eskiw and 
Fraser 2011). 
Regarding nuclear organization, a general conclusion from the above studies is that the 
interior of the nucleus is not a uniform compartment. Chromosomes occupy defined 
spatial regions termed ‘‘territories’’, which are often further organized on the basis of 
gene density and activity (Vaquerizas, Akhtar et al. 2011, de Wit and de Laat 2012, 
Dostie and Bickmore 2012, Ethier, Miura et al. 2012, Sexton, Yaffe et al. 2012). Gene-
rich regions are found more toward the center of the nucleus, whereas gene-poor 
regions are located closer to the nuclear periphery. Although the mechanisms are 
unclear, rearrangements toward the periphery are proposed to be a consequence of 
interactions with the nuclear envelope (Zuleger, Robson et al. 2011). Additionally, 
active genes are generally found at the surface of a chromosomal territory, whereas 
inactive or repressed genes are buried in the interior (Vaquerizas, Akhtar et al. 2011, de 
Wit and de Laat 2012, Dostie and Bickmore 2012, Ethier, Miura et al. 2012). Highly 
expressed genes have also been observed to reside in foci that have been termed 
‘‘transcription factories’’ (Razin, Gavrilov et al. 2011). These observations and others 
have led to the idea that colocalization may lead to coregulation (Dai and Dai 2012).  
In addition, recent Hi-C data in Drosophila further correlate intra- and 
interchromosomal interactions with transcriptionally active regions, whereas inactive 
domains remain confined within their respective chromosomal territories (Sexton, 
Yaffe et al. 2012). For example the identification of the β-globin locus control region 
and gypsy insulators in Drosophila established looping as the predominant paradigm 
for enhancer-promoter interactions, and there are now many examples of enhancer-
promoter communication that occur as a result of looping (Krivega and Dean 2012). 
Recent experiments in Drosophila directly correlate enhancer-promoter interactions 
with cell type-specific gene expression using a new method called cgChIP (cell- and 
gene-specific ChIP) (Agelopoulos, McKay et al. 2012). In addition to cis-looping 
models, enhancers can also interact with promoters in trans. In Drosophila, this process 
is called transvection and has been observed between Hox complexes on homologous 
chromosomes (Duncan 2002). In vertebrates, trans enhancer-promoter interactions 
have been observed during odorant receptor choice in olfactory neurons (Lomvardas, 
Barnea et al. 2006).  
However, other studies using glycocorticoid-inducible gene expression in cell lines did 
not observe significant chromosomal rearrangements upon activation (Hakim, Sung et 
al. 2011). Therefore, we must be cautious in making broad interpretations regarding 
the role of nuclear architecture in gene regulation, as observations can be highly 
specific to a particular gene or group of genes. New advances in microscopy may help 
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to sort out data from cross-linking-based studies by visualizing interactions in situ 
(Joseph, Orlov et al. 2010). Below, all the layers of transcriptional regulation are 
summarized schematically in Fig. 9. 
 
 
                                                                                                                 (Lelli, Slattery et al. 2012) 
 
Figure 9. Overview of eukaryotic gene regulation. Within the nucleus of a cell, chromosomes occupy 
defined spatial regions called territories. Interactions between adjacent territories can correlate with 
transcriptionally active chromatin in transcription factories or silenced chromatin in polycomb group 
(PcG) bodies. Posttranslational modification of TFs, such as phosphorylation (P), can influence nuclear 
import (dashed arrows) through nuclear pore complexes (NPCs) in response to extracellular signals. 
Posttranslational modifications of histones, such as methylation (Me), can also correlate with the 
transcriptional state of associated genes. The position of nucleosomes can restrict access of TFs by 
occluding binding sites (colored rectangles). Lastly, TF recognition of specific binding sites, either as 
monomers or as a part of a complex with other proteins, also contributes to proper recruitment or 
release of RNA polymerase from the transcriptional start site (TSS). Abbreviations: K, kinase; Ph, 
phosphatase. 
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Additionally, apart from the established role of TFs and CRMs in the transcriptional 
gene control recent studies and the ENCODE project have highlighted the substantial 
role of non-coding RNAs (ncRNAs) in gene expression through modulation of 
transcriptional and posttranscriptional processes (Bartel 2009, Orom and Shiekhattar 
2011, Ebert and Sharp 2012, Lee 2012, Rinn and Chang 2012, Wright and Ciosk 2013). 
Briefly, miRNAs, which are the best studied of the various classes of ncRNAs, fine 
tune the levels of target messenger RNAs (mRNAs). Some long ncRNAs (lncRNAs) 
recruit chromatin regulators to specific regions of the genome and thereby modify gene 
expression, and some apparently do not have a function but are simply a product of a 
transcriptional event that is itself regulatory (Latos, Pauler et al. 2012). 
 
 
1.6b Modes of action of TFs 
 
In prokaryotes, single TFs are able to regulate gene expression. However, this type of 
gene regulation is usually insufficient for eukaryotic gene regulation. Instead, 
eukaryotes rely on combinatorial transcriptional inputs into CRMs to regulate gene 
expression in space and time (Istrail and Davidson 2005). The specific recruitment of 
many individual factors refines expression on the basis of cellular context, timing of 
expression, and extracellular signals. For example, the same binding sites in the same 
CRM of the Drosophila nidogen gene have been shown to bind different forkhead 
domain TFs in different tissues, with distinct regulatory outputs (Zhu, Ahmad et al. 
2012). Alternatively, multiple homeobox (Hox) TFs, which have highly similar DNA-
binding specificity as monomers, can target the same gene via distinct CRMs in 
different tissues (Enriquez, Boukhatmi et al. 2010). It also appears that TFs can bind 
non-canonical motifs in certain contexts, although the mechanism by which these 
motifs are distinguished from canonical motifs remains unclear (Badis, Berger et al. 
2009, Busser, Shokri et al. 2012). Regulation can be further refined by PTMs of TFs, 
which can affect subcellular localization, DNA binding, and protein-protein 
interactions (Tootle and Rebay 2005, Benayoun and Veitia 2009, Bernard and Harley 
2010, Charlot, Dubois-Pot et al. 2010, Daitoku, Sakamaki et al. 2011). Some 
researchers propose a PTM code in which multisite PTM events provide an important 
regulatory mechanism for different signaling pathways to affect TF function and 
influence gene expression (Benayoun and Veitia 2009). Below, the mechanisms that 
dictate the assembly of TFs in the CRMs are presented briefly in Fig.10.  
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                (Lelli, Slattery et al. 2012) 
 
Figure 10. Cis-regulatory module (CRM) assembly and cooperative DNA-binding models. This image 
depicts three different models of CRM assembly and related cooperativity mechanisms. (a) The 
enhanceosome model requires strict modular cooperativity between all TFs. (b) In contrast, the 
flexibility of the Billboard and TF Collective models permits different cooperativity mechanisms to 
control CRM assembly. (c) In the case of DNA allostery, interactions between the DNA sequence and 
the TF can facilitate conformational changes in the TF that result in the recruitment of different 
regulatory complexes (rounded rectangles) in a sequence-specific manner. (e) Classical cooperativity 
uses protein-protein interactions between TFs to facilitate cooperative binding. These types of 
cooperative interactions help to increase TF DNA-binding specificity by restricting recruitment to 
dimeric sites (A+B). In the case of latent specificity, direct protein-protein interactions alter binding 
specificities so that TFs recognize novel composite sites (A’B’). (f) Lastly, collaborative competition 
between TFs and nucleosomes can lead to cooperative binding when the binding of one TF provides 
access for another TF to bind a neighboring site. 
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1.7 Transcriptional regulation of SNCA  
 
As has already been mentioned, genetic alterations in SNCA are closely linked to 
familial and sporadic PD. Briefly, several lines of evidence have directly linked 
increased levels of WT SNCA with dysfunctional and abnormal ASYN deposition and 
neurodegeneration in humans and in animal models, while polymorphisms within and 
around the SNCA gene locus are correlated to increased PD risk. Collectively, these 
studies support the over-arching idea that dysregulation of SNCA levels, leading to its 
excess accumulation and aggregation, is a major factor in PD pathogenesis. 
Nonetheless, to date not much is known about the regulation of SNCA in general, let 
alone about its transcriptional regulation. 
 
From previous studies it is well established that under physiological conditions ASYN 
protein levels are developmentally induced in the rat brain (Petersen, Olesen et al. 
1999) and in rat neuronal cell cultures (Murphy, Rueter et al. 2000, Rideout, Dietrich 
et al. 2003, Vogiatzi, Xilouri et al. 2008), following determination of neuronal 
phenotype and establishment of synaptic connections. In contrast, Snca mRNA levels 
follow a different expression pattern. More specifically in the central nervous system 
(CNS) of rodents the mRNA levels of Snca begin to rise at the end of embryonic life 
and reach their highest level during the first weeks of postnatal life. Following this 
period, Snca mRNA levels drop considerably (Petersen, Olesen et al. 1999), even 
though protein levels are stable (Li, Lesuisse et al. 2004), suggesting that the protein is 
regulated in adulthood by additional post-transcriptional and post-translational 
modifications. The mechanisms involved in the developmental transcriptional 
regulation of SNCA remain elusive to a great extent. Moreover, Snca expression levels 
are modulated in conditions that alter plasticity or confer injury (George, Jin et al. 1995, 
Kholodilov, Neystat et al. 1999, Vila, Vukosavic et al. 2000, Manning-Bog, 
McCormack et al. 2002), but again, the mechanisms involved are unclear. It is possible, 
that the mechanisms involved in the developmental process and in plasticity-induced 
conditions share common features. 
 
Conversely, under pathological conditions in PD there has been controversy regarding 
the expression levels of SNCA mRNA in the brains of sporadic PD patients, with studies 
reporting both increased and decreased levels of SNCA (Rockenstein, Hansen et al. 
2001, Kingsbury, Daniel et al. 2004, Chiba-Falek, Lopez et al. 2006, Dachsel, Lincoln 
et al. 2007, Papapetropoulos, Adi et al. 2007). However, Grundemann et al. 
(Grundemann, Schlaudraff et al. 2008), by applying laser-capture microdissection 
reported increased SNCA mRNA levels in the surviving nigral neurons derived from 
PD brains compared to control samples. Protein levels are not obviously increased 
overall in PD brains, although clearly there is a transition favoring the insoluble 
components, including monomeric and oligomeric ASYN. Interestingly, it has been 
reported that in certain mouse models of neurodegenerative diseases, including an 
inducible SNCA model, reversal of expression of the causative proteins ameliorated 
neurodegeneration (Yamamoto, Lucas et al. 2000, Zu, Duvick et al. 2004, Nuber, 
Petrasch-Parwez et al. 2008, Lim, Kehm et al. 2011). Therefore, if SNCA levels could 
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be controlled then certain aspects of the disease phenotype could be halted or even 
reversed. 
 
Toward that direction, previous work in our laboratory utilizing primarily the rat 
pheochromocytoma PC12 cell line but also primary neuronal cultures in order to study 
the mechanisms involved in the transcriptional regulation of SNCA, resulted in some 
interesting novel insights regarding this complex process. PC12 cells is a model system 
used frequently to study the mechanisms of the neurotrophin-mediated differentiation 
of proliferating neuronal precursors to post-mitotic, differentiated neuron-like cells that 
possess many characteristics of sympathetic neurons (Greene and Tischler 1976).  Rat 
cortical cultures is a well-established primary neuronal cell model system that 
represents an abundant and relatively homogeneous source of post-mitotic neurons 
from the CNS with at least 95% purity (Rideout and Stefanis 2002) which allow the 
performance of several biochemical assays and most importantly neurons that are 
affected in later stages of PD progress (Mattila, Rinne et al. 2000). We have confirmed 
that Snca is induced (mRNA and protein) in differentiated PC12 cells (Stefanis, 
Kholodilov et al. 2001, Clough and Stefanis 2007) and rat cortical neurons upon 
maturation of the cultures (Vogiatzi, Xilouri et al. 2008, Clough, Dermentzaki et al. 
2011). We have demonstrated that the neurotrophin-mediated upregulation of SNCA in 
PC12 cells involves the extracellular signal- regulated kinase (ERK) and the 
phosphatidyl-inositol 3 kinase (PI3K) pathways along with transcriptional control 
elements lying within the intron 1 region of the SNCA gene locus (Clough and Stefanis 
2007). Notably, in PC12 cells, SNCA promoter deletion constructs (related to the full 
human SNCA 10.7-kb promoter construct) including either the core promoter of SNCA 
or the intron 1 region alone demonstrated high transcriptional activity, whereas 
constructs including both the core promoter and intron 1 were inactive. Strikingly, in 
rat cortical cultures we observed the exact opposite pattern, deletion constructs 
including both the core promoter and intron 1 were transcriptionally active, whereas 
those that contained the core promoter and intron 1 in isolation were inactive. 
Additionally, these effects were mediated only through the Trk and PI3K signaling 
pathways. Further, application of exogenous brain-derived neurotrophic factor (BDNF) 
recapitulated these effects, although inhibition of BDNF did not lead to any appreciable 
alteration in the levels of Snca, suggesting that BDNF, although sufficient for Snca 
mRNA induction, is not the main factor involved in the Snca induction with maturation 
in culture (Clough, Dermentzaki et al. 2011). Below, the differences in SNCA 
transcriptional activity of different SNCA promoter constructs between PC12 cells and 
rat cortical cultures are presented briefly in Fig.11. 
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Figure 11. Differential SNCA transcriptional activity in PC12 cells and in rat cortical cultures. The top 
cartoon shows the 5' genomic region of human SNCA.  Exons are depicted as closed boxes and introns 
as lines. The canonical 5’ transcriptional start site is depicted with an angled arrow at the start of exon 
1. ATG marks the translational start site at exon 2.  Luciferase constructs for this region are depicted as 
lines connected to a LUC-labeled box. Activation in the luciferase assay (V) or lack of induction (X) is 
dependent on the transcriptional elements present (core promoter and intron 1) and the cell system 
(differentiated PC12 cells and rat cortical cultures [corts]). The constructs Human 5'-2kb and Rat 5'-
452bp contain the core promoter of SNCA, while the 1.9-kb construct contains both the core promoter 
and intron1.   
 
 
In parallel, an independent study by Scherzer et al. (Scherzer, Grass et al. 2008) 
confirmed the importance of SNCA intron 1 region by reporting that the GATA-2 TF 
can occupy intron 1 and further modulate SNCA expression in dopaminergic cells. 
However, a recent study, by Brenner et al. (Brenner, Wersinger et al. 2015), even though 
identified through bioinformatics analysis putative binding sites for GATA-2 in SNCA 
intron 1, instead revealed significant occupancy for GATA-2 within intron 2. 
Additionally, several studies have highlighted the involvement of intron 1 methylation, 
as an epigenetic mechanism to modulate SNCA. Two independent studies (Jowaed, 
Schmitt et al. 2010, Matsumoto, Takuma et al. 2010) reported that decreased 
methylation of the CpG islands spanning the intron 1 area of SNCA was associated with 
increased expression of SNCA, importantly, intron 1 hypomethylation was observed in 
postmortem brains of patients with sporadic PD. Interestingly, the CpG islands within 
intron 1 that were mainly found hypomethylated were the ones located within predicted 
consensus TF binding sites (TFBSs), suggesting that SNCA intron 1 methylation-
mediated transcriptional regulation may depend on the binding of specific TFs. Further, 
Wang et al. (Wang, Wang et al. 2013) also observed increased SNCA expression in 
various cell lines including dopaminergic neurons following intron 1 hypomethylation. 
Besides neuronal cell lines and brain samples, hypomethylation of SNCA intron 1 was 
also evident in blood samples from PD patients compared to controls (Ai, Xu et al. 
2014, Pihlstrom, Berge et al. 2015), suggesting that SNCA intron 1 hypomethylation 
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could serve as a potential biomarker for PD. Interestingly, SNCA intron 1 
hypomethylation in blood samples was also associated with the Rep-1 polymorphism 
located 5' of SNCA (Ai, Xu et al. 2014) and rs3756063 polymorphism located 3' of 
SNCA (Pihlstrom, Berge et al. 2015), thus further supporting a link between SNCA 
variability, promoter methylation, and PD risk. Conversely, the methylation status of 
the SNCA intron 1 CpG islands in peripheral leukocytes is still under debate with other 
studies reporting SNCA intron 1 hypomethylation in PD patients compared with normal 
controls (Tan, Wu et al. 2014) and studies reporting no difference (Richter, Appenzeller 
et al. 2012, Song, Ding et al. 2014). Therefore, the potential of SNCA methylation as a 
biomarker in PD warrants further investigations. Further, γ-synuclein, a member of the 
synuclein family has also been shown to contain critical elements within its first intron 
(Lu, Gupta et al. 2001, Surgucheva and Surguchov 2008). In a recent study by Sterling 
et al. (Sterling, Walter et al. 2014) a number of functional non-coding conserved 
regions, located in the intron 1 region of SNCA were also found to be involved in its 
transcriptional activity. Collectively, the above data further strengthen the importance 
of the intron 1 region in the transcriptional control of SNCA.  
Following that notion, we screened for regulatory elements in the intron 1 region of 
SNCA. Through cross-species alignment (Clustal W; Larkin et al 2007) and 
MatInspector analysis for identifying putative TFBSs (with human, rat and mouse 
sequences) we identified a novel TF named zinc finger and SCAN domain containing 
21 (ZSCAN21) to be at least one of the factors responsible for the observed SNCA 
induction in differentiated PC12 cells (Clough, Dermentzaki et al. 2009). Briefly, we 
found that a binding site for ZSCAN21 at the very beginning of intron 1 of SNCA is 
required for its transcriptional activity in PC12 cells, since deletion of this binding site 
from the human intron 1 construct resulted in significant (~50%) decrease in the 
luciferase assay. Likewise, Zscan21-mediated small-interfering RNA (siRNA) 
silencing led to decreased luciferase activity from the human intron 1 construct (~50%) 
when compared with control scrambled siRNA and also significantly inhibited ASYN 
expression. Additionally, electromobility shift assay (EMSA) analysis revealed the 
presence of a protein in the nuclear extract of PC12 cells that was able to specifically 
bind to Zscan21 DNA probes. Therefore, these results conclusively demonstrated the 
involvement of ZSCAN21 in the transcriptional regulation of SNCA in PC12 cells. At 
this point we must mention that current analysis utilizing an updated version of 
MatInspector Software revealed a second putative binding site for ZSCAN21 in the 
intron 1 region of SNCA 130 bp downstream related to the first ZSCAN21 binding site 
that we also included in the present study. An additional ZSCAN21 putative binding 
site located very 5' to the SNCA promoter was not included.  Below, the basic regulatory 
elements of intron 1 region of SNCA gene are presented schematically in Fig.12. 
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Figure 12. Schematic of human SNCA intron 1 regulatory elements. Exons 1 and 2 are depicted as 
boxes, with the translated regions filled in and the untranslated regions as hatched boxes. The intron 
1 is depicted by a line. The bent arrow marks the canonical transcription start site at exon 1 whereas 
ATG marks the translational start site at exon 2. Red filled stars at the 5' prime of intron 1 represents 
the putative binding site for the ZSCAN21 TF (Clough, Dermentzaki et al. 2009, Brenner, Wersinger et 
al. 2015) whereas green stars the putative GATA-2 binding sites (Scherzer, Grass et al. 2008). CpG 
islands spanning intron 1 region as described in Jowaed et al. (Jowaed, Schmitt et al. 2010) are 
presented as a white hatched box.  
 
 
ZSCAN21 (synonyms: Zipro 1, RU49, Zfp38, NY-REN1, CTfin51) is a DNA binding 
TF that belongs to the Krüppel C2H2-type zinc finger protein family. In general, zinc 
finger TFs can exert either positive or negative regulation of genes (Laity, Lee et al. 
2001). Diversity in the modular multi-finger protein family is determined by the 
conserved domains found outside the zinc finger region. These domains include 
BTB/POZ (Bardwell and Treisman 1994), KRAB (Bellefroid, Poncelet et al. 1991), 
and SCAN (Williams, Blacklow et al. 1999). They usually control selective association 
of the TFs with other cellular factors essential for regulation, subcellular localization, 
DNA binding or transcription. In particular, the SCAN domain is restricted to 
vertebrates and can act as a mediator of both homo and heterodimerization (Williams, 
Blacklow et al. 1999, Sander, Haas et al. 2000, Schumacher, Wang et al. 2000, Stone, 
Maki et al. 2002, Sander, Stringer et al. 2003). It is an 82–88 amino acid highly 
conserved domain (Williams, Blacklow et al. 1999, Sander, Haas et al. 2000, Honer, 
Chen et al. 2001, Stone, Maki et al. 2002), forming a structurally independent module 
with 5 distinct α-helices in each monomer (Ivanov, Stone et al. 2005). Human 
ZSCAN21 shares 82% homology with mouse and rat ZSCAN21 and is primarily 
localized in the nucleus. An important difference is observed at the N-terminal region 
where human ZSCAN21 lacks 77 residues of the trans-activation region relative to 
rodent ZSCAN21 (Carneiro, Silva et al. 2006). Mouse ZSCAN21 (Zfp-38) reportedly 
function as a TF, containing 3 sequence repeats that show trans-activation activity 
(Chowdhury, Goulding et al. 1992). It binds to a bipartite motif (5'-AGTAC-3') 
showing higher affinity to motifs separated by 2–7 nucleotide (Yang, Zhong et al. 
1996). Human ZSCAN21 has been shown to form homodimers and also heterodimers 
with SCAND1 (Carneiro, Silva et al. 2006), a SCAN family protein that lacks the zing 
finger region (Sander, Haas et al. 2000). Importantly, from high throughput 
bioinformatics analysis (two-hybrid and high affinity mass spectrometry), human 
ZSCAN21 has been predicted to interact with many co-repressors or co-activators. 
Intriguingly mouse ZSCAN21, although sharing 97% amino acid similarity in the 
SCAN domain with the human protein, has been reported not to form homodimers and 
to interact only with zinc finger and SCAN containing domain 26 (Williams, Blacklow 
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et al. 1999). Regarding its role in the CNS it has been shown to participate in the 
proliferation of granule cell precursors during post-natal development (Alder, Cho et 
al. 1996, Yang, Zhong et al. 1996, Yang, Wynder et al. 1999). In addition, in the 
peripheral nervous system it is reportedly involved in the activation of non-myelinating 
Schwann cells in general, and terminal Schwann cells in particular (Ellerton, 
Thompson et al. 2008). Regarding SNCA, a recent study has shown that overexpression 
of ZSCAN21 can both repress SNCA and increase SNCB expression in the SHSY5Y 
cell line (Wright, McHugh et al. 2013). Moreover, a study by Brenner et al. (Brenner, 
Wersinger et al. 2015) reported that ZSCAN21 and GATA-2 bind directly to the intron 
1 and intron 2 region of SNCA, respectively in human brain tissue. Given the important 
role of ZSCAN21 in the transcriptional regulation of SNCA in neuronal-like cells 
(PC12 and SHSY5Y) as well as the fact that ZSCAN21 binds to the intron 1 region of 
SNCA in human brain tissue, we wished to investigate further its role in the 
transcriptional regulation of SNCA in primary neuronal cultures, and in particular, in 
vivo.  
  
 
 
 
                                                                                                            (PUBMED / Conserved domains database) 
 
Figure 13. Schematic of ZSCAN21 conserved domains. ZSCAN21 consists of the SCAN oligomerization 
domain which is found in several vertebrate proteins that contain C2H2 zinc finger motifs, many of 
which may be TF playing a role in cell survival and differentiation. This protein-interaction domain can 
mediate homo-and hetero-oligomerization of SCAN-containing proteins. Seven zinc fingers C2H2 type, 
which is the classical zinc domain. The two conserved cysteine and histidine residues co-ordinate a zinc 
ion. The C2H2 zinc finger is composed of two short beta strands followed by an alpha helix. The amino 
terminal part of the helix binds the major groove in DNA binding zinc fingers. 
 
 
Besides the importance of intron 1 in the transcriptional control of SNCA, several lines 
of evidence have also highlighted the presence of other regulatory elements, including 
cis-regulatory elements of the SNCA gene as well as TFs, involved in its transcription. 
To date, the best characterized polymorphic variant in the SNCA gene, that has been 
reported to act as a modulator of SNCA transcription in different cell lines and in vivo, 
is the Rep-1 dinucleotide repeat in the 5'-promoter region of SNCA that is also 
associated with PD risk. Specifically, Rep-1 has been shown to have a reproducible 
effect on regulating transcriptional SNCA in transiently transfected neuronal cell lines 
(Chiba-Falek and Nussbaum 2001, Chiba-Falek, Touchman et al. 2003), in a Tg mouse 
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model (Cronin, Ge et al. 2009) and in human brain (Linnertz, Saucier et al. 2009). In 
all these studies, the extended Rep-1 PD-‘‘risk’’ allele was associated with elevated 
SNCA levels compared to the shorter Rep-1 PD-‘‘protective’’ allele. Interestingly, 
deletion of the Rep-1 element resulted in a significant reduction of SNCA expression 
compared to the full construct (Touchman, Dehejia et al. 2001, Cronin, Ge et al. 2009). 
Therefore, these results, suggested that Rep1 might act as an enhancer element to 
upregulate SNCA mRNA levels. However, Fuchs et al (Fuchs, Tichopad et al. 2008), 
even though they reproduced the Rep-1 effect on SNCA levels in human blood, did not 
detect an effect in the brain. This discrepancy with the study performed by Linnertz et 
al (Linnertz, Saucier et al. 2009) could be attributed to differences in sample size. 
Linnertz et al. included 144 brain samples, whereas Fuchs et al. analyzed 24.  Further, 
the Rep-1 repeat has been found to interact with a nuclear protein, the poly (ADP-
ribose) polymerase 1 (PARP-1). Formation of this complex led to decreased SNCA 
promoter/enhancer transcriptional activity in luciferase reporter assays in SHSY5Y 
cells, while inhibition of the enzymatic activity of PARP-1 instead increased SNCA 
Promoter/Enhancer activity (Chiba-Falek, Kowalak et al. 2005), suggesting this 
regulation might be transcriptionally-driven, at least in part. Interestingly, inhibition of 
the enzymatic activity of PARP-1 along with deletion of the Rep 1 repeat resulted in 
decreased SNCA promoter/enhancer activity, indicating the possibility that PARP-1 
might interact with other sites along the SNCA promoter/enhancer region, thus allowing 
PARP-1 to play a dualistic role in SNCA transcriptional regulation. 
Previous work in our laboratory, through luciferase-based assays with different length 
constructs of the SNCA promoter, unveiled a complex network of cis-regulatory 
elements, lying 5' of exon1 and within exon1, that play a role in the transcriptional 
regulation of SNCA in PC12 cells. MatInspector software analysis for the identification 
of conserved putative TFBSs in this area revealed several TF candidates. Among the 
TFs tested, only ZNF219 was found to be involved in SNCA regulation. Specifically, 
si-RNA-mediated silencing of ZNF219 resulted in a moderate increase of ASYN levels 
in PC12 cells. However, the presence of multiple ZNF219 binding sites (3 sites) in the 
promoter of SNCA as well as the differential response (repressor or activator) observed 
upon inhibition of ZNF219 in the luciferase assay of different length SNCA promoter 
constructs indicated that its role in the regulation of SNCA is complex (Clough, 
Dermentzaki et al. 2009).  
Furthermore, regarding the 3' SNCA region, the SNPs rs356219 and rs365165 located 
in the 3'-UTR of SNCA and which are also in linkage disequilibrium have been shown 
to influence SNCA levels in different brain regions. Fuchs et al. (Fuchs, Tichopad et al. 
2008) reported higher SNCA mRNA correlated with rs356219 disease allele in the 
substantia nigra of the midbrain, and with the protective allele in the cerebellum. 
Conversely, Linnertz et al. (Linnertz, Saucier et al. 2009) reported higher SNCA mRNA 
levels correlated with the rs356219 and rs365165 protective alleles in the temporal 
cortices and midbrain and were unchanged among the genotypes in the frontal cortices. 
Additionally, Mizuta et al. (Mizuta, Takafuji et al. 2013) demonstrated no significant 
differences in SNCA mRNA levels in the brain or lymphoblasts from PD patients 
harboring either the disease or protective rs356219 polymorphism. The discrepancies 
among these studies might be from the number and variation of samples. In the same 
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study, Mizuta et al. (Mizuta, Takafuji et al. 2013) also identified that the yin-yang 1 TF 
(YY1) binds to the protective rs356219 allele and further regulates the expression of 
lncRNA RP11-115D19.1 located in the 3'-UTR of SNCA. Interestingly, a positive 
correlation was observed among RP11-115D19.1, SNCA, and YY1 expression levels 
in autopsied cortices, suggesting their functional interaction in vivo and perhaps 
unveiling a possible novel mechanism regulating SNCA expression. 
Recent studies have also reported the presence of conserved non-coding areas around 
and within the SNCA gene that are associated with SNCA expression. Sterling et al. 
(Sterling, Walter et al. 2014) found 12 conserved DNA sequences in the SNCA gene 
locus that either enhanced or reduced the expression of a reporter gene. Briefly, three 
elements upstream of the SNCA gene displayed an approximately 1.5-fold increase in 
expression. Of the intronic regions, 3 showed a 1.5-fold increase and 2 others indicated 
a 2- and 2.5-fold increase in expression, respectively. Three elements downstream of 
the SNCA gene showed a 1.5- and 2.5-fold increase. Lastly, one element downstream 
of SNCA had a reduced expression of the reporter gene of 0.35-fold of normal activity. 
Additionally, a study by Lutz et al. (Lutz, Saul et al. 2015) identified a CT-rich region 
spanning intron 4 of SNCA that acts as an enhancer element. Specifically, 4 distinct 
haplotypes were detected within this highly-polymorphic-low complexity CT-rich 
region. One of these haplotypes was significantly associated with elevated SNCA 
mRNA levels as well as with increased risk to develop LBV/AD. These results 
demonstrate that the SNCA gene contains cis-regulatory regions that might regulate its 
transcription and expression. Further studies, mainly in disease-relevant tissue types, 
will be important to understand the functional impact of regulatory regions and specific 
PD-associated SNPs in the disease process. 
 
1.8 Degradation of ASYN: another level of regulation  
 
Besides transcriptional control, several proteins are further regulated at the post-
transcriptional and / or post-translational level. Principally, aggregation-prone proteins 
including ASYN are reportedly regulated post-translationally via degradation 
pathways. In general, degradation mechanisms play a major role in the regulation of 
steady state levels of proteins. Regarding ASYN, its degradation has been 
controversial. Work in our laboratory as well as other studies have supported that the 
bulk of degradation of at least monomeric WT ASYN in neuronal cell systems is 
mediated through the lysosomal pathways of chaperone-mediated autophagy and 
macroautophagy (Cuervo, Stefanis et al. 2004, Vogiatzi, Xilouri et al. 2008, Alvarez-
Erviti, Rodriguez-Oroz et al. 2010) and that dysregulation of these degradation 
pathways may be a contributing factor to PD pathogenesis. Conversely, soluble ASYN 
is reportedly degraded by the proteosomal pathway (Bennett MC 1999 (Bennett, 
Bishop et al. 1999, Tofaris, Layfield et al. 2001, Ebrahimi-Fakhari, Cantuti-Castelvetri 
et al. 2011). It is possible that the exact species and pools of ASYN determine its 
degradation pathway since ASYN oligomeric forms cannot be subject to proteasomal 
degradation and rather inhibit the ubiquitin proteasome system (Lindersson, Beedholm 
et al. 2004, Zhang, Tang et al. 2008).   
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Additionally, the distribution of ASYN to different cellular clearing pathways does not 
only depend on monomeric versus multimeric forms but also depends on PTMs. PTMs 
of ASYN such as phosphorylation, SUMOylation and ubiquitination are prominent in 
PD and are primarily involved in ASYN aggregation as well as clearance. In the case 
of ASYN clearance, PTMs presumably act as molecular switches that determine the 
fate of the protein and its preference for a certain proteolytic pathway. Regarding 
ASYN, ubiquitination is one trigger that controls the partitioning of the protein 
between the proteasomal and autophagy systems. Monoubiquitinated ASYN has been 
shown to be degraded preferentially by the proteasome, whereas deubiquitinated 
ASYN was targeted to the autophagy pathway (Rott, Szargel et al. 2011). Another 
trigger is phosphorylation. Overexpression of the PLK2 kinase increases ASYN 
phosphorylation and mediates the selective clearance of ASYN through autophagic 
degradation and accordingly causes reduced ASYN toxicity (Oueslati, Schneider et al. 
2013). Further, studies in yeast as PD model have shown that SUMOylated ASYN is 
primarily targeted to the autophagy pathway, whereas non-SUMOylated ASYN is 
primarily channeled to the proteasome (Shahpasandzadeh, Popova et al. 2014). 
  
It is well established that protein quality control mechanisms play an essential role for 
the accumulation of misfolded and oligomeric protein species in neurodegenerative 
diseases. Therefore, a better understanding of the interplay between ASYN 
modifications and degradation pathways could provide a more specific targeting of 
ASYN to cellular clearing pathways as a therapeutic strategy for PD and other 
synucleinopathies. 
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2. AIM 
 
SNCA is an established susceptibility gene for familial and sporadic PD, one of the 
most common human neurodegenerative disorders. Increased SNCA levels are also 
causative for PD. However, to date, the biochemical pathways and transcriptional 
elements involved in SNCA expression are to a great extent elusive. Previous work in 
our laboratory as well as several other studies have highlighted the importance of the 
intronic region of SNCA in its transcriptional regulation. Specifically, ZSCAN21, 
whose putative binding sites lie within intron 1, was found to exert a key role in the 
transcriptional regulation of SNCA in neuronal-like cells. Therefore, given the 
importance of ZSCAN21 in SNCA control we undertook this present study in order to 
extend our findings related to the role of ZSCAN21 in primary neuronal cultures and, 
in particular, in vivo. For this purpose, we utilized virus-mediated approaches to 
downregulate as well as overexpress Zscan21 in neurons in order to evaluate its role in 
Snca regulation. We used two different cell-culture systems, cortical and hippocampal 
neuron cultures and neurosphere cultures. These cultures are in vitro systems that 
mimic different stages of neuronal development, since Snca is developmentally 
regulated. Likewise, in vivo, we also assessed the role of Zscan21 in Snca regulation at 
two different developmental stages: one early in development and one later (adult). The 
last part of our study included the genetic screening of DNA blood samples from PD 
and control subjects for putative polymorphisms in the binding site for ZSCAN21 
specifically as well as the intron 1 region in general. Such studies may cement 
ZSCAN21 as an important regulator of SNCA transcription, and may provide potential 
therapeutic targets not only for PD but also for other synucleinopathies. 
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3. MATERIALS AND METHODS 
 
3.1 Rat cortical and hippocampal neuron cultures  
 
Cultures of Wistar rat (embryonic day 17, E17) cortical or hippocampal neurons were 
prepared as described previously (Rideout and Stefanis 2002, Dietrich, Rideout et al. 
2003). Dissociated cells were plated onto poly-D-lysine-coated 12-well dishes at a 
density of approximately 5.5 × 105 cells / well. The cells were maintained in Neurobasal 
medium (Gibco, Rockville, MD, USA; Invitrogen, Carlsbad, CA, USA), with B27 
serum-free supplements (Gibco; Invitrogen), L-glutamine (0.5 mM), and 
penicillin/streptomycin (1%). More than 95% of the cells cultured under these 
conditions represent postmitotic neurons (Rideout and Stefanis 2002). The time in 
culture of cells was calculated using days in vitro (DIV), with the day of plating 
designated as 0 DIV.  
 
For experiments using the various TRC2-pLKO lentiviruses (shZSCAN21/1, 
shZSCAN21/2, shZSCAN21/4, shscrambled), cultured cortical or hippocampal 
neurons were infected at 4 DIV at a multiplicity of infection (MOI) of 1. At 5 or 7 days 
post-infection cortical or hippocampal cultures were processed for RNA and protein 
isolation respectively. Additionally, cultures were visualized for infection efficiency 
under an inverted microscope and representative images were recorded (Leica DMIRE 
2 microscope). For experiments using the adenoviruses (AV) (ZSCAN21, EGFP) 
cultured cortical cultures were infected at 4 DIV with an MOI of 100 and collected at 
5 days post-infection. For the luciferase assays, cortical cultures were infected at 4 DIV 
with an MOI of 1 with the above lentiviruses. At 3 days post-infection, the cultures 
were transfected with a variety of luciferase constructs and processed for luciferase 
activity at 48 h post-infection. 
 
 
3.2 Rat neurosphere cultures 
 
Neurosphere cultures were prepared from rat cortical and hippocampal tissue from E16 
Wistar rat embryos and maintained in suspension in full medium + growth factors 
(+GFs): 1:1 mixture of Dulbecco’s modified Eagle’s medium (1 g/L D-Glucose, L-
Glutamine, Pyruvate; Sigma)  and F12 nutrient mixture (Sigma), plus  20 ng/mL human 
epidermal growth factor (hEGF; R&D Systems) and 20 ng/mL human basic fibroblast 
growth factor (bFGF; R&D Systems), 20 μg/mL insulin (Sigma), 1x B27 supplement 
(Gibco), 0.25 mM L-glutamine and 1% penicillin/streptomycin  to promote the 
production of the neurospheres. The neurospheres were passaged 2–3 times before 
plating in poly-D-lysine-coated plates in the presence of full medium (Kaltezioti, 
Kouroupi et al. 2010, Kaltezioti, Antoniou et al. 2014). The next day, the cultures were 
infected with lentiviruses overnight, and the following day, the medium was changed 
with full medium -growth factors (-GFs): the same as the full medium +GFs without 
hEGF and bFGF in order to promote differentiation. The cultures were then harvested 
on the 5th day of differentiation. 
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3.3 Western immunoblotting 
 
Primary neuron or neurosphere cultures were washed twice in phosphate-buffered 
saline (PBS) and then harvested in RIPA lysis buffer (150 mM NaCl, 50 mM Tris PH 
8.0, 0.1% sodium dodecyl sulfate, 1% NP-40; Sigma, 2 mM EDTA). Brain tissues were 
homogenized again in RIPA lysis buffer and clear lysate was isolated following 
centrifugation at 50.000 × g in 4°C. Protein concentrations were determined using the 
Bradford method (Bio-Rad Laboratories, Hercules, CA, USA). A variable amount of 
protein in the lysates was mixed with 4 × Laemmli buffer prior to running on 12% 
sodium dodecyl sulfate polyacrylamide gels. Following transfer to a nitrocellulose 
membrane, the blots were probed with antibodies directed against: ASYN (1:1000; BD 
Biosciences, Sparks, MD, USA), ZSCAN21 (GenScript or home-made), ERK (loading 
control; 1:5000; Santa Cruz Biotechnology), β-actin (1:5000; Sigma), and GAPDH 
(1:1000; Santa Cruz Biotechnology). Blots were probed with horseradish peroxidase-
conjugated secondary antibodies (mouse and rabbit), visualized with a LumiSensor 
HRP kit (GenScript) and exposed to Super RX film (Fuji Film). Following scanning of 
the images with Adobe Photoshop, Gel Analyzer software version 1 was used to 
quantify the intensity of the bands. In all cases, the levels of ASYN and ZSCAN21 
were normalized to those of ERK or β-actin for quantification and statistical analysis. 
 
 
3.4 Immunocytochemistry 
 
Neurosphere cultures grown on 24-well plates with coverslips were fixed with 3.7% 
formaldehyde for 25 min at 4°C. Blocking was with 10% normal goat serum and 0.4% 
Triton X-100 for 1 h at room temperature (RT). Primary antibodies including ASYN 
(1:600; BD Biosystems), ZSCAN21 (1:400; Santa Cruz, ZNF-38 [H-68]: sc-98315 or 
GenScript; home-made) and TUJ1 (1:2000; Sigma), were applied overnight at 4°C, 
followed by fluorescent secondary antibodies: 1:250; rabbit Cy2, 1:250; mouse Cy3, 
1:250; mouse Cy2 (Jackson ImmunoResearch) for 1 h at RT. The fluorescent marker 
Hoechst (1 mM; Sigma) or TO-PRO (1mM) was used to assess cell nuclei. Cultures 
were visualized under a confocal upright microscope (LEICA TCS SP5) and 
representative images were recorded.  
 
 
3.5 Immunohistochemistry 
 
Wistar rats were perfused intracardially through the ascending aorta with physiological 
saline under pentobarbital anaesthesia, followed by ice cold 4% paraformaldehyde. The 
brains were removed and post-fixed overnight in the same preparation of 
paraformaldehyde, then transferred to 15% sucrose overnight, and then to 30% sucrose 
overnight. The brains were frozen with isopentane under dry ice. The brains were 
cryosectioned through the coronal plane in 20 mm increments, and every section 
throughout the hippocampus was collected. Immunohistochemical staining was carried 
out on embedded sections and on slides.  
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Regarding the fluorescent immunohistochemistry (FI) assay, the sections were first 
washed with PBS, followed by antigen retrieval with 10 mM citrate buffer, blocking in 
2% normal goat serum (NGS) and 0.1% Triton-X-100 and incubation for 48 h at 4°C 
with the following primary antibodies: ASYN (1:600; BD Biosystems), ZSCAN21 
(1:400; Santa Cruz), and NeuN (1:300; Millipore). They were then incubated with the 
following secondary antibodies: rabbit Cy3 (1:250), mouse Cy3 (1:250), mouse Cy2 
(1:250) (Jackson ImmunoResearch) for 1 h incubation at RT. Sections were visualized 
under a confocal upright microscope (LEICA TCS SP5) and representative images 
were recorded.  
  
Regarding 3,3′-diaminobenzene (DAB) staining, the sections were first quenched for 
10 min in 3% H2O2/10% methanol mixture and subsequently blocked with 10% NGS 
for 1 h at RT. The monoclonal ASYN antibody (1:600; BD Biosystems) was added for 
48 h, followed by incubation with a biotinylated anti-rabbit antibody (1:1500; Vector 
Laboratories) in 1% NGS for 1 h and avidin–biotin peroxidase complex for 1 h in RT 
(ABC Elite; Vector Laboratories). Staining was visualized using diaminobenzidine 
(Sigma) as a chromogen. Specificity was tested in adjacent sections with the primary 
or the secondary antibody omitted. The sections were stained with cresyl violet (Nissl 
staining), and then dehydrated in graded ethanol and cover slipped. The sections were 
visualized under a bright field microscope (DML S2) and representative images were 
recorded.  
 
 
3.6 Dissociation and fluorescence-activated cell sorting (FACS) of rat adult brain 
 
For dissociation and debris removal of rat adult brain tissue prior to FACS analysis we 
followed the protocol of Guez-Barber et al. (Guez-Barber, Fanous et al. 2012). In more 
detail, AAV-transduced rat brains were extracted under ice and washed with PBS to 
remove remaining blood. GFP-positive areas of the brains (identified under a 
stereoscope) were isolated, minced with razorblades, and placed in a 15-mL tube with 
Hibernate A (BrainBits) (Brewer, Torricelli et al. 1993, Brewer 1997) medium. The 
supernatant was discarded and 4 mL of Accutase solution (Sigma, A6964) 
supplemented with 8 μL DNase (10 mg/mL stock) were added. The tissue was triturated 
gently (10-20 times) and placed on a shaker at 4°C for 1 h for enzymatic dissociation. 
Afterwards, the digested tissue was centrifuged at 1400 rpm for 10 min at 4°C. The 
pellet was resuspended in 5 mL Hibernate A medium and further processed with fire 
polished Pasteur pipettes of decreasing diameter until single cell level. The clear 
supernatant was first passed through a 70-μm cell strainer (Falcon, 352350) (pre-wet / 
to remove cell clusters and large debris) in a 50 mL tube and centrifuged at 1500-2000 
rpm for 10 min at 4°C. The procedure was repeated using a 40-μm cell strainer (Falcon, 
352340). 
 
Percoll (P1644; Sigma), removal of debris: Small cellular debris that was not restrained 
by the cell strainers was reduced by density centrifugation through a three-density step 
gradient of Percoll. One milliliter of each solution (high density solution: 3.426 mL 
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Hibernate + 824.5 μL Percoll + 97.8 μL of 1M NaCl; Medium density solution: 3.600 
mL Hibernate + 650.5 μL Percoll + 76.5 μL of 1M NaCl; Low density solution: 3.770 
mL Hibernate + 480.3 μL Percoll + 59.5 μL of 1M NaCl) was layered carefully in a 
15-mL tube, with the highest density solution at the bottom. The filtered cell suspension 
was applied to the top of this gradient and centrifuged at 430 x g for 3min. The cloudy 
top layer (~2 mL) containing debris was removed and discarded. Cells in the remaining 
layers were pelleted by centrifugation at 550 × g for 5min (the cells are not actually 
pelleted, they gather in an interphase). The cells were resuspended in Cell Sorting 
Buffer (2% FBS, 2 mM EDTA in PBS/filtered through a 0.2-μm filter) in a 15-mL tube 
and centrifuged at 1400 rpm for 10 min at 4°C.  
 
The pellet was resuspended again in the Cell Sorting Buffer for labelling with the 
following primary antibodies: cell surface markers PE mouse anti-rat CD24 (clone 
HIS50; BD Biosciences, 562104) and alexa fluor 647 anti-rat C90.1 (Thy-1.1) 
(Biolegends, 202507). These antibodies have been reported to label neuronal cells 
(Pruszak, Ludwig et al. 2009, Yuan, Martin et al. 2011). For labelling, 2 μg of each 
antibody were added to 5 mL total sample (0.4 μg/mL) and incubated in the dark for 
approximately 1 h at 4°C (with shaking every 10-15min). The cells were centrifuged 
at 1400 rpm for 10 min at 4°C, washed once in Cell Sorting Buffer and incubated with 
the dye DAPI (0.5 – 1 μg/mL) for 5 min. Cells were then centrifuged at 1400 rpm for 
10 min at 4°C, resuspended in Cell Sorting Buffer and passed through a 50-μm pre-
wetted filter to the specified sorting tubes for FACS analysis. 
For FACS analysis the Fluorescence-Activated Cell Sorter ARIA IIu was used. The 
cells were passed through a 70-μm nozzle, with a starting flow rate of 1 that was 
gradually increased to 4. The filters used were Blue (488 nm) for GFP, Yellow-Green 
(561 nm) for PE CD24, Red (638 nm) for Alexa 647 CD90 and Violet (405 nm) for 
DAPI. A small portion of the sample was incubated without antibodies to gate the cells 
according to their light scattering characteristics. Duplet exclusion was also included. 
Non-transduced tissue was used (control) to set the threshold for the GFP-positive 
signal. Importantly, a small portion of test samples labeled with fluorescent dyes were 
used to identify the neuronal subpopulation. Colocalozation of GFP (+), CD24 (+) and 
CD90 (+) marked our population of interest that was further sorted in RNase-free tubes 
at 4°C for RNA isolation. Colocalization of GFP (-), CD24 (+), and CD90 (+) marked 
our negative neuronal population that served as the internal control in our study. This 
population was also sorted.   
 
3.7 RNA extraction and cDNA synthesis  
 
Total RNA was extracted from different brain regions, primary neuronal cultures and 
neurosphere cultures using TRIzol (Invitrogen). DNase (Promega, 1U/μg) was added 
to remove any remaining DNA. RNA concentration was determined 
spectrophotometrically at 260 nm, while the quality of purification was determined by 
a 260 nm / 280 nm ratio that showed values between 1.7 and 2.0, indicating high RNA 
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quality. cDNA was generated with the M-MLV Reverse Transcription System 
(Promega). For the reaction we used: 1–2 μg total RNA, 1× Buffer, 500 ng oligo-dT 
primer, 2 mM dNTPs, 40 U RNasin, and 200 U M-MLV enzyme.  
 
Regarding the FACS assay, total RNA was extracted using an RNeasy Kit (QIAGEN) 
according to the manufacturer’s instructions and cDNA was synthesized using the 
Superscript II Reverse Transcription System (Invitrogen, 18064). For the reaction we 
used: 80 ng RNA, 1× Buffer, 500 oligo-dT primer, 0.5 mM dNTPs, 0.01 M DDT, 40 U 
RNasin, and 200 U Superscript II enzyme. 
 
 
3.8 Reverse transciption PCR  
 
Semi-quantitative reverse-transcription PCR was performed using cDNA as a template 
from different brain areas. For the PCR reaction we used the Thermopol Taq 
polymerase system (New England Biolab, M0267). For the reaction we used: 1× 
Buffer, 0.5 mM dNTPs, 0.5 μM primers, 1.25 U enzyme, 0.08 μg cDNA template. The 
primers used to perform the PCR were:  ZSCAN21-F', ZSCAN21-R', SNCA-F', 
SNCA-R', β-actin-F', β-actin-R' (details in the Primer List). The PCR conditions were: 
95°C for 4 min, 94°C for 30 s, 56°C for 30 s, 72°C for 30 s (30 cycles), and 72°C for 
5 min. Products were subsequently resolved on agarose gels stained with ethidium 
bromide 
 
3.9 Real Time PCR  
 
In most cases we utilized a Platinum Taq Kit (Invitrogen, 10966) along with home-
made Cyber Green solution. Duplicates or triplicates of each sample were assayed by 
relative quantitative real-time PCR using the Light Cycler Roche 96 machine to 
determine the levels of expression of different mRNAs. As a reference gene for 
normalization we used β-actin. The primers used for each target (SNCA RT-F’, SNCA 
RT-R', ZSCAN21 RT-F', ZSCAN21 RT-R', OVERZSCAN21 RT-F', OVERZSCAN21-
RT-R', β-ACTIN RT-F', β-ACTIN RT-R') are listed below in 3.21 
 
Each cDNA sample, derived from 1–1.5 μg total RNA from primary neuronal and 
neurosphere cultures, was diluted 1/20 before use for the amplification assay. At least 
3 independent runs (overall ≥ 6 repeats) were assessed for each mRNA target. The 
reaction conditions were: 1× Buffer (-Mg), 1.5 mM MgCl2, 0.2 mM dNTPs, 0.2 μM 
primers, template < 500 ng, 2 U Platinum Taq, and Cyber Green (home-made). The 
PCR conditions were: 95°C for 180 s, 95°C for 10 s, 60°C for 15 s, 72°C for 15 s (45 
cycles), and 95°C for 60 s, 65°C for 60 s, 95°C for 10s, and 37°C for 30s. 
 
As a negative control for the specificity of amplification, we used no template samples 
in each plate. No amplification product was detected in the control reactions. Data were 
analyzed automatically with a threshold set in the linear range of amplification. The 
cycle number at which any particular sample crossed that threshold (Ct) was then used 
to determine fold difference, whereas the geometric mean of the control gene (β-actin) 
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served as a reference for normalization. Fold difference was calculated as 2-ΔΔCt 
(Livak and Schmittgen 2001). 
Regarding the FACS assay and the chromatin immunoprecipitation assay (CHIP) we 
used the Bio-Rad kit instead of the home made Cyber Green as it is more sensitive for 
low concentration-starting material. The PCR settings were: 95°C for 30 s, 55°C for 50 
s (repeat 45 cycles), and 55°C for 10 min, 95°C for 10 s, 55°C for 60 s, and 98°C for 1 
s.  
 
 
3.10 Transfection and luciferase assay 
 
All 5'-promoter constructs of SNCA utilized in this study are inserted in the pGL3-
empty vector (Promega). The 10.7-kb construct used in this study was a kind gift from 
Drs Nussbaum and Chiba-Falek (Chiba-Falek and Nussbaum 2001). The 1.9-kb and 
intron 1 constructs were generated as described previously (Clough and Stefanis 2007, 
Clough, Dermentzaki et al. 2009). The constructs lacking the first putative ZSCAN21 
binding site (1.9d), the second putative ZSCAN21 binding site (1.9sec) as well as both 
(1.9dd) were constructed using the 1.9kb construct as a template via site-directed 
mutagenesis with a QuikChange Lightning Site-Directed Mutagenesis Kit (Promega, 
210518). All transfections were performed using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions and as described previously (Clough and 
Stefanis 2007). Briefly, for the luciferase assay all transfections were performed in 12- 
well tissue culture dishes with 5.5× 105 cells/well with 1.6 μg per well of target vector 
and 1/50 (of the target vector) of TK-Renilla (internal control) (Promega). Four μL of 
lipofectamine per well were determined to give the best transfection efficiency in 
primary neurons. All transfections were performed for 4 h in plain Neurobasal medium 
for cortical cultures and plain neurosphere buffer for differentiated neurosphere 
cultures. Next, complete medium was added. In all luciferase assays, the cells were 
harvested at 48 h after the addition of complete medium to the cells. Luciferase activity 
was detected with the Dual Luciferase Assay (Promega) according the manufacturer’s 
instructions. This particular “dual” system allows the use of two enzymes, luciferase 
(experimental) and Renilla (control) within a single system. Typically, the 
“experimental” reporter is correlated with the effect of specific experimental 
conditions, while the activity of the co-transfected “control” reporter provides an 
internal control that serves as the baseline response. Normalizing the activity of the 
experimental reporter to the activity of the internal control minimizes experimental 
variability caused by differences in cell viability or transfection.  
 
3.11 3' Rapid amplification of cDNA ends  
 
Total RNA extraction was performed with TRIzol (Ambion) from rat embryonic 
cortical cultures treated with the lentivirus shZSCAN21/4 or control (without any 
treatment). Then, DNase treatment (Promega) removed any remaining DNA 
contamination. Following this, ~ 2.5 μg of total RNA were converted into cDNA using 
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a Reverse Transcriptase Superscript II system (Invitrogen) and an oligo-dT adapter 
primer (1× Buffer, 0.5 μM AP primer, 0.5 mM dNTPs, 0.01 M DDT, 40 U RNasin, and 
200 U Superscript II). Next we treated our samples with RNase H in order to remove 
the original RNA template. 
Subsequently, cDNA was amplified by PCR using the Platinum Tag Polymerase Kit 
(Invitrogen), a gene-specific primer (GSP) that anneals to a ZSCAN21 exon sequence, 
and a reverse universal amplification primer (UAP) that contains only the unique 
sequence of the oligo-dT adapter primer and not the oligo-dT sequence (Primer list). 
The reaction conditions were: 1× PCR Buffer (-Mg), 1.5 mM MgCl2, 0.2 mM dNTPs, 
0.2 μM primers, and 2 U Platinum Tag. The PCR conditions were: 94°C for 2 min, 
94°C for 30 s, 62°C for 30 s, 72°C for 1 min, (30 cycles), and 72°C for 5 min. Next, 
the PCR products were separated in a 2% agarose gel and evaluated further by 
sequencing. In the present study we utilized the primers below (section 3.21).  
 
3.12 Chromatin immunoprecipitation assay   
 
CHIP experiments were performed according to Kaltezioti et al. (Kaltezioti, Kouroupi 
et al. 2010, Kaltezioti, Antoniou et al. 2014). In detail, for every independent 
experiment, ~5–6 10-cm plates (1.0 × 107 cortical neurons /plate) were used. The 
cultures were processed for the CHIP assay on the 8th day of culture. The cells were 
fixed with formaldehyde, 1% final concentration, in the medium for 10 min at RT. The 
reaction was stopped by adding 0.137 M glycine while shaking for 1–2 min at RT. The 
medium was discarded, the cells were washed twice with PBS, collected in PBS, and 
finally centrifuged at 1.500 rpm for 10 min at 4°C. The pellet was resuspended in 1 mL 
cell lysis buffer (5 mM HEPES pH: 8.0, 85 mM KCl, 0.5% NP-40, 1× protease 
inhibitors (PI), 10 μL/mL phenylmethanesulfonylfluoride [PMSF]) and left on ice 30 
min to lyse. The lysate was centrifuged at 5000 rpm for 10 min at 4°C and the pellet 
(containing the nuclei) was resuspended in 1 mL nuclei lysis buffer (50 mM Tris-HCl, 
pH: 8.0, 10 mM EDTA pH: 8.0, 1% SDS, 1× PI, 10 μL/mL PMSF) and incubated on 
ice for 10 min.  
 
An aliquot (40μL) from the lysate was kept to check chromatin before sonication and 
the rest of the sample was sonicated (30% amplitude 1 s on / 1 s off, total time 9 min 
on ice the whole time). Following sonication, phenol:chloroform purification in 40 μL 
of sample before and after sonication was performed as well as agarose gel separation 
(1.5%) to check the size of the chromatin fragments in both conditions. We expected 
fragments between 800–200 bp. Next, the sonicated sample was centrifuged at 13.000 
rpm for 15min at 4°C, and the supernatant was kept (contains the chromatin). The 
absorbance was measured (OD 260/280 nm) and aliquots of 100 μg per CHIP reaction 
were made. 
 
Next, agarose beads were pre-cleared (here we used agarose A beads (Santa Cruz) since 
they work better for polyclonal antibodies). The beads were washed three times with 
PBS prior to the pre-clearing reaction: beads, 0.35 mg/mL bovine serum albumin 
(BSA), 0.55 μg/mL t-RNA, and CHIP buffer w/o SDS (16.7 mM Tris-HCl pH:8.0, 
 50 
 
167mM NaCl, 1.2mM EDTA pH:8.0, 1.1% Triton-X-100, 1× PI, 10 μL/mL PMSF) to 
a final volume of 1 mL, under rotation at RT for 2 h. 
 
Subsequently, 4 volumes of CHIP full buffer (16.7 mM Tris-HCl pH: 8.0, 167 mM 
NaCl, 1.2 mM EDTA pH: 8.0, 1.1% Triton-X-100, 0.01% SDS, 1× PI, 10 μL/mL 
PMSF) were added to the chromatin samples (100 μg each) along with 30 μL of pre-
cleared agarose beads and rotated for 1 h at 4°C. Next, the samples were centrifuged at 
3000 rpm for 5 min at 4°C and the supernatant was collected (10% of the supernatant 
from one sample was kept aside as INPUT). For the CHIP reaction, to each pre-cleared 
chromatin sample were added: either 10 μg of the antibody of interest; here ZSCAN21 
(GenScript) or 10 μg of the same isotype (rabbit polyclonal) irrelevant antibody (c-
myb; Santa Cruz) as a negative control (IgG control), 0.01 mg/mL BSA, 0.02 μg/mL 
t-RNA, 30 μL magnetic beads (Dynabeads Protein G / Invitrogen) until a final volume 
of 1 mL. The samples were rotated overnight at 4°C. 
 
Next day, the beads were collected (using a magnet) and the supernatant was discarded. 
Sequential washes under rotation for 7 min at 4oC with Low Salt Wash buffer (20 mM 
Tris-HCl pH: 8.0, 2 mM EDTA pH:8.0, 500 mM NaCl, 1% Triton-X-100, 0.1% SDS, 
1 μL/mL PMSF), High Salt Wash buffer (20 mM Tris-HCl pH:8.0, 2 mM EDTA pH: 
8.0, 150 mM NaCl, 1% Triton-X-100, 0.1% SDS, 1 μL/mL PMSF/ 1 mL/tube) and 
LiCl Wash buffer (10 mM Tris-HCl pH:8.0, 1 mM EDTA pH:8.0, 250 mM LiCl, 1% 
deoxycholic acid, 0.1% SDS, 1% NP-40, 1 μL/mL PMSF). The beads were washed 
again twice with TE buffer (10 mM Tris-HCl pH: 8.0, 1 mM EDTA pH: 8.0) and finally 
eluted in 125 μL Elution buffer (100 Mm NaHCO3, 1% SDS) and a 15 min incubation 
at 65°C (twice / final volume 250 μL).  
 
For reverse cross-linking, a final concentration of 0.2 M NaCl was added to every 
sample and incubated at 65°C overnight. The same procedure was also applied to the 
INPUT samples.  The next day, 2 μL RNase A (10 μg/μL) were added followed by 
incubation at 37°C for 1 h. Then, 1 μL/tube Proteinase K (20 mg/mL) was added 
followed by incubation at 55°C for 2 h. Finally, the samples were purified via column 
purification (PCR clean up Kit; Macherey-Nagel) in a total volume of 50 μL.  
 
For Real-Time PCR we diluted the purified samples 1/10 and used the CHIP 
ZSCAN21-F', CHIP ZSCAN21-R', CHIP 3' SNCA-F’, CHIP 3' SNCA-R’, CHIP 
OLIG2-F' and CHIP OLIG2-R' primers (Primer list). 
 
 
3.13 ZSCAN21 deletion constructs 
 
ZSCAN21 binding site deletion constructs were constructed via site-directed 
mutagenesis with a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent). 
The deletion constructs were 1.9d ZSCAN21, which lacks the first ZSCAN21 binding 
site, 1.9dd ZSCAN21, which lacks both binding sites and 1.9 sec ZSCAN21, which 
lacks the second ZSCAN21 binding site. The primers were designed using the 
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QuikChange Primer Design Program available online at: 
www.agilent.com/genomics/qcpd (Primer list). 
The reaction conditions were: 1× Buffer, 50 ng ds DNA, 1.25 ng sense and antisense 
primers, 1 μL dNTPs (kit), 1.5 μL Quick Solution, 1 μL enzyme. The PCR conditions 
were: 95°C for 2 min, 95°C for 20 s, 60°C for 10 s, 68°C for 4 min (30 s/kb of plasmid 
length), (17 cycles), and 68°C for 5 min. 
 
3.14 Lentiviral vector construction and virus production 
 
The small hairpin RNAs (shRNAs) against ZSCAN21 (3 targets) and scrambled were 
cloned into the TRC2-pLKO vector (Sigma) containing the U6 promoter, the selection 
marker puromycin and the woodchuck hepatitis post-transcriptional regulatory element 
(WPRE). The shRNAs were inserted in the AgeI/EcoRI multiple cloning site. The 
sense/antisense primers that were used for each shRNA were pLKO ZSCAN21/1 
sense/antisense, pLKO ZSCAN21/2 sense/antisense, pLKO ZSCAN21/4 
sense/antisense and  pLKO SCRAMBLED sense/antisense (Primer list). Additionally 
we cloned the EGFP sequence from another vector using PCR with BamHI-EGFP-F' 
and BamHI-EGFP-R' (Primer list) before the puromycin sequence in the TRC2-pLKO 
vector by digesting the vector and the EGFP PCR product with BamHI enzyme and 
then ligating both pieces. Subsequently, for the production of the viral particles, 
HEK293 cells (10, 150-mm dishes for each lentivirus) grown to approximately 70–
80% confluence were transfected using the calcium-phosphate method with the TRC2-
pLKO-EGFP-shRNA vector, the pCMV delta R8.2 plasmid (encoding the HIV-1 
GAG/POL, Tat and Rev regulatory genes), and the pMD2.G plasmid (encoding the 
VSVG packaging gene). After 3 days incubation, the supernatant was collected, 
centrifuged to discard cell debris, passed through a 0.45-μm filter and centrifuged at 
26.000 rpm in a Sorvall Discovery 100SE ultra-centrifuge with a TH-641 rotator for 3 
h at 4oC. The pellet was then resuspended in filtered 1× HBSS in PBS with 0.5% BSA 
under mild vortexing for 30min at 4oC, centrifuged at 2.000 rpm for 30 s, aliquoted 
into sterile Axygen tubes, and kept at -80oC. The titration of the viral preparation was 
performed in HeLa cells following serial dilutions of each lentivirus by FACS analysis 
of the GFP signal. The titer was then calculated by the mathematical equation: % GFP 
positive cells × dilution of virus × no. of cells infected / 100. In general the titer of the 
lentiviruses were ~ 1–2 ×108 transduction units (TU)/mL. 
 
3.15 Adeno-associated vector (AAV) construction and virus production 
 
The shRNAs of interest (ZSCAN21/2 and scrambled) were cloned into an rAAV 
backbone plasmid containing the synapsin-1 promoter, WPRE, and bovine growth 
hormone polyA site. The shRNA primers were the pLL3.7 ZSCAN21/2 sense and 
antisense and the pLL3.7 SCRAMBLED sense and antisense (Primer list). The 
expression cassette is flanked by AAV2 inverted terminal repeats. The shRNAs were 
inserted in the HpaI/XhoI multiple cloning site. The sense/antisense primers that were 
used for each shRNA were the pLL3.1 ZSCAN21/2 sense/antisense and the pLL3.1 
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SCRAMBLED sense/antisense (Primer list).  Subsequently, for the production of viral 
particles, HEK293 cells grown to approximately 70–80% confluence were double-
transfected using the calcium-phosphate method with the rAAV plasmid and helper 
plasmids encoding essential AV packaging and AAV6 capsid genes. After 3 days 
incubation, the cells were harvested and lysed by performing 3 freeze-thaw cycles in a 
dry ice/ethanol bath. After treatment with Benzonase nuclease (Sigma), the lysate was 
purified using a discontinuous iodixanol gradient followed by Sepharose Q column 
chromatography, and finally concentrated with a 100-kD cut-off column (Millipore 
Amicon Ultra). To determine the titer of the viral stock solutions quantitative PCR with 
primers and probes targeting the inverted terminal repeat sequence was performed 
(Grimm, Kern et al. 1998, Zolotukhin, Byrne et al. 1999, Xilouri, Brekk et al. 2013). 
The titer for AAV/shZSCAN21/2 was: 3 × 1014 TU/mL and 1.8 × 1014 TU/mL for 
AAV/shscrambled. 
 
3.16 Adenoviral vector (AV) construction and virus production  
 
The rat ZSCAN21 overexpression AV vector was generated using the following steps. 
We first performed PCR from cDNA of rat cortical cultures with the OVERZSCAN21-
F' and OVERZSCAN21-R' primers (Primer list) to isolate the coding sequence of 
ZSCAN21. Next, the rat ZSCAN21 sequence was cloned first into a modified version 
of the PENTR.GD entry vector and then introduced into the pAd/ PL-DEST Gateway 
vector (Invitrogen). Second-generation E1, E3, and E2a-deleted recombinant human 
serotype 5 adenoviruses (rAd) were generated, as described previously (He, Zhou et al. 
1998, Xilouri, Kyratzi et al. 2012). Viral vector stocks were amplified from plaque 
isolates in order to guarantee homogeneity. Final vector stocks were purified and 
concentrated using double discontinuous and continuous CsCl gradients. Viral titers of 
purified vector stocks were determined in infected HEK 293A cells following serial 
dilutions of the viral preparation using an Adeno-X Rapid Titer Kit (Clontech) 
following the mathematical equation: infected cells/field × 38.2 × dilution factor / viral 
volume. The titer was expressed as viral particles/mL and it was calculated as 1.97 × 
1011 viral particles /mL for rAd-ZSCAN21. As a negative control we used rAd-GFP 
with a titer of 1.55 × 1011 viral particles/mL, which had already been made in our 
laboratory. 
 
3.17 Animals 
 
Post-natal P3 or 2-month old adult Wistar rats (180-200 g) were housed in a cage (2–3 
animals per cage for adults) with free access to food and water under a 12 h light/dark 
cycle. All experimental procedures performed were approved by the Institutional 
Animal Care and Use Committee of the Biomedical Research Foundation of the 
Academy of Athens. 
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3.18 Stereotaxic surgical procedure 
 
For adult rats all surgical procedures were performed under general anesthesia using 
isoflurane. After placing the animal into a stereotaxic frame (Kopf Instruments), 4 μL 
recombinant AAV solution was injected unilaterally into the dentate gyrus of 
hippocampus at 2 different sites. The coordinates of the first injection site were -3.0 
mm anteroposterior (AP) from the bregma, -1.5 mm mediolateral (ML) from the 
bregma, and -3.6 mm dorsoventral (DV) from the scalp, and the coordinates of the 
second injection site were -4.56 mm AP from the bregma, -2.6 mm ML from the 
bregma, and -3.2 mm DV from the scalp, according to the rat stereotaxic atlas (Paxinos 
and Watson, 1998). The tooth bar was adjusted to 2.3 mm. Injection was performed 
using a pulled glass capillary (diameter of 60–80 mm) attached to a Hamilton syringe 
with a 22 s gauge needle. After delivery of the viral vector using an injection rate of 
0.1 mL/15s, the capillary was held in place for 5min, retracted 0.1 mm, and, after 1 
min, was slowly withdrawn from the brain  
For post-natal day 3 rats (P3 rats) we used a specific stereotaxic unit (model 900 small 
animal stereotaxic unit; Kopf Instruments). We first anesthetized the pups under ice 
and then placed them in the stereotaxic frame that was kept cold during the surgical 
procedure with dry ice and ethanol. We performed bilateral stereotaxic injections in the 
ventricles (2 μL / ventricle, titer: 7.0 × 1013 TU/mL). We targeted the ventricles by 
calculating approximately two-fifth of the distance between the lambda and each eye  
(Kim, Ash et al. 2013). 
 
3.19 Control and PD patient samples for intron 1 genomic analysis 
Control and PD patient blood samples were collected by the Special Outpatient Clinic 
of Mobility and Memory Disorders of Attikon Hospital, as well as from the General 
Hospital of Syrou, within the framework of the Parkinsonian patients Biobank creation 
program that was funded by the General Secretariat for Research and Technology, 
Greece. To date, approximately 500 samples have been collected in 3:1 ratio of patients 
versus controls. Both groups were age and gender matched. Detailed clinical records 
following the participants’ consent were included. The protocols regarding the 
collection and analysis of the samples have been filed and approved from the 
corresponding hospital committees. In the present study, for screening the intron 1 
region of the SNCA gene we performed PCR with specific primers (INTRON 1 F', 
INTRON 1 R' / primer list) that bind to the 5'-region within the first exon of SNCA and 
to the 3'-region in intron 1 (the final product includes approximately two thirds of the 
intron 1 region of SNCA from its start) in collaboration with Professor Thomas Gasser 
(University of Tubingen). The resulting 917-bp PCR products were further processed 
with sequence analysis. In total, 400 samples were sequenced (~200 control and ~200 
PD).  
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3.20 Statistical analysis 
 
Statistical analysis was performed using unpaired t-test for single analyses. Where 
multiple testing was required, a one-way analysis of variance (ANOVA) test was 
utilized, with a post hoc Tukey’s HSD test. P-values < 0.05 were considered significant. 
All statistical analyses were performed using GraphPad Prism 5 Demo suite software. 
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3.21 Primer List 
 
ZSCAN21-F′: 5′- CAGAAGCAGTCTTGGGAGAAA-3′  
ZSCAN21-R′: 5′-TCTCCCTTTCCAGGTTGTTG-3′  
SNCA-F′: 5′-CTGCCACTGGTTTTGTCAAG-3′  
SNCA-R′: 5′-TGTACGCCATGGAAGAACAC-3′  
β-ACTIN-F′: 5′-TGGCTCCTAGCACCATGA-3′  
β-ACTIN-R′: 5′-CCACCAATCCACACAGAG-3′ 
SNCA RT-F′: 5′-GCCTTTCACCCCTCTTGCAT-3′ 
SNCA RT-R′: 5′-TATCTTTGCTCCACACGGCT-3′ 
ZSCAN21 RT-F′: 5′-CGGTTGTGCTATGGTTCAGC-3′ 
ZSCAN21 RT-R′: 5′-ACACTCCAAACCTGGGACTC-3′ 
OVERZSCAN RT-F′: 5′-CTGTGGATGCCAGCCCTAAA-3′ 
OVERZSCAN RT-R′: 5′-CGCTTTCTTGGGTCCTGAGT-3′ 
β-ACTIN RT-F′: 5′-TGGCTCCTAGCACCATGA-3′ 
β-ACTIN RT-R′: 5′-CCACCAATCCACACAGAG-3′ 
AP: 5′-CAGGACCGATTAACCAGGGTCGAACACTTTTTTTTTTTTTTTTT-3′ 
UAP: 5′-CAGGACCGATTAACCAAGGGTCGAACAC-3′ 
GSP: 5′-TGGGAAGGCTTTCAGCCACAGCTCCAAC-3′ 
2nd GSP: 5′-CAGCGTCTGCTAGGCCTGCTCCAGGAGA -3′ 
pLKO ZSCAN21/1 SENSE: 5′-
CCGGGCCAGCCCTAAATATGAGTTTCTCGAGAAACTCATATTTAGGGCTGGCTTTTTG-3′ 
pLKO ZSCAN21/1 ANTISENSE: 5′-
AATTCAAAAAGCCAGCCCTAAATATGAGTTTCTCGAGAAACTCATATTTAGGGCTGGC-3′ 
pLKO ZSCAN21/2 SENSE: 5′-
CCGGGCTCCAACCTTACCCTTCATTCTCGAGAATGAAGGGTAAGGTTGGAGCTTTTTG-3′ 
pLKO ZSCAN21/2 ANTISENSE: 5′-
AATTCAAAAAGCTCCAACCTTACCCTTCATTCTCGAGAATGAAGGGTAAGGTTGGAGC-3′ 
pLKO ZSCAN21/4 SENSE: 5′-
CCGGGTGTAAGGAGTGTGGCAAAGCCTCGAGGCTTTGCCACACTCCTTACACTTTTTG-3′ 
pLKO ZSCAN21/4 ANTISENSE: 5′-
AATTCAAAAAGTGTAAGGAGTGTGGCAAAGCCTCGAGGCTTTGCCACACTCCTTACAC-3′ 
pLKO SCRAMBLED SENSE: 5′-
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTTG-3′ 
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pLKO SCRAMBLED ANTISENSE :5′-
AATTCAAAAACAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTG
TTG-3′ 
pLL3.7 ZSCAN21/2 SENSE: 5′-
TGCTCCAACCTTACCCTTCATTTTCAAGAGAAATGAAGGGTAAGGTTGGAGCTTT
TTTC-3′ 
pLL3.7 ZSCAN21/2 ANTISENSE: 5′-
TCGAGAAAAAAGCTCCAACCTTACCCTTCATTTCTCTTGAAAATGAAGGGTAAGG
TTGGAGCA-3′ 
pLL3.7 SCRAMBLED SENSE: 5′-
TGCTGATTCCGCCTAAAGATTCAAGAGATCTTTAGGCGGAATCAGCTTTTTTC-3′ 
pLL3.7 SCRAMBLED ANTISENSE: 5′-
TCGAGAAAAAAGCTGATTCCGCCTAAAGATCTCTTGAATCTTTAGGCGGAATCAG
CA-3′ 
 
BamHI-EGFP-F′: 5′-GAGAGGATCCCGCCACCATGGTGAGCAAGGGC-3′ 
BamHI-EGFP-R′: 5′-GAGAGGATCCTCACTTGTACAGCTCGTCCATGCCGAGA-3′ 
OVERZSCAN21 F′: 5′-CAGAGATCTATGACCAAGGTGGTGGGCATGG-3′ 
OVERZSCAN21 R′: 5′-CAGGAATTCTTACTGTACCTCTCCCTCTCCA-3′   
CHIP ZSCAN F′: 5′-GAAGCCTAGAGAGCCGGTAAG-3′ 
CHIP ZSCAN R′: 5′-CCGAGTGATGTACTTTCCAGTCA-3′ 
3′ CHIP Snca F′: 5′-AGATGGGCAAGGTATGGCTG-3′ 
3′ CHIP Snca R′: 5′-CCCAAGGAAAACAGTGCATCG-3′ 
CHIP OLIG 2 F′: 5′-AGCCTAGGGGGATTACAGGG-3′ 
CHIP OLIG 2 R′: 5′-ACCAGGTTCTGGAGCGAATG-3′ 
EGFP F′: 5′-CCCGACAACCACTACCTGAG-3′ 
EGFP R′: 5′-GTCCATGCCGAGAGTGATCC-3′ 
1.9 DEL ZSCAN21 SENSE: 5′-AGCAGAGGGACTCAGGTTGTGGATCTAAACGG-3′ 
1.9 DEL ZSCAN21 ANTISENSE: 5′-CCGTTTAGATCCACAACCTGAGTCCCTCTGCT-
3′ 
1.9 DEL SEC ZSCAN21 SENSE: 5′-GTCTCTGGGAGGTGGTCCCTTTGGGGAG-3′ 
1.9 DEL SEC ZSCAN21 ANTISENSE: 5′-CTCCCCAAAGGGACCACCTCCCAGAGAC-
3′ 
INTRON 1 F′:5′-GCGGAGAACTGGGAGTGGCCATTC-3′ 
INTRON 1 R′: 5′-GCTAACAGGTTGATGGTGGAAAGG-3′ 
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4. RESULTS 
 
4.1 Expression of ZSCAN21 in the central nervous system  
 
As has already been mentioned, experiments in our laboratory have highlighted 
ZSCAN21 as an important regulator of SNCA expression in the PC12 cell line. 
Therefore, in the present study, we wished to characterize further the role of ZSCAN21 
in primary neuronal cultures and most importantly in vivo. Toward this direction, we 
first checked whether ZSCAN21 is expressed in vivo in different brain areas, where 
ASYN is known to be expressed (midbrain, striatum, olfactory bulbs, hippocampus, 
cortex, and cerebellum) and which are linked to varying degrees with PD pathology. 
Of note, previous experiments in our laboratory using semiquantitative RT-PCR 
demonstrated the expression of Zscan21 in different neuronal cells, including cortical 
and sympathetic neuronal cultures (Clough, Dermentzaki et al. 2009). Thus, we 
isolated different rat brain areas (as aforementioned) from two developmental stages, 
i.e., embryonic (E17) and adult (~2 months), to test for ZSCAN21 mRNA and protein 
expression, since limited information regarding ZSCAN21 was available. Regarding 
mRNA expression, we performed a TRIzol-based RNA extraction, cDNA synthesis, 
and RT-PCR assay. For PCR amplification we used specific primers for Zscan21, Snca, 
and β-actin (control) (Primer list). Regarding protein expression, following 
homogenization and lysis of the tissues we performed western blot analysis using a 
polyclonal antibody we generated against ZSCAN21 (GenScript), which in limited 
exposures of the film led to the appearance of a single specific band at the expected 
molecular weight. We detected the expression of ZSCAN21, both mRNA and protein, 
in all brain areas tested (Fig. 14). Additionally, the expression of ASYN was also 
verified in these areas in agreement with previous studies (Neystat, Lynch et al. 1999, 
Chiba-Falek, Lopez et al. 2006, Grundemann, Schlaudraff et al. 2008, Linnertz, Saucier 
et al. 2009). Interestingly, we also noticed that ZSCAN21 was more robustly expressed 
at the embryonic stage compared to adult brain (with a more profound difference at the 
protein level) following a reverse pattern to that of ASYN expression.  
 
Α)                                                                Β) 
 
                                                                                                                                    
 
 
 
ADULT EMBRYONIC EMBRYONIC ADULT 
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Figure 14. ZSCAN21 expression (mRNA and protein) in different brain areas from embryonic and 
adult rats. Different brain areas were isolated from embryonic (E18) and adult rats. The brain areas 
were: midbrain (MID) or midbrain dorsal (MD) and midbrain ventral (MV), striatum (STR), olfactory 
bulbs (OB), frontal cortex (FC), cerebellum (CER) and hippocampus (HIP). Following homogenization, 
RNA or protein isolation was performed. Α) RT-PCR for Zscan21, Snca, and β-actin (loading ctl); (-) : 
negative ctl, (+) : PC12 cell lysate. B) Western blot for ZSCAN21, ASYN, and β-actin (loading ctl). 
Expression of ZSCAN21 (mRNA, protein) was detected in all tested brain areas, both embryonic and 
adult. Similarly, the expression of ASYN was also verified as expected.  
 
 
 
4.2 Developmental expression profile of ZSCAN21 in the central nervous system 
 
To establish a complete picture of the expression profile of ZSCAN21 during 
development and by extension of ASYN we further analyzed additional developmental 
stages from the rat brain including: Ε17, P1, P3, P5, P7 or P8, P10, P12 or P13, P16 and 
adult (~2 months). The brain region we decided to focus mainly our study on was the 
hippocampus. First, ZSCAN21 is highly and selectively expressed in the granule cells 
of the dentate gyrus (DG) of the hippocampus (Yang, Zhong et al. 1996). Second and 
most important, increasing lines of evidence involve the hippocampus mainly with the 
non-motor symptoms of PD, including primarily cognitive impairment and dementia 
that affect a high percentage of PD patients. Following the same protocol, we performed 
RNA and protein extraction from different developmental stages of the hippocampus. 
At the mRNA level, Zscan21 was increased developmentally until the P10 stage and 
then its levels started to decrease. Likewise, Snca was also increased developmentally 
during the first weeks of postnatal life, but its levels dropped later in the adult stage, 
verifying previous studies (Petersen, Olesen et al. 1999) (Fig. 15A). At the protein level, 
ZSCAN21 decreased gradually (following the mRNA expression pattern), whereas 
ASYN increased developmentally (in contrast to the mRNA expression pattern) (Fig. 
15B). Similar results were obtained for the cortex (data not shown). In conclusion, there 
was no clear correlation between the expression levels of ZSCAN21 and ASYN during 
development in vivo. However, we were interested in investigating the involvement of 
ZSCAN21 in Snca transcription at different developmental stages in vitro and in vivo, 
in order to verify whether this differential ZSCAN21 expression during development 
could diversely regulate Snca expression levels.  
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A)                B) 
 
 
 
Figure 15. ZSCAN21 (mRNA and protein) expression profile at different developmental stages. The 
hippocampus was isolated from different developmental stages of rat brain: E17, P1, P3, P5, P7 or P8, 
P10, P12 or P13, P16, and adult (`2months). Then, the tissues were homogenized and processed for RT-
PCR or western blot analysis. A) RT-PCR for the amplification of Zscan21, Snca, and β-actin (loading 
control) with specific primers. Zscan21 mRNA expression was developmentally increased until the P10 
stage and then its levels started to decrease. Accordingly, Snca mRNA levels increased during the first 
weeks of postnatal life and then were significantly reduced during adulthood. B) Western blot against 
ZSCAN21, ASYN and ERK (loading control). ZSCAN21 protein was reduced during development 
(following the mRNA expression pattern) while ASYN increased (in contrast to the mRNA expression 
pattern).  
 
 
We additionally performed FI in cryostat-cut sections from rat brain of different 
developmental stages (P5, P10, P15, and adult) with a specific antibody against 
ZSCAN21 (Santa Cruz). This antibody gave a more specific staining compared to the 
home-made GeneScript antibody and was used for all immunohistochemistry 
experiments presented here. Similarly, we verified the same pattern of expression for 
ZSCAN21 during development. Representative images are shown in Fig. 16. 
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A) 
 
B) 
 
 
 
Figure 16. ZSCAN21 expression at different developmental stages in the hippocampus. A) Coronal 
section of the rat brain. The hippocampus is denoted with a red box. Higher magnification highlights 
the DG, cornu ammonis 1 (CA1), cornu ammonis 2 (CA2), and cornu ammonis 3 (CA3) areas of the 
hippocampus. B) Cryostat-cut sections (20 μm) from different developmental stages of the rat brain 
were immunolabeled with a fluorescent specific antibody against ZSCAN21 (Santa Cruz/red) and the 
nuclear marker TO-PRO (blue). As a secondary antibody, Cy3-rb was used. In addition, sections that 
were not incubated with a primary antibody (CTL) were also used as a negative control. A gradual 
reduction of the ZSCAN21 FI signal can be observed clearly as the age of the animal increases. The CTL 
condition represents the background signal of the tissue. Representative images from the DG of the 
hippocampus (20 ×) via an upright confocal microscope. 
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4.3 Neuronal expression of ZSCAN21  
 
We next assessed whether ZSCAN21 is expressed in neurons. Therefore, we performed 
an FI assay using cryostat-cut sections, from P5 and P10 rat brains where ZSCAN21 is 
expressed robustly, with specific antibodies against ZSCAN21 and the neuronal marker 
NeuN (Millipore). We observed co-localization of ZSCAN21 and NeuN expression in 
nuclei in different brain areas, indicating that ZSCAN21, as expected for a TF, has a 
nuclear localization, and is indeed expressed in neurons. Representative images are 
shown in Fig.17. 
 
 
 
Figure 17. Neuronal expression of ZSCAN21 in the rat brain. Cryostat-cut sections (20 μm) from P10 rat brain 
were immunolabeled with a fluorescent specific antibody against ZSCAN21 (Santa Cruz/red) and the 
neuronal marker NeuN (green).  TO-PRO (blue) is indicative of nuclear staining. Cy3-rb and Cy2-ms were 
used as a secondary antibody. Co-localization of ZSCAN21 and NeuN is evident in the merged pictures. 
Representative images from the DG of the hippocampus (HIP) and cortex (63×) via an upright confocal 
microscope. 
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4.4 Co-expression of ZSCAN21 and ASYN in postnatal rat brain.  
 
Several studies has shown that ASYN presents a cell soma staining pattern early in 
development, whereas in the adult brain it exhibits a diffuse pattern of reactivity 
throughout the neuropil (Bayer, Jakala et al. 1999, Galvin, Schuck et al. 2001, 
Raghavan, Kruijff et al. 2004, Kahle 2008). Therefore, we selectively used cryostat-
cut sections from different postnatal stages from rat brain (P5, P10, P15, and P22) to 
verify the cell soma staining of ASYN and also to check for co-localization between 
ASYN and ZSCAN21 via FI analysis. In parallel we used sections that were not 
incubated with a primary antibody (CTL) as a negative control (data not shown). We 
detected cell soma staining of ASYN until P15, as well as co-expression with 
ZSCAN21. Representative images are shown in Fig. 18. 
 
 
 
Figure 18. Co-expression of ZSCAN21 and ASYN in postnatal rat brain. Cryostat-cut sections (20 μm) 
from P5 rat brain were immunolabeled with fluorescent specific antibodies against ASYN (BD 
Biosciences), ZSCAN21 (Santa Cruz/red) and the nuclear marker TO-PRO (blue). As secondary antibodies 
Cy3-rb and Cy2-ms were used. ASYN was expressed in the cell soma of neurons and co-expressed with 
ZSCAN21 (merged) in early developmental stages. Representative images from the DG of the 
hippocampus (40×, 63×) via a confocal upright microscope. 
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To eliminate the possibility of non-specificity regarding the cell soma staining for 
ASYN, we further performed an immunohistochemistry assay based on the organic 
substance DAB in cryostat-cut sections from P5 and adult (negative control) rat brains. 
ASYN was immunolabeled with a specific antibody and NISSL staining served as a 
cell soma marker for neurons. In parallel, we performed competition experiments for 
ASYN by incubating the ASYN antibody together with an excess of recombinant 
ASYN in order to neutralize the binding capacity of the antibody (negative control). 
Similarly, we again detected the cell soma staining pattern of ASYN in P5 rat brain 
sections in contrast to the adult brain, thus verifying the presence of cell soma staining 
of ASYN in the postnatal brain. Representative images are shown in Fig.19 
   
 
Figure 19. Verifying cell soma staining of ASYN in the early postnatal rat brain via DAB staining. 
Cryostat-cut sections (20 μm) from P5 and adult rat brain were immunolabeled with specific antibodies 
against ASYN (BD Biosciences/brown). NISSL staining was used as a marker of neuronal cell soma 
staining (blue). ASYN was expressed in the cell soma of neurons in the P5 brain, but not in the adult 
(neuropil staining). Competition experiment served as a negative control. Representative images from 
the DG of the hippocampus (40×) via a bright field microscope. 
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4.5 Zscan21 downregulation upregulates Snca in rat neuronal primary cultures  
 
Since we verified, at least in certain developmental stages, ZSCAN21 co-expression in 
different brain areas with ASYN in vivo, our next step involved the construction of 
shRNA lentiviruses selectively silencing Zscan21 in order to evaluate its involvement 
in the regulation of Snca. Lentiviruses constitute a useful tool for transducing dividing 
as well as non-dividing cells with high efficiency and allow the stable expression of a 
transgene or short hairpin (shRNA). In the current study, we designed 3 shRNAs 
against Zscan21 (shZSCAN21/1, shZSCAN21/2, and shZSCAN21/4) as well as 
scrambled shRNA (control virus) that targets no known sequence in the rat genome. 
The above shRNAs were cloned in the TRC2-pLKO lentivirus-vector (Invitrogen), 
which is widely used for downregulating different proteins in primary cultures as well 
as in in vivo systems with high efficacy (Zufferey, Nagy et al. 1997, Zufferey, Dull et 
al. 1998, Stewart, Dykxhoorn et al. 2003, Moffat, Grueneberg et al. 2006, Yamamoto 
and Tsunetsugu-Yokota 2008). In addition, we incorporated the EGFP reporter protein 
in the vector for monitoring the efficiency of transduction. Of note, we had also utilized 
the pLL3.7 lentivirus-vector in initial experiments, but unfortunately we were unable 
to achieve efficient downregulation of Zscan21 repeatedly. 
As a first step toward evaluating potential alterations of Snca expression due to Zscan21 
downregulation, we infected rat embryonic cortical cultures with the shZSCAN21-
expressing lentiviruses. As already mentioned, this is a well-established primary 
neuronal cell model system that represents an abundant and relatively homogeneous 
source of post-mitotic neurons from the CNS with at least 95% purity (Rideout and 
Stefanis 2002). The efficiency of infection was monitored with the EGFP reporter 
protein. We were able to achieve almost 100% efficiency of infection in the rat cortical 
cultures for the shZSCAN21/1, shZSCAN21/2 and shscrambled lentiviruses (Fig. 20A). 
At 5 days post-infection, the cultures were harvested and processed either for RNA or 
protein isolation. The mRNA and protein levels of ZSCAN21 and ASYN were 
evaluated with real-time PCR and western blotting, respectively. We observed 
significant downregulation of ZSCAN21 of ~50% at both the mRNA and protein level 
(for both Zscan21 targets). Regarding ASYN we observed a significant increase at both 
mRNA and protein (for both Zscan21 targets), a reverse expression pattern compared 
to PC12 cells (Clough, Dermentzaki et al. 2009). Similar results were also obtained 
from primary hippocampal cultures (tested only with shZSCAN21/2), thus further 
validating the specificity of these results. We should also mention that different time 
points were assessed for ZSCAN21 and ASYN expression levels from the ones shown. 
Shorter time points (<96 h) had no effect upon ASYN and later time points (>5 days) 
demonstrated comprised cell integrity. 
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Figure 20. Snca mRNA is increased following downregulation of Zscan21 (shZSCAN21/2 and 
shZSCAN21/1) in rat primary neuronal cultures.  Cortical or hippocampal cultures were prepared from 
embryonic day 17 (E17) rats. The neurons were infected at day 4 of culture with shZSCAN21/2, 
shZSCAN21/1, or shscrambled (control) lentiviruses at an MOI of 1. At 5 (for cortical cultures) or 7 days 
(for hippocampal cultures) post-infection, the cultures were assessed for Zscan21 and Snca mRNA 
expression with real-time PCR. A) Efficiency of transduction in rat cortical cultures (20×) (the same 
efficiency was observed in hippocampal cultures / data not shown). B) Quantification of results from 5 
independent experiments performed in triplicate. Results are presented as a mean, ±SEM (n = 15). 
Statistical analysis was performed via an unpaired t-test. Downregulation of Zscan21 (shZSCAN21/2) 
leads to statistical significant increase of Snca (P < 0.0001) in rat embryonic cortical cultures. D) 
Quantification of results from 2 independent experiments. Results are presented as a mean, ±SEM (n = 
8). Statistical analysis was performed via an unpaired t-test. Downregulation of Zscan21 (shZSCAN21/1) 
led to statistically significant increase of Snca expression (P < 0.0001) in rat embryonic cortical cultures. 
C) Quantification of results from 4 independent experiments performed in triplicate. Results are 
presented as a mean, ±SEM (n = 12). Statistical analysis was performed via an unpaired t-test. Similarly, 
downregulation of Zscan21 (shZSCAN21/2) led to a statistically significant increase of Snca expression 
(P < 0.0001) in rat embryonic hippocampal cultures. β-actin, loading control.  
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Figure 21. ASYN protein is increased following downregulation of Zscan21 in rat primary neuronal 
cultures. Cortical or hippocampal cultures were prepared from E17 rats. The neurons were infected at 
day 4 of their culture with shZSCAN21/2, shZSCAN21/1, or shscrambled (control) lentiviruses at an MOI 
of 1. At 5 (for cortical cultures) or 7 days (for hippocampal cultures) post-infection, the cultures were 
assessed for ZSCAN21 and ASYN protein expression with western blot analysis. A) Western blot analysis 
and quantification of results from 4 independent experiments performed in triplicate. Results are 
presented as a mean, ±SEM (n = 12). Statistical analysis was performed via an unpaired t-test. 
Downregulation of Zscan21 (shZSCAN21/2) led to a statistically significant increase of ASYN expression 
(P < 0.01) in rat embryonic cortical cultures. β-actin, loading control. B) Western blot analysis and 
quantification of results from 1 independent experiment in quadruplicate. Results are presented as a 
mean, ±SEM (n = 4). Statistical analysis was performed via unpaired t-test. Downregulation of Zscan21 
(shZSCAN21/1) led to a statistically significant increase of ASYN expression (P < 0.05) in rat embryonic 
cortical cultures. β-actin, loading control. C) Western blot analysis and quantification of results from 3 
independent experiments performed in triplicate. Results are presented as a mean, ±SEM (n = 9). 
Statistical analysis was performed via an unpaired t-test. Similarly, downregulation of Zscan21 
(shZSCAN21/2) led to a statistically significant increase of ASYN expression (P < 0.01) in rat embryonic 
hippocampal cultures. β-actin, loading control.    
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4.6 Promoter activity assay of SNCA following downregulation of Zscan21 in rat 
primary cultures. 
 
To measure the transcriptional activity of the SNCA promoter following Zscan21 
silencing, we utilized the Dual Luciferase Reporter assay (Promega), a genetic reporter 
system widely used to study eukaryotic gene expression and cellular physiology. 
Different deletion constructs of the 5' promoter of SNCA have been systematically 
examined for transcriptional activity in differentiated PC12 as well as in cortical 
primary cultures in previous experiments in our laboratory (Clough and Stefanis 2007, 
Clough, Dermentzaki et al. 2009, Clough, Dermentzaki et al. 2011). These experiments 
showed that the 1.9-kb deletion construct (which includes the core promoter and the 
1st intron of SNCA) and the intron 1 construct demonstrated a reverse pattern of 
transcriptional activity in the above cell systems.  
In the present study, given the fact that Zscan21-mediated downregulation upregulates 
ASYN at the mRNA and protein level, we wished to evaluate further whether this 
induction results from increased transcriptional activity of the SNCA promoter. To 
address this issue, we utilized the 1.9-kb luciferase construct, which is highly induced 
in the luciferase assay (in contrast to intron 1) in rat cortical cultures, intron 1 construct 
and the 10.7-kb luciferase construct. The 10.7-kb construct is also induced in the 
luciferase assay in rat cortical cultures (Clough, Dermentzaki et al. 2011) and most 
importantly contains the NACP/Rep-1 polymorphism that has been correlated with PD 
risk in several studies (Chiba-Falek and Nussbaum 2001, Maraganore, de Andrade et 
al. 2006, Cronin, Ge et al. 2009, Linnertz, Saucier et al. 2009). Therefore, we infected 
rat embryonic cortical cultures with either the shZSCAN21/2, shZSCAN21/1 or 
shscrambled lentiviruses. At 3 days post-infection we transfected these cultures with 
the 10.7-kb, 1.9-kb, intron1 and pGL3-empty (control vector) luciferase constructs, and 
we performed the luciferase assay at 48 h later. Notably, we observed significant 
induction in the luciferase assay following Zscan21 downregulation with the 
shZSCAN21/2 and shZSCAN21/1 targets compared to shscrambled for the 1.9-kb 
promoter construct that contains the core promoter of SNCA. Therefore, Zscan21 
silencing increases SNCA transcription at the promoter level. However, we did not 
observe any significant alterations for the 10.7-kb construct or the intron 1 construct. 
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Figure 22. Increased transcriptional activity of the SNCA promoter following Zscan21 downregulation 
in rat cortical cultures. Cortical cultures were prepared from E17 rats. The neurons were infected at 
day 4 of their culture with shZSCAN21/2, shZSCAN21/1, or shscrambled (control) lentiviruses at an MOI 
of 1. At 3 days post-infection, the cultures were transfected with the 10.7 (kb), 1.9 (kb), intron 1 (Int1), 
and pGL3 basic -empty vector luciferase constructs. At 48 hours post-transfection, the cells were lysed 
and assessed for the luciferase assay. A) Relative luciferase activity of the 10.7-kb (P < 0.0001), 1.9-kb 
(P < 0.0001), and intron 1 (Int1) luciferase constructs compared to pGL3-empty vector in naïve cortical 
cultures. Quantification of results from 4 independent experiments performed in duplicate. Results are 
presented as a mean, ±SEM (n = 8). Statistical analysis was performed via an unpaired t-test. B) 
Quantification of results from 5 independent experiments performed in duplicate for 1.9-kb and 10.7-
kb and 3 independent experiments performed in duplicate for intron1 (Int1). Results are presented as 
a mean, ±SEM (n = 10, n = 6, respectively). Statistical analysis was performed via an unpaired t-test. 
Significant induction in the luciferase assay following Zscan21 downregulation (shZSCAN21/2, Z2) 
compared to scrambled (fold induction set as 1 for each construct in the scrambled condition) for the 
1.9-kb construct (P < 0.0001), but not for the 10.7-kb and intron 1 (Int1) constructs. C) Quantification 
of results from 1 experiment performed in triplicate for the 1.9-kb construct. Results are presented as 
a mean, ±SEM (n = 3). Statistical analysis was performed via an unpaired t-test. Significant induction in 
the luciferase assay following Zscan21 downregulation (shZSCAN21/1, Z1) compared to scrambled (fold 
induction set as 1 for each construct) for the 1.9-kb construct (P < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** ** *** 
*** 
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4.7 Assessment of ZSCAN21 mode of SNCA transcriptional regulation in rat 
cortical cultures.   
 
So far, our data indicated the involvement of ZSCAN21 in the transcriptional 
regulation of SNCA at the level of its promoter in rat primary neuronal cultures, though 
they could not provide sufficient information as to whether this regulation was direct 
or indirect. Previous experiments in our laboratory have shown that ZSCAN21 directly 
regulates SNCA via its binding site in the intron 1 area of SNCA in differentiated PC12 
cells (Clough, Dermentzaki et al. 2009), but most important, a recent study by Brenner 
et al. (Brenner, Wersinger et al. 2015) reported that ZSCAN21 binds to the intron 1 
region in vivo in human brain tissue. Therefore, there was enough evidence to support 
the hypothesis that ZSCAN21 regulates SNCA transcription by binding to its intron 1 
region. To validate this conjecture, first we performed a CHIP assay in rat cortical 
cultures to examine whether ZSCAN21 binds directly to the predicted consensus sites 
in the intron 1 region. In the intron 1 region of SNCA, there are two predicted binding 
sites for ZSCAN21 conserved in human and rat (MatInspector), one at the very 
beginning of intron 1 and one approximately 130 bases downstream. For the CHIP 
assay, we designed specific primers to include the region (~150 bases) with both 
putative ZSCAN21 binding sites. For the immunoprecipitation we used the ZSCAN21 
GenScript antibody as well as a negative control (IgG control) irrelevant antibody of 
the same isotype (c-myb). Additionally, we used primers amplifying either a distant 
region in the same gene (an area in the exon / intron 4 region of Snca / 3' SNCA) or a 
region in another gene (in this case the OLIG2 gene) as negative controls. We found 
an increase of approximately 15-fold in the case of the ZSCAN21 antibody compared 
to the irrelevant IgG control for the 150 bp designated region in the intron 1 region in 
the real-time PCR assay. Regarding the negative control regions for 3' SNCA and 
OLIG2, we observed an approximately 4- and 2-fold signal, respectively. These data 
indicate that it is very likely that ZSCAN21 binds to the intron 1 region of Snca in rat 
cortical neuronal cultures. Further, we designed constructs lacking the first putative 
ZSCAN21 binding site (1.9d), the second putative ZSCAN21 binding site (1.9sec), as 
well as both binding sites (1.9dd), using the 1.9kb construct (which is highly induced 
in the luciferase assay in cortical cultures) as a template via site-directed mutagenesis.  
Then, we performed luciferase assays in primary cortical cultures. The 1.9-kb construct 
again, like before, demonstrated robust induction of luciferase activity. Interestingly, 
overall, we did not detect a significant alteration between the 1.9-kb construct and the 
1.9-kb deletion constructs.  
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Figure 23. CHIP assay and SNCA promoter activity following deletion of ZSCAN21 binding sites in 
intron 1. A) Schematic of a CHIP assay. Cross-linking is performed directly in cell culture followed by cell 
lysis and chromatin fragmentation. Next, chromatin pre-clearing is performed to reduce non-specific 
binding. A small portion of the pre-cleared sample is kept as input (positive ctl) and the rest undergoes 
CHIP either with a specific antibody for the protein of interest, or an irrelevant antibody of the same 
isotype (IgG/negative ctl) along with magnetic beads. The immunoprecipitated protein-DNA complex is 
disrupted, and the DNA is eluted and further amplified with specific primers (real-time PCR). If CHIP is 
successful, there will be a significant difference between the number of cycles for the sample of interest 
(specific antibody) and the negative ctl (irrelevant IgG antibody) denoted by the exponential curves in 
the PCR software. B) Schematic of the rat Snca gene:  exons are depicted as boxes and introns as lines. 
The specific location in the rat Snca gene of the amplified area containing the two ZSCAN21 putative 
binding sites (ZSCAN21) as well as the amplified non-specific area (3' SNCA) are presented. Rat cortical 
cultures were harvested at day 8 and processed for the CHIP assay. The antibodies used for 
immunoprecipitation were ZSCAN21 (10 μg; Genscript antibody) and c-myb (10 μg; irrelevant antibody).  
We observed a 15-fold increase for ZSCAN21 compared to the irrelevant antibody (IgG). For 3' SNCA 
(negative control on the same gene locus) we detected an approximately 4-fold induction and a 2.5-
fold induction for OLIG2 (negative control on a different gene) compared to IgG. Quantification of 
results (real time-PCR) from 3 independent experiments. C) Cortical cultures were transfected at day 7 
with the 1.9-kb construct, ZSCAN21 deletion constructs (1.9d, 1.9dd, and 1.9 sec), and pGL3 basic empty 
vector (control). At 48 h post-transfection, the cells were lysed and assessed for luciferase assay. 
Quantification of results from 4 independent experiments performed in duplicate and normalized 
according to the pGL3 empty vector. Results are presented as a mean, ±SEM (n = 8). Statistical analysis 
was performed via one way ANOVA and post hoc Tukey’s test. We observed no statistically significant 
differences between the 1.9-kb and the ZSCAN21 deletion constructs. 
 
 
4.8 Silencing of Zscan21 in differentiated cultures derived from neurospheres. 
 
We also examined the interplay between ZSCAN21 and SNCA in free-floating cultures 
of neural stem cells termed neurospheres (Reynolds and Weiss 1992). Neurospheres 
represent an early developmental model system, and since ZSCAN21 demonstrates the 
highest levels of expression very early in development, it seemed plausible to examine 
its role upon Snca regulation in that system. Generally, neurospheres are derived from 
a single-cell suspension of neural stem and progenitor cells isolated from the fetal or 
adult CNS. In our case, we isolated the cortex and hippocampus from embryonic (E16) 
rat brains, and following mechanical dissociation, we cultured the starting population 
as a single cell suspension in medium containing EGF and FGF which drive the 
neurosphere formation (Vescovi, Reynolds et al. 1993, Morshead, Reynolds et al. 
1994, Gritti, Parati et al. 1996, Reynolds and Weiss 1996, Tropepe, Sibilia et al. 1999). 
Next, following a few passages (usually P2-P3), these neurospheres were dissociated 
and plated in poly-D-lysine-coated plates either in the presence of the above growth 
factors as proliferating cultures or in the absence of these factors as differentiated 
mixed cultures that consist of neurons, astroglia and oligodendroglia. The percent of 
neurons in the cultures is approximately 15-20%. We must mention that the maturation 
state of the differentiated cultures is completely different from that of primary cultures. 
These differentiated neurons derived from neurospheres are positive for beta-III tubulin 
(TUJ1 / early neuronal marker) and almost negative for NeuN (mature neuronal 
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marker). In our study, we utilized the differentiated cultures, since ASYN is not 
detected in the proliferating cultures (data not shown). Immunohistochemistry against 
ZSCAN21, ASYN, and TUJ1 verified the co-expression of ZSCAN21 and TUJ1 as 
well as ASYN and TUJ1 (Fig 24). 
 
Α)                                                               
    
B) 
 
 
 
Figure 24. Neuronal expression of ZSCAN21 and ASYN in differentiated neurospheres. Neurosphere 
cultures derived from the cortex and hippocampus of E16 rat embryos following 2 passages were 
dissociated and plated for differentiation. On the 3rd day of differentiation, the cultures were 
immunolabeled with antibodies against TUJ1 (early neuronal marker) ZSCAN21 (GenScript), and ASYN 
(C20). As secondary antibodies, Cy3-ms (red) and Cy2-rb (green) were used. We detected co-
localization A) of TUJ1 with ZSCAN21 and B) of TUJ1 with ASYN. Representative images for each 
antibody separately and merged from an upright microscope (40×).  
 
 
 
 
 
 
 
 74 
 
We next infected these differentiated cultures with the shZSCAN21 lentiviruses 
(shZSCAN21/1 and shZSCAN21/2) and shscrambled (control) and assessed them for 
ZSCAN21 and ASYN expression levels at 5 days post-infection. We observed high 
infection efficiency for all lentiviruses (Fig. 25A). Significant silencing of Zscan21 
with both lentiviruses surprisingly led to decreased levels of ASYN at both the mRNA 
and protein level (Fig 25 B, C, and D). This finding is in contrast to previous results in 
the primary neuronal cultures, where we detected increased ASYN levels. 
  
Α)                                                              
  
 
Β) 
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Figure 25. Lentivirus-mediated silencing of Zscan21 (shZSCAN21/2 and shZSCAN21/1) leads to 
decreased levels of ASYN in differentiated neurosphere cultures. Neurosphere cultures derived from 
the cortex and hippocampus of E16 rat embryos following 2 passages were dissociated and plated for 
differentiation. On the 1st day of differentiation, the cultures were infected with shZSCAN21/2, 
shZSCAN21/1, or shscrambled lentiviruses. At 5 days post-infection, the cultures were harvested and 
assessed for immunocytochemistry, real-rime PCR, and western blotting. A) Efficiency of transduction 
for shZSCAN21/2, shZSCAN21/1 and shscrambled lentiviruses (20×). B) Immuno-labeling against 
ZSCAN21 in both shZSCAN21/2 and shscrambled conditions. Cy3-rb (red) was used as a secondary 
antibody. GFP is the reporter marker of the lentiviruses. Downregulation was noted in the shZSCAN21 
condition compared to shscrambled. Representative images from a confocal microscope (63×). C) 
Quantification of mRNA results from 3 independent experiments performed in triplicate. Results are 
presented as a mean, ±SEM (n = 9). Statistical analysis was performed via an unpaired t-test. 
Downregulation of Zscan21 (shZSCAN21/2) led to a statistically significant decrease of Snca expression 
(P < 0.001). β-actin, loading control. D) Quantification of mRNA results from 2 independent 
experiments performed in quadruplet. Results are presented as a mean, ±SEM (n = 8). Statistical 
analysis was performed via an unpaired t-test. Downregulation of Zscan21 (shZSCAN21/1) led to a 
statistically significant decrease of Snca expression (P < 0.001). β-actin, loading control E) 
Representative western blot. Zscan21 downregulation (shZSCAN21/2 [Z2] and shZSCAN21/1 [Z1]) led 
to decreased ASYN levels. β-actin, loading control.    
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We also tried to test whether Zscan21 silencing reduces SNCA transcription at the 
promoter level in the differentiated neurosphere cultures by performing luciferase 
assays. Again, we utilized the 1.9-kb SNCA promoter construct for this assay. We 
observed a great variation among independent experiments (data not shown), that 
overall indicated no significant effect upon SNCA promoter activity following 
shZSCAN21/2 silencing. However, in the differentiated neurosphere cultures, we know 
that only a small percentage of cells represents early neurons (15-20%) and most cells 
are glia thus, since transfection of the 1.9-kb promoter construct is random, we do not 
know what percentage of neurons are transfected each time and we also cannot exclude 
the possibility that the 1.9-kb construct can also be affected in unpredictable ways by 
the other cell populations present. Concluding, it is rather difficult to test directly 
whether Zscan21 silencing indeed reduces SNCA promoter activity in these cultures.  
 
 
4.9 Evaluating the role of ZSCAN21 upon Snca regulation in different 
developmental stages in vivo. 
 
For the in vivo experiments we produced AAVs targeting Zscan21 expression. The 
reason we utilized AAVs over lentiviruses is due to their increased transduction 
efficacy in in vivo settings (with the TRC2-pLKO lentiviruses we were unable to 
transduce neuronal cells in vivo). Specifically, for the AAVs used in the current study, 
shRNA expression was driven by a synapsin promoter that ensures the selective 
transduction of neurons. In addition, a GFP selection marker was also incorporated in 
the AAV vector sequence for the visualization of the signal. We focused on studying 
the role of ZSCAN21 on Snca regulation in vivo in two developmental stages due to 
the differential regulation of Snca transcription following Zscan21 silencing in the 
neurosphere cultures (early developmental stage) and the rat primary neuronal cultures 
(representing a more mature stage). The shZSCAN21 target that was cloned in the 
AAV vector was shZSCAN21/2. We achieved high neuronal transduction efficiency 
in both developmental stages with AAV/shZSCAN21/2 and AAV/shscrambled. 
Regarding the early developmental stage, we performed stereotaxic delivery of both 
AAVs in the lateral ventricles of postnatal day 3 (P3) rat brains using a specific 
stereotaxic unit for pups according to Kim et al. (Kim, Ash et al. 2013). We followed 
this approach as it is particularly difficult to target a specific brain area at such a young 
age. The AAVs, due to the small diameter of their viral particles (~20-30 nm), have the 
ability to spread efficiently through the lateral ventricles and transduce proximal brain 
areas, including the hippocampus, which was of most interest to us in the present study. 
The amount of the AAVs injected was 7.0 × 1013 TU/mL (2 μL/ventricle) for both 
AAVs. The animals were sacrificed at 1 month post-infection and the brain samples 
were processed either for FI or cell sorting for RNA analysis. Immunohistochemistry 
of cryostat-cut brain sections with the neuronal NeuN marker revealed sufficient 
neuronal transduction mainly in the areas surrounding the ventricles, such as the 
striatum, cortex and hippocampus. In most cases, neuronal transduction was more 
evident in the hippocampus. In parallel, brain samples were processed for cell sorting 
in order to isolate the infected neurons for mRNA analysis of Zscan21 and Snca 
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expression for both AAVs. To achieve efficient cell sorting we utilized the GFP 
reporter marker of the AAVs along with antibodies for neuronal cell surface markers. 
The neuronal cell surface markers used were the PE-CD24 (BD Biosciences) and Alexa 
Fluor 647 CD90.1 (BioLegend) antibodies. For each animal (AAV/shZSCAN21 or 
AAV/shscrambled) we sorted two different cell populations, the transduced population 
that was positive for GFP, CD24 and CD90 and the non-transduced population that 
was negative for GFP and positive for CD24 and CD90. The non-transduced 
population served as an internal control for the endogenous cargo. We assessed these 
sorted samples for Zscan21 and Snca mRNA expression. We achieved robust 
downregulation of Zscan21 in the case of the AAV / shZSCAN21-treated animals 
versus AAV/shscrambled and ctl (non-transduced population) according to real-time 
PCR analysis. Additionally, the animals that demonstrated the highest downregulation 
were also highly enriched for the GFP signal, thus substantiating the effectiveness of 
the sorting assay utilized. Nevertheless, Snca levels remained unchanged following 
Zscan21 downregulation. Of note, from the total of 11 animals (5 AAV/shZSCAN21, 
6 AAV/shscrambled) that underwent sorting, only 3 were highly enriched for the GFP 
signal in the case of AAV/ shZSCAN21 and 3 in the case of AAV /shscrambled viruses. 
This was due to variation in the transduction efficiency of both AAVs following 
stereotaxic injection in the ventricles (also evident in the immunohistochemistry assay) 
of P3 rats.  
 
A) 
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C)  
 
 
Figure 26. AAV-mediated silencing of Zscan21 did not alter Snca levels in the early postnatal rat brain. 
A) Cryostat-cut sections (20μm) from 1-month-old rat brains stereotaxically injected with 
AAV/shZSCAN21 or AAV/shSCRAMBLED (at P3) were immunolabeled with the NeuN neuronal marker. 
The Cy3-rb was used as a secondary antibody. The GFP reporter marker of the AAVs demonstrated the 
efficiency of transduction in both the AAV/shZSCAN21 and AAV/shSCRAMBLED condition. Co-
localization of NeuN (red) and GFP (green) was observed in the merged picture. Representative images 
from the DG of the hippocampus (63×) via a confocal microscope. B) Schematic of FACS protocol 
including dissociation of tissue to a cell suspension, removal of debris by filtration and Percoll gradient 
centrifugation, immunolabeling of cells with cell surface neuronal markers (CD24, CD90), and 
purification of GFP-positive neurons using FACS analysis. A typical light scatter plot showing distinct 
clusters for debris and cells is presented. Each dot represents one event detected by the laser. Forward 
scatter (FSC) represents the size of the event while side scatter (SSC) represents granularity of the 
event. The box indicates the area of mainly cell bodies that was sorted for subsequent RNA extraction 
and downstream use in quantitative real-time PCR. Criteria set for sorting were duplet exclusion, 
colocalization of the CD45/CD90 signal and positive GFP signal. From the gated area we had 
approximately 11% positive cells that were sorted for the AAV/shSCRAMBLED samples and 
approximately 18% positive cells that were sorted for the AAV/ZSCAN21 samples. C) Quantification of 
results from real-time PCR. β-actin, loading control. Results are presented as a mean, ±SEM (n = 5 for 
control scrambled [CTL SCR], n = 4 for control ZSCAN21 [CTL ZSCAN21], n = 3 for AAV/shscrambled 
[SCR] and n = 3 for AAV/shZSCAN21 [ZSCAN21]. Statistical analysis was performed via an unpaired t-
test. Significant downregulation of Zscan21 expression (P < 0.01) did not significantly affect Snca levels.  
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Although we did not observe any significant change in the Snca levels following 
downregulation of Zscan21 expression in the early developmental stages of the rat 
brain where ZSCAN21 is expressed robustly, we were nevertheless interested in further 
investigating whether (in contrast) the low expression levels of ZSCAN21 observed in 
the adult brain could be involved in Snca transcription. For this purpose, we again 
performed stereotaxic injections utilizing the above AAVs targeting the DG of the 
hippocampus in 2-month-old rats. For this assay we used a total of 12 adult rats (6 
AAVshZSCAN21, 6 AAVshSCRAMBLED). The injections were performed at 2 
distinct sites of the DG of the hippocampus in the right hemisphere of the brain in order 
to transduce efficiently a more extended area. The coordinates of the injection sites 
were: 1st AP: -3.0, ML: -1.5, and DV: -3.6, and 2nd AP: -4.56, ML: -2.6, and DV: -
3.3. The amount of the virus injected for both AAVs was 7.0 × 1013 TU/mL (2μL / 
injection site). The animals were sacrificed at 2-months post-infection and the brain 
samples were processed either for FI or biochemical assays. Immunohistochemistry of 
cryostat-cut brain sections with the neuronal NeuN marker revealed widespread 
neuronal transduction of the DG of the hippocampus.  The immunohistochemistry 
assay was performed in 1 animal per group.  The remaining 5 animals in each group 
were processed for Zscan21 and Snca mRNA levels.  We also isolated the right infected 
area of the DG of the hippocampus through a stereoscope by visualizing the GFP 
signal. We also isolated the same area from the left hemisphere (non-injected) that 
represents the endogenous levels of expression for each animal. We then isolated total 
RNA (TRIzol-based) and performed real-time PCR. We observed significant Zscan21 
downregulation in the group of AAV/shZSCAN21 animals compared to 
AAV/shscrambled. Similarly to the early postnatal stage, we were not able to detect 
significant alterations in Snca levels between the two groups.  
Α) 
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Β) 
  
Figure 27. AAV-mediated silencing of Zscan21 did not alter Snca levels in the DG of the hippocampus 
in adult rat. A) Cryostat-cut sections (20 μm) from 4-month-old rat brains stereotaxically injected with 
AAV/shZSCAN21 or AAV/shSCRAMBLED (at 2-months of age) were immunolabeled with the NeuN 
neuronal marker. The Cy3-rb was used as a secondary antibody. The GFP reporter marker of the AAVs 
demonstrated the efficiency of transduction in both the AAV/shZSCAN21 and AAV/shSCRAMBLED 
condition. Co-localization of NeuN (red) and GFP (green) was observed in the merged picture. 
Representative images from the DG of the hippocampus (5×, 63×) via a confocal microscope. B) 
Quantification of the results from real-time PCR. β-actin, loading control. Results are presented as a 
mean, ±SEM (n = 5 for AAV/shZSCAN21 and n = 4 for AAV/shscrambled). Statistical analysis was 
performed via an unpaired t-test. Significant downregulation of Zscan21 expression (P < 0.01) did not 
significantly affect Snca levels.  
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4.10 Overexpression of Zscan21 in cortical neuronal cultures 
 
Since Zscan21 silencing increased Snca at its promoter, mRNA, and protein level in 
cultured E17 cortical neurons, we were interested in examining whether Zscan21 
overexpression could suppress Snca expression. For this purpose, we produced AVs 
expressing the rat Zscan21 coding sequence to overexpress Zscan21 in rat cortical 
neuronal cultures. AVs, similarly to lentiviruses, have the ability to transduce post-
mitotic cells with high efficiency. Zscan21 coding sequence cloning as well as the AV 
production are summarized in the Materials and Methods section. We first tested for 
ZSCAN21 overexpression in HEK293T cells, and indeed, we had a high rate of 
overexpression (Fig. 28A). Regarding cortical neuronal cultures we detected high 
efficiency of transduction in the case of the AV/GFP control virus (Fig. 28B). On the 
contrary, the AV/ZSCAN21 virus does not contain a GFP reporter; therefore, we could 
not visualize its overexpression directly. Surprisingly, following a western blot assay, 
we were able to detect only slight ZSCAN21 overexpression that was evident at early 
time points (24 and 48 h) (Fig. 28D). We tested different MOIs (50-400), but overall, 
there was no substantiated difference in the ZSCAN21 overexpression profile. For 
further experiments we chose to work with an MOI of 100 since it gave efficient 
transduction and conferred no toxicity. Conversely, at the mRNA level, we could detect 
robust Zscan21 overexpression starting from an approximately 15-fold difference 
compared to endogenous levels at the early time point of 24 h, then 10-fold at 48 h, 5- 
fold at 72 h and lastly 3.5-fold at 5 days. The gradual reduction seen in the 
overexpressed Zscan21 mRNA levels over time is expected, due to the episomal nature 
of the AV expression. Additionally we excluded the possibility that this mRNA 
overexpression detected with real-time PCR could be attributed to Zscan21 AV cDNA, 
as cDNA from OVERZSCAN21 samples had an almost 32-64 fold difference 
compared to cDNA samples that were not reverse transcribed (negative control). As 
expected, since ZSCAN21 overexpression was not evident at the protein level, we did 
not detect any alteration in Snca mRNA and protein levels at any of the time points 
tested.  
The fact that Zscan21 mRNA overexpression is not followed by subsequent ZSCAN21 
protein overexpression, suggests that ZSCAN21 protein levels must be under tight 
regulation either at the post-transcriptional or post-translational level, or perhaps a 
combination of both.  
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A) 
 
 
B) 
          
 
C) 
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D) 
  
 
 
Figure 28. ZSCAN21 protein levels are under tight regulation in rat cortical neuronal cultures. A) 
HEK293T cells were infected with the AV/OVERZSCAN21 AV at serial MOIs (2.5, 5, 10, and 20) or 
transfected with the calcium phosphate method with the adenoviral plasmid pDEST / ZSCAN21 (pdest 
/ positive control) and another plasmid overexpressing the murine Zscan21, the 3'-FLAG pCI mouse 
Zscan21 (pCI / positive control). Uninfected cells were also used as negative control (ctl). 
Overexpression of ZSCAN21 was evident following infection of HEK293T cells even at the lowest MOI. 
Cortical neuron cultures were prepared from E17 rats. The neurons were infected at day 4 of their 
culture with the AV/OVERZSCAN21 or AV/GFP (control) AVs at an MOI of 100. The cultures were 
collected at different time points (24h, 48h, 72h, and 5 days) and assessed for Zscan21 and Snca mRNA 
and protein levels with real-time PCR and western blot analysis, respectively. B) Efficiency of 
transduction of AV/GFP virus in rat cortical cultures (20×). C) Quantification of results from real time 
PCR (2 experiments). β-actin, loading control. Overexpression of Zscan21 mRNA was evident at all time 
points tested. Snca mRNA levels remained unaltered. D) Representative western blots: one with all 
time points and one magnified on the 48 h time point where ZSCAN21 slight overexpression was more 
evident. This slight overexpression of ZSCAN21 was observed only at early time points (24 h and 48 h), 
and ZSCAN21 ran slightly higher on the blot compared to endogenous protein, suggesting that 
overexpressed ZSCAN21 is possibly subjected to post-translational modifications. 
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4.11 Another target for silencing Zscan21 (shZSCAN21/4) strongly reduced Snca 
expression in rat cortical cultures.  
 
From the above experiments it was evident that Zscan21 downregulation with 2 shRNA 
targets leads to increased ASYN levels at both the mRNA and protein level in cortical 
neuron cultures. In parallel we also used another shZSCAN21 target, shZSCAN21/4. 
This target was able to downregulate Zscan21 expression in rat cortical cultures as 
efficiently as the other two targets. In contrast though, we noticed that the expression 
levels of ASYN instead of being increased like the other two targets, were significantly 
decreased both at the mRNA and protein level (Fig. 29B, C). Notably, ASYN protein 
was almost completely depleted (Fig 29C). SNCA transcriptional activity, measured 
through luciferase assays based on the 1.9- and 10.7-kb constructs, was also 
significantly decreased (Fig 29D).  
 
A) 
                    
 
 
B)  
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C) 
 
 
D) 
  
 
Figure 29 ASYN is significantly decreased following Zscan21 downregulation with shZSCAN21/4 in rat 
cortical cultures. Cortical cultures were prepared from E17 rats. The neurons were infected at day 4 of 
their culture with shZSCAN21/4 or shscrambled (control) lentiviruses, at an MOI of 1. At 5 days post-
infection, the cultures were assessed for ZSCAN21 and ASYN mRNA and protein expression with real-
time PCR and western blotting, respectively, or at 3 days post-infection the cultures were transfected 
with the 10.7 -kb, 1.9-kb, intron 1, and pGL3 basic -empty vector luciferase constructs. At 48 h post- 
transfection, the cells were lysed and assessed for the luciferase assay A) Efficiency of transduction 
(20×). B) Quantification of mRNA results from 4 independent experiments performed in triplicate. 
Results are presented as a mean, ±SEM (n = 12). Statistical analysis was performed via an unpaired t-
test. Downregulation of Zscan21 led to a statistically significant decrease of Snca expression (P < 
0.0001).  β-actin, loading control C) Western blot analysis and quantification of results from 3 
independent experiments performed in triplicate. Results are presented as a mean, ±SEM (n = 9). 
Statistical analysis was performed via an unpaired t-test. Downregulation of Zscan21 led to a statistically 
significant decrease of ASYN expression (P < 0.0001) in rat embryonic hippocampal cultures. β-actin, 
loading control.  D) Quantification of results from 3 independent experiments performed in duplicate 
for 1.9-kb and 10.7-kb constructs. Results are presented as a mean, ±SEM (n = 6). Statistical analysis 
was performed via an unpaired t-test. Significant reduction in the luciferase assay following Zscan21 
downregulation compared to scrambled (fold induction set as 1 for each construct) for the 1.9-kb (P < 
0.01) and 10.7-kb (P < 0.001) constructs. 
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Interestingly, in addition to the downregulation of ZSCAN21, we also observed an 
increase of another band below ZSCAN21 in western blot analysis. This band in the 
experiments with the shZSCAN21/2 target was either decreased or unchanged. 
Therefore, we wondered whether this band that was detected with the ZSCAN21 
polyclonal antibody (GenScript) and was increased in the case of shZSCAN21/4, could 
potentially play a role in the observed downregulation of Snca. The predominant 
scenario that we wanted to test was whether this protein represents a truncated 
ZSCAN21 protein that arises from alternative splicing of the basic Zscan21 mRNA 
product. In that case, this putative alternative splicing product could be increased in a 
compensatory manner to the downregulation of ZSCAN21 and further decrease Snca 
expression. Supporting evidence towards this hypothesis was the fact that 
shZSCAN21/4 binds more 3' to the last exon (exon 4) of Zscan21 mRNA compared to 
shZSCAN21/2 and shZSCAN21/1. Additionally, the protein that would result from that 
difference matches the size of the other band in the western blot with the ZSCAN21 
GenScript antibody. Conversely, with the Santa Cruz ZSCAN21 antibody, we were 
unable to detect the second band, but since this antibody recognizes an epitope more 3' 
in the ZSCAN21 protein than the GenScript antibody, it is possible that it may not target 
the putative truncated ZSCAN21 protein. Therefore, in order to shed more light on this 
assumption we decided to utilize the 3' RACE assay.  
 
A)                                                           
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
gi|219273450|ref|NM_001012021.2| Rattus norvegicus zinc finger and SCAN domain containing 
21 (Zscan21), mRNA 
  
ATGACCAAGGTGGTGGGCATGGCCACAGTTCTGGGCCCCAGGCCACCTCAGGAGTCTATGGGACCTTCGCCCATTAAAGTTGAAGAGGATGAAGAAAAAGAC
AAGTGCCGCCCTAGCCTAGAGCTATCCCGAAAGCGCTTCAGGCAGTCTAGAAACCAGGACACTCTTGAGCCAATGGGACCTTCAACCATTAAAGCTGAAGAGG
AGGAAGACAAGGACAAGGGCCACCCTAGCCTAGAGCTATCCCGTAAGAGCTTCAAGCAGTTTGGGTACCATGACACTTTGGAACAGTTGGGACCTTCGACTGT
TAAAGCTGAAGAGGATGAAGAGAAGGACAAGGGCCGCCCTAGCCTAGAGATATCCCGTCAGCGCTTCAGGCAGTTTGGGTACCATGACACTCCTGGGCCCCG
AGAGGCACTGAGCCAGCTTCGGGTGCTCTGCTGTGAGTGGCTACAGCCTGAGATCCACACCAAGGAGCAGATTCTAGAGCTACTGGTTCTGGAGCAGTTCCTG
ACCATCCTGCCCCGAGAGCTCCAGGCCTGGGTACAGCAGCACTGCCCTGAGAGTGCAGAGGAGGCCGTCACTCTCCTGGAAGACCTGGAGCAAGAACTGGAT
GAGCCTGGACTGCAGGTCTCATCTCCAAATGAACAGAAGCAGTCTTGGGAGAAAATATCAACTTCAGGAACTGCAATGGAGTCCTTAAGCAGCACTGAGACCC
AGCCTGTGGATGCCAGCCCTAAATATGAGTTTTGGGGGCCCCTGTACATCCAAGAGACTGGTGAAGAGGAGGTTTTCACTCAGGACCCAAGAAAGCGCCAAG
GTTTTAAATTGAATCCGCAGAAGGAGGACTCAGCAGATGAGCAGAGAAGTTCTGAAGAAGAGTCTCATGCAGGTGGACTCAAAAGAAACATCATGCCCATGAT
CACTGCCAATAAGTATGGATCGAGGTCAGAAAGGCAGTGGGCCAACAACCTGGAAAGGGAGAGAGGGGCAAAAGCCTCTCTTCAAGACACGGGATCCAGGA
AAGGGGCAGAACCAGCGTCTGCTAGGCCTGCTCCAGGAGAGAAACGTTACATATGTGCAGAGTGTGGGAAGGCCTTTAGCAATAGCTCAAACCTCACTAAACA
CCGGAGAACACACACTGGGGAGAAGCCTTACGTGTGCACCAAGTGTGGGAAGGCTTTCAGCCACAGCTCCAACCTTACCCTTCATTACCGGACACATCTGGTG
GACCGGCCCTATGACTGTAAGTGTGGGAAAGCCTTTGGGCAGAGCTCAGACCTCCTTAAACATCAGAGGATGCACACAGAAGAGGCGCCCTATCAGTGTAAAG
ACTGTGGGAAAGCCTTCAGTGGGAAGGGCAGCCTCATTCGACACTATCGCATCCACACAGGGGAGAAGCCCTATCAGTGCAATGAGTGTGGAAAGAGTTTTA
GTCAGCATGCAGGTCTCAGTTCCCATCAACGCCTGCATACAGGGGAGAAACCCTATAAGTGTAAGGAGTGTGGCAAAGCCTTCAACCATAGTTCGAATTTTAAT
AAGCATCACAGAATCCATACTGGTGAAAAACCCTATTGGTGTAACCACTGTGGGAAAACCTTCTGTAGCAAGTCAAATCTTTCCAAGCATCAGAGAGTCCACAC
TGGAGAGGGAGAGGTACAGTAA 
RAT ZSCAN21 AMINO ACID SEQUENCE 
 
MTKVVGMATVLGPRPPQESMGPSPIKVEEDEEKDKCRPSLELSRKRFRQSRNQDTLEPMGPSTIKAEEEEDKDKGHPSLELSRKSFKQFGYHDTLEQLGPSTVKAEEDEE
KDKGRPSLEISRQRFRQFGYHDTPGPREALSQLRVLCCEWLQPEIHTKEQILELLVLEQFLTILPRELQAWVQQHCPESAEEAVTLLEDLEQELDEPGLQVSSPNEQKQSW
EKISTSGTAMESLSSTETQPVDASPKYEFWGPLYIQETGEEEVFTQDPRKRQGFKLNPQKEDSADEQRSSEEESHAGGLKRNIMPMITANKYGSRSERQWANNLERER
GAKASLQDTGSRKGAEPASARPAPGEKRYICAECGKAFSNSSNLTKHRRTHTGEKPYVCTKCGKAFSHSSNLTLHYRTHLVDRPYDCKCGKAFGQSSDLLKHQRMHTEE
APYQCKDCGKAFSGKGSLIRHYRIHTGEKPYQCNECGKSFSQHAGLSSHQRLHTGEKPYKCKECGKAFNHSSNFNKHHRIHTGEKPYWCNHCGKTFCSKSNLSKHQRV
HTGEGEVQ 
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Figure 30. Zscan21 shRNAs and GenScript antibody target sites.  A) Zscan21 mRNA coding sequence. 
The translation start site (ATG) and end site (TAA) are highlighted in gray. The shZSCAN21/1, 
shZSCAN21/2, and shZSCAN21/4 target sites are highlighted with yellow, purple, and green, 
respectively. B) ZSCAN21 protein sequence. The antigen recognition site for the ZSCAN21 GenScript and 
ZSCAN21 Santa Cruz antibodies are denoted in red and blue, respectively. 
 
 
4.12 3' Rapid amplification of cDNA ends of Zscan21  
 
As aforementioned, we wanted to test the scenario of an alternatively spliced Zscan21 
variant that could explain the discrepancy observed in Snca expression following 
Zscan21 downregulation with the two different shRNA targets (shZSCAN21/2 and 
shZSCAN21/4). Therefore, we performed 3' RACE. In general, RACE is a procedure 
for the amplification of nucleic acid sequences from a messenger RNA template 
between a defined internal site and either the 3' or the 5' end of the mRNA. Specifically, 
3' RACE takes advantage of the natural poly(A) tail found in mRNA as a generic 
priming site for PCR, thus, mRNAs are converted into cDNA using reverse 
transcriptase and an oligo-dT adapter primer that also bears a unique sequence in its 5' 
region that does not target any known sequence in the genome; here, the rat genome. 
Specific cDNA is then amplified by PCR using a GSP that anneals to exon sequences 
and a reverse UAP that contains only the unique sequence of the oligo-dT adapter 
primer. This permits the capture of unknown 3' mRNA sequences that lie between the 
exon and the poly (A) tail. These unknown 3' mRNA sequences can be visualized in 
an agarose gel and further evaluated by sequencing.  
We used 2 GSPs termed GSP and 2ndGSP for Zscan21 in exon 4 around the binding site 
of the first shRNA target (shZSCAN21/2), in order to be certain of the specificity of the 
result. We extracted total RNA from cortical cultures in naïve conditions (CTL) or 
infected with the shZSCAN21/4 lentivirus (Z4). In the second condition, if our 
hypothesis regarding the presence of an alternative splicing variant of Zscan21 was true, 
we should detect a PCR product smaller in length and increased in expression compared 
to CTL. Accordingly, as demonstrated in the gel below (Fig. 31), there was a 
predominant band detected at approximately 900 and 1000 bp for GSP/UAP and 2nd 
GSP/UAP, respectively, which matches the size expected for the basic transcript. 
Moreover, we observed a significant downregulation in the Z4 condition both for the 
GSP/UAP and 2nd GSP/UAP primer sets at this molecular weight compared to CTL. 
In addition, the difference between the GSP and 2ndGSP PCR product was 
approximately 100 bp. Additionally, we noticed in the Z4 condition, both for the 
GSP/UAP and 2nd GSP/UAP primer sets a band with increased intensity compared to 
CTL that was lower in the gel, which could possibly represent the hypothetical 
alternatively spliced variant of Zscan21. Therefore, we gel extracted these bands and 
sent for sequencing the intense bands that represent the basic Zscan21 transcript from 
CTL samples and the bands that might represent the putative alternative Zscan21 
transcript from Z4 samples, from both the GSP/UAP and 2nd GSP/UAP conditions. 
From the sequencing reaction, we had a 100% positive match for the basic Zscan21 
transcript in both the GSP/UAP and 2nd GSP/UAP conditions, whereas we had a match 
for the transmembrane mRNA tetraspanin for the putative Zscan21 alternative 
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transcript band. To eliminate the possibility of contamination with other non-specific 
products in the case of the putative Zscan21 alternative transcript PCR product (the 
bands were more faint), we further cloned the PCR product from the 2nd GSP/UAP Z4 
condition (the band was more evident and tight than the band in the GSP/UAP) in the 
TOPO-TA vector and assessed different clones with sequencing. Again, the sequencing 
result was positive in most cases for tetraspanin mRNA and in one case for 
phosphoglucomutase 1 mRNA.  Therefore, Zscan21 does not seem to be alternative 
spliced, at least not in the 3' region of exon 4 that we examined. One explanation for 
the shZSCAN21/4 target could be that it might mediate an off-target effect on another 
molecule that in turn mediates the reduction of Snca expression. shRNA interference 
can reportedly disturb endogenous microRNA biogenesis, which again can result in off-
target effects (Pan, de Ruiter et al. 2011). Alternatively, the lower band recognized by 
the ZSCAN21 antibody may represent a perhaps closely related cross-reacting protein 
that may also have modulatory effects on Snca regulation.  
 
A) 
gi|219273450|ref|NM_001012021.2| Rattus norvegicus zinc finger and SCAN domain containing 
21 (Zscan21), mRNA 
CCGGTTGTGCTATGGTTCAGCCGCTGTGAGGATTCCAGACTCCAAAGCGGTTCTGAGTCACGGTGAGCCTGCGAGTCCCAGGTTTGGAGTGTGGCACTTTAAGAA
CCAGAAACCCAAAGGCTCCAGGCCTACTCCTAAGAGTCCTGCTGGTTCTGGAGTCTGTGTCATGACCAAGGTGGTGGGCATGGCCACAGTTCTGGGCCCCAGGCC
ACCTCAGGAGTCTATGGGACCTTCGCCCATTAAAGTTGAAGAGGATGAAGAAAAAGACAAGTGCCGCCCTAGCCTAGAGCTATCCCGAAAGCGCTTCAGGCAGT
CTAGAAACCAGGACACTCTTGAGCCAATGGGACCTTCAACCATTAAAGCTGAAGAGGAGGAAGACAAGGACAAGGGCCACCCTAGCCTAGAGCTATCCCGTAAG
AGCTTCAAGCAGTTTGGGTACCATGACACTTTGGAACAGTTGGGACCTTCGACTGTTAAAGCTGAAGAGGATGAAGAGAAGGACAAGGGCCGCCCTAGCCTAGA
GATATCCCGTCAGCGCTTCAGGCAGTTTGGGTACCATGACACTCCTGGGCCCCGAGAGGCACTGAGCCAGCTTCGGGTGCTCTGCTGTGAGTGGCTACAGCCTGA
GATCCACACCAAGGAGCAGATTCTAGAGCTACTGGTTCTGGAGCAGTTCCTGACCATCCTGCCCCGAGAGCTCCAGGCCTGGGTACAGCAGCACTGCCCTGAGA
GTGCAGAGGAGGCCGTCACTCTCCTGGAAGACCTGGAGCAAGAACTGGATGAGCCTGGACTGCAGGTCTCATCTCCAAATGAACAGAAGCAGTCTTGGGAGAA
AATATCAACTTCAGGAACTGCAATGGAGTCCTTAAGCAGCACTGAGACCCAGCCTGTGGATGCCAGCCCTAAATATGAGTTTTGGGGGCCCCTGTACATCCAAGA
GACTGGTGAAGAGGAGGTTTTCACTCAGGACCCAAGAAAGCGCCAAGGTTTTAAATTGAATCCGCAGAAGGAGGACTCAGCAGATGAGCAGAGAAGTTCTGAA
GAAGAGTCTCATGCAGGTGGACTCAAAAGAAACATCATGCCCATGATCACTGCCAATAAGTATGGATCGAGGTCAGAAAGGCAGTGGGCCAACAACCTGGAAA
GGGAGAGAGGGGCAAAAGCCTCTCTTCAAGACACGGGATCCAGGAAAGGGGCAGAACCAGCGTCTGCTAGGCCTGCTCCAGGAGAGAAACGTTACATATGTGC
AGAGTGTGGGAAGGCCTTTAGCAATAGCTCAAACCTCACTAAACACCGGAGAACACACACTGGGGAGAAGCCTTACGTGTGCACCAAGTGTGGGAAGGCTTTCA
GCCACAGCTCCAACCTTACCCTTCATTACCGGACACATCTGGTGGACCGGCCCTATGACTGTAAGTGTGGGAAAGCCTTTGGGCAGAGCTCAGACCTCCTTAAACA
TCAGAGGATGCACACAGAAGAGGCGCCCTATCAGTGTAAAGACTGTGGGAAAGCCTTCAGTGGGAAGGGCAGCCTCATTCGACACTATCGCATCCACACAGGG
GAGAAGCCCTATCAGTGCAATGAGTGTGGAAAGAGTTTTAGTCAGCATGCAGGTCTCAGTTCCCATCAACGCCTGCATACAGGGGAGAAACCCTATAAGTGTAA
GGAGTGTGGCAAAGCCTTCAACCATAGTTCGAATTTTAATAAGCATCACAGAATCCATACTGGTGAAAAACCCTATTGGTGTAACCACTGTGGGAAAACCTTCTGT
AGCAAGTCAAATCTTTCCAAGCATCAGAGAGTCCACACTGGAGAGGGAGAGGTACAGTAAGTGTCCATTTCTGTCTGTTGTTATTGTTGTAAACGTTAGAATGTG
AATGCTAGGAAGAAGCTCTGTAATGCATTTCATGTTTGATAGTAGGTTTGGCTCTAGTCATCGAGGGGTGCCTTGGAGGGAGAGCTCCACAGCAATAGAGTAGA
CAAGAGAGGTCTACAGAGCAGCCGGGAGCTCCACACTGGTCACCTCTACCAGCAGGGTCCCTCCTCACACTCCAGGCTCCAGTGTACTGTGTGTCCAGTATAGTT
AAGGAAGAGACATTAAAATTGTTTAACTGTTTTAACATGTATTCCACAGTTGTAGTTTGTAAAGAATTGAGCCACCTTGAACAGTCTGATTCAGAATAAACGTATA
GCATCATGTAAAAAAAAAAAAAAAAAA 
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B) 
                                                                        
 
 
Figure 31. 3' RACE for Zscan21. A) Rat Zscan21 mRNA sequence as well as the positions of the GSP 
(green) and 2ndGSP (blue) primers. TAA in gray is the stop codon and the remaining 3' area is the 3’UTR 
that ends at the poly (A) tail. Β) The 3’ RACE PCR products in an agarose gel; the basic Zscan21 transcript 
is denoted by a green box for GSP/UAP (~900 bp) and 2ndGSP/UAP (~1000 bp) in the CTL condition and 
the putative Zscan21 alternative transcript is denoted by a red box for GSP/UAP (~550 bp) and 
2ndGSP/UAP (~650 bp) in the Z4 condition.  
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4.13 Genomic analysis of the intron 1 region in PD patients and control samples. 
 
Previous and current work in our laboratory has established the intron 1 region of the 
SNCA gene locus and by extent the ZSCAN21 as key regulatory elements of Snca 
transcription in the PC12 cell line as well as in primary neurons. Therefore, it is 
plausible that polymorphisms within intron 1, and more specifically, in the ZSCAN21 
binding site could potentially be correlated with PD susceptibility. In order to address 
this issue, we collected and screened DNA samples from PD and control subjects for 
SNPs following sequencing analysis of part of intron 1. We screened approximately 
200 DNA samples from PD and control patients in collaboration with Professor 
Thomas Gasser (Tubingen University). The sequenced intron 1 region included the two 
putative ZSCAN21 binding sites, the GATA-2 binding site (Scherzer, Grass et al. 
2008) and the CpG methylated islands (Jowaed, Schmitt et al. 2010) (Fig. 32A). 
Regarding the ZSCAN21 first binding site that we chose to focus mainly on in the 
present study, only one rare variant was identified that nonetheless had the same 
incidence in the PD and control samples. Likewise, several common and rare variants 
were detected in the sequenced area of intron 1 that also exhibited no difference in 
incidence between the PD and control samples (Fig. 32 B).  
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNCA INTRON 1  
GCTGCAGGGAAAGCAGCGAGCGCCGGGAGAGGGGCGGGCAGAAGCGCTGACAAATCAGCGGTGGGGGCGGAGAGCCGAGGAGAAGGAGAAGGAGGAGGAC
TAGGAGGAGGAGGACGGCGACGACCAGAAGGGGCCCAAGAGAGGGGGCGAGCGACCGAGCGCCGCGACGCGGAAGTGAGGTGCGTGCGGGCTGCAGCGCA
GACCCCGGCCCGGCCCCTCCGAGAGCGTCCTGGGCGCTCCCTCACGCCTTGCCTTCAAGCCTTCTGCCTTTCCACCCTCGTGAGCGGAGAACTGGGAGTG
GCCATTCGACGACAGGTTAGCGGGTTTGCCTCCCACTCCCCCAGCCTCGCGTCGCCGGCTCACAGCGGCCTCCTCTGGGGACAGTCCCCCCCGGGTGCCG
CCTCCGCCCTTCCTGTGCGCTCCTTTTCCTTCTTCTTTCCTATTAAATATTATTTGGGAATTGTTTAAATTTTTTTTTTAAAAAAAGAGAGAGGCGGGGA
GGAGTCGGAGTTGTGGAGAAGCAGAGGGACTCAGGTAAGTACCTGTGGATCTAAACGGGCGTCTTTGGAAATCCTGGAGAACGCCGGATGGGAGACGAAT
GGTCGTGGGCACCGGGAGGGGGTGGTGCTGCCATGAGGACCCGCTGGGCCAGGTCTCTGGGAGGTGAGTACTTGTCCCTTTGGGGAGCCTAAGGAAAGAG
ACTTGACCTGGCTTTCGTCCTGCTTCTGATATTCCCTTCTCCACAAGGGCTGAGAGATTAGGCTGCTTCTCCGGGATCCGCTTTTCCCCGGGAAACGCGA
GGATGCTCCATGGAGCGTGAGCATCCAACTTTTCTCTCACATAAAATCTGTCTGCCCGCTCTCTTGGTTTTTCTCTGTAAAGTAAGCAAGCTGCGTTTGG
CAAATAATGAAATGGAAGTGCAAGGAGGCCAAGTCAACAGGTGGTAACGGGTTAACAAGTGCTGGCGCGGGGTCCGCTAGGGTGGAGGCTGAGAACGCCC
CCTCGGGTGGCTGGCGCGGGGTTGGAGACGGCCCGCGAGTGTGAGCGGCGCCTGCTCAGGGTAGATAGCTGAGGGCGGGGGTGGATGTTGGATGGATTAG
AACCATCACACTTGGGCCTGCTGTTTGCCTGAGTTTGAACCACACCCCGAGTGAGCAGTTAGTTCTGTTGCCTACGCCTTTCCACCATCAACCTGTTAGC
CTTCTTCTGGGATTCATGTTAAGGATACCCCTGACCCTAAGCCTCCAGCTTCCATGCTTCTAACTCATACTGTTACCCTTTAGACCCCGGGAATTTAAAA
AAGGGGTTAATCTTTTCATGCAACTCCACTTCTGAAATGCAGTAATAACAACTCAGAGGATTCATCCTAATCCGTGGTTAGGTGGCTAGACTTTTACTAG
CCAAGATGGATGGGAGATGCTAAATTTTTAATGCCAGAGCTAAAAATGTCTGCTTTGTCCAATGGTTAAATGAGTGTACACTTAAAAGAGTCTCACACTT
TGGAGGGTTTCTCATGATTTTTCAGTGTTTTTTGTTTATTTTTCCCCGAAAGTTCTCATTCAAAGTGTATTTTATGTTTTCCAGTGTGGTGTAAAGGAAT
TCATTAG 
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B) 
 
 
Fig 32. SNPs in the intron 1 region of SNCA in PD and control samples. A) Regulatory elements of SNCA 
intron 1. The boundaries of the area sequenced are highlighted in red. The start and end of SNCA intron 
1 region are highlighted in yellow. The two putative ZSCAN21 binding sites are indicated in purple, the 
GATA-2 putative binding site in green and the CpG islands are included in the area highlighted in blue. 
B) In total, 197 control and 204 PD samples were screened for putative SNPs in intron 1 of SNCA that 
could confer PD risk.  The first column demonstrates the variants that were identified. (rs) stands for 
common variants, whereas the other represent rare polymorphisms. We have highlighted the 
polymorphism in the ZSCAN21 binding site in green and the numbers of individuals that carried this 
polymorphism in control and PD samples are indicated with red boxes. Three individuals shared the 
polymorphism in the ZSCAN21 binding site in the control and PD group; thus no correlation with PD 
was identified for polymorphism. Regarding the rest of the intron 1 region, no correlation with PD was 
achieved for the common and rare variants. The small table demonstrates the total number of PD and 
control samples tested as well as the percentage of females in each group. 
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5. DISCUSSION  
 
Although SNCA levels play a critical role in familial and sporadic PD, and potentially 
in other neurodegenerative conditions, and under normal conditions in the control of 
synaptic neurotransmission, the mechanisms that regulate SNCA transcription are not 
well understood. Previous experiments in our laboratory mainly used the model system 
of PC12 cells to examine such mechanisms. This stemmed from our original 
observation that SNCA mRNA and protein levels increase following treatment with 
growth factors (NGF and bFGF) in this system, in parallel to the well-known 
phenomenon of induced neuronal differentiation (Stefanis, Kholodilov et al. 2001). In 
this earlier work, we found that cultured cortical neurons also showed marked Snca 
induction with maturation in culture, mimicking a phenomenon observed during 
development (Rideout, Dietrich et al. 2003).  
In particular, in PC12 cells, we were able to map out the signaling pathways and 
transcriptional elements involved in NGF and bFGF-mediated SNCA induction with 
the use of varying lengths of human SNCA promoter region via luciferase based assays. 
Briefly, pharmacological and molecular modulation of the ERK and PI3-K signaling 
pathways inhibited SNCA induction, indicating the involvement of these pathways in 
SNCA transcriptional control. Such control was achieved, at least in part, through 
elements in intron 1 of SNCA and, specifically, within its first and third quadrants 
(Clough and Stefanis 2007). Subsequent work has shown that the element within the 
first quadrant represents the binding site for the TF ZSCAN21, and that the 
transcriptional control region is quite complex, involving additional TFs, such as 
ZNF219 (Clough, Dermentzaki et al. 2009). Specifically, regarding ZSCAN21 it was 
conclusively shown to be involved in Snca regulation since Zscan21-mediated down-
regulation via RNA interference as well as deletion of its binding site in the intron 1 
region significantly suppressed Snca levels in (Clough, Dermentzaki et al. 2009). 
 
Most important, previous work in rat cortical cultures revealed important similarities 
and differences with the PC12 cell line. There were significant differences in activity 
between constructs of varying length throughout almost the extent of the promoter 
region, indicating the existence of multiple transcriptional control regions. A basic 
difference, however, between the PC12 cells and the primary cortical neurons was that 
in the former case the intron 1 region was sufficient for the induction of SNCA 
transcriptional activity, whereas in the latter both intron 1 and the core promoter were 
necessary. This finding indicated that these regions contained important regulatory 
elements that interacted in a different fashion in each system (Clough, Dermentzaki et 
al. 2011). Differences and similarities were also noted in terms of the biochemical 
signaling pathways involved.  In PC12 cells, the ERK pathway was involved in the 
transcriptional control of SNCA (Clough and Stefanis 2007), but that was not the case 
in cultured cortical neurons. In contrast, the PI3-K pathway was required in both 
models for SNCA transcriptional activation.  
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In parallel, further downstream within intron 1, another group has mapped out another 
important element for SNCA transcriptional control, the TF GATA-2 (Scherzer, Grass 
et al. 2008). Additionally, several studies have reported that SNCA intron 1 methylation 
can modulate SNCA expression and most importantly decreased methylation in intron 
1 is evident in PD brain and blood specimens compared to healthy controls (Jowaed, 
Schmitt et al. 2010, Matsumoto, Takuma et al. 2010, Richter, Appenzeller et al. 2012, 
Wang, Wang et al. 2013, Ai, Xu et al. 2014, Tan, Wu et al. 2014, Pihlstrom, Berge et 
al. 2015). Besides, a number of conserved non-coding genomic regions in the SNCA 
gene, including the intron 1 region, have been shown to contribute to SNCA 
transcriptional activity (Sterling, Walter et al. 2014). Overall, these data reinforce the 
importance of the intron 1 regulatory region in the transcriptional control of SNCA. 
In the present study, we focused on the ZSCAN21 TF and its potential involvement in 
Snca transcription in primary neuronal cultures and in vivo. Since ZSCAN21 is an 
important regulator of Snca transcription in differentiated PC12 cells (ZSCAN21-
mediated downregulation significantly reduced Snca levels), we wished to validate 
further this scenario for isolated neurons and notably, in vivo. Importantly, a study by 
Yang et. al. (Yang, Wynder et al. 1999) demonstrated no significant phenotypic or 
functional alterations in Zscan21-/- BAC transgenic mice; thus, if Zscan21 silencing 
could successfully reduce Snca levels in vivo, as in PC12 cells, it would not only 
establish its important role in Snca transcription but it could also serve as a potential 
therapeutic target for PD.  
Toward this direction, we first verified ZSCAN21 expression both at the mRNA and 
protein level in different rat brain areas where ASYN is also present. Interestingly, we 
noticed that ZSCAN21 (mRNA and protein) is present at high levels developmentally 
until the P10 stage and then its levels start to decrease, in different brain regions 
including the cortex and hippocampus. Additionally, we verified the expression of 
ZSCAN21 in neuronal cells, since ASYN is expressed in neurons. While we were 
interested in using the Zscan21 -/- BAC transgenic mice (Yang, Wynder et al. 1999) for 
our study, unfortunately we were informed that these mice were no longer available 
due to technical issues. Therefore, we switched direction toward constructing shRNA- 
expressing lentiviruses against Zscan21 that could efficiently silence ZSCAN21 in 
post-mitotic neurons. We utilized the TRC2-pLKO lentivirus vector (Invitrogen), 
which is used widely to downregulate different proteins in primary cultures as well as 
in vivo systems with high efficacy (Zufferey, Nagy et al. 1997, Zufferey, Dull et al. 
1998, Stewart, Dykxhoorn et al. 2003, Moffat, Grueneberg et al. 2006, Yamamoto and 
Tsunetsugu-Yokota 2008). We constructed 3 lentiviruses against Zscan21 
(shZSCAN21/1, shZSCAN21/2, and shZSCAN21/4) as well as scrambled (control 
virus) that targets no known sequence in the rat genome. We found that significant 
downregulation of ZSCAN21 at the mRNA and protein level (for shZSCAN21/1 and 
shZSCAN21/2 target), surprisingly led to an increase of ASYN expression at both the 
mRNA and protein level, the opposite expression pattern to that observed in 
differentiated PC12 cells. Similar results were obtained from primary hippocampal 
cultures, thus further validating the specificity of the result. In the same way, Zscan21 
silencing was also found to further increase the activity of the 1.9-kb SNCA promoter 
construct in the luciferase assay compared to scrambled conditions. It should be noted 
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here that the third lenti-shRNA targeted against Zscan21, shZSCAN21/4, gave an 
opposite profile to the others, most likely due to off-target effects, although the 
possibility of the compensatory upregulation of an alternate Zscan21 transcript could 
not be discarded completely, despite the negative results with the 3' RACE analysis. 
Therefore, Zscan21 silencing leads to increased SNCA promoter transcriptional activity 
that subsequently results in elevated ASYN mRNA and protein levels in rat primary 
neuronal cultures. As already mentioned, rat cortical cultures and PC12 cells share 
important differences in the transcriptional activity of different SNCA promoter 
constructs, with the most basic one being that the 5' of exon 1 (core promoter) and 
intron 1 regions act synergistically in primary cultures (1.9-kb construct includes both 
elements and presents promoter activity), whereas in PC12 cells they elicit activity in 
isolation (intron 1, core promoter, present promoter activity alone). Therefore, the 
observed differences in the activity of the SNCA promoter constructs between these 
two cell systems could possibly account for the discrepancy observed in Snca levels 
following Zscan21 downregulation.   
Next, since there was evidence indicating that ZSCAN21 binds to the intron 1 region 
of SNCA in differentiated PC12 cells (Clough, Dermentzaki et al. 2009) and in vivo in 
human brain tissue (Brenner, Wersinger et al. 2015), we performed a CHIP assay for  
ZSCAN21 in rat cortical neuronal cultures to verify this finding. Indeed we found that 
the region containing the two putative binding sites for ZSCAN21 was significantly 
enriched (~15 fold) in the sample that was chromatin-immunoprecipitated with an 
antibody specific to ZSCAN21 compared to an irrelevant antibody, suggesting that 
ZSCAN21 either binds directly to the intron 1 region of Snca or interacts as a co-factor 
with a TF that binds to this region. To discriminate further whether ZSCAN21 directly 
or indirectly regulates SNCA transcription, we designed constructs lacking the putative 
binding sites for ZSCAN21 in the intron 1 area of SNCA in isolation as well as in 
combination. As a template we used the 1.9-kb construct that is highly induced in the 
luciferase assay in cortical cultures to introduce the binding site deletions. Intriguingly, 
overall we did not detect any significant alterations between the 1.9 kb construct and 
the 1.9-kb deletion constructs. Therefore, one explanation is that ZSCAN21 may not 
directly regulate SNCA transcription by binding to its predicted binding sites but rather 
indirectly as a co-factor. Nonetheless, since the luciferase assay is actually an artificial 
platform that involves distinct promoter elements, therefore it lacks the whole genomic 
context and genomic interactions present in the endogenous environment and we 
cannot exclude the possibility that due to these limitations we are unable to detect any 
alterations in the luciferase assay in the constructs lacking the ZSCAN21 binding sites.      
 
In parallel, we also studied the role of ZSCAN21 upon Snca transcription in 
neurosphere cultures, since ZSCAN21 is expressed robustly early in development. 
Neurospheres are free-floating cultures of neural stem cells that can be differentiated 
toward neurons, astroglia and oligodendroglia by the application of growth factors. In 
our study we used differentiated cultures, since ASYN was not detected in the 
proliferating state. At this point we must mention that differentiated neurospheres 
cultures and cortical cultures are in vitro systems that mimic different stages of neuronal 
development. Neurons in differentiated neurospheres cultures represent early neurons 
(TUJ1 [+], NeuN [-]) whereas neurons in cortical cultures represent mature post-mitotic 
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neurons (TUJ1 [+], NeuN [+]). To our surprise, we found that significant silencing of 
Zscan21 with both lentiviruses led to decreased levels of ASYN at both the mRNA and 
protein level, in contrast to the increased ASYN levels in primary neuronal cultures. 
The inability to perform trustworthy luciferase assays in neurosphere cultures limits the 
comparison of these cultures with the PC12 and cortical neuron cell culture systems, 
but, with the available data, it would seem that Zscan21-mediated regulation of Snca 
mRNA may be more similar in neurospheres and PC12 cells, where ZSCAN21 
silencing also leads to decreased Snca expression (Clough, Dermentzaki et al. 2009). 
This differential Snca regulation by ZSCAN21 in the above cell systems could be 
attributed to different reasons. The most likely scenario is that this difference in Snca 
transcription reflects the different developmental stages that these two systems, cortical 
neurons and neurosphere cultures, represent. Specifically, it is well known that defined 
sets of TFs are expressed during development to orchestrate specific regulatory 
functions and interactions that are distinct to each developmental stage. Additionally, 
many TFs can act as either activators or repressors of transcription depending on the 
co-factors associated. ZSCAN21 is known to form homo- and heterodimers with other 
TFs via its SCAN protein-protein interaction domain (Williams, Blacklow et al. 1999, 
Carneiro, Silva et al. 2006). In general, ZSCAN21 is associated with positive regulation 
of transcription (Chowdhury, Goulding et al. 1992). However, recent data from affinity 
capture mass spectometry and two-hybrid assays (Woods, Mesquita et al. 2012, 
Rolland, Tasan et al. 2014, Huttlin, Ting et al. 2015) have shown that ZSCAN21 can 
physical interact with many TFs, being either co-activators or co-repressors. RCOR1 
(REST corepressor 1), ZSCAN3, and Zkscan4 are examples of TFs that function as 
repressors. Therefore, we could posit that ZSCAN21 can either activate or repress a 
gene target; here Snca, depending on the TF associated. Therefore, early in development 
ZSCAN21 could interact with a co-activator (ZSCAN21 silencing leads to decreased 
Snca levels), while later in development it could interact with a co-repressor (ZSCAN21 
silencing leads to increased Snca levels) to regulate Snca. Moreover, this difference in 
Snca regulation could also be attributed to the type of culture itself, differentiated 
neurospheres are mixed neural cultures, whereas primary neuronal (cortical and 
hippocampal) cultures represent more than 95% pure neurons; thus, different cell type 
interactions could lead to different expression phenotypes.  
 
Regarding the in vivo experiments we produced AAVs targeting ZSCAN21 expression. 
The reason we utilized AAVs over lentiviruses is due to their increased transduction 
efficacy in vivo (with the TRC2-pLKO.1 lentiviruses we were unable to transduce 
neuronal cells in vivo). Specifically, for the AAVs used in the current study, shRNA 
expression is driven by the synapsin promoter that ensures the selective transduction of 
neurons. Since we detected an opposite pattern of Snca regulation following Zscan21 
downregulation in neurospheres (early neurons / reduced Snca) and in primary neuronal 
cultures (mature neurons / increased Snca), we decided to study the role of ZSCAN21 
in Snca regulation in vivo at two different developmental stages, one early post-natal 
and one young adult. Regarding the early developmental stage, we performed injections 
targeting the lateral ventricles of P3 rat brain and assessed animals for Zscan21 and 
Snca mRNA levels at 1-month post-injection. We achieved robust downregulation of 
Zscan21 in the case of the AAV/shZSCAN21 treated animals versus to 
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AAV/shscrambled and ctl (non-transduced population) according to real-time PCR 
analysis. However, Snca levels remained unchanged following Zscan21 
downregulation.  
Although we did not observe any significant changes in Snca levels following 
downregulation of Zscan21 in the early developmental stages of the rat brain where 
ZSCAN21 is expressed robustly, we further examined whether (in contrast) the low 
expression levels of ZSCAN21 present in the adult brain are involved in Snca 
transcription. We again performed stereotaxic injections utilizing the above AAVs 
targeting the DG area of the hippocampus in 2-months-old rats.  
The DG of the hippocampus was chosen for different reasons. First, ZSCAN21 is 
highly and selectively expressed in the granule cells of the DG (Yang, Zhong et al. 
1996). Secondly, we observed significant co-localization of ZSCAN21 and ASYN in 
this region (Figure 5). Additionally, the involvement of the hippocampus in the non-
motor symptoms of PD has gained increasing attention. Fatigue and depression have 
been related to hippocampal serotonergic dysfunction by positron emission 
tomography with specific metabolites of serotonergic metabolism (Pavese, Metta et al. 
2010, Ballanger, Klinger et al. 2012). Besides, the hippocampus is modulated by 
dopaminergic input from the ventral tegmental area and the olfactory bulb and by 
noradrenergic input from the locus coeruleus and may thus be involved in drive and 
mood regulation (Goto and Grace 2005). Cognitive deficits in PD are heterogeneous 
and may include cholinergic and noradrenergic dysfunction impacting hippocampal 
functions reviewed in (Kehagia, Barker et al. 2010). The extent of hippocampal LB 
pathology has also been correlated with the degree of dementia in PD patients 
(Churchyard and Lees 1997). Significant hippocampal atrophy has been observed on 
magnetic resonance imaging of patients with PDD when compared to non-demented 
PD patients reviewed in (Calabresi, Castrioto et al. 2013). Additionally, alterations of 
hippocampal connectivity by diffusion tensor imaging in PD patients predicted the 
emergence of declarative memory deficits (Carlesimo, Piras et al. 2012). Notably, 
selective hyposmia in PD is related to hippocampal and striatal dopamine denervation 
(Bohnen, Gedela et al. 2008). Therefore, hippocampal dysfunction is common in PD 
patients and most possibly contributes to different non-motor symptoms of PD. 
Further, regarding ASYN and hippocampal alterations it has been reported that 
truncated human ASYN (1-120) on a mouse ASYN null background leads to cognitive 
alterations before the occurrence of motor abnormalities (Costa, Sgobio et al. 2012). 
Additionally, hippocampal slices treated with ASYN oligomers have impaired long-
term potentiation (Diogenes, Dias et al. 2012). In the same way, preformed fibrils 
generated from full-length and truncated recombinant ASYN can penetrate 
hippocampal primary neurons and promote the formation of insoluble PD-like LBs 
(Volpicelli-Daley, Luk et al. 2011). In an inducible transgenic ASYN mouse model, 
the abnormal accumulation of ASYN in the hippocampus is associated with cognitive 
loss and causes synaptic deficits (Lim, Kehm et al. 2011). Importantly, it has also been 
reported that reduced neurogenesis in the DG could have a crucial role in the 
pathogenesis of depression and other non-motor symptoms of PD. Accordingly, a study 
by Kohl et al (Kohl, Winner et al. 2012) reported that the expression of transgenic 
A53T ASYN in developing DG neurons severely impaired neurogenesis.  This body 
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of work highlights the importance of the hippocampal accumulation of ASYN in the 
pathogenesis of PD and other synucleinopathies, and suggests that the regulation of 
SNCA expression in this region may be of critical importance.  
In the present study even though we were able to detect significant Zscan21 
downregulation in the hippocampus of AAV/shZSCAN21-injected adult animals 
compared to AAV/shscrambled, we were unable to detect significant alterations in 
Snca mRNA levels, similarly to the early postnatal stage. This lack of effect in Snca 
levels in both developmental stages possibly indicates the presence of compensatory 
mechanisms that regulate Snca transcription in vivo. Additionally, it could also mean 
that ZSCAN21 might have a role in earlier developmental regulation of Snca levels, 
where ZSCAN21 is expressed robustly, but to examine this will require manipulating 
ZSCAN21 levels earlier than 1-month. Ideally, this could be achieved with the use of 
a Zscan21 knock-out animal that would allow us to assess Snca expression throughout 
development. In contrast, an AAV-driven Zscan21 silencing approach is limited due 
to the fact that it requires long intervals (>15 days) for efficient downregulation of the 
target gene.      
Next, since Zscan21 silencing increased Snca levels in rat cortical cultures, we decided 
to examine further whether Zscan21 overexpression could suppress Snca. For this 
purpose, we produced AVs expressing rat Zscan21. Interestingly, we found that even 
though we had robust Zscan21 mRNA overexpression, we could only detect a small 
amount of ZSCAN21 protein that was only evident at the early time points (24 h and 
48 h). However, in parallel, we also tested if ZSCAN21 could be significantly 
overexpressed at the protein level in HEK293T cells. Therefore, it seemed plausible 
that Zscan21 mRNA could be regulated at the post-transcriptional or post-translational 
level so that its protein levels remain steady. Supporting evidence toward this 
hypothesis was a study by Yang et al (Yang, Wynder et al. 1999), where BAC 
transgenic mice overexpressing ZSCAN21 presented increased proliferation and at the 
same time increased cell death in the internal granule layer of the cerebellum, thus 
indicating that increased levels of ZSCAN21 can be toxic to neurons, and that neurons, 
to prevent this, should have its levels under tight control.  Additionally, several zinc 
finger TFs that play important role in proliferation and differentiation during 
development are known to be under tight post-transcriptional or post-translational 
control, since deregulation of their expression can lead to pathological phenotypes 
(Rebollo and Schmitt 2003, Mingot, Vega et al. 2009, Yien and Bieker 2013). 
ZSCAN21 has a role in the proliferation of progenitor cells in the cerebellum (Yang, 
Wynder et al. 1999); thus, its levels could also be strictly regulated. To date, post-
transcriptional regulation for steady-state protein levels involves many mechanisms, 
including RNA-binding proteins that play a critical role in RNA nuclear export, mRNA 
stability, modification, turnover and regulation of the translation process as reviewed 
in (Glisovic, Bachorik et al. 2008), miRNAs that regulate translational repression or 
mRNA degradation as reviewed in (Filipowicz, Bhattacharyya et al. 2008, Valinezhad 
Orang, Safaralizadeh et al. 2014) and epigenetic regulation at the RNA level where 
mRNA is subjected to chemical modifications that can affect protein expression as 
reviewed in (Yue, Liu et al. 2015). Conversely, a signal dictating increased protein 
synthesis (e.g., viral-mediated overexpression of a protein) could also be poised post-
 99 
 
translationally by increased clearance of the overexpressed protein via the proteasome 
system through ubiquitination as reviewed in (Wang, Pattison et al. 2013). Supporting 
evidence toward this hypothesis is the fact that the slightly overexpressed ZSCAN21 
protein was detected a little higher than the endogenous ZSCAN21 protein on the 
western blot, indicating that perhaps the overexpressed protein is post-translationally 
modified with ubiquitin, which subsequently leads to its clearance. However, this needs 
to be investigated further. It is interesting to note that although the mRNA levels of 
Zscan21 remain stable beyond P13, its protein levels continue to fall, especially in 
adulthood (Fig.15), suggesting that such tight post-transcriptional regulation of 
ZSCAN21 levels also occurs in vivo. Interestingly, a study by Wright et al. (Wright, 
McHugh et al. 2013) revealed that overexpression of ZSCAN21 was able to 
significantly reduce SNCA levels in SHSY5Y cells. The fact that we could also detect 
overexpression of ZSCAN21 in another cell line, i.e., HEK293T cells, but not in 
cortical neuron cultures, suggests that ZSCAN21 protein levels must be selectively 
under tight regulation in neurons and not in cell lines. 
Collectively, our data indicate that ZSCAN21 is a TF diversely involved in the process 
of SNCA transcriptional regulation dependent upon the neuronal culture system tested 
(cortical cultures and neurospheres). However, the fact that no alteration of Snca levels 
was evident following ZSCAN21 downregulation in vivo, implies that ZSCAN21 is 
not a main regulator of Snca transcription in vivo, at least at the developmental stages 
that were tested. These data imply the presence of alternative or perhaps compensatory 
mechanisms that regulate SNCA transcription in such settings. In combination with the 
inability to overexpress ZSCAN21 in post-mitotic neurons, likely due to its strict post-
transcriptional / post-translational control, it would appear that, in the context of 
synucleinopathies, attempts to modulate SNCA transcription based on ZSCAN21 
manipulation may not be fruitful.   
The last part of our study involved the examination of possible alterations in SNCA 
intron 1 sequences that may be involved in PD, given the accumulating evidence from 
our own laboratory and others regarding the importance of this region in SNCA 
transcriptional control. We were especially interested to see whether the 5' ZSCAN21 
binding site we had identified with a regulatory role in SNCA transcription in PC12 
cells would show genetic variability that could be related to the development of PD.  
To this end, we sequenced a large part of intron 1, including this ZSCAN21 binding 
site, in DNA derived from controls and PD patients.  Although a number of 
polymorphic variants were detected, including a rare one within the 5' ZSCAN21 
binding site, none were associated with the disease in this cohort. For that reason, we 
did not further aim to match the remaining common and rare variants with the second 
ZSCAN21 binding site, the GATA-2 binding site, as well as the CpG islands. 
Additionally, Brenner et al (Brenner, Wersinger et al. 2015) reported that TFBSs of 
ZSCAN21 and GATA-2 were not polymorphic by analyzing 300 DNA samples from 
PD patients.  Currently, we are assessing more PD and control samples in order to 
verify conclusively that the lack of a possible correlation was not due to small sample 
limitations.  
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Although further studies are needed, these data collectively suggest that genetic 
variability within the ZSCAN21 binding sites in intron 1 is not linked to PD 
pathogenesis. It may be worthwhile to investigate genetic variability within the 
ZSCAN21 gene itself and possible links to PD risk; however further evidence regarding 
the importance of ZSCAN21 in SNCA transcriptional control would need to be 
provided to make this endeavor worthwhile.  
At this point we must mention that targeted therapeutic gene modulation is the practice 
of altering the expression of a gene transcriptionally or post-transcriptionally, with a 
view to alleviate some form of ailment. Specifically, TF-involved therapeutic strategies 
for modulating the expression of a gene can be achieved either at the transcriptional 
level with the use of designer zinc-finger proteins or post-transcriptionally with RNA-
interference. In the first case zinc-finger proteins capitalize on the DNA-binding 
capacity of natural zinc-finger domains to modulate the expression of specific target 
areas of the genome (Choo, Sanchez-Garcia et al. 1994, Kang and Kim 2000, Carvin, 
Parr et al. 2003, Snowden, Zhang et al. 2003, Urnov, Miller et al. 2005, Papworth, 
Kolasinska et al. 2006, Lara, Wang et al. 2012), while in the latter case of RNA-
interference, it aims to selectively silence a TF whose levels are implicated in 
dysregulation (Kim and Rossi 2007, Peer, Park et al. 2008, Darcan-Nicolaisen, 
Meinicke et al. 2009, de Franca, Mesquita Junior et al. 2010, Rettig and Behlke 2012). 
In our case, since Zcscan21-/- mice (Yang, Wynder et al. 1999) reportedly bear no 
systematic or phenotypic abnormality, we were keen to test whether ZSCAN21 could 
regulate Snca levels in vivo, as in that case, ZSCAN21 could be used as a novel 
therapeutic approach for modulating SNCA levels and possibly even treat PD and/or 
other synucleinopathies. Nevertheless, despite its significant involvement in regulating 
Snca levels in primary neuronal cells this finding could not be replicated in vivo, 
possibly due to compensatory mechanisms that govern the more complex in vivo 
systems. Therefore, ZSCAN21 is not a main regulator of Snca in vivo. 
Notwithstanding, another hypothesis could be that the transcriptional regulation of 
SNCA in not driven by a master regulator but instead involves a network of interactions 
between TFs and cis regulatory elements within and around SNCA. Supporting 
evidence toward this scenario is the very complicated transcriptional architecture of 
the promoter of SNCA and the fact that SNCA is transcriptionally induced in the 
luciferase assay in cortical neuronal cultures only when the core promoter and the 
intron 1 region act synergistically and not in isolation. Therefore, given the complex 
nature of this control, perhaps strategies aiming at signaling pathways or more directly 
targeting the specific gene in other regulatory regions involved in SNCA transcription 
would be more worthwhile. Conversely, the basic control of ASYN levels in adulthood 
occurs post-transcriptionally, as mRNA levels are very low; hence, strategies 
addressing ASYN clearance may be more fruitful in this setting.  
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A novel cell death pathway that is partially caspase dependent,
but morphologically non-apoptotic, elicited by proteasomal
inhibition of rat sympathetic neurons
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Hardy J. Rideout* and Leonidas Stefanis*,
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There is accumulating evidence that proteasomal dysfunction
may occur in neurodegenerative diseases, and that it may
play a role in disease pathogenesis (Ciechanover and Brundin
2003). The availability of selective pharmacological prote-
asomal inhibitors has enabled the modeling of proteasomal
dysfunction in neuronal cell cultures. We and others have
shown that application of such reagents leads to the
formation of cytoplasmic inclusions and cell death in various
neuronal cell types (reviewed by Rideout and Stefanis 2006;
Lang-Rollin and Stefanis 2006). Cell death in such cases
demonstrates the biochemical and morphological features of
apoptosis (Qiu et al. 2000; Rideout et al. 2001; Rideout and
Stefanis 2002; Lang-Rollin et al. 2004; Rideout et al. 2005).
In particular, as relates to cultured primary neonatal mouse
sympathetic neurons, we have found that application of the
proteasomal inhibitors Z-IE(OtBu)Ala-Leu-al (PSI) and
lactacystin leads to rapid apoptotic death within 24–48 h.
This death is accompanied by cytochrome c release and
caspase 3 activation, and can be completely blocked by bcl-2
over-expression, the deletion of Bax or the application of the
general caspase inhibitor Boc-aspartyl-ﬂuoromethylketone
(BAF) (Lang-Rollin et al. 2004).
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Abstract
Proteasomal dysfunction has been linked to neurodegenera-
tion. Pharmacological proteasomal inhibitors may have
pro-survival or pro-death effects in neuronal cells. We have
previously found that application of such agents to mouse
sympathetic neurons leads to activation of the intrinsic apop-
totic pathway. We show here that in rat sympathetic neurons
proteasomal inhibition leads to a form of death that is mor-
phologically non-apoptotic, with features of autophagy. The
intrinsic apoptotic pathway is activated in a delayed fashion
compared with mouse neurons, and is in part responsible for
death, as evidenced by the partial protective effects of bcl-xL
and the general caspase inhibitor Boc-aspartyl-fluorometh-
ylketone. Death is accompanied by induction of Bim and
caspase activation, but caspase 3 activation is lacking;
3-methyl-adenine inhibits macroautophagy, but has a rela-
tively small pro-survival effect. We conclude that a complex
array of pro- and anti-apoptotic effects elicited by proteasomal
inhibition in rat sympathetic neurons leads to partial engage-
ment of the intrinsic apoptotic pathway and a morphologically
non-apoptotic, autophagic form of death. The species differ-
ence with mouse neurons is underscored by the fact that
proteasomal inhibitors are protective against apoptosis elic-
ited by nerve growth factor deprivation in rat, but not mouse,
sympathetic neurons. The type of death described herein may
be relevant to neurodegenerative diseases, where morpho-
logical evidence for apoptosis has been scant.
Keywords: autophagy, Bim, caspase 3 independent, neu-
rodegeneration, protein degradation.
J. Neurochem. (2008) 105, 653–665.
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There is however a body of literature that suggests that
application of proteasomal inhibitors may also lead to anti-
apoptotic effects (reviewed by Canu and Calissano 2006). It
is posited that in certain models an early induction of
proteasomal activity is necessary to degrade more rapidly
key anti-apoptotic molecules and to thus propagate the
apoptotic pathway (Canu and Calissano 2006). One of the
ﬁrst demonstrations of this phenomenon was offered by
Sadoul et al. 1996, who showed that application of the
selective proteasomal inhibitor lactacystin led to inhibition of
apoptosis induced by nerve growth factor (NGF) deprivation
in rat sympathetic neurons. The differential effects of
pharmacological proteasomal inhibitors on survival have
been attributed in part to the magnitude of proteasomal
inhibition achieved and the time length of the exposure (Lin
et al. 1998; Canu et al. 2000; Canu and Calissano 2006;
Lang-Rollin and Stefanis 2006).
In view of our ﬁndings in mouse sympathetic neurons
mentioned above (Lang-Rollin et al. 2004) and the reported
protective effects of proteasomal inhibitors in rat sympathetic
neurons (Sadoul et al. 1996), we were interested to examine
the effects of proteasomal inhibitors on rat sympathetic
neurons. Initial experiments, described herein, showed that
such treatment leads to a delayed cell death that does not
demonstrate the morphological features of apoptosis. In this
manuscript, we have attempted to characterize this interesting
cell death pathway, and to ascertain its differences from the
classical apoptotic pathways elicited by NGF deprivation in
rat sympathetic neurons and by proteasomal inhibition in
mouse sympathetic neurons.
Materials and methods
Culture of rat and mouse sympathetic neurons
For the experiments described herein, C57/bL mice and Wistar or
Spague–Dawley rats were used. All procedures were approved and
followed the regulations of the Institutional Animal Care Commit-
tees of Columbia University or of the Biomedical Research
Foundation of the Academy of Athens. Sympathetic neuron cultures
were derived from sympathetic ganglia of 0- to 1-day-old mouse or
rat pups (Stefanis et al. 2004). Following trypsinization, the ganglia
were plated on 24 wells or 35 mm dishes, in Roswell Park Memorial
Institute 1640 medium containing 5% heat-inactivated horse serum
and 100 ng/mL mouse NGF (Sigma, St Louis, MO, USA). One day
after plating, the antimitotics uridine and 5-ﬂuorodeoxyuridine
(10 lmol/L each, Sigma) were added.
Transfections and constructs
Over-expression of various genes of interest was achieved by
lipofectamine-mediated transfection, using Lipofectamine 2000
(Invitrogen Life Technologies, Carlsbad, CA, USA). Transfection
of rat sympathetic neuron cultures was performed 3–6 days after
plating, as described previously for mouse sympathetic neurons
(Lang-Rollin et al. 2004). The enhanced green ﬂuorescent protein
(EGFP), myc-tagged PAI2 and Flag-tagged bcl-xL constructs
utilized have been described previously (Lang-Rollin et al. 2004,
2005). In co-transfection experiments, we veriﬁed that more than
80% of the neurons expressing EGFP also over-expressed bcl-xL
(data not shown). We have also transfected neurons with a GFP-LC3
plasmid, kindly provided by Tamotsu Yoshimori, National Institute
of Genetics, Japan.
Induction and assessment of neuronal death
At days 3–6 after plating, the proteasomal inhibitors lactacystin
(Fenteany et al. 1994) or PSI (Figueiredo-Pereira et al. 1994)
(Calbiochem, San Diego, CA, USA) or vehicle (control, ctl) were
added to the sympathetic neuron cultures, with or without the general
caspase inhibitor BAF (Sigma) (100 lmol/L). In experiments with
the macroautophagy inhibitor 3-methyl-adenine (3-MA; Sigma), this
reagent was added at a concentration of 10 mmol/L 24 h after the
application of PSI. The poly-ADP ribose polymerase (PARP)
inhibitor benzamide (Sigma, diluted in ethanol), was added concur-
rently with PSI at concentrations of 50 or 150 nmol/L, whereas the
permeability transition pore (PTP) inhibitors cyclosporine A and
bongkrekik acid were used at concentrations of 1 and 2 lmol/L,
respectively. At deﬁned time points, we labeled living cultures with
the dye ethidium homodimer (EH; Molecular Probes, Eugene,
OR, USA; 1 lmol/L) and the nuclear dye Hoechst 33342 (Sigma,
1 lg/lL) for 20 min. Cultures were rinsed twice with phosphate-
buffered saline (PBS), and then visualized at 40· in an inverted
ﬂuorescence microscope (Leica DM IRB, Wetzlar, Germany). EH
only accumulates in the nucleus of cells with permeabilized cell
membranes, and thus labeling with this dye serves as an index of
death. We therefore assessed in each case the percentage of neuronal
nuclei (Hoechst-positive) that were also EH positive. At least 100
neurons in each well were assessed for EH uptake. As an alternative
to EH, in some experiments we also used in a similar fashion
propidium iodide (PI; Sigma) at a ﬁnal concentration of 5 lmol/L.
To perform NGF deprivation, cultures were rinsed twice with
serum-free medium, and then complete medium was added together
with anti-NGF antibody (Ab) (Upstate Biotechnology, Waltman,
MA, USA 1 : 200). NGF deprivation was performed in mouse or rat
sympathetic neurons in the presence or absence of lactacystin (1 or
10 lmol/L). Apoptotic death was quantiﬁed by assessing the
percentage of sympathetic neurons that showed nuclear condensation
and formation of chromatin clumps. Twenty-four hours after NGF
deprivation the neurons were rinsed in PBS, and then ﬁxed with 3.7%
paraformaldehyde at 4C for 20 min. They were then labeled with the
nuclear dye Hoechst 33342 (Sigma, 1 lg/lL) for 20 min, and then
rinsed in PBS and visualized in the inverted ﬂuorescence microscope.
At least 100 neurons in each well were assessed for features of nuclear
apoptosis.
For the assessment of the effect of bcl-xL on survival, we co-
transfected this construct or myc-tagged PAI2 MUT as a negative
ctl. Thirty-six hours later we applied the proteasomal inhibitors or
vehicle, and, 48–72 h later, labeled the cultures with EH, as above.
We then counted the percentage of GFP-positive cells that showed
EH uptake. At least 50 neurons were counted in each well.
All counts were performed in three separate wells, and are
reported as mean ± SEM. They are representative of at least two
independent experiments. Representative images were obtained
using a SPOT digital camera (Diagnostic Instruments, Inc., Sterling
Heights, MI, USA).
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Cell labeling and immunostaining
Immunostaining was performed as described previously (Lang-
Rollin et al. 2004, 2005). Brieﬂy, neurons plated in 24-well dishes
coated with collagen were ﬁxed with paraformaldehyde, as above,
and blocked with 10% normal goat serum in PBS, containing 0.4%
Triton X-100, followed by incubation with the primary Ab in 2%
goat serum in PBS for 1 h at 25C. Speciﬁc antibodies used were:
mouse anti-cytochrome c (BD Biosciences Pharmingen, Palo Alto,
CA, USA; 1 : 500), anti-GFP (Synaptic Systems, Goettingen,
Germany; 1 : 300), anti-Flag (mouse monoclonal M2, Sigma;
1 : 400), anti-Myc (mouse monoclonal, clone 9E10, derived from
a hybridoma, 1 : 10), anti-apoptosis inducing factor (AIF) (mouse
monoclonal clone E1, 1 : 200; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and rabbit anti-active caspase 3 (R & D Systems,
Minneapolis, MN, USA; 1 : 1000). In certain experiments, an LC3
rabbit polyclonal Ab was utilized (a gift from Tamotsu Yoshimori,
National Institute of Genetics, Japan; 1 : 500). In this case, ﬁxation
was performed with methanol, at )20C for 5 min, and all
subsequent steps of immunostaining were performed in the absence
of Triton X-100. Antigens were detected with ﬂuorescent secondary
antibodies (1 : 250; Jackson Immuno-Research, West Grove, PA,
USA), and the cultures were visualized using standard epiﬂuores-
cence microscopy with a 40· objective.
We also used the dye caspACE [FITC-VAD-FMK from Promega
(Madison, WI, USA), at a ﬁnal concentration of 10 lmol/L] for
assessment of caspase activation. Cultures were exposed for 30 min at
37C, and then rinsed three times with PBS prior to ﬁxation, as above.
All counts were performed in three separate wells for each
condition, with 100 cells counted in each well. Results are reported
as mean ± SEM, and are representative of at least two independent
experiments. Representative images were obtained using a SPOT
digital camera.
Western immunoblotting
Sympathetic neuron cultures in 35-mm dishes were rinsed with PBS,
and then triturated off the dish in PBS. Cells were then spun down,
and resuspended in a small volume (50–80 lL) of buffer containing
50 mmol/L Tris (pH 7.6), 150 mmol/L NaCl, 2 mmol/L EDTA, and
1% NP-40, supplemented with protease inhibitors (Roche Molecular
Biochemicals Inc., Indianapolis, IN, USA). Lysates were left on ice
for 20 min, and then centrifuged at 10 000 g to remove insoluble
material. Protein concentrations were measured using the Bradford
assay (Bio-Rad Laboratories, Hercules, CA, USA). Lysates were
combined with 4· sodium dodecyl sulfate (SDS) sample buffer and
separated by SDS–polyacrylamide gel electrophoresis. Immuno-
blotting was performed using anti-ERK-2 (rabbit polyclonal, Santa
Cruz; 1 : 2000), anti-Bax (mouse monoclonal, Santa Cruz;
1 : 1000), anti-Bim (rabbit polyclonal, StressGen, San Diego, CA,
USA; 1 : 1000), anti-caspase-2 (anti-Nedd, Troy et al. 1997; at
1 : 500), or anti-X-linked inhibitor of apoptosis protein (XIAP)
(MBL, Woburn, MA, USA; 1 : 1000) antibodies. Blocking,
application of secondary antibodies and developing of the blots
were performed as described previously (Rideout et al. 2001;
Rideout and Stefanis 2002; Lang-Rollin et al. 2004).
DNA ladder detection
Both attached and ﬂoating cells from sympathetic neuron cultures
were centrifuged (800 g, 10 min) and washed with PBS. The pellet
was resuspended in a buffer containing 100 mmol/L Tris–HCl,
200 mmol/L NaCl, 10 mmol/L EDTA; pH 8. After addition of an
equal volume of digestion buffer (100 mmol/L Tris–HCl, pH 8,
200 mmol/L NaCl, 10 mmol/L EDTA, 0.4% SDS, and 200 lg
proteinase K), the cell lysate was incubated at 55C overnight.
Subsequently, DNA was extracted twice with phenol–chloroform
and the aqueous phase was treated with Rnase (20 lg/mL). After
incubation for 30 min at 37C, DNA was precipitated with ice-cold
ethanol and resolved in water. Yield and purity of DNA were
determined by measuring the optical density at 260 and 280 nm.
Electrophoresis was carried out on a 1.0% agarose gel and ladder
formation of oligonucleosomal DNA (5 lg of each sample) was
detected under ultraviolet light.
Electron microscopy
Rat sympathetic neuron cultures were treated either with no
additives or with 10 lmol/L PSI for 60 h. The cultures were then
rinsed with PBS, and ﬁxed for one hr at 4C with 2% glutaraldehyde
in 2 mmol/L CaCl2, and 100 mmol/L sodium cacodylate. The
samples were then processed for electron microscopy as previously
described (Stefanis et al. 2001; Lang-Rollin et al. 2003; Rideout
et al. 2004).
Statistical analysis
Comparisons were performed using Student’s t-test, with the level of
signiﬁcance set at 0.05.
Results
Application of proteasomal inhibitors to rat sympathetic
neurons leads to delayed death that is morphologically
non-apoptotic
Given the uncertainties about the pro-survival or pro-death
effects of proteasomal inhibition on rat sympathetic neurons,
we applied the selective proteasomal inhibitors lactacystin
(Fenteany et al. 1994) or PSI (Figueiredo-Pereira et al.
1994), or vehicle (ctl) to such cultures. Concentrations of
1 lmol/L of these reagents failed to induce death even
after 72 h of application. At the higher concentrations of
10 lmol/L, we did not observe any death for 16–20 h. Some
neurons however started to show some loss of their smooth
phase-bright appearance, bloating, blebbing and retraction of
neuritic processes during this period. Neuronal death started
being apparent ﬁrst after 24 h after the application of the
reagents, and was more marked for PSI. Neuronal death due
to NGF deprivation occurred more rapidly and was consid-
erably more robust (Fig. 1a and b). Because some neurons
that had extensive vacuolization and neurite retraction did
not manifest EH or PI incorporation, whereas others, while
maintaining phase brightness, showed EH or PI uptake, we
have used EH or PI incorporation as an index of cell death in
all subsequent experiments, as a more deﬁnitive assay for
death, instead of counts of phase bright neurons. Interest-
ingly, the morphology of the nuclei of dying neurons was
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largely non-apoptotic. In all experiments, in cultures derived
from two different strains of rats (Sprague–Dawley and
Wistar), < 10% of dying neurons showed the classical
fragmented apoptotic nucleus with apoptotic clumps, that
characterizes both the death of mouse sympathetic neurons
following proteasomal inhibition (Lang-Rollin et al. 2004)
and the death of rat sympathetic neurons following NGF
deprivation. In contrast, almost all dying neurons displayed
uptake of EH in non-apoptotic non-fragmented nuclei that
displayed a relatively homogeneous pattern of labelling.
Such nuclei were often peanut/crescent shaped. Characteris-
tic examples of lactacystin- and PSI-treated cultures labeled
with EH are shown, and contrasted with NGF-deprived
cultures (Fig. 1c).
To conﬁrm these results at the ultrastructural level, we
assessed cultures treated with PSI by electron microscopy.
We were unable to detect any apoptotic proﬁles in such
cultures. However, we detected a signiﬁcant number of
neurons with eccentric, peanut/crescent-shaped nuclei. Such
nuclei occasionally showed a small degree of chromatin
condensation (Fig. 2, top right panel). In many neurons,
extensive vacuolization of the cytoplasm was apparent
(Fig. 2, top right panel). On higher power, some, but not
all, of the identiﬁed vacuolar structures appeared to have
double membranes (Fig. 2, bottom left panel). Through
random assessment of 20 electron micrograph pictures from
PSI-treated cultures and 13 pictures from ctl cultures, we
have found that approximately 65% of neurons in PSI-treated
cultures exhibit extensive vacuolization, much higher than
the background degree of vacuolization seen in ctl cultures.
We also investigated whether the classical hallmark of
apoptosis, DNA laddering, was observed in proteasomal
inhibitor-treated cultures. Forty-eight hours after PSI appli-
cation, there was no evidence of DNA laddering (Fig. 2,
lower right panel).
We conclude that rat sympathetic neuron cultures treated
with PSI or lactacystin die in a delayed fashion, and that this
death is morphologically non-apoptotic.
1 2 3
Fig. 2 Z-IE(OtBu)Ala-Leu-al (PSI) application to rat sympathetic
neurons leads to non-apoptotic death by ultrastructural criteria. Rat
sympathetic neurons were treated with 10 lmol/L PSI or no additives
(control, ctl). Sixty hours later the cultures were fixed and processed
for electron microscopy. Representative scanned images are shown.
The black bar measures 1 lmol/L. Note the peanut/crescent-shaped
nucleus in the PSI-treated cultures, with a mild degree of chromatin
condensation. The cytoplasm contains a large number of vacuolar
structures. A higher power view of these structures is shown in the
lower left panel. Arrow heads indicate the presence of double mem-
branes. Bottom left panel: rat sympathetic neuron cultures were
treated with 10 lmol/L PSI for 48 h (lane 1), no additives (lane 2), or
with 10 lmol/L of the DNA damaging agent camptothecin for 16 h
(lane 3). The neurons were then harvested for assessment of DNA
laddering, as described in Materials and methods. The lane on the left
represents molecular weight markers. Note the appearance of lad-
dering only in the camptothecin-treated cultures (lane 3).
(a) (b)
(c)
Fig. 1 Application of proteasomal inhibitors to rat sympathetic neu-
rons leads to death with a non-apoptotic nuclear morphology. (a and b)
Rat sympathetic neuron cultures were treated either with no additives
(control, ctl) or with 10 lmol/L Z-IE(OtBu)Ala-Leu-al (PSI) (a) or
10 lmol/L lactacystin (lact, b), or deprived of nerve growth factor
()NGF, a), as described in Materials and methods. At successive time
points after application of the reagents or NGF deprivation, the cul-
tures were incubated with the nuclear dyes propidium iodide (PI) and
Hoechst, and the percentage of neurons with Hoechst labeling that
showed PI incorporation was assessed (n = 3, with at least 100 neu-
rons counted per well for each condition). (c) Rat sympathetic neurons
were treated with 10 lmol/L lactacystin or PSI. Sixty hours later the
dye ethidium homodimer, together with the nuclear dye Hoechst, was
applied to the cultures. Untreated ctl and lactacystin (lact) or PSI-
treated cultures were examined in a fluorescence microscope and
representative images were obtained. As a positive control for apop-
totic morphology of death, cultures were deprived of NGF for 48 h
()NGF). Note the non-apoptotic, ethidium-positive, peanut/crescent-
shaped nuclei in the lact and PSI-treated cultures.
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Caspases other than caspase 3 are involved in the death of
rat sympathetic neurons exposed to proteasomal inhibitors
Given the evidence for a morphologically non-apoptotic form
of death, we were interested to examine next whether caspases
participated in this death. Caspase participation is generally
synonymous with apoptosis, but there are instances where
caspases have been associated with death that is morpholog-
ically non-apoptotic (Stefanis 2005). We used two approaches
to identify at the single cell level activation of caspases. We
labeled the cultures with caspACE, a cell-permeable ﬂuores-
cence-linked general caspase inhibitor that detects activated
caspases that bind to the inhibitor moiety, and then ﬁxed the
cultures and performed immunostaining with an Ab speciﬁc
for the activated form of caspase 3. As a positive ctl, we used
NGF-deprived cultures. In such trophic factor-deprived
cultures, there was complete concordance between caspACE
and caspase 3 activation. In contrast, cultures treated with
lactacystin for 50 h showed very little caspase 3 relative to
caspACE activation (Fig. 3a–c). Thus, many neurons in
lactacystin-treated cultures were caspACE positive, but
caspase 3 negative (Fig. 3a). Similar results were achieved
with PSI at this time point (data not shown). This was not
because of the exact time of sampling because throughout the
time course of 16–72 h of exposure to PSI the percentage of
neurons with positive staining for activated caspase 3
remained low (Fig. 3d).
Caspase 3-independent death has been linked to death via
activation of PARP in the setting of exposure of post-natal
cortical neurons to DNA damaging agents (Johnson et al.
1999). To ascertain whether PARP activation could be
involved in death in this model, we used the well-character-
ized PARP inhibitor benzamide. At concentrations of 50 and
150 nmol/L, we found no protective effect against PSI-
induced death (Fig. 3e). Higher concentrations of benzamide
were toxic to the cultures.
To examine whether the caspase activation observed with
the caspACE assay was relevant to the death of the cells
following proteasomal inhibition, we treated the cultures
with the general caspase inhibitor BAF in combination with
lactacystin or PSI. We found that BAF, at 100 lmol/L,
partially inhibited the death of proteasomal inhibitor-treated
neurons (Fig. 4a). BAF diminished the caspACE activation
to a commensurate degree (Fig. 4b). We conclude that
caspases other than caspase 3 are at least in part involved in
death in this model.
Effects of proteasomal inhibitors on mitochondrial
function
As caspases appeared to be involved, we wished to examine
whether other elements of apoptotic pathways were activated
in these cultures following proteasomal inhibition. Events at
the level of the mitochondria, such as cytochrome c release
and loss of mitochondrial transmembrane potential, are
thought to be central in apoptotic pathways (Adams and Cory
2001). We found that both PSI and lactacystin induced these
phenomena (Fig. 5a and b). Opening of the PTP, accompa-
nied by release of other pro-apoptotic mitochondrial proteins,
such as AIF, is thought to be involved in large-scale DNA
fragmentation and non-apoptotic death (Stefanis 2005). We
wished to test therefore whether such phenomena could play
a role in neuronal death in the current model. We found
however that the PTP inhibitors cyclosporine A or bon-
gkrekik acid had no effect on the loss of mitochondrial
transmembrane potential or on survival following lactacystin
application (Fig. 5c and d). Furthermore, we failed to ﬁnd
evidence for AIF translocation to the nucleus (data not
shown).
We conclude that mitochondrial alterations such as
cytochrome c release and loss of mitochondrial transmem-
brane potential occur following proteasomal inhibition of
sympathetic neurons. Opening of the PTP and AIF release do
not appear to contribute to these phenomena or to neuronal
death in this model.
Over-expression of bcl-xL partially protects against cell
death and cytochrome c release induced by proteasomal
inhibitors in rat sympathetic neurons
To examine whether cytochrome c release was regulated, as
in other models, by members of the bcl-2 family (Adams and
Cory 2001), we over-expressed bcl-xL or a ctl vector, and
then treated the cultures with PSI. We found that bcl-xL
prevented to a signiﬁcant extent cytochrome c release
(Fig. 6a and b). Furthermore, bcl-xL over-expression was
associated with a signiﬁcant reduction in cell death,
commensurate with the effects on cytochrome c release.
The effect of bcl-xL on survival was similar to that observed
with application of BAF (Fig. 6c and d).
Based on the results with bcl-xL, which showed that bcl-2
family members were involved in death, we wished to
examine whether pro-apoptotic members of this family were
up-regulated in this model. We found that, similar to mouse
sympathetic neurons, the BH3-only protein Bim was up-
regulated at the protein level (Fig. 6e). In contrast, Bax levels
were unaffected (data not shown). We also wished to
examine whether the previously observed lack of caspase 3
activation could be due to induction of an endogenous
inhibitor. IAPs, and in particular XIAP, have been shown to
play this role (Stefanis 2005). However, we found no
induction of XIAP with proteasomal inhibition (Fig. 6e).
We conclude that elements of the intrinsic apoptotic
pathway are activated in this model, and are, at least in part,
responsible for neuronal cell death.
Macroautophagy occurs in rat sympathetic neurons treated
with proteasomal inhibitors, but is not responsible for
death
Our electron microscopy results suggested that macroauto-
phagy could be induced in this cell system, given that certain
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of the vacuolar structures identiﬁed contained double mem-
branes (Clarke 1990). To examine this further, we ﬁrst
performed transfections with an LC3-GFP vector. LC3 is the
mammalian homolog of the yeast autophagy gene Atg8, and
is involved in early autophagosome formation. The change of
its pattern of localization from a diffuse cytosolic to
punctuate indicates conversion of LC3-I to LC3-II, which
associates with autophagosomal membranes (Rubinsztein
et al. 2005). In these experiments we used rapamycin, a
known inducer of autophagy (Rubinsztein et al. 2005), as a
positive ctl. We were unable to see a signiﬁcant consistent
change in the pattern of GFP ﬂorescence following the
application of rapamycin or proteasomal inhibitors, although
in some cases, especially following treatment with PSI, a hint
of a punctuate pattern of labeling was observed (data not
shown). Immunostaining with a polyclonal LC3 Ab yielded a
(a)
(b)
(d) (e)
(c)
Fig. 3 Application of lactacystin to rat sympathetic neurons leads to
activation of caspases other than caspase 3. Rat sympathetic neurons
were exposed to no additives (control, ctl) or lactacystin (lact) for 50 h,
or deprived of nerve growth factor (NGF) for 40 h, labeled with the
caspACE fluorescent compound, and then fixed and immunostained
with an antibody (Ab) directed against active caspase 3, and counter-
stained with Hoechst. The cultures were then visualized under a
fluorescent microscope. In (a), representative images are shown. The
percentage of sympathetic neurons that showed caspACE positivity
and active caspase 3 immunostaining is reported for lactacystin-
treated (b) or NGF-deprived cultures (c). The results reported are the
mean ± SEM (n = 3, 100 neurons assessed in each of three wells).
(d) Rat sympathetic neurons cultures were exposed to either no
additives or to 10 lmol/L Z-IE(OtBu)Ala-Leu-al (PSI). At successive
time points the cultures were fixed and immunostained with an Ab
directed against active caspase 3, and counter-stained with Hoechst.
The percentage of activated caspase 3-positive neurons in PSI-trea-
ted cultures relative to untreated control cultures is indicated for each
time point. (e) Rat sympathetic neurons were exposed for 48 h to
either no additives (ctl), 10 lmol/L PSI alone (PSI) or in combination
with 50 or 150 nmol/L benzamide, and then assessed for the
percentage of neurons with Hoechst labeling that showed propidium
iodide (PI) incorporation (n = 3, with 100 neurons counted per well for
each condition).
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more consistent pattern of punctuate labeling for endogenous
LC3 following proteasomal inhibitor application, that was
never observed in ctl cultures (Fig. 7a). This pattern however
was only seen in a minority of the proteasomal inhibitor-
treated cultures. We therefore also used mono-dansyl-cadav-
erine (MDC) labeling as an alternative method. MDC was
thought to label autophagosome structures, but recently it has
become clear that it mainly labels late autophagolysosomes
(Niemann et al. 2000; Rubinsztein et al. 2005). We found
that in ctl cultures the pattern of MDC labeling was diffuse in
all cells. Following rapamycin application, many neurons
displayed a punctate pattern of labeling. The application of
proteasomal inhibitors led to the appearance of intense label-
ing of even larger structures. When we applied PSI together
with BAF, this labeling pattern was still apparent, indicating
that it was not dependent on caspase activation (Fig. 7b).
To examine whether the observed apparent induction of
autophagolysosome formation was indeed dependent on
macroautophagy, we used the macroautophagy inhibitor 3-
MA together with PSI. We indeed observed a 64% reduction
in the percentage of neurons that showed globular labeling
with MDC compared to cultures treated with PSI alone. Co-
administration of 3-MA also signiﬁcantly ameliorated sur-
vival, but the magnitude of this effect was smaller, about
22% (Fig. 7c).
We conclude that there is activation of macroautophagy
following proteasomal inhibitor application to sympathetic
neurons, but that this activation plays a relatively minor role
in death in this model.
Application of proteasomal inhibitors inhibits death
induced by NGF deprivation in rat, but not mouse,
sympathetic neurons
The above results suggest that in rat sympathetic neurons
there is an impediment for the full activation of the apoptotic
pathway following proteasomal inhibition. This is likely to
manifest at least at two levels, ﬁrst in the delayed (relative to
the mouse system) loss of cytochrome c and second in the
relative lack of caspase 3 activation. Sadoul et al. (1996) had
previously reported that application of lactacystin and PSI to
rat sympathetic neurons was actually protective against NGF
deprivation-induced death. We wished to examine whether
we could reproduce this ﬁnding, which has been controver-
sial (Zhai et al. 2003), to ascertain whether proteasomal
inhibition in these neurons may exert anti-apoptotic effects.
In view of the rapid apoptotic death induced by proteasomal
inhibitors in mouse sympathetic neurons (Lang-Rollin et al.
2004), we have also performed similar experiments in the
mouse system, to examine the possibility that there may be a
species difference in the induction of such anti-apoptotic
responses. In these experiments, we have also used lower
doses of lactacystin (1 lmol/L), so as to minimize the
induction of pro-death pathways observed with the higher
doses.
We ﬁnd that, as reported by Sadoul et al. (1996),
proteasomal inhibition with lactacystin leads to an abrogation
of the NGF deprivation-induced apoptotic pathway in rat
sympathetic neurons. This effect appears to be mediated
upstream of cytochrome c release and subsequent caspase 3
activation (Fig. 8a). In contrast, no such effect is discerned in
mouse sympathetic neurons (Fig. 8b). If anything, a small
additive effect on apoptosis was observed when NGF
deprivation and lactacystin were combined.
We conclude that in rat sympathetic neurons application of
proteasomal inhibitors leads to an induction of anti-apoptotic
signaling, that is likely to play a role in the delayed nature
and the altered morphological features of death when
proteasomal inhibitors are applied at higher doses. In
contrast, in mouse sympathetic neurons, proteasomal inhibi-
tion does not lead to an induction of anti-apoptotic effects.
Fig. 4 General caspase inhibition partially prevents death of rat
sympathetic neurons exposed to proteasomal inhibition. (a) Rat
sympathetic neurons were exposed to no additives (ctl), 10 lmol/L
lactacystin or Z-IE(OtBu)Ala-Leu-al (PSI) in the presence or absence
of Boc-aspartyl-fluoromethylketone (BAF) (100 lmol/L). Sixty hours
later the cultures were assessed for the percentage of neurons that
showed ethidium homodimer (EH) uptake. The results reported are
the mean ± SEM (n = 3, 100 neurons assessed in each of three
wells). BAF led to significant inhibition of death induced by lact
(p < 0.05) or PSI (p < 0.01, Student’s t-test), *p < 0.05 and **p < 0.01.
(b) Rat sympathetic neurons were exposed to no additives (ctl) or PSI
in the presence or absence of BAF (100 lmol/L). Sixty hours later the
cultures were labeled with the CASPase compound, and then fixed.
The percentage of neurons that showed CASPase positivity was as-
sessed in each case. The results reported are the mean ± SEM
(n = 3, 100 neurons assessed in each of three wells). BAF led to
significant inhibition of CASPase positivity induced by lact (p < 0.05,
Student’s t-test), *p < 0.05.
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Discussion
The data presented herein indicate that following proteaso-
mal inhibition of rat sympathetic neurons there is an
induction of apoptotic signaling, but that the outcome at
the morphological level is non-apoptotic death. The
morphology that we observe, with the peanut/crescent-
shaped nuclei and the cytoplasmic vacuolization, is quite
characteristic. We are not aware of similar descriptions of
dying cells in the literature. It will be interesting to see
whether this, to our knowledge, novel morphology of dying
neurons, occurs in other situations, and in particular neuro-
degenerative conditions, where proteasomal dysfunction is
thought to occur (Ciechanover and Brundin 2003), and
where evidence for classical apoptotic morphology has been
scant (Stefanis et al. 1997). Our ﬁndings highlight the
discrepancy between morphological apoptosis and apoptotic
signaling, and suggest that the lack of morphological
apoptosis should not necessarily indicate lack of involvement
of apoptotic pathways in neuronal death.
The morphological features of death in this model are
likely to be the result of a constellation of effects, but we
believe that our data support a scenario in which application
of high doses (10 lmol/L) of the proteasomal inhibitors PSI
and lactacystin to rat sympathetic neurons leads to the
induction of both pro- and anti-apoptotic signaling, as
previously reported in other systems (Lang-Rollin et al.
2004; Butts et al. 2005; Yew et al. 2005). The pro-death
signaling eventually prevails, but the death that occurs is
delayed, and, when it ﬁnally occurs, it is non-apoptotic in
morphology. Evidence for this scenario is provided by: (i) the
delayed induction of cytochrome c release and death in the
rat versus the mouse model; (ii) the fact that lactacystin
prevents apoptosis induced by trophic deprivation by acting
upstream of cytochrome c release; and (iii) the dissociation of
caspACE versus activated caspase 3 positivity following
proteasomal inhibition, but not NGF deprivation. These data
point to the idea that following proteasomal inhibition in rat
sympathetic neurons, and in parallel to pro-apoptotic signal-
ing, there are at least two anti-apoptotic signals elicited: one
that acts at a level prior to cytochrome c release, and the
other further downstream, at the level of effector caspases.
In experiments in other cellular systems where proteaso-
mal inhibitors have been shown to exert anti-apoptotic
functions, their primary site of action has been shown to lie
upstream of cytochrome c release (Bobba et al. 2002). It is
likely that proteasomal inhibitors exert these effects, at least
in part, by up-regulation of anti-apoptotic factors that are
normally degraded by the proteasome. In a recent manu-
script, it was proposed that the pro-survival transcription
factor MEF2 may be the molecule involved, as it was up-
regulated with proteasomal inhibitors in cerebellar granule
Fig. 5 Proteasomal inhibition in rat sympathetic neurons leads to
mitochondrial perturbations. (a and b) Rat sympathetic neurons were
treated with no additives, or with 10 lmol/L Z-IE(OtBu)Ala-Leu-al
(PSI) or lactacystin for 36 or 48 h. The cultures were then either fixed
and immunostained for cytochrome c and counter-stained for Hoechst
(a), or labeled with the mitochondrial due tetramethylrhodamine methyl
ester (TMRM) (b). The percentage of neurons that showed loss of
mitochondrial staining for cytochrome c (a) or loss of TMRM labeling
(b) was assessed for each condition. The results reported are the
mean ± SEM (n = 3, 100 neurons assessed in each of three wells). (c
and d) Rat sympathetic neuron cultures were treated with no additives
(ctrl), or with 10 lmol/L lactacystin (lact) alone, or in combination with
1 lmol/L cyclosporine A (CsA) or 2 lmol/L bongkrekik acid (BA).
Forty-eight hours later the cultures were labeled with TMRM (c) or EH
(d), and the percentage of neurons that showed TMRM loss (c) or EH
uptake (d) was assessed in each condition. The results reported are
the mean ± SEM (n = 3, 100 neurons assessed in each of three
wells).
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neurons induced to undergo death by serum/potassium
deprivation (Butts et al. 2005). Whatever the nature of these
upstream anti-apoptotic effects, they are eventually over-
whelmed by pro-death signals, such as the accumulation of
Bim, and eventually engagement of the apoptotic pathway at
the level of the mitochondria occurs.
The activation of cytochrome c release however is not
sufﬁcient to fully engage the apoptotic pathway and to lead
to an apoptotic morphology in our model. Based on the
dissociation between caspase 3 activation and general
caspase activation, as judged by caspACE labeling, the lack
of apoptotic morphology is likely to be due to an inhibition
of speciﬁc caspases, including caspase 3. In the absence of
such caspase 3-like caspases, other caspases execute death,
but this death lacks the morphological features of apoptosis,
which likely depend on the presence of caspase 3. This
(a) (b)
(c)
(e)
(d)
Fig. 6 bcl-xL over-expression prevents cytochrome c release and
death of proteasomal inhibitor-treated rat sympathetic neurons. (a and
b) Rat sympathetic neurons were co-transfected with bcl-xL and EGFP
or with PAI2M and EGFP, and 36 h later exposed to either no addi-
tives or to 10 lmol/L Z-IE(OtBu)Ala-Leu-al (PSI). Sixty hours later, the
cultures were fixed and immunostained for cytochrome c and EGFP
and counter-stained with the Hoechst nuclear dye. Representative
fluorescence photomicrographs of PSI-treated cultures are shown in
(a). Arrow heads depict transfected neurons, in the top panel upon co-
transfection with PAI2M and in the bottom with bcl-xL. Asterisks depict
non-transfected neurons. Note that in the top panel the transfected
neuron has lost cyt c staining, whereas this is maintained in the bottom
panel. The non-transfected neuron in the top panel maintains cyt c
staining, whereas this is lost in the non-transfected neuron in the
bottom panel. The percentage of EGFP-positive neurons that showed
loss of mitochondrial staining for cytochrome c was assessed for each
condition The results reported in (b) are the mean ± SEM (n = 3, at
least 75 neurons assessed in each of three wells). Bcl-xL co-expres-
sion led to significant inhibition of cyt c loss induced by PSI when
compared to PAI2M (p < 0.005, Student’s t-test), ***p < 0.005. (c and
d) Rat sympathetic neurons were transfected and treated as above,
and 60 h later, the cultures were labeled with ethidium homodimer
(EH) and visualized under a fluorescent microscope. EGFP-PAI2M co-
transfected cultures were also treated with the combination of PSI and
100 lmol/L BAF. Representative fluorescence photomicrographs of
PSI-treated cultures are shown in (c). Arrow heads depict transfected
neurons and the corresponding location for the EH dye, in the top
panel upon co-transfection with PAI2M and in the bottom with bcl-xL.
Note that in the top panel one of the transfected neurons shows EH
uptake, whereas this does not occur in the two neurons in the bottom
panel. The non-transfected neuron in the top panel maintains cyt c
staining, whereas this is lost in the non-transfected neuron in the
bottom panel. The results reported in (d) are the mean ± SEM (n = 3,
at least 75 neurons assessed in each of three wells). Bcl-xL co-
expression or BAF co-application led to significant inhibition of EH
uptake induced by PSI when compared with PAI2M (p < 0.0005,
Student’s t-test), ****p < 0.0005. (e) Rat sympathetic neurons were
treated with no additives or with 10 lmol/L lactacystin for 24 h, and
then harvested for western immunoblotting with antibodies (Abs) di-
rected against Bim (top panel) or XIAP (middle panel) or ERK-2
(bottom panel).
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scenario is supported by the phenotype in caspase 3 null
mice, in which developmental neuronal death does occur, but
is morphologically non-apoptotic (Oppenheim et al. 2001).
In our model, our data with the caspACE labeling and the
inhibition of death with BAF indicate that caspases other
than caspase 3 are involved in neuronal non-apoptotic death.
Whether this is the case in dying neurons in caspase 3 null
mice is unknown. We suggest that here again this phenom-
enon may be due to the up-regulation of a speciﬁc caspase 3
(or caspase 9) inhibitor with proteasomal inhibition in rat
sympathetic neurons. XIAP was an obvious candidate for
such an effect, but immunoblot analysis failed to detect a
difference in its expression.
These ﬁndings question the absolute link between apop-
totic morphology and caspases, and suggest that caspases
other than caspase 3 can mediate death that is morpholog-
ically non-apoptotic. Similar insights have been gained in
other systems. Caspase 2 is an especially interesting
candidate in this regard (Yu et al. 2003), but in preliminary
experiments in our model we have not detected caspase 2
processing by using western immunoblotting (data not
shown).
The survival-promoting effects that we have observed with
BAF and bcl-xL over-expression have been roughly compa-
rable, and account for an inhibition of 50–75% of death. It is
unknown whether the remainder of the dying neurons follow
a pathway that is completely different from the classical
apoptotic pathway, or whether the lack of a complete effect
reﬂects limitations of the strategies utilized. We believe that
the latter possibility is more likely, as BAF did not
completely block caspACE labeling in this model, and its
effect in this regard was commensurate to its survival-
promoting effects.
The vacuoles detected in proteasome inhibitor-treated
neurons in our ultrastructural studies suggested the possibil-
ity of the induction of macroautophagy in this model. Some
of the vacuolar structures appeared to be delimited by double
membranes, consistent with this possibility (Clarke 1990;
Rubinsztein et al. 2005). We performed studies with LC3
immunostaining and LC3-GFP transfections to ascertain
whether indeed autophagosomes were formed in this model.
The former strategy more consistently showed punctuate
LC3 labeling with proteasomal inhibition, but this was not a
widespread phenomenon. This likely reﬂects a relative lack
of sensitivity of this method in detecting changes, at least in
the experimental system that we have utilized, perhaps
(a)
(b)
(c)
Fig. 7 Macroautophagy induction by application of proteasomal
inhibitors to rat sympathetic neurons, but little attenuation of death with
a macroautophagy inhibitor. (a) Rat sympathetic neuron cultures were
exposed to no additives (control, ctl) or to 10 lmol/L lactacystin (lact)
or Z-IE(OtBu)Ala-Leu-al (PSI) for 48 h, and then fixed and immuno-
stained for LC3 (top panel) and co-stained with Hoechst (bottom
panel). Cultures were then visualized under a fluorescent microscope.
Representative images are depicted. Note the diffuse LC3 staining in
control cultures and the appearance of discrete punctate staining in
some neurons in cultures treated with proteasomal inhibitors. (b) Rat
sympathetic neuron cultures were exposed to rapamycin (rapa,
500 nmol/L), PSI with or without Boc-aspartyl-fluoromethylketone
(BAF), or lactacystin (lact) for 48 h, and then labeled with mono-
dansyl-cadaverine (MDC). Cultures were then visualized under a
fluorescent microscope. Representative examples are shown. Note
the fine, punctuate appearance of the labeling in rapamycin-treated
neurons, and the coarser, globular pattern in proteasomal inhibitor-
treated neurons. (c) Rat sympathetic neuron cultures were treated with
PSI alone, or PSI together with the macroautophagy inhibitor 3-me-
thyl-adenine (3-MA) (10 mmol/L). Of note, 3-MA was added 24 h after
PSI application. Sixty hours after PSI application, the cultures were
labeled with MDC or ethidium homodimer (EH) and assessed for the
percentage of neurons that showed globular-punctate labeling of MDC
and EH uptake. The results are the mean ± SEM (n = 3, at least 250
neurons assessed per condition in each of three separate experi-
ments); 3-MA significantly inhibited the MDC globular pattern to 36%
of cultures treated with PSI alone (p < 0.01, paired Student’s t-test).
There was also a significant effect on cell death, as assessed but EH
uptake, but the magnitude of this effect was much lower (78%
EH-positive neurons compared with cultures treated with PSI alone,
p < 0.01, paired Student’s t-test).
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because, as suggested by Aviva Tolkovsky, sympathetic
neurons may use alternative mammalian isoforms of Atg8 to
form autophagosomes (Rubinsztein et al. 2005).
To extend the results with LC3 immunolabeling, we also
used the dye MDC, which in this cellular system proved to
be a more sensitive indicator of macroautophagy induction.
Background labeling with this dye in ctl cultures was
uniformally diffuse, whereas it became intensely globular
and punctate with the application of proteasomal inhibitors.
The use of this reagent to detect autophagosomes is
controversial, but, at the very least, it appears to label in
part acidic autophagolysosomes (Niemann et al. 2000). The
fact that the changes observed with proteasomal inhibitors in
MDC labeling were in part reversed by the macroautophagy
inhibitor 3-MA indicates that these changes reﬂect ongoing
macroautophagy. Despite a marked effect on MDC labeling,
3-MA exerted a relatively smaller effect on death in PSI-
treated cultures. This indicates that the process of macro-
autophagy has, if anything, a minor impact on death in this
model. We have previously achieved similar results in other
systems, in which, despite the induction of macroautophagy,
macroautophagy inhibition did not impact death (Lang-
Rollin et al. 2003; Rideout et al. 2004). The difference in the
results we have obtained and the results of others, that have
shown protective effects of 3-MA application in models
where macroautophagy occurs (Xue et al. 1999; Canu et al.
2005), may be that we have always applied 3-MA in a
delayed fashion, so as to avoid its non-speciﬁc effects on
early signaling pathways. In any case, our results in this
model indicate that although the morphology of death is
autophagic and non-apoptotic, thus qualifying as autophagic,
type IIb death, according to the Clarke (1990) nomenclature,
the autophagic process is not a major determinant of neuronal
death. As we have previously discussed, this does not
exclude the possibility that macroautophagy may have a
minor role in the current setting, but a more prominent role in
neuronal death in other settings.
Our results also show a clear difference between sympa-
thetic neurons derived from mice and rats. This difference
cannot be due to different developmental stages, because in
both cases we varied the time neurons were cultured prior to
the application of proteasomal inhibitors, without any
resultant change in the respective death morphologies. The
difference was apparent in both the morphology of death and
in the differential ability of the proteasomal inhibitors to
suppress NGF deprivation-induced death only in the rat
cultures. We believe these results can be explained by the
presence in the rat, but not the mouse, sympathetic neuron
cultures of certain proteins that exert anti-apoptotic effects
and that are up-regulated by proteasomal inhibition. Thus,
apart from differences in dosing and timing of exposure to
proteasomal inhibitors, species differences may account for
discrepancies in pro- or anti-apoptotic effects of proteasomal
inhibition. It is interesting to note that rat pheochromocytoma
PC12 cells, as we have reported (Rideout et al. 2001),
undergo morphologically apoptotic death when treated with
proteasomal inhibitors. However, when these cells are treated
with NGF, and assume a neuronal-like phenotype resem-
bling that of sympathetic neurons, and then treated with
proteasomal inhibitors, they show a percentage of dying
cells with the same non-apoptotic nuclear morphology that
we have observed in the rat sympathetic neurons (data not
shown). Thus, it is likely that the putative anti-apoptotic
(a)
(b)
Fig. 8 Proteasomal inhibition prevents nerve growth factor (NGF)
deprivation-induced apoptosis in rat, but not mouse sympathetic
neurons. (a) Rat sympathetic neuron cultures were either untreated
(control, ctl) or deprived of nerve growth factor ()NGF) in the presence
or absence of 1 or 10 lmol/L lactacystin. Twenty-four hours later the
cells were fixed and immunostained with antibodies against cyto-
chrome c and active caspase 3, counter-stained with Hoechst and
visualized under a fluorescent microscope. The percentage of sym-
pathetic neurons that showed loss of mitochondrial cytochrome c
staining, active caspase 3 and apoptotic nuclear morphology is re-
ported for each condition. The results reported are the mean ± SEM
(n = 3, 100 neurons assessed in each of three wells). (b) Mouse
sympathetic neuron cultures were either untreated (ctl) or deprived of
NGF in the presence ()NGF + lact) or absence ()NGF) of 1 lmol/L
lactacystin, or treated with 1 lmol/L lactacystin alone (lact). Twenty-
four hours later the cells were fixed and immunostained with anti-
bodies against cytochrome c and active caspase 3, counter-stained
with Hoechst and visualized under a fluorescent microscope. The
percentage of sympathetic neurons that showed loss of mitochondrial
cytochrome c staining, active caspase 3 and apoptotic nuclear
morphology is reported for each condition. The results reported are
the mean ± SEM (n = 3, 100 neurons assessed in each of three
wells).
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proteins that modify the phenotype of death in rat sympa-
thetic neurons are also induced with neuronal differentiation
of PC12 cells.
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Parkinson’s disease (PD) is a common neurodegenerative
disease whose symptoms include tremor, rigidity, bradykine-
sia and abnormalities of posture and gait (Shastry 2003).
Pathologically PD is characterized by substantia nigra
neuronal degeneration, leading to striatal dopamine deﬁ-
ciency, although more widespread neuronal degeneration also
occurs (Braak et al. 2003). Surviving neurons harbor Lewy
bodies containing accumulations of a-synuclein (SNCA),
ubiquitin, and neuroﬁlament (Surguchov 2008). Mutations in
speciﬁc genes leads to familial forms of PD (Cookson et al.
2008); of these genes, SNCAwas the ﬁrst to be linked to PD
through the identiﬁcation of the A53T mutation (Polymero-
poulos et al. 1997); two further missense point mutations
have been described (Kru¨ger et al. 1998; Zarranz et al. 2004).
In addition to this link between SNCA mutations and PD,
there is also evidence indicating that over-expression of wild-
type SNCA is sufﬁcient to cause the disease. Over-expres-
sion of wild-type SNCA leads to phenotypes resembling PD
in various animal models (Feany and Bender 2000; Masliah
et al. 2000; Kirik et al. 2002). Triplications (Singleton et al.
2003) and duplications (Chartier-Harlin et al. 2004) of the
SNCA gene locus lead to PD in a dose-dependent fashion.
Polymorphisms in the promoter sequence, in particular the
non-amyloid component of plaques (NACP)-REP1 dinucle-
otide repeat, located 10.7 kb upstream of the SNCA gene,
and in 3¢-regions of SNCA confer susceptibility to develop-
ing PD in case/control studies (Chiba-Falek and Nussbaum
2001; Farrer et al. 2001; Pals et al. 2004; Mueller et al.
2005; Maraganore et al. 2006). However, it is not known if
the non-amyloid component of plaques (NACP)-REP1
polymorphism is responsible for this increased risk or if it
is in linkage disequilibrium with the actual causative agent.
There has been controversy regarding the expression levels
of SNCA in the brains of sporadic PD patients, with a number
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Abstract
Alpha-Synuclein (SNCA) is an abundant neuronal protein
involved in synaptic neurotransmission. SNCA expression
levels have been strongly implicated in Parkinson’s disease
pathogenesis. We have previously demonstrated that in the
PC12 cell line elements in intron 1 may mediate SNCA tran-
scriptional regulation in response to neurotrophins. We have
now identified transcription factor (TF) binding sites in intron 1
and the 5¢-promoter of SNCA. A binding site for the TF zinc
finger and SCAN domain containing (ZSCAN)21 in the 5¢-region
of intron 1 is required for intron 1 transcriptional activity. Small
interfering RNA against ZSCAN21 inhibits activation in the
luciferase assay and diminishes SNCA protein levels in naı¨ve
and neurotrophin-treated PC12 cells and in primary cultured
cortical neurons, demonstrating that ZSCAN21 is a novel
transcriptional regulator of SNCA in neuronal cells. The 5¢-
promoter of SNCA has a complex architecture, including mul-
tiple binding sites for the TF zinc finger protein (ZNF)219, which
functions as both an activator and a repressor. Targeting
ZSCAN21 or other TFs controlling SNCA transcriptional activity
may provide novel therapeutic avenues not only for Parkinson’s
disease but also for other synucleopathies.
Keywords: a-synuclein, cortical neurons, neurotrophins,
Parkinson’s disease, PC12.
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of studies reporting both increased and decreased levels of
SNCA (Rockenstein et al. 2001; Kingsbury et al. 2004;
Chiba-Falek et al. 2006;Dachsel et al. 2007; Papapetropoulos
et al. 2007). However, in an elegant study, laser-captured
microdissection clearly demonstrated signiﬁcantly elevated
SNCA mRNA levels in individual, surviving neuromelanin-
and tyrosine hydroxylase-positive substantia nigra dopami-
nergic neurons from idiopathic PD brains (Gru¨ndemann et al.
2008).
In certain mouse models of neurodegenerative diseases,
reversal of expression of the causative proteins can amelio-
rate neurodegeneration, including in an inducible model of
SNCA over-expression (Yamamoto et al. 2000; Zu et al.
2004; Nuber et al. 2008), indicating that if expression of
SNCA can be controlled then certain aspects of the disease
phenotype can be halted and even reversed.
We have used the model system of rat pheochromocytoma
PC12 cells to examine the transcriptional control of SNCA.
This model system is often used to study the mechanisms
of neurotrophin-mediated differentiation of proliferating
neuronal precursors to post-mitotic, differentiated neuron-
like cells, which possess many characteristics of sympa-
thetic neurons (Greene and Tischler 1976). We had initially
determined that SNCA was transcriptionally up-regulated in
this model (Stefanis et al. 2001), and, proposed that intron 1
is an important transcriptional control region of the SNCA
gene (Clough and Stefanis 2007), as was independently
conﬁrmed (Scherzer et al. 2008). In this study, we provide
evidence that the transcription factor (TF) zinc ﬁnger and
SCAN domain containing (ZSCAN)21, which binds to a
site within intron 1, is a key regulator of SNCA transcrip-
tion. We have also expanded our study to the characteri-
zation of the 5¢-promoter region and identiﬁed a role for
the TF zinc ﬁnger protein (ZNF)219, which can function as
both a transcriptional repressor and activator. Such studies
further advance our understanding of the transcriptional
regulation of SNCA and offer the potential for modulation
of SNCA levels within neuronal cells.
Materials and methods
Cell culture
PC12 cells were cultured as previously described (Stefanis et al.
2001) on rat-tail collagen coated tissue culture dishes in RPMI-1640
medium (Sigma, St Louis, MO, USA) supplemented with 5%
heat-inactivated fetal bovine serum, 10% heat-inactivated horse
serum, 200 lM L-glutamine, and 1% penicillin/streptomycin (com-
plete medium). PC12 cells were differentiated in complete medium
containing either 50 ng/mL recombinant human nerve growth factor
(NGF; a generous gift from RINAT Neuroscience, Paolo Alto, CA,
USA) or 50 ng/mL basic ﬁbroblast growth factor (bFGF; Sigma).
For experiments using the kinase inhibitors, cells were pre-incubated
with the inhibitors for 45 min prior to the addition of the neurotro-
phins. U0126 was added to the complete media at a concentration of
25 lM. The following inhibitors (Sigma) were also used: LY294002
(25 lM), SP600125 (10 lM), and SB203580 (30 lM).
Primary neuronal cultures
Cultures of Wistar rat (embryonic day 18) cortical neurons were
prepared as previously described (Dietrich et al. 2003);
1.5 · 106 cells were plated onto poly-D-lysine-coated six-well
dishes. Cells were maintained in Neurobasal medium (Gibco,
Rockville, MD, USA; Invitrogen, Carlsbad, CA, USA), with B27
serum-free supplements (Gibco; Invitrogen), L-glutamine (0.5 mM),
and penicillin/streptomycin (1%). More than 98% of the cells
cultured under these conditions represent post-mitotic neurons
(Rideout and Stefanis 2002).
Cloning/subcloning
The following clones were generated with a PCR approach from
previously cloned constructs (Chiba-Falek and Nussbaum 2001;
Clough and Stefanis 2007). Del ZSCAN21 was cloned from
intron 1 with the following primers: F, 5¢-TACCTGTGGATC-
TAAACGGGCGTCTT-3¢ and R, 5¢-CCTTTACACCACACTG-
GAAAAC-3¢. The H5¢-2 kb (F, 5¢-AGGGACACAACATCTGA-
GCA-3¢), H5¢-1 kb (F, 5¢-AGGGACACAACATCTGAGCA-3¢),
and 1.8 kb (F, 5¢-CTCCCGATCTCCACAAGAGT-3¢) constructs
were also cloned via PCR from the previously described
constructs (Chiba-Falek and Nussbaum 2001) with a common
reverse primer in the ﬁrst exon (Ex1-R- 5¢-AAAGGCA-
GAAGGCTTGAAGG-3¢). H5¢-352 bp was digested from the
H5¢-2 kb construct in TOPO-TA (Invitrogen) with the enzymes
SmaI and SpeI. The SpeI site was blunt-ended using Klenow
(Promega, Madison, WI, USA) and the fragment was then
subcloned into the pGL3 basic (Promega) SmaI site.
The rat R5¢-452 bp promoter was cloned with a PCR approach
from genomic DNA extracted from the PC12 cell line (F,
5¢-TTCGGGGTTAAAACAAATGG-3¢ and R, 5¢-TTCCTCCTGTT-
TTCCCCAAT-3¢). All constructs were sequenced to verify the
accuracy of the PCR. All sequences generated by PCR were initially
cloned into the TOPO-TA vector (Invitrogen) and then subcloned
into the pGL3-basic luciferase vector (Promega).
Small-scale deletion constructs
Sequential 5¢-deletions of the SNCA promoter and intron 1 were
made with the Erase-a-Base system (Promega) according to the
manufacturer’s instructions. Brieﬂy, 10 lg of plasmid was linearized
and then digested with exonuclease III in a timed manner to generate
deletions of a certain size. Following digestion, plasmids were
religated and transformed into bacteria. The end points of the
deletions were determined by sequencing. The deleted inserts were
then subcloned into the pGL3-basic luciferase vector (Promega) for
use in the luciferase assay.
Transfection and luciferase assay
All transfections were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions and as
previously described (Clough and Stefanis 2007). For the
luciferase assays, all promoter sequences were cloned into the
pGL3-basic luciferase vector (Promega); this plasmid was also
used as the empty-control vector in these assays. Brieﬂy, for the
luciferase assay, all transfections were performed in six-well tissue
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culture dishes with 2.0 · 105 cells/well with 2.0 lg per well of
target vector and 0.5 lg of thymidine kinase-renilla (internal
control). In all luciferase assays, the cells were harvested at day
2.5 post-transfection. All transfections were performed overnight
and complete medium was added the following day. Samples for
western immunoblotting were harvested 48 h post-transfection. For
the small interfering RNA (siRNA) experiments, 25 nM siRNA
was co-transfected with the target luciferase vector. The following
siRNAs were used (all from Qiagen, Valencia, CA, USA): Zipro1
(ZSCAN21; #186910), ZNF219 (#1869160), and All Star Negative
Control (#1027281).
Luciferase assays were detected with the Dual Luciferase Assay
(Promega) according to the manufacturer’s instructions. Graphs
show the mean value of at least three experiments with error bars
depicting the SEM. All values were calculated relative to the
screened vector in untreated PC12 cells.
We (Clough and Stefanis 2007) and others (Madziar et al. 2005)
have observed a two- to threefold induction for the empty pGL3-
basic luciferase vector in the presence of both NGF and bFGF in the
PC12 cell line. All statistical analyses were performed to account for
the level of activation observed in pGL3-basic.
RT-PCR assay
Total RNA was extracted from PC12 cells on day 3 following the
start of treatment using Trizol (Invitrogen). cDNA was generated
with the Reverse Transcription System (Promega) according to the
manufacturer’s instructions. We then performed RT-PCR, using the
cDNA as a template. In preliminary experiments, all primer pairs
were optimized to be in the log-exponential phase of ampliﬁcation.
The following primers were used to perform the PCR: a-SNCA,
F 5¢-TTCTGCGGAAGCCTAGAGAG-3¢ and R 5¢-TCCTCCAA-
CATTTGTCACTTGC-3¢*; b-actin, F 5¢-TCACCATGGATGATGA-
TATCGCC-3¢* and R 5¢-CCACACGCAGCTCATTGTAGAAGG-
3¢*; ZSCAN21, F 5¢-CAGAAGCAGTCTTGGGAGAA-3¢ and R
5¢-TCTCCCTTTCCAGGTTGTTG-3¢; ZNF219, F 5¢-CCCCTT-
CTGTGGGAAATCTT-3¢ and R 5¢-CAGGTAGCAGAGGCCT-
GAGT-3¢; and hepatocyte nuclear factor 4 (HNF4), F 5¢-TAG-
CAGAGATGAGCCGTGTG-3¢ and R 5¢-GAGTCATACTGCC-
GGTCGTT-3¢ (all primers marked * from Baptista et al. 2003).
Products were subsequently resolved on 1.5% agarose gels stained
with ethidium bromide.
Western immunoblotting
PC12 cells were washed twice in phosphate-buffered saline and then
harvested in lysis buffer (150 mM NaCl, 50 mM Tris pH 7.6, 0.1%
sodium dodecyl sulfate, 1% NP-40 (Sigma), and 2 mM EDTA).
Protein concentrations were determined using the Bradford method
(Bio-Rad, Hercules, CA, USA). Fifty microgram of lysates were
mixed with 2x Laemmli buffer prior to running on 12% sodium
dodecyl sulfate–polyacrylamide gels. Following transfer to a nitro-
cellulose membrane, blots were probed with antibodies directed
against: (i) SNCA (BD Biosciences, San Jose, CA, USA) and
(ii) extracellularly regulated kinase (ERK) (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Blots were probed with horseradish
peroxidase-conjugated secondary antibodies and visualized with
Western Lightning (Perkin Elmer, Waltham, MA, USA) and exposed
to Super RX ﬁlm (Fuji Film, Fuji USA, Valhalla, NY, USA).
Following scanning of the images with Adobe Photoshop (Adobe
Systems Inc., San Jose, CA, USA), IMAGEJ software (Abramoff et al.
2004) was used to quantify the intensity of the bands.
Electromobility shift assay
Double-stranded probeswere designed for the humanTF binding sites
identiﬁed inMATINSPECTOR (Cartharius et al. 2005) for ZSCAN21 (5¢-
GACGAGGGGTAGGGGGTGGTCCC-3¢), ZNF219 (5¢-GACGA-
GGGGTAGGGGGTGGTCCC-3¢), HNF4 (5¢-CGAATGTCTCCT-
TTGGGCCATGGGA-3¢), Sp1 (5¢-ATTCGATCGGGGCGGGGC-
GAGC-3¢), and Oct1 (5¢-TGTCAATGCAAATCACTAGAA-3¢).
Probes were 3¢-labeled with biotin (Biotin 3¢-End DNA Labeling
Kit; Pierce, Rockford, IL, USA). For electromobility shift assay
(EMSA), 20 fmol labeled double-stranded oligonucleotides were
incubated in Parker buffer (8% Ficoll, 20 mM HEPES, pH 7.9,
50 mMKCl, 1 mMEDTA, and 0.5 mMdithiothreitol), 1 lg poly(dI/
dC), 12 lg of nuclear extract and incubated at 21C for 20 min.
Sampleswere resolved on a 4%non-denaturing acrylamide gel at 4C,
transferred to Hybond N+ membrane (Amersham Biosciences, GE
Healthcare, Piscataway, NJ, USA) and developed (LightShift Chemi-
luminescent EMSA Kit; Pierce; Clough et al. 2004).
Cell sorting
PC12 cells (1.0 · 107 cells) were transiently co-transfected with
25 nM siRNA (ZSCAN21, ZNF219, or scrambled control) and 5 lg
enhanced green ﬂuorescent protein (EGFP) in 10 cm tissue culture
dishes. Cells were harvested and resuspended in phosphate-buffered
saline with 10% fetal bovine serum and 0.5 mM EDTA to a ﬁnal
concentration of 1.0 · 107 cells/mL. Non-transfected PC12 cells
were used to choose the starting pool of cells for sorting and to
determine the threshold of green ﬂuorescence. By using the 488 nm
laser Coherent Sapphire solid state of BD FACSaria Cell Sorter,
green cells were detected at the emission spectrum of FITC (515–
545 nm), similar to that of EGFP. The sorted samples were used to gen-
erate cell lysates for western immunoblotting (Kyratzi et al. 2008).
Immunocytochemistry and SNCA quantification
Rat cortical neuron cultures from embryonic day 16 fetuses were
plated onto poly-D-lysine-coated 24-well plastic dishes for immuno-
cytochemistry at a density of 1.5 · 105 cells/well. Cultured neurons
were transiently transfected at day 8 with 0.5 lg EGFP and 25 nM of
each siRNA (scrambled control, ZSCAN21, or ZNF219). After 48 h,
cells were ﬁxed in 3.7% p-formaldehyde for 15 min at 4C and then
blocked for 45 min with 10% normal goat serum with 0.4% Triton
X-100, followed by incubation with the following primary antibodies
overnight at 4C: SNCA (BDBiosciences) and GFP rabbit polyclonal
(Synaptic Systems, Goettingen, Germany). Following incubation
with ﬂuorescent secondary antibodies (Cy2 or Cy3; Jackson Immuno
Research, West Grove, PA, USA) for 50 min at 21C, nuclei were
visualized with Hoechst 33258 (1 lM; Sigma). To determine the
relative changes in SNCA expression 100 photos per condition
were taken from four wells of EGFP-transfected cells. SNCA levels
were measured as intensity mean by the IMAGEJ program for all
EGFP-transfected cells per condition. Mean intensities for each
siRNAwere then binned together for analysis (10 units/bin).
Statistics
Statistical analysis was performed using the Student’s t-test for
single analyses. Where multiple testing was required, a one-way
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ANOVA test was utilized, with a post hoc Tukey’s Honestly
Signiﬁcant Difference (HSD) test. Values of p < 0.05 were
considered signiﬁcant. All statistical analyses were performed using
the GRAPHPAD PRISM 4 suite of software (GraphPad Software, Inc.,
San Diego, CA, USA).
Results
Identification and characterization of SNCA intron 1
transcriptional response elements
We had previously identiﬁed two regions in the ﬁrst intron of
SNCA that confer the neurotrophin-based luciferase response
in PC12 cells by generating large-scale deletion constructs
that divided the full-length human intron (1063 bp) into four
quadrants: an element that was responsive to both NGF and
bFGF treatment was located in the 319 bp ﬁrst quadrant
(1063–744 bp) at the 5¢-end of the intron; there was also an
NGF-only-responsive element located in the 194 bp third
quadrant (502–302 bp) (Clough and Stefanis 2007).
We generated a series of small-scale deletion clones in
these areas to localize TF binding sites. For the ﬁrst quadrant,
the level of activation in the luciferase assay upon treatment
with NGF or bFGF signiﬁcantly drops upon deletion of the
ﬁrst 28 bp of this sequence (p < 0.001; Fig. 1a). The level of
activation observed for this ﬁrst clone was not signiﬁcantly
different from any of the sequential deletion constructs and is
at the same level as when the entire ﬁrst quadrant is deleted
(744 bp construct). These data indicated that both the NGF
and bFGF response elements are located in the same 28 bp
region and may be the same site.
Cross-species alignment (CLUSTALW; Larkin et al. 2007)
and MATINSPECTOR analysis in this 28 bp region (with
human, rat, and mouse sequences) identiﬁed three con-
served TF binding sites for the TFs: zinc ﬁnger- and scan
domain-containing protein 21 (ZSCAN21), paired box gene
1, and forkhead box N1. To identify which of these binding
sites was responsible for the induction observed in the
luciferase assay, we deleted the 6 bp binding site for
(a)
(b)
(c)
Fig. 1 Localization of intron 1 response elements. Luciferase assays
for NGF (open columns) and bFGF (hashed columns) treated PC12
cells. (a) PC12 cells were transfected with a series of deletion con-
structs, cloned into a luciferase vector, covering the first quadrant of
SNCA intron 1; following transfection, the cells were treated with NGF
or bFGF and harvested for the luciferase assay 2.5 days later.
Induction is shown relative to the same construct in naı¨ve PC12 cells.
Fold induction of luciferase activity was reduced for all deletion con-
structs compared with the full-length intron 1 sequence (1063 bp) for
both NGF and bFGF treatment (p < 0.001); there were no significant
differences between consecutive constructs. (b) PC12 cells trans-
fected with the full-length intron 1 sequence (Intron 1), intron 1 minus
the ZSCAN21 binding site (del ZSCAN), or a construct lacking the first
quadrant of intron 1 (744 bp). Cells were treated with NGF for 2.5 days
and then assayed for luciferase activity. We observed a significant
reduction of activation between the full-length intron 1 sequence and
the del ZSCAN and 744 bp constructs (NGF: p < 0.01 and bFGF:
p < 0.001). There were no significant differences in the levels of
activation between the del ZSCAN and 744 bp constructs for either
NGF or bFGF treatment, where Intron 1, full-length intron 1 (1063 bp);
del ZSCAN, intron 1 with the ZSCAN21 site deleted; 744 bp, intron 1
lacking the first quadrant. (c) PC12 cells were transfected with a series
of deletion constructs covering the third quadrant of SNCA intron 1,
cloned into the pGL3-basic luciferase vector, and incubated in the
presence of NGF. The results are shown relative to induction for the
same construct in naı¨ve PC12 cells. We observed a significant loss of
activation, to background levels (as observed for the empty pGL3-
basic luciferase vector) between the 341 and 302 bp constructs
(p < 0.001).
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ZSCAN21 from the immediate 5¢-end of the intron 1
sequence. In the presence of NGF the luciferase activity of
the construct lacking the ZSCAN21 binding site (del
ZSCAN) was signiﬁcantly reduced compared with the
full-length intron 1 sequence (p < 0.001; Fig. 1b). There
was no signiﬁcant difference between the ZSCAN21
deletion construct and the 744 bp construct. A similar
pattern was observed in the presence of bFGF. These data
suggest that ZSCAN21 is the TF responsible for the
luciferase induction in this region and that both neuro-
trophins act through the same TF.
Small-scale deletion constructs in the third quadrant of
intron 1 were screened to identify the putative binding site
for the NGF-responsive element there. As seen in Fig. 1c, a
signiﬁcant drop in luciferase activity was observed between
the 341 and 302 bp constructs (p < 0.001). Cross-species
sequence alignment and MATINSPECTOR analysis identiﬁed a
single conserved binding site for the TF HNF4 that overlaps
the 302 bp deletion site.
Electromobility shift assays for the binding sites of
ZSCAN21 and HNF4 from this region with nuclear extract
from NGF-treated PC12 cells demonstrated speciﬁc shifts for
both sets of probes (Fig. 2a, lanes 2 and 7) that could be
competed out in the presence of excess unlabelled probe
(Fig. 2a, lanes 3 and 8). We still observed the shift for both
sets of probes in the presence of an excess of unlabelled non-
(a)
(b)
(c)
(d)
Fig. 2 Characterization of intron 1 transcription factors. (a) EMSA for
the ZSCAN21 and HNF4 binding sites from intron 1. ZSCAN21 and
HNF4 oligonucleotide probes were incubated with nuclear extracts
from NGF-treated and naı¨ve PC12 cells. Double-stranded probes for
ZSCAN21 and HNF4 are run in lanes 1 and 6, respectively, in the
absence of nuclear extract. A shift is observed for both sets of probes
when they are incubated with PC12 nuclear extract from NGF-treated
cells (lanes 2 and 7). We observe a reduction of shifted probe in the
presence of 100·Æmolar excess of cold competitor for both probes
(lanes 3 and 8); in the presence of 100· molar excess of Oct1 or Sp1
(for ZSCAN21 and HNF4, respectively) non-specific cold competitor
the shift is not competed out (lanes 4 and 9). We also observe the shift
of both probes in the presence of nuclear extract from naı¨ve PC12
cells (lanes 5 and 10). (b) RT-PCR for ZSCAN21 in PC12 cells. Naı¨ve
and neurotrophin-treated PC12 cells express mRNA for the TF
ZSCAN21, with no significant difference in levels between the naı¨ve
and neurotrophin-treated cells. (1) Naı¨ve (Ctrl), (2) NGF-treated
(NGF), and (3) bFGF-treated PC12 cells (bFGF). Transfection of
naı¨ve PC12 cells with siRNA against ZSCAN21 (ZSCAN siRNA)
reduced the levels of ZSCAN21 mRNA by 54% (± 8%) when com-
pared with scrambled siRNA-treated cells (scr siRNA). (4) Scrambled
control siRNA-treated PC12 cells; (5) ZSCAN21 siRNA-treated PC12
cells, where ZSCAN, ZSCAN21; ACT, b-actin loading control. (c)
siRNA against ZSCAN21 down-regulate the NGF induction of human
(open columns) and rat (hashed columns) intron 1 in the luciferase
assay in PC12 cells. (1) Human intron 1 + NGF + scrambled siRNA;
(2) human intron 1 + NGF + ZSCAN21 siRNA; (3) human intron 1
lacking the ZSCAN21 binding site + NGF; (4) rat intron
1 + NGF + scrambled siRNA; and (5) rat intron 1 + NGF + ZSCAN21
siRNA. There was significant loss of luciferase activity for both human
(p < 0.001) and rat (p < 0.005) sequences in the presence of siRNA
against ZSCAN21. For the human sequence, there was no significant
difference in activation between the siRNA-treated intron 1 construct
and the construct lacking the ZSCAN21 binding site, where *p < 0.005
and **p < 0.001 significance when compared with scrambled siRNA-
treated cells. (d) Down-regulation of endogenous SNCA expression in
the PC12 cell line. PC12 co-transfected with EGFP and siRNA
(ZSCAN21 or control scrambled siRNAs) were cell sorted and then
probed for SNCA expression with western immunoblotting. (1)
PC12 + NGF + control scrambled siRNA; (2) PC12 + NGF +
ZSCAN21 siRNA; (3) naı¨ve PC12 + control scrambled siRNA; (4)
naı¨ve PC12 + ZSCAN21 siRNA. We observed a reduction of induction
of SNCA levels in the presence of NGF and siRNA of 56% (± 5%)
when compared with NGF-treated cells in the presence of control
scrambled siRNA. There was a reduction of the steady state levels of
SNCA in naı¨ve cells in the presence of siRNA against ZSCAN21 of
48% (± 2%) when compared with control scrambled siRNA-treated
cells (the apparent higher levels of SNCA in the naı¨ve cells are a result
of an over-exposure of the membrane to film), where SNCA, a-syn-
uclein; ERK, loading control.
 2009 The Authors
Journal Compilation  2009 International Society for Neurochemistry, J. Neurochem. (2009) 110, 1479–1490
Transcriptional regulation of a-synuclein | 1483
speciﬁc probe (Fig. 2a, lanes 4 and 9). We were also able to
detect a speciﬁc shift for this probe in nuclear extracts
derived from naı¨ve PC12 cells (Fig. 2a, lanes 5 and 10).
These data indicate that there is a protein in the nuclear
extracts of both naı¨ve and neurotrophin-treated cells that is
able to speciﬁcally bind to the DNA probes.
ZSCAN21 mRNA was detected in both naı¨ve, NGF- and
bFGF-treated PC12 cells with RT-PCR (Fig. 2b, lanes 1, 2,
and 3), but we were unable to detect HNF4 (data not shown).
There were also no signiﬁcant changes in the levels of
ZSCAN21 mRNA between the naı¨ve and neurotrophin-
treated PC12 cells, as determined by this semi-quantitative
method. We also veriﬁed the expression of ZSCAN21 in
cultured sympathetic neurons (data not shown).
We then assessed whether ZSCAN21 was the TF involved
in SNCA regulation via its binding site in intron 1. Down-
regulation of ZSCAN21 with siRNA (Fig. 2b, lane 5)
signiﬁcantly reduced, by 50%, the luciferase activity from
the human intron 1 construct when compared with control
scrambled siRNA (Fig. 2c, bars 1 and 2; p < 0.001). There
was no signiﬁcant difference between the levels of inhibition
of intron 1 luciferase activity by ZSCAN21 siRNA and those
observed for a construct lacking the ZSCAN21 binding site
in the presence of NGF (Fig. 2c, bars 2 and 3). siRNA
against ZSCAN21 was also able to signiﬁcantly inhibit the
NGF-activation from the rat intron 1 sequence when
compared with scrambled siRNA control-treated cells
(Fig. 2c, bars 4 and 5; p < 0.005).
Small interfering RNA for ZSCAN21 (or scrambled
control siRNA) was co-transfected with an EGFP-expressing
vector into PC12 cells which were naı¨ve or subsequently
treated with NGF. These cells were cell sorted and the EGFP-
positive transfected cells were then analyzed for SNCA
levels (Fig. 2d). We observed a clear inhibition of SNCA
expression in both the naı¨ve (Fig. 2d, lanes 3 and 4) and in
the NGF-treated state (Fig. 2d, lanes 1 and 2) in the presence
of siRNA for ZSCAN21 when compared with control
scrambled siRNA. These results conclusively demonstrate
that ZSCAN21 is a TF involved in the regulation of SNCA in
PC12 cells.
(a) 
(b) 
(c) 
(d) 
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Characterization of the 5¢-promoter of SNCA
Our initial analysis of the SNCA promoter showed that the
intron 1-based luciferase activity of NGF or bFGF was
completely abolished with constructs that contained both
intron 1 and the canonical transcriptional start site (TSS) 5¢ of
exon 1 (3.4 and 1.9 kb in Fig. 3a; Clough and Stefanis
2007). This raised the possibility of an inhibitory interaction
between the 5¢-promoter and intron 1 leading to the observed
loss of luciferase activity. To investigate this further we
cloned 2 and 1 kb of the human SNCA 5¢-promoter (H5¢-2
and 1 kb; Fig. 3a), lacking intron 1 and observed a
signiﬁcant induction of luciferase activity with NGF when
compared with the empty pGL3-basic luciferase vector
(p < 0.001; Fig. 3b) with no signiﬁcant difference of induc-
tion between either of these constructs. There was no
signiﬁcant increase of luciferase activity for the human 2 or
1 kb sequences in the presence of bFGF in this assay (data
not shown). To validate this induction for the human
sequences we cloned a smaller 452 bp fragment from the
rat 5¢-promoter (R5¢-452 bp; Fig. 3a) and assayed this in the
presence of NGF and bFGF; we observed a nine- and sixfold
induction of luciferase activity, respectively (NGF:
p < 0.001; bFGF: p < 0.005). The induction for the human
5¢-promoter upon treatment with NGF is not solely depen-
dent upon the presence of the core promoter, as a construct
containing only 352 bp of the promoter (H5¢-352 bp;
Fig. 3a) did not have increased luciferase activity in the
presence of either NGF or bFGF (Fig. 3b). Therefore, upon
isolation from the regulatory elements in intron 1, the
canonical human TSS and 5¢-promoter sequences are able to
respond to NGF and the rat TSS is able to respond to both
NGF and bFGF treatment in the luciferase assay.
We previously identiﬁed an essential role for the mitogen-
activated protein (MAP)/ERK signaling pathway for both
NGF and bFGF induction of the endogenous levels of SNCA
and for intron 1 in the luciferase assay (Clough and Stefanis
2007). There is also an involvement of the phosphatidylino-
sitol-3¢-kinase/Akt pathway for the endogenous expression of
SNCA.
We assessed the kinase pathways implicated in the
induction of the 5¢-promoter in the luciferase assay for both
human and rat sequences. The NGF-induced activation was
signiﬁcantly inhibited using a pharmacological inhibitor of
the MAP/ERK kinase pathway, for both the human and rat
5¢-sequences (Fig. 3c; U0: p < 0.001). For the human 2 and
1 kb 5¢-sequences, we also observed a signiﬁcant inhibition
upon application of an inhibitor of p38-mitogen-activated
protein kinase (Fig. 3c; SB2: p < 0.002). For the rat
sequence, we also observed a signiﬁcant inhibition of
induction for NGF upon inhibition of c-Jun N-terminal
kinase (JNK) (Fig. 3c; SP6: p < 0.01). The differences in the
responses of the human and rat sequences may be related to
the sizes of the constructs used and/or the presence/absence
of TF binding sites. We had previously examined the effects
Fig. 3 SNCA 5¢-promoter. (a) Depicts the 5¢-genomic structure of hu-
man SNCA. Exons are depicted as closed boxes, and introns as lines.
The two promoter sites are depicted by bent arrows, with the putative
intron 1 promoter as a dashed line. Black box indicates the translational
start site in exon 2. Upper panel, luciferase constructs containing both
the canonical transcriptional start site and intron 1 sequences (1.9 and
3.4 kb) are not induced in the luciferase assay in the presence of either
NGF or bFGF (cross mark). Constructs lacking this 5¢-sequence (intron
1 or 1.34 kb) are strongly activated in this assay upon treatment with
neurotrophins (tick mark; Clough and Stefanis 2007). Lower panel,
conserved TF binding sites in the 5¢-promoter and exon 1. Conserved
ZNF219 binding sites (indicated by stars) within the promoter of SNCA.
We identified a critical region involved in the repression of the 1.9 kb
construct, as the observed induction with the smaller 1.8 kb construct
allowed us to localize this element to a 141 bp region. The human
5¢-constructs of 2 and 1 kb, containing this critical area, were activated in
the luciferase assay, as was the rat 5¢-452 bp construct (R5¢-452 bp). A
lack of activation from a smaller human 5¢-construct (H5¢-352 bp) nar-
rowed this critical area down to 62 bp. There was only one conserved
binding site in this area; ZNF219. Two other ZNF219 sites were detected
in this area and are depicted with gray stars. (b) Luciferase induction for
the 5¢-promoter sequence in the absence of intron 1. Human 5¢-se-
quence containing the 5¢-promoter (H5¢-2 and 1 kb) are significantly
induced in the presence of NGF, but not bFGF (data not shown;
p < 0.001), when compared with neurotrophin-treated empty pGL3-
basic luciferase vector (Control); this activation was lost for a smaller
352 bp fragment of the 5¢-promoter (H5¢-352). There was also signifi-
cant activation from a 452 bp fragment of the rat 5¢-promoter (R5¢-452)
in the presence of NGF (p < 0.001) and for bFGF (p < 0.005) when
compared with the levels of activation observed for the empty luciferase
vector. (c) Pharmacological inhibition of the MEK/ERK pathways (U0)
significantly reduces the neurotrophin induction of luciferase activity for
human (open bars, H5¢-2 and 1 kb) and rat (hashed bars, R5¢-452)
sequences for both NGF and bFGF when compared with control-treated
cells. Inhibition with this compound is to the same level as that observed
for the empty pGL3-basic vector in the presence of either neurotrophin.
Induction from the human sequences was also significantly repressed
with an inhibitor of the p38-MAPK pathway (SB2), but this was not
replicated for the rat sequences. There was also a significant inhibition of
luciferase activity for the rat sequences with NGF in the presence of an
inhibitor of the c-Jun N-terminal kinase (JNK) pathway (SP6), which was
not replicated for the human sequences. Inhibitors: U0, MAP/ERK; LY2,
phosphatidylinositol-3¢-kinase; SB2, p38-MAPK; SP6, c-Jun N-terminal
kinase (JNK); *p < 0.01 and **p < 0.001. (d) Serial deletion constructs
for the human 5¢-promoter region reveal the presence of additional
regulatory elements. The induction observed for NGF (clear bars) or
bFGF (hashed bars) for each construct is shown relative to the level of
induction observed for the same construct in naı¨ve PC12 cells. We ob-
serve significant luciferase activity for the 1.8 kb construct, which con-
tains 273 bp of the 5¢-promoter, when compared with the 1.9 kb
construct. There is a further significant increase in activation for the
1.55 kb construct (that contains 70 bp of the 5¢-core promoter). This
activation is then lost for the next smallest construct that terminates 7 bp
inside exon 1 (1.47 kb).
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of these inhibitors on the total levels of SNCA mRNA
and protein and had only observed an effect with inhibitors
of the MAP/ERK and phosphatidylinositol-3¢-kinase path-
ways. We also examined the signaling pathways involved
in the bFGF induction of the luciferase assay for the
rat 5¢-promoter sequences, where only inhibition of the
MAP/ERK pathway was able to inhibit luciferase induc-
tion (Fig. 3c; U0: p < 0.001). These data indicate that the
5¢-canonical promoter is regulated, like intron 1, primarily
through the MAP/ERK signaling pathway.
We generated a series of 5¢-deletions from the human
1.9 kb luciferase construct to identify the elements in the
5¢-promoter of SNCA that were responsible for the inhibition
of the luciferase assay (Fig. 3a). In the presence of NGF or
bFGF, we observed signiﬁcant activation after deleting
141 bp from the 5¢-end of the 1.9 kb construct (1.8 kb;
Fig. 3a and d), indicating the presence of a repressor element
in this region. There was a further increase in luciferase
activity with the next construct (1.55 kb; Fig. 3a and d),
which terminates 70 bp 5¢ from the start of exon 1 and
includes the core promoter. Intriguingly, once the core
promoter is removed (1.47 kb; Fig. 3a and d), the luciferase
activation for both NGF and bFGF falls to background
levels.
We examined constructs that contained only the 5¢-SNCA
promoter sequence and not intron 1. We observed a different
pattern of activation for this same region, as constructs that
contained the region between 1.9 and 1.8 kb (H5¢-2 kb, H5¢-
1 kb, and R5¢-452 bp) were active in the luciferase assay
(Fig. 3b). However, we observed no luciferase induction by
NGF for the H5¢-352 bp construct that terminates 3¢ of this
region (Fig. 3b). This construct narrowed the critical region
down to 62 bp. There was only one conserved binding site
for the TF zinc ﬁnger protein 219 (ZNF219; Sakai et al.
2000, 2003) in this region (Fig. 3a).
Electromobility shift assay with the ZNF219 binding site
in the human 5¢-promoter generated speciﬁc shifts for the
probe in the presence of nuclear extract from NGF-treated
PC12 cells (Fig. 4a, lane 2) that could be competed out in the
presence of an excess of the unlabelled speciﬁc probe
(Fig. 4a, lane 3), but not the non-speciﬁc probe (Fig. 4a, lane
4). We also detected a speciﬁc shift for this probe in nuclear
extracts from naı¨ve PC12 cells (Fig. 4a, lane 5).
Expression of ZNF219 in the PC12 cell line was detected
with RT-PCR in both naı¨ve and NGF-treated cells with no
difference in the levels of ZNF219 in these two conditions
(Fig. 4b, lanes 1–3). ZNF219 was also expressed in cultured
sympathetic neurons (data not shown). Co-transfection of
naı¨ve PC12 cells with siRNA against ZNF219 reduced the
levels of ZNF219 mRNA by 50% (± 3%; Fig. 4b, lane 5)
when compared with control scrambled siRNA-treated cells
(Fig. 4b, lane 4). siRNA for ZNF219 (or scrambled control)
were co-transfected with the pCMS-EGFP vector in PC12
cells, which were subsequently treated with NGF for 2 days
followed by cell sorting. We observed a moderate induction
of SNCA protein levels in the presence of the siRNA against
ZNF219 of 39% (± 6%; Fig. 4c, lane 2) when compared with
scrambled control siRNA transfected cells (Fig. 4c, lane 1;
p < 0.05).
We co-transfected the 1.9 kb luciferase construct with
siRNA against either ZNF219 or scrambled control in the
presence of NGF. As seen in Fig. 4d, we did not observe any
induction in the luciferase assay for this construct as would
be expected from our deletion data. However, the full-length
1.9 kb construct contains three putative binding sites for
ZNF219 and it is possible that there are interactions between
these multiple sites that may be responsible for the observed
repression/activation of luciferase levels. For the human 1 kb
and the rat 452 bp 5¢-promoter sequences, siRNA against
ZNF219 signiﬁcantly repressed luciferase induction in the
presence of NGF when compared with control scrambled
siRNA-treated cells (p < 0.01).
These data indicate that ZNF219 is involved in the
transcriptional regulation of SNCA. The presence of multiple
binding sites for ZNF219 in the promoter of SNCA and the
differential responses observed upon inhibition of the
expression of ZNF219 indicate that its role in the regulation
of SNCA is complex. The available data suggest a scenario
in which ZNF219, by inducing 5¢-promoter elements,
inhibits SNCA transcription via intron 1.
Down-regulation of SNCA in primary cortical neurons with
ZSCAN21 and ZNF219 siRNA.
We then extended our ﬁndings to primary neuron cell
cultures. Cortical neuron cultures were selected because they
represent a homogenous source of near-pure post-mitotic
neurons. We veriﬁed by RT-PCR the expression of ZSCAN21
and ZNF219 mRNA in these neurons (data not shown). These
cultures were then co-transfected with an EGFP-expressing
vector and siRNA against either scrambled control,
ZSCAN21 or ZNF219. Immunoﬂuorescence staining for
SNCA revealed a clear down-regulation of SNCA levels in
the presence of siRNA against ZSCAN21 and ZNF219 when
compared against scrambled control siRNA (Fig. 4e). There
is a clear increase of the percentage of cells in the lower
intensity bins (11–20 and 21–30 units), in ZNF219 (57.3%)
and ZSCAN21 (61.1%) siRNA-treated cultures compared
with control scrambled siRNA (15.9%). These data indicate
that the majority of ZSCAN21 and ZNF219 siRNA-trans-
fected cells were expressing lower levels of SNCA protein
than control scrambled siRNA-treated cells. Therefore, both
TFs appear to act as positive regulators of SNCA transcription
in this primary neuronal cell culture setting.
Discussion
There is now a large body of evidence to indicate that
dysregulation of SNCA is a risk factor in developing PD. To
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further determine the mechanisms that govern the transcrip-
tional regulation of SNCA we examined its promoter to
identify transcriptional control elements. In this study, we
characterize the role of two TFs, ZSCAN21, and ZNF219 in
the expression of SNCA.
Intron 1 is a key regulatory region of SNCA transcription
We have now expanded upon our previous work, in which
we demonstrated that the ﬁrst intron of SNCA was an
unappreciated transcriptional regulatory region (Clough and
Stefanis 2007). Since our original report, a binding site for
the TF GATA binding protein 1 (GATA-1) has been
identiﬁed, also located in intron 1 (Scherzer et al. 2008),
further strengthening the importance of this region in the
regulation of SNCA. This site is distinct from the two
elements we describe here and appears, based on its location,
to not be important in regulating the neurotrophic induction
of SNCA as determined by the luciferase assay. In this study,
(a) (d)
(e)
(b)
(c)
Fig. 4 ZNF219 and SNCA transcriptional regulation. (a) EMSA for the
5¢-TF binding site of ZNF219 with nuclear extracts from NGF-treated
and naı¨ve PC12 cells. (1) Double-stranded probes for ZNF219 in the
absence of nuclear extract. (2) A shift is observed when probe is
incubated with NGF-treated PC12 nuclear extract. (3) In the presence
of 100·Æmolar excess of cold ZNF219 competitor this shift is reduced
and (4) the presence of 100· molar excess of non-specific cold
competitor has no effect upon the levels of shifted probe. (5) We also
observed a shift of the probe in the presence of nuclear extract from
naı¨ve PC12 cells. (b) RT-PCR for ZNF219 in PC12 cells. Naı¨ve and
neurotrophin-treated PC12 cells express mRNA for the TF ZNF219,
with no significant difference in levels between naı¨ve and neurotro-
phin-treated cells. (1) Naı¨ve (Ctrl), (2) NGF-treated (NGF), and (3)
bFGF-treated PC12 cells (bFGF). Treatment of naı¨ve PC12 cells with
siRNA against ZNF219 (ZNF siRNA) reduced the levels of ZNF219
mRNA by 50% (± 5%) when compared with scrambled siRNA-treated
cells (scr siRNA). (4) Scrambled control siRNA-treated PC12 cells; (5)
ZNF219 siRNA-treated PC12 cells, where ZNF, ZNF219; ACT, b-
actin loading control. (c) Down-regulation of endogenous SNCA
expression in the PC12 cell line. PC12 co-transfected with EGFP and
siRNA were cell sorted and then probed for SNCA expression with
western immunoblotting. (1) PC12 + NGF + control scrambled
siRNA; (2) PC12 + NGF + ZSCAN21 siRNA. There was a small but
significant induction of SNCA levels in the presence of NGF and
ZNF219 siRNA of 39% (± 6%; lane 2) when compared with NGF-
treated cells in the presence of control scrambled siRNA (p < 0.05;
lane 1); SNCA, a-synuclein; ERK, loading control. (d) Inhibition of
NGF induction of the luciferase assay by ZNF219 siRNA in PC12
cells. In the presence of siRNA against ZNF219, there was no sig-
nificant up-regulation for the 1.9 kb construct. We observed a signif-
icant reduction in luciferase activity from both the human 5¢-1 kb
(H5¢-1 kb) and rat 5¢-452 bp (R5¢-452 bp) constructs when compared
with scrambled siRNA-treated cells (p < 0.01), where SCR, scram-
bled siRNA; ZNF219, ZNF219 siRNA; *p < 0.01. (e) Down-regulation
of SNCA in Primary Cortical Neurons with ZSCAN21 and ZNF219
siRNA. Graph shows the quantification of SNCA levels from 100
EGFP-transfected rat cortical neurons. Intensity of staining for SNCA
was standardized and the individual scores for cells were grouped into
bins of 10 units/bin. We observed a clear down-regulation of the mean
intensity of SNCA immunofluorescent staining in neurons transfected
with siRNA against ZNF219 and ZSCAN21 when compared with
control scrambled siRNA-transfected cells. The majority of transfected
cells for these two siRNA are in the two lowest detectable bins (11–20
and 21–30).
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we identiﬁed two putative binding sites for TFs in this
region. The ﬁrst is at the 5¢-end of intron 1 and is responsive
to both NGF and bFGF induction in the luciferase assay. The
TF ZSCAN21 that binds to this DNA element is a zinc
ﬁnger-containing TF. It is a member of a large family of TFs
that contain a SCAN domain that mediates protein–protein
interactions (Edelstein and Collins 2005). ZSCAN21 is
expressed in a wide range of tissues, including the CNS (Su
et al. 2004). We have conﬁrmed its expression in primary
neurons, and, by using an siRNA approach, we conclusively
demonstrate its involvement in SNCA regulation in naı¨ve
and neurotrophin-treated PC12 cells, as well as in cultured
cortical neurons.
As there were no changes in the mRNA levels for
ZSCAN21 in PC12 cells in the presence or absence of
neurotrophins and no discernible difference in the bandshifts
observed for nuclear extracts from naı¨ve or neurotrophin-
treated cells, we believe that changes in the protein levels of
ZSCAN21 (and ZNF219) are not responsible for the up-
regulation of SNCA. It is possible that its phosphorylation or
acetylation status, or that of an interacting partner, could be
responsible for the observed induction of SNCA expression
(Park et al. 2007; Siu et al. 2008).
These data further demonstrate the importance of the ﬁrst
intron of SNCA in the transcriptional regulation of SNCA, as
no other binding sites for ZSCAN21 could be identiﬁed
within the SNCA promoter. Gamma-synuclein, a member of
the synuclein family, has also been shown to contain critical
transcriptional regulatory elements within its ﬁrst intron
(Lu et al. 2001; Surgucheva and Surguchov 2008).
We were unable to identify the TF that binds to the critical
region in the third quadrant of intron 1, which responds
solely to NGF-treatment in the luciferase assay. Therefore
there is an, as yet, unidentiﬁed TF that binds to this DNA
sequence and regulates the NGF luciferase induction for this
area of intron 1.
Interaction between elements in the 5¢-promoter and
intron 1
As we observed no luciferase activity for constructs that
contained both intron 1 and the 5¢-promoter, we examined
whether the 5¢-promoter could function in isolation from
these important intron 1 regulatory regions, and we indeed
observed that this was the case. Interestingly, the core
promoter is not sufﬁcient on its own to respond to
neurotrophins in the luciferase assay. The main kinase
signaling pathways utilized for the induction from these rat
and human 5¢-promoter sequences is the MAP/ERK path-
way, as previously seen for intron 1 (Clough and Stefanis
2007).
ZNF219 and SNCA transcriptional regulation
Deletion of 141 bp from the 5¢-end of the 1.9 kb construct
led to the identiﬁcation of a binding site for the TF ZNF219,
which appears to be responsible for the inhibition of
activation in the luciferase assay of constructs containing
both this site and intron 1. Constructs containing just the
5¢-promoter gave a similar, but inverse, correlation in the
luciferase assay; those that contained this critical region were
activated in the presence of NGF, but a construct lacking this
region lost all activation. This indicates that this element can
function as both an activator and a repressor of SNCA
transcription depending upon the presence/absence of other
genomic elements.
ZNF219 is a member of the Kru¨ppel-like zinc ﬁnger gene
family and is a 77 kDa protein containing nine sets of C2H2
zinc ﬁnger structures (Sakai et al. 2003). ZNF219 is widely
expressed in many tissues, including the cerebellum, sub-
stantia nigra, hippocampus, and cerebral cortex (Sakai et al.
2000; Lein et al. 2007). ZNF219 functions as a repressor of
transcriptional activation in the promoter of the high-mobility
group nucleosome binding domain 1 gene and competes for
binding to its target sequence with members of the Sp1
family of transcriptional activators (Sakai et al. 2003). In
support of this view, in the luciferase assay, we observed no
activation for constructs that contained either three or one
ZNF219 binding sites. For constructs that contained two
ZNF219 binding sites we observed an increase in luciferase
activity. Therefore, the exact involvement of ZNF219 in the
regulation of SNCA is somewhat unclear, and will require
further characterization by deleting individual and multiple
sites in the context of the full 1.9 kb construct.
In agreement with its proposed function as a transcrip-
tional repressor we observed a small, but signiﬁcant, increase
in the levels of endogenous SNCA protein levels upon
inhibition of ZNF219 with siRNA in NGF-treated PC12
cells, when compared with scrambled siRNA-treated cells
(Fig. 4c). This effect may be because, in the context of the
whole gene, down-regulation of ZNF219 leads to a release of
its inhibitory effect on the intron 1 regulatory regions,
leading to intron 1-mediated transcriptional activation. In
cortical neuron cultures, the intron 1 and 5¢-promoter
response elements cooperate in the luciferase assay (R.L.
Clough, G. Dermentzaki, M. Haritou, A. Petsakou and L.
Stefanis, unpublished data). Down-regulation of ZNF219 by
siRNA in these cells led to a decrease in SNCA protein
expression, indicating that in this setting ZNF219 acts as a
transcriptional activator of SNCA expression. These data
clearly indicate that ZNF219 functions as both an activator
and a repressor of transcription and that this role may depend
on the cell type and interactions with other binding proteins
and response elements.
We demonstrate here that the SNCA gene has a compli-
cated transcriptional architecture with elements outside of the
core promoter having differential effects upon the expression
of SNCA. The ability to modulate SNCA expression levels
through targeting of speciﬁc TFs may provide a therapeutic
strategy against the over-expression of SNCA in PD and in
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other synucleopathies. Further studies will be needed to
characterize the role of these TFs in the regulation of SNCA
in vivo and to identify other transcriptional targets that they
may have in the CNS. It will also be of interest to screen for
polymorphisms in the two TFs (ZSCAN21 and ZNF219) and
their binding sites in the SNCA promoter in PD patients and
to examine if they have a functional effect upon the levels of
SNCA expression.
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Alpha-synuclein (SNCA) is an abundant neuronal protein of
uncertain function with a predominant pre-synaptic localiza-
tion. It is likely involved in the control of neurotransmission,
possibly by modifying the assembly of the soluble NSF
attachment protein receptor complex (Chandra et al. 2005;
Larsen et al. 2006; Burre´ et al. 2010). In addition, SNCA has
been genetically and pathologically linked to the develop-
ment of Parkinson’s disease (PD). SNCA is thought to
comprise the building block of Lewy Bodies (LBs) and Lewy
neurites that pathologically characterize PD; furthermore,
point mutations or multiplications of the SNCA locus lead to
autosomal dominant PD in rare families (Cookson et al.
2008). The multiplication cases, in particular, indicate that
increased levels of even wild-type (WT) SNCA can lead to
PD. Consistent with this notion, the over-expression of WT
SNCA also leads to phenotypes resembling PD in various
animal models (Feany and Bender 2000; Masliah et al. 2000;
Kirik et al. 2002; Vekrellis et al. 2004).
Even sporadic PD is genetically linked to SNCA. A
number of polymorphisms in the promoter sequence and 3¢
regions of SNCA confer susceptibility to developing PD in
case/control studies (Farrer et al. 2001; Pals et al. 2004,
Mueller et al. 2005; Hadjigeorgiou et al. 2006; Mizuta
et al. 2006). One of these polymorphisms, the non-amyloid
component precursor (NACP) complex dinucleotide repeat
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Abstract
Alpha-synuclein (SNCA) is a predominantly neuronal protein
involved in the control of neurotransmitter release. The levels
of SNCA expression are closely linked to the pathogenesis of
Parkinson’s disease; however, the biochemical pathways and
transcriptional elements that control SNCA expression are not
well understood. We previously used the model system of
neurotrophin-mediated PC12 cell neuronal differentiation to
examine these phenomena. Although these studies were
informative, they were limited to the use of a cell line; there-
fore, in the current work, we have turned our attention to
cultured primary rat cortical neurons. In these cultures, SNCA
expression increased with time in culture, as the neurons
mature. Luciferase assays based on transient transfections of
fusion constructs encoding components of the transcriptional
control region of SNCA identified various promoter areas that
have a positive or negative effect on SNCA transcription. In-
tron 1, previously identified by us as an important regulatory
region in the PC12 cell model, cooperates with regions 5¢ to
exon 1 to mediate gene transcription. Using selective phar-
macological tools, we find that tyrosine kinase receptors and
the phosphatidyl-inositol 3 kinase signaling pathway are in-
volved in mediating these effects. The exogenous application
of the neurotrophin brain-derived neurotrophic factor (BDNF)
is sufficient on its own to promote the transcriptional activation
of SNCA through this pathway, but a neutralizing antibody
against BDNF failed to affect SNCA transcription in maturing
cultures, suggesting that BDNF is not the main factor involved
in maturation-induced SNCA transcription in this model.
Further in vivo studies are needed to establish the role of
neurotrophin signaling in the control of SNCA transcription.
Keywords: brain-derived neurotrophic factor, intron, neuro-
trophin, Parkinson’s disease, transcription, tyrosine kinase
receptor.
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located 10.7 kb upstream of the SNCA gene (Chiba-Falek
and Nussbaum 2001) conferred an odds ratio of 1.43 in a
large meta-analysis when compared with control subjects
(Maraganore et al. 2006); however, it is still not known if the
NACP–REP polymorphism is responsible for this increased
risk or if it is in linkage disequilibrium with the actual
causative agent. More recently, unbiased genome-wide asso-
ciation studies established that the SNCA gene represents one
of the very few genetic loci conclusively linked to sporadic
PD (Satake et al. 2009; Simo´n-Sa´nchez et al. 2009; Edwards
et al. 2010).
There has been controversy regarding the expression
levels of SNCA in the brains of sporadic PD patients, with a
number of studies reporting either increased or decreased or
unchanged levels of SNCA (Neystat et al. 1999; Rockenstein
et al. 2001; Beyer et al. 2004; Kingsbury et al. 2004; Chiba-
Falek et al. 2006; Dachsel et al. 2007; Papapetropoulos et al.
2007). However, in an elegant study, Gru¨ndemann et al.
(2008) used laser-captured microdissection to clearly dem-
onstrate signiﬁcantly elevated SNCA mRNA levels in
individual, surviving neuromelanin- and tyrosine hydroxy-
lase-positive substantia nigra dopaminergic neurons from
idiopathic PD brains when compared with control brains.
Collectively, the above data indicate that the regulation of
SNCA expression through elements within or around the
SNCA locus may be important for PD pathogenesis.
Conversely, although not speciﬁcally studied, the regulation
of SNCA expression may also be important for the control of
synaptic transmission. From a therapeutic standpoint, control
of SNCA expression could represent a target for novel PD
therapeutics.
Despite the obvious importance of the expression of
SNCA, very little is known about the mechanisms, signaling
pathways, and transcriptional elements that regulate its
expression. SNCA is developmentally induced in the rat
brain (Petersen et al. 1999; Kholodilov et al., 2001; Vogiatzi
et al. 2008) and in rat neuronal cell cultures (Rideout et al.
2003; Vogiatzi et al. 2008). Following an initial surge, the
expression levels of SNCA reach a plateau in adult rodent
brain (Petersen et al. 1999; Adamczyk et al. 2005).
In previous studies, to examine the mechanisms involved
in the developmental induction of SNCA, we have used the
model system of PC12 pheochromocytoma clone cells. In
this system, SNCA is up-regulated upon neuronal differen-
tiation with nerve growth factor (Stefanis et al. 2001). This
up-regulation involves the extracellular receptor kinase
(ERK) and phosphatidyl-inositol 3 kinase (PI3-K) pathways,
and transcriptional control elements within intron 1 (Clough
and Stefanis 2007); the transcription factor Zipro1 was
identiﬁed as at least one of these factors in a subsequent
study (Clough et al. 2009).
In this study, we have turned to cultured embryonic rat
cortical neurons as another model cell system to examine the
mechanisms involved in SNCA transcriptional regulation.
We have used these neurons because they represent a rich,
homogeneous source of CNS neurons that mature in culture
and that, as we had previously reported, during this process
up-regulate SNCA protein levels (Rideout et al. 2003).
Moreover, these neurons are affected in the later stages of the
PD disease process; indeed, the development of SNCA
pathology in cortical regions correlates with the impaired
cognition observed in PD with dementia (Mattila et al.,
2000). Two other related disorders, dementia with LBs and
LB variant of Alzheimer’s disease also harbor SNCA-
positive LBs in cortical neurons (Vekrellis et al. 2004;
Cookson et al. 2008). Therefore, cortical neurons represent
an affected population in PD and represent a valuable model
to study SNCA transcriptional regulation.
The present studies in cultured cortical neurons underscore
similarities and differences to our previous results in the
PC12 cell system and reinforce the idea that extracellular
signaling via growth factors may potently modulate neuronal
SNCA levels.
Materials and methods
Cortical neuronal cultures
Cultures of Wistar rat (embryonic day 18, E18) cortical neurons
were prepared as previously described (Rideout and Stefanis 2002;
Dietrich et al. 2003). Dissociated cells were plated onto poly-
D-lysine-coated six-well or 12-well dishes at a density of approx-
imately 1.5–2.0 · 106 cells/cm2. Cells were maintained in Neuro-
basal medium (Gibco, Rockville, MD, USA; Invitrogen, Carlsbad,
CA, USA), with B27 serum-free supplements (Gibco; Invitrogen),
L-glutamine (0.5 mM), and penicillin/streptomycin (1%). More than
98% of the cells cultured under these conditions represent post-
mitotic neurons (Rideout and Stefanis 2002). The time in culture of
cells was calculated using days in vitro (DIV), with the day of
harvesting designated as 0 DIV.
For experiments using the various kinase pathway inhibitors, the
cultured cortical neurons were pre-incubated with the inhibitors for
45 min prior to the addition of the growth factors. U0126 (Sigma, St
Louis, MO, USA) was added to the complete media at 25 lM,
LY294002 (Sigma) at 25 lM; SP600125 (Sigma) at 10 lM; and
SB203580 (Sigma) at 30 lM. For western blot analysis, the cells
were cultured for a total of 5 days in the presence of the inhibitors
and for the luciferase assays, the cells were cultured for 2 days. The
Trk inhibitor K252a (Sigma) was added to the culture medium at a
concentration of 200 nM.
For experiments using exogenous brain-derived neurotrophic
factor (BDNF), BDNF (50 ng/mL; Prospec, Rehovot, Israel) was
added to the culture medium and replaced with fresh medium every
2 days.
To neutralize the activity of endogenous BDNF, days 1 and 8
cortical cultures in six-well dishes were cultured in media containing
a BDNF-neutralizing antibody (10 lg/mL; Chemicon International,
Temecula, CA, USA) or a control antibody matched for species and
class (c-myc, 400 ng/mL; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for 5 days. The media were replaced every 2 days. The
cells were visualized under phase-microscopy and representative
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images were recorded (Leica DFC 350FX; Leica Microsystems,
Wetzlar, Germany).
Western immunoblotting
Cortical neurons were washed twice in phosphate-buffered saline
and then harvested in lysis buffer (150 mM NaCl, 50 mM Tris
pH7.6, 0.1% sodium dodecyl sulfate, 1% NP-40; Sigma, 2 mM
EDTA). Protein concentrations were determined using the Bradford
method (Bio-Rad Laboratories, Hercules, CA, USA). Ten lg of
lysates were mixed with 2 · Laemmli buffer prior to running on
12% sodium dodecyl sulfate–polyacrylamide gels. Following
transfer to a nitrocellulose membrane, blots were probed with
antibodies directed against: (i) a-synuclein (1 : 1000; BD Bio-
sciences, Sparks, MD, USA) and (ii) ERK (loading control;
1 : 5000; Santa Cruz Biotechnology). Blots were probed with
horseradish peroxidase-conjugated secondary antibodies and visu-
alized with Western Lightning (Perkin Elmer, Waltham, MA, USA)
and exposed to Super RX ﬁlm (Fuji Film, P. Phaliro, Greece).
Following scanning of the images with Adobe Photoshop, Image J
software (NIH, Bethesda, MD, USA) was used to quantify the
intensity of the bands. In all cases, the levels of SNCA were
normalized to those of ERK for quantiﬁcation and statistical
analysis.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from cortical neuron cultures using
Trizol (Invitrogen) and cDNA was generated with the Reverse
Transcription System (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. We then performed RT-PCR, using
the cDNA as a template. In preliminary experiments, all primer
pairs were optimized to be in the log-exponential phase of
ampliﬁcation. The following primers were used to perform the
PCR: a-synuclein-F – 5¢-ttctgcggaagcctagagag-3¢, a-synuclein-R –
5¢-tcctccaacatttgtcacttgc-3¢*; b-actin-F – 5¢-tcaccatggatgatgatatc-
gcc-3¢*, b-actin-R – 5¢-ccacacgcagctcattgtagaagg-3¢* (all primers
marked * from Baptista et al. 2003). Products were subsequently
resolved on agarose gels stained with ethidium bromide. All
RT-PCR results are calculated as the ratio of SNCA to b-actin
mRNA, and then compared across conditions.
Transfection and luciferase assay
The 1.46, 3.4, 3.8, 4.1, 6.2, 9.8, and 10.7 kb constructs used in this
study were a kind gift from Drs Nussbaum and Chiba-Falek (Chiba-
Falek and Nussbaum 2001). The human intron 1 (int1), rat intron 1
(rint1), human 5¢ 2-kb promoter (H5¢-2 kb), and rat 5¢ 452-bp
promoter (Rat 5¢-452 bp) constructs were generated as previously
described (Clough and Stefanis 2007; Clough et al. 2009).
All transfections were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions and as
previously described (Clough and Stefanis 2007). Brieﬂy, for the
luciferase assay all transfections were performed in 6 well tissue
culture dishes with 6.0 · 105 cells/well with 2.0 lg per well of
target vector and 0.5 lg of TK-renilla (internal control) (Promega).
A 1 : 3 ratio of transfected DNA to lipofectamine was determined to
give the best transfection efﬁciency in cortical neurons. All
transfections were performed overnight and complete medium was
added the following day.
In all luciferase assays, the cells were harvested 2 days after the
addition of the complete media to the cells. Luciferase assays were
detected with the Dual Luciferase Assay (Promega) according the
manufacturer’s instructions. Graphs show mean value of at least
three experiments with error bars depicting the standard error of the
mean. All values were ﬁrst normalized against Renilla activity in the
same experiment to control for transfection efﬁciency and then
calculated relative to the screened vector in untreated cortical
neurons.
Statistical analysis
Statistical analysis was performed using the Student’s t-test, for
single analyses. Where multiple testing was required, a one-way
ANOVA test was utilized, with a post hoc Tukey’s HSD test. p-Values
< 0.05 were considered signiﬁcant. All statistical analyses were
performed using the GraphPad Prism 4 suite of software (GraphPad
Software, Inc., San Diego, CA, USA).
Results
Developmental regulation of SNCA in cultured cortical
neurons
Alpha-synuclein has been shown to be developmentally
induced in rat brain (Petersen et al. 1999; Vogiatzi et al.
2008), and we have shown that this effect can be replicated in
cultured CNS neurons, a situation in which neurons mature
in culture (Rideout et al. 2003; Vogiatzi et al. 2008). To
begin to study the mechanisms involved in such regulation,
we ﬁrst veriﬁed in our cultured cortical neurons this
induction of SNCA at the level of protein (Figure S1a). We
determined that this developmental induction of SNCA is
controlled, at least in part, by transcriptional regulation, as
we observed a twofold increase in the levels of mRNA for
SNCA after 8 DIV when compared with the levels observed
after 1 DIV using RT-PCR (Figure S1b).
Multiple elements in the SNCA promoter are involved in its
developmental regulation in cortical neurons
We then used the luciferase assay with a range of different
length SNCA promoter constructs (Chiba-Falek and Nuss-
baum 2001) to identify regions of the promoter involved in
the developmental transcriptional regulation of SNCA
(Fig. 1a). We observed signiﬁcant levels of induction for
all constructs from 1.9 to 10.7 kb in length when compared
with the control empty luciferase construct (Ctrl). We
observed no induction from the 1.46 kb construct, which
terminated in the ﬁrst exon of SNCA 3¢ of the canonical
transcriptional start site (TSS). This observation is of interest
as it is the opposite to that which we observed in the rat
PC12 cell line in which induction of SNCA by neurotro-
phins results in an activation for constructs lacking the
canonical TSS (Fig. 1b; Clough and Stefanis 2007; Clough
et al. 2009). In the PC12 cell line, constructs that contain
both the canonical TSS (including approximately 500 bp of
the 5¢ promoter) and intron 1 fail to show activation in the
presence of neurotrophins (Clough and Stefanis 2007;
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Clough et al. 2009). We observed signiﬁcant increases in
activation between the contiguous constructs 1.9 and 3.4 kb
(p < 0.05) and 9.8 and 10.7 kb (p < 0.001); there were also
signiﬁcant decreases in activation between the 3.4 and
3.8 kb (p < 0.01) and 6.2 and 9.8 kb (p < 0.01) constructs
(one-way ANOVA with Tukey’s post hoc test). Of particular
interest is the signiﬁcant increase in activation observed
between the 9.8 and 10.7 kb constructs as the larger
construct contains the complex dinucleotide repeat NACP–
REP (Touchman et al. 2001); polymorphisms in this region
have been linked to an increased risk of developing PD
(Maraganore et al. 2006).
We then examined if the canonical 5¢ promoter or intron 1
would work in isolation in the luciferase assay as we had
previously seen in the PC12 cell line (Fig. 1b; Clough and
Stefanis 2007; Clough et al. 2009). We observed no
induction in the luciferase assay when we compare the level
of activation observed in DIV 8 cultures against DIV 1
cultures for the human (Int1) or rat (Rint1) intron 1
sequences, 2 kb of the human 5¢ promoter lacking intron 1
(H5¢-2kb) or 452 bp of the rat 5¢ promoter (R5¢-452 bp;
Fig. 1c). Therefore, in the cortical neuron system canonical
5¢ promoter elements and Intron 1 do not work in isolation,
but rather in unison to mediate SNCA transcription.
SNCA developmental induction is regulated through the
PI3-K pathway
We then examined if any of the major kinase signaling
pathways were involved in the developmental regulation of
SNCA. Using pharmacological inhibitors to the mitogen-
activated protein kinase/ERK (U0126), PI3-K (LY294002),
c-jun N-terminal kinases (SP600125), and p38-MAPK
(SB203580) pathways, we ﬁrst screened the protein levels
of SNCA (Fig. 2a). We only observed a signiﬁcant reduction
Fig. 1 Developmental regulation by multiple elements in the alpha-
synuclein (SNCA) promoter. (a) Induction in the luciferase assay for 5¢
promoter constructs longer than 1.9 kb in length. Induction in the
luciferase assay was determined by comparing the levels of induction
observed in cultures transfected at days in vitro (DIV) 1 and those
transfected at DIV 8, and then harvested at DIV 3 and 10, respectively.
We observe a clear induction for all constructs 1.9 kb and larger.
Significant increases in induction were observed between the following
constructs: 1.9 versus 3.4 kb and 9.8 versus 10.7 kb. We also ob-
served significant reductions in induction between: 3.4 versus 3.8 kb
and 6.2 versus 9.8 kb. *p < 0.05; **p < 0.01; ***p < 0.001 for one-way
ANOVA with Tukey’s post hoc test (n = 3 per construct). (b) Cartoon
depicting the 5¢ genomic structure of human SNCA. Exons are de-
picted as closed boxes, and introns as lines. The two promoter sites
are depicted by bent arrows, with the putative intron 1 promoter with a
dashed line. Luciferase constructs for this region are depicted as lines
connected to a LUC-labeled box. Stars indicate the localization of
previously identified transcription factor binding sites in the 5¢ promoter
and intron 1 sequences (Clough and Stefani 2007; Clough et al. 2009).
Ticks represent activation in the luciferase assay and crosses repre-
sent a lack of induction. Constructs containing the canonical tran-
scriptional start site and intron 1 sequences are induced in the
luciferase assay in cultured cortical neurons (cross-mark), as as-
sessed in the present experiments (see results in a). Constructs
containing either the 5¢ promoter sequence (Human 5¢-2kb or Rat 5¢-
452 bp) or intron 1 (for human and rat sequences) in isolation are not
induced in this assay (see results below in c). This is the opposite
pattern of induction compared to that observed in PC12 cells in the
presence of neurotrophins, based on our previous results (Clough
et al. 2007; Clough et al. 2009). (c) Luciferase assay for the isolated 5¢
promoter region and intron 1 sequence of SNCA. There was a sig-
nificant induction for the 1.9 kb construct for DIV 8 cultures compared
with DIV 1 cultures (containing intron 1 and 5¢ promoter sequences;
***p < 0.001, Student’s t-test); however, we observed no significant
developmental induction from constructs containing only the human
(Int1) or rat (Rint1) intron 1 sequences for DIV 8 cultures compared
with DIV 1 cultures. We also observed no significant induction from the
5¢ promoter sequences for either the human (H5¢-2kb) or rat (R5¢-
452 bp) constructs (n = 3 per construct).
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in the levels of SNCA for the inhibitor to the PI3-K pathway
in cultures incubated from DIV 1–6 and in cultures from DIV
8–13. Using the luciferase assay with the 1.9 kb construct,
we observed a reduction in the levels of activation for this
construct in cells treated from DIV 1 to 3. For older cultures
(DIV 8–10), this reduction in activation was more pro-
nounced (Fig. 2b). SNCA mRNA levels, as measured with
RT-PCR, were decreased with LY treatment in cultures
treated from DIV 1–6 (Fig 2c).
The PI3-K intracellular signaling pathway is generally
activated in response to extracellular factors, and is classi-
cally involved in growth factor signaling. The involvement
of the PI3-K pathway in SNCA regulation in this model
posed the possibility that growth factor signaling, acting in a
paracrine or autocrine fashion, may be responsible for the
observed phenomenon. To examine this in a general fashion,
we applied the general tyrosine kinase receptor (Trk receptor)
inhibitor k252a to the cultures. We found that this compound
substantially diminished SNCA protein levels both in early
(left panels) and in later (right panels) cultures (Fig 3).
We conclude that the PI3-K pathway is the major pathway
regulating the induction of SNCA in this cell culture system
following extracellular signaling via Trk receptors.
Increased SNCA induction in the presence of the
neurotrophin BDNF
Our data with LY2 and k252a suggested to us that the
induction of SNCA with maturation in culture may be under
the control of exogenous factors secreted by the cultured
cortical neurons. Cultured cortical neurons secrete the
neurotrophins BDNF, neurotrophin (NT)3, NT4/5 (Sometani
et al. 2001). We assessed the levels of SNCA in cultures
incubated over a 5-day period in the presence of BDNF. As
seen in Fig. 4(a), we observed signiﬁcant increases in SNCA
protein in cultures incubated from DIV 1 to 6 or from DIV 8
to 13 in BDNF (p < 0.05, Student’s t-test), when compared
with untreated controls. At the level of mRNA, we also
observed a signiﬁcant increase in the levels of SNCA for
both early (DIV 1–6) and late (DIV 8–13) cultures (p < 0.05,
Student’s t-test), when compared with untreated controls,
Fig. 2 Developmental induction of SNCA is controlled through the
phosphatidyl-inositol 3 kinase (PI3-K) signaling pathway. (a) Western
immunoblot of samples harvested from early (DIV 1–6) and late (DIV
8–13) cultures of cultured cortical neurons treated for 5 days with
various pharmacological inhibitors of the major kinase signaling
pathways. For both sets of cultures, we observe a clear inhibition of
the developmental induction of SNCA following treatment with LY, the
PI3-K inhibitor. This was confirmed in multiple experiments (n = 3),
which are depicted on the right panel. LY caused a significant inhibition
of SNCA levels at both time points (DIV 1–6, **p < 0.001; DIV 8–13,
*p < 0.01; one-way ANOVA with Tukey’s post hoc test). C, control; U0,
U0126 (MEK/ERK inhibitor); LY, LY294002 (PI3-K inhibitor); SB,
SB203580 (p38-MAPK inhibitor); SP, SP6 (JNK inhibitor); SNCA; a-
synuclein; ERK, Erk loading control; and DIV, days in vitro. (b) Lucif-
erase assay for the 1.9 kb luciferase construct in the presence (LY) or
absence of LY2 (Ctrl), a pharmacological inhibitor of the PI3-K path-
way. We observed reduced levels of activation in early (DIV 1–3) and
late (DIV 8–10) cultures in the presence of LY2 (n = 3; both *p < 0.05,
Student’s t-test). Ctrl, control; LY, LY294002 (PI3-K inhibitor); and DIV,
days in vitro. The levels of induction for the DIV 8–10 cultures in the
luciferase assay are measured relative to those observed in the DIV
1–3 cultures. DIV, days in vitro; LY, LY294002 (PI3-K inhibitor); and
Ctrl, control. (c) Cultured cortical neurons treated with an inhibitor of
the PI3-K pathway (LY+) from days 1 to 6 in culture exhibit significantly
reduced levels of mRNA for SNCA when compared with untreated
control cells (LY)) (n = 3; *p < 0.01, Student’s t-test). The graph
represents the quantification of three independent samples. +, treated
with the inhibitor of the PI3-K pathway; ), control cells; SNCA, a-
synuclein; ACT, b-actin loading control; DIV, days in vitro; and LY,
LY294002 (PI3-K inhibitor).
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Fig. 3 Developmental induction of alpha-synuclein (SNCA) is inhib-
ited by the Trk inhibitor k252a. Cultured cortical neurons were treated
with the general Trk inhibitor k252a (+) or left untreated ()) from days
1 to 6 (left panel) or from days 8 to 13 (right panel). Lysates were then
generated and used for western immunoblotting with antibodies
against SNCA (top) or ERK (bottom, as loading control). Quantification
of the results from multiple experiments (n = 3) is presented on the
right. With both treatments at the different time points, k252a signifi-
cantly reduced SNCA levels (**p < 0.01 for days 1–6 and *p < 0.05 for
days 8–13, Student’s t-test).
Fig. 4 Increased alpha-synuclein (SNCA)
transcriptional induction in the presence of
the neurotrophin brain-derived neurotrophic
factor (BDNF). (a) Western immunoblot
demonstrating that BDNF treatment (+) for
5 days significantly increases the protein
levels of SNCA in both early [days in vitro
(DIV) 1–6] and late (DIV 8–13) cultures of
cortical neurons when compared with un-
treated ()) cultures (n = 3; *p < 0.05, Stu-
dent’s t-test). (b) RT-PCR demonstrates
that BDNF treatment (+) for 5 days signifi-
cantly increases the mRNA levels of SNCA
in early (DIV 1–6) and late (DIV 8–13) cul-
tures of cortical neurons when compared
with untreated ()) cultures (n = 3; p < 0.05,
Student’s t-test). (c) The luciferase assay
reveals a differential mode of action of
BDNF in early and late cultures of cortical
neurons. In all three promoter constructs
examined (1.9, 3.4, and 4.1 kb), we ob-
served a small, but significant increase in
activation of the luciferase assay in early
cultures (DIV 1–3) treated with BDNF when
compared with control cultures (n = 3;
*p < 0.05, Student’s t-test). In late cultures
(DIV 8–10), we observe a significant
reduction in the activation of the luciferase
assay for BDNF-treated cultures when
compared with control cells (n = 3;
*p < 0.05, Student’s t-test). Levels of
induction for the DIV 8–10 cultures in the
luciferase assay are measured relative to
DIV 1–3 cultures. DIV, days in vitro; ),
control untreated cells; +, BDNF-treated
cells; SNCA, a-synuclein; ERK, Erk loading
control; and ACT, b-actin loading control.
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although the difference was marginal in the latter case
(Fig. 4b).
In an indicative experiment, we examined the levels of
SNCA protein in cultures continuously treated with BDNF
from DIV 1 until DIV 13 and compared them with the levels
observed in control untreated cells (Figure S2). As we had
observed in Figure S1(a), the levels of SNCA in control
cultures reach a plateau after 7 DIV, although in the current
experiment the level of induction was higher, reaching about
sixfold compared with day 1. For cultures treated with
BDNF, we observe higher levels of SNCA from day 3
onwards and the levels of SNCA keep increasing until DIV
11 when they too reach a plateau. This increase of SNCA
levels over a longer time period that control cells in the
presence of BDNF is analogous to the in vivo setting where
the levels of SNCA keep increasing at least until P21
(Vogiatzi et al. 2008).
In the luciferase assay, we observed a consistent pattern of
activation in the presence of BDNF in early cultures (DIV 1–
3) and a reduction of activation with BDNF treatment in the
later cultures (DIV 8–10; Fig. 4c), when compared with
untreated control cells. This pattern was observed for a
number of different length SNCA promoter constructs (1.9,
3.4, and 4.1 kb) indicating that it was a general feature of the
SNCA promoter. It would appear therefore that these
transcriptional elements are responsible for the BDNF-
induced SNCA induction only in the early cultures.
We then examined if the BDNF molecule signaled through
the same PI3-K pathway as the putative secreted factor
responsible for the developmental induction of SNCA. As
expected (see Fig. 2), the pharmacological inhibitor of the
PI3-K pathway LY2 applied over days 1–6 signiﬁcantly
decreased SNCA protein levels in cultures not treated with
BDNF. LY2 also reduced the induction observed in the
presence of BDNF to background levels (Fig. 5a). We
Fig. 5 Brain-derived neurotrophic factor (BDNF) and the develop-
mental induction of SNCA. (a) Developmental induction and BDNF
induction signal through the same kinase signaling pathway. Western
immunoblot of protein harvested from cultured cortical neurons [days
in vitro (DIV) 1–6] showing that co-incubation of a phosphatidyl-inositol
3 kinase (PI3-K) inhibitor and BDNF abolishes the induction of SNCA
observed in the presence of BDNF on its own, that is, there was no
significant difference in the levels of SNCA between conditions Ctrl
and BDNF+LY cells. Ctrl, control cells; BDNF, BDNF treatment
(**p < 0.001 vs. Ctrl; one-way ANOVA with Tukey’s post hoc test); LY,
treatment with a pharmacological inhibitor of the PI3-K pathway
(LY294002; *p < 0.05 vs. Ctrl; one-way ANOVA with Tukey’s post hoc
test); BDNF + LY, treatment with BDNF and LY294002 (##p < 0.001
vs. BDNF; one-way ANOVA with Tukey’s post hoc test). No other
inhibitor of the major kinase signaling pathways (MEK/ERK, JNK, and
p38-MAPK) significantly altered the BDNF effect (data not shown). (b)
Developmental induction and BDNF induction signal through the same
kinase signaling pathway as determined by the luciferase assay. We
observed similar inhibition of the luciferase assay for the 1.9 kb con-
struct as to what we observed for SNCA protein levels in Fig. 2(b).
Ctrl, control cells; BDNF, BDNF treatment (*p < 0.01 vs. Ctrl; one-way
ANOVA with Tukey’s post hoc test); LY, treatment with a pharmaco-
logical inhibitor of the PI3-K pathway (LY294002; *p < 0.01 vs. Ctrl;
one-way ANOVA with Tukey’s post hoc test); and BDNF + LY, treatment
with BDNF and LY294002 (#p < 0.01 vs. BDNF; one-way ANOVA with
Tukey’s post hoc test; n = 3 per condition). (c) Phenotypic changes
associated with treatment of cultured cortical neurons with a neutral-
izing antibody to BDNF. In cultures from DIV 1 to 6, we observed a
loss of cell bodies and fine neuritic network and a thickening and
elongation of some cell processes in association with the application of
an anti-BDNF antibody when compared with cells treated with a
control antibody (c-myc). In these early cultures, we also observed
some clustering of the surviving cell bodies. In DIV 8–13 cultures, we
again observed a loss of cell bodies and a thickening of the cell pro-
cesses, when compared with the control-treated cultures (n = 3). (d)
Neutralizing antibody to BDNF has no effect upon the developmental
induction of SNCA. We observed no differences in the levels of SNCA
protein in either early (DIV 1–6) or late (DIV 8–13) cultures treated with
a neutralizing antibody to BDNF (+) when compared with cultures
treated with a control antibody to c-myc ()) (n = 3).
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observed no effects of inhibition of the other major kinase
signaling pathways (mitogen-activated protein kinase–ERK,
c-jun N-terminal kinases, and p38-MAPK) on the induction
observed upon addition of exogenous BDNF (data not
shown). Similar repression of the BDNF effect upon
inhibition of the PI3-K pathway were observed for the
luciferase assay with the 1.9 kb construct in cultures treated
from DIV 1 to 3 (Fig. 5b).
Cultured cortical neurons were then treated with a
neutralizing antibody to BDNF to verify if they do indeed
use BDNF in the regulation of SNCA (Fig. 5c). We
observed no signiﬁcant differences in the levels of SNCA
in early (DIV 1–6) or late (DIV 8–13) cultures upon
treatment with this neutralizing antibody. This suggests that
BDNF is not a required factor responsible for the matura-
tional induction of SNCA in these neurons. Phenotypically,
treatment of cortical cultures with this neutralizing BDNF
antibody (anti-bdnf) from DIV 1–6 (upper panel) or DIV 8–
13 (lower panel) resulted in a loss of neuronal cell bodies
and ﬁne neuritic network, a clustering of neurons, and a
thickening and an elongation of some cell processes, when
compared to cells treated with a control antibody (c-myc;
Fig. 5d), conﬁrming that the antibody had biological effects
at the doses utilized.
Discussion
Although SNCA levels play a critical role in familial and
sporadic PD, potentially in other neurodegenerative condi-
tions, and in the control of synaptic neurotransmission, the
mechanisms that regulate SNCA transcription are not well
understood. We have previously used the model system of
PC12 cells to examine such mechanisms. This stemmed from
our original observation that mRNA and protein levels of
SNCA increase following treatment with growth factors in
this system, in parallel to the well-known phenomenon of
induced neuronal differentiation (Stefanis et al. 2001). We
expanded these studies by showing that SNCA levels are
similarly regulated by basic ﬁbroblast growth factor (bFGF),
but not glial cell line-derived neurotrophic factor, in ventral
midbrain dopaminergic neurons, although, in this cell culture
system, the main determinant of SNCA induction was
maturation with time in culture. In this same work, we found
that cultured cortical neurons also showed marked SNCA
induction with maturation in culture, mimicking a phenom-
enon observed during development (Rideout et al. 2003).
In this work, we have used cultured cortical neurons to
examine in more detail the mechanisms regulating the
transcription of SNCA in primary CNS neurons, as our
previous mechanistic work relied heavily on the use of the
PC12 cell line. Our results indicate that there are important
similarities and differences between the two model cell
culture systems. In our prior work in PC12 cells, we were
able to map out the signaling pathways and transcriptional
elements involved in nerve growth factor- and bFGF-
mediated SNCA induction. Brieﬂy, pharmacological and
molecular modulation of the ERK and PI3-K signaling
pathways inhibited SNCA induction, indicating the involve-
ment of these pathways in SNCA transcriptional control.
Such control was achieved, at least in part, through
elements in intron 1 of SNCA and, speciﬁcally, within its
ﬁrst and third quadrants (Clough and Stefanis 2007).
Subsequent work has shown that the element within the
ﬁrst quadrant represents the binding site for the transcrip-
tion factor Zipro1 (ZSCAN21), and that the transcriptional
control region is quite complex, involving additional
transcription factors, such as ZNF219 (Clough et al.
2009). Further downstream within Intron 1, another group
has mapped out another important element for SNCA
transcriptional control, the transcription factor GATA-2
(Scherzer et al. 2008).
The complex organization of the SNCA promoter region
has been veriﬁed in the current work using varying lengths of
this region in luciferase reporter assays and assessing
luciferase activity over time in culture. It should be noted
that these results are based on transient transfections, and may
not reﬂect experiments under stable conditions. There are
signiﬁcant differences in activity between constructs of
varying length throughout almost the extent of the promoter
region, indicating the existence of multiple transcriptional
control regions. A basic difference, however, between the
PC12 cells and the primary cortical neurons is that in
the former case the intron 1 region was sufﬁcient for the
induction of SNCA transcriptional activity, whereas in
the latter it is not (Fig. 1). Furthermore, in the PC12 cells,
regions 5¢ of exon 1 are sufﬁcient to induce SNCA
transcriptional activity, whereas in the cortical neurons they
are not. In fact, these two regions, the 5¢ region to exon 1 and
intron 1, appear to act antagonistically in PC12 cells
(transcriptional activity can be elicited with each region in
isolation, but not when they are present together), whereas
they act synergistically in cortical neurons maturing in culture
(transcriptional activity can be elicited only when they are
present together, but not separately; Fig. 1b). This activity
indicates that in both systems these regions contain important
regulatory elements, but that they interact in a different
fashion in each system.
Our current data, therefore, reinforce the importance of
intron 1 regulatory regions in the transcriptional control of
SNCA, as in the cortical neuron cultures they are necessary
for SNCA transcriptional activation. This is in agreement
with our previous data that indicated that Zipro 1, a
transcription factor with a binding site at the very 5¢-end of
intron 1, mediates SNCA transcription, as its down-regula-
tion via RNAi signiﬁcantly suppressed SNCA protein levels
in these cultures (Clough et al. 2009).
Differences and similarities are also noted in terms of
the biochemical signaling pathways involved. Although in
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the PC12 cell model, the ERK pathway is involved in the
transcriptional control of SNCA (Clough and Stefanis 2007),
this is not the case in cultured cortical neurons (Fig. 2). In
contrast, the PI3-K pathway is required in both models for
SNCA transcriptional activation. Therefore, modulation of
this pathway may provide a more general means through
which to limit excessive levels of SNCA. This, however,
entails potential toxicity as the Akt/PI3-K pathway is a major
regulator of survival (Chong et al. 2005).
A recent study suggested that the over-expression of
another major genetic cause of PD, leucine-rich repeat kinase
2, activates the ERK pathway and, through this induction,
leads to a slight increase of SNCA levels in non-neuronal
cells. Of note, only WT leucine-rich repeat kinase 2, but not
the PD-associated mutant, had this effect (Carballo-Carbajal
et al. 2010). Another elegant study in enteric neurons has
also identiﬁed the Ras/ERK pathway as a regulator of alpha-
synuclein transcriptional activation in enteric neurons fol-
lowing elevation of cAMP or depolarization (Paillusson
et al. 2010). Our present study suggests that a note of caution
is required regarding the generalization of these ﬁndings in
other systems, as even within neuronal populations context-
dependent effects are signiﬁcant, and the ERK pathway may
not represent a general mechanism for the transcriptional
regulation of SNCA. In vivo studies will be required to more
conclusively demonstrate involvement of these signaling
pathways in SNCA transcription.
Our results with the general inhibitor of Trk receptors
indicate that such receptors are involved in the induction of
SNCA in cultured cortical neurons. The fact that this induction
mimics ex vivo the developmental induction observed in vivo
raises the possibility that similar mechanisms mediated by
growth factor signaling may control SNCA induction in vivo,
at least in the developing rodent CNS. In cortical neuron
cultures, TrkB and TrkC receptors are expected to mediate
responses to naturally secreted growth factors, such as BDNF,
NT3, and NT4–5, which can mediate autocrine or paracrine
effects (Maisonpierre et al. 1990). BDNF is the best charac-
terized of these neurotrophins in terms of its potential
relationship to PD, as BDNF promotes the survival of nigral
neurons in PD experimental models (Hyman et al. 1991), it is
required for complete nigrostriatal neuronal development
(Baquet et al. 2005; Oo et al. 2009), and it is down-regulated
in PD brains (Howells et al. 2000); furthermore, polymor-
phisms within the BDNF gene may be linked to PD (Momose
et al. 2002), although this is controversial (Xiromerisiou et al.
2007). We decided, therefore, to focus on this neurotrophin in
this study. We have found that BDNF is sufﬁcient to induce
SNCA transcriptional activity through the same signaling
pathway (i.e., PI3 kinase-dependent) and response elements as
the stimulus of time in culture. However, the inhibition of
BDNF signaling through the use of neutralizing antibodies had
no effect on SNCA levels. This indicates that although BDNF
is sufﬁcient for the activation of Trk receptors and the
subsequent induction of SNCA transcription, it is not the main
neurotrophin responsible for this effect during maturation in
culture. The possibility remains that the other secreted
neurotrophins, for example, NT3 or NT4/5, could function
in a compensatory manner because of the lack of functional
BDNF.
Our current and previous (Stefanis et al. 2001; Rideout
et al. 2003; Clough and Stefanis 2007; Clough et al. 2009)
studies collectively suggest that neurotrophins and growth
factors such as bFGF have the potential to regulate the levels
of SNCA. Further studies will be required to ascertain
whether such neurotrophin-mediated effects actually occur in
the in vivo setting, especially during development or in
situations where SNCA levels change in the setting of
plasticity (George et al. 1995) or toxic insults (Vila et al.
2000). It is tempting to speculate, given the localization of
SNCA at the pre-synaptic terminals and its likely function in
the regulation of synaptic release that such modulation of
SNCA may serve to mediate the effects of neurotrophins,
such as BDNF, on neuroplasticity.
In conclusion, we provide here evidence for the complex
architecture of the SNCA transcriptional regulatory region
in the context of primary cortical neurons that mature in
culture. In this setting, the regulatory regions 5¢ to exon 1
and in intron 1 cooperate for the induction of SNCA
transcription. These effects are mediated through Trk and
PI3-K signaling. The application of exogenous BDNF
simulates these effects, but inhibition of its effect in
maturing cultures does not lead to an appreciable alteration
in the levels of SNCA, suggesting that BDNF is not the
main factor involved in the induction of SNCA with
maturation in culture. These ﬁndings highlight the complex
regulation and context dependency of SNCA transcriptional
control that relies, at least in part, on extracellular signaling
via neurotrophins.
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 Alpha-synuclein  (AS)  dimers  can  be detected  in  human  erythrocytes.
 No  difference  in  AS  monomer  between  Gaucher  disease  (GD)  patients  and  controls.
 Increase  of  dimer  to  monomer  ratio  of AS  in  GD  patients  vs.  controls.
 No  change  of  AS  monomer  with  aging.
 Increase  of  AS  dimer  to monomer  ratio  with  aging.
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a  b  s  t  r  a  c  t
Gaucher  disease  (GD)  patients  and carriers  of  glucocerebrosidase  mutations  are  at  an  increased  risk  for
Parkinson’s disease  (PD).  The  presynaptic  protein  alpha-synuclein  (AS)  is linked  to PD.  In the  current  work
we examined  biochemical  properties  of  AS  in GD  patients.  We  generated  membrane-enriched  lysates
from  erythrocytes  of  27  patients  with  GD  and  32 age-  and  sex-matched  controls  and  performed  Western
immunoblotting  with  antibodies  against  AS. Levels  of monomeric  AS  did  not  differ between  GD patients
and  controls  and  did  not  change  as  a  function  of  age. However,  the  ratio of  dimeric  to  monomeric  AS  was
signiﬁcantly increased  in  GD  patients,  and  showed  a signiﬁcant  positive  correlation  with  age.  Therefore,
two  major  risk  factors  for PD,  aging  and  GD  status,  are  associated  with  an  increased  AS dimer  to  monomer
ratio  in  erythrocytes.  This  ratio  needs  to  be  validated  in  further  studies  as  a potential  biomarker  for  PD
risk.
© 2012 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Gaucher disease (GD) is a rare autosomal recessive disorder
characterized by a deﬁciency of the lysosomal enzyme gluco-
cerebrosidase (GBA), leading to accumulation of its substrate
glucocerebroside [11]. A body of work has emerged demonstrating
an association between GD and Parkinson’s disease (PD). In partic-
ular, GD patients [3] and heterozygote carriers of GBA mutations
[17,21,8] have an increased risk of developing PD, and subjects
with GBA mutations who develop Parkinsonism demonstrate on
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cal Research Foundation of the Academy of Athens, Soranou tou Efesiou 4, Athens
11527, Greece. Tel.: +30 210 6597214; fax: +30 210 6597545.
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autopsy the typical neuropathological hallmarks of PD [17,8].  The
mechanism through which GBA mutations predispose to PD is
unknown.
Based on genetic, neuropathological and experimental data,
alpha-synuclein (AS) has emerged as a major player in PD patho-
genesis. It is widely believed that the pathway of AS misfolding,
oligomerization and ﬁbrillization, collectively termed aggregation,
participates in neurodegeneration in PD and other synucle-
inopathies [6].  Although AS aggregates in PD cases associated with
GBA mutations [17,8,10], it is unknown whether AS levels are actu-
ally elevated in GD patients, and whether AS provides the link
that connects GD with PD. To address this issue, we  have exam-
ined material derived from GD red blood cells (RBCs), an abundant
source of AS, and compared levels of AS monomeric and dimeric
species with those present in RBCs of an age- and gender-matched
control group. In the process, we  have also assessed whether AS in
RBCs manifests age-dependent alterations.
0304-3940/$ – see front matter ©  2012 Elsevier Ireland Ltd. All rights reserved.
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2. Materials and methods
2.1. Standard protocol approvals, registrations and patient
consents
The protocol of the study was approved by the Institutional
Boards and Ethics Committees of each institution involved in the
study (Institute of Child Health, Athens, Greece; Evaggelsimos
Hospital, Athens, Greece; Attikon Hospital, Athens, Greece). Most
samples were available from stored material at the Department
of Enzymology and Cellular Function, Institute of Child Health.
For new samples obtained during the course of the study, writ-
ten informed consent was obtained from all patients (or guardians
of patients) participating in the study.
2.2. Population of patients and controls
Blood samples from 27 Gaucher patients, both male (11
patients) and female (16 patients) were studied. Their age ranged
from 7 days to 77 years (mean age 39.8 years). The control group
comprised 32 age and sex-matched normal subjects (13 male sub-
jects; 19 female subjects; age ranging from 12 days to 78 years;
mean age 35.2 years). The Department of Enzymology and Cel-
lular Function, Institute of Child Health, provided GD, as well
as most control samples. GD was diagnosed through assaying of
glucocerebrosidase in leucocytes and/or skin ﬁbroblast culture.
Control samples were derived from children who tested negative
for peroxisome diseases (plasmalogens and long chain fatty acid
levels were estimated in erythrocytes and in plasma serum sam-
ples respectively) or healthy adult hospital/laboratory personnel.
Additional controls were obtained from the Second Department of
Neurology, Attikon Hospital, and the Department of Neurosurgery,
Evaggelismos Hospital, Athens, Greece. These included patients
with degenerative disease of the spine or healthy volunteers.
2.3. Obtaining of samples and protein extraction
Red blood cell (RBC) pellets were prepared from heparinized
blood samples through spinning at 2200 × g for 10 min  at 4 ◦C and
3 consecutive washing steps with 1 volume of 0.9% NaCl. The RBC
pellets were stored at −80 ◦C in 0.9% NaCl (1:1, v/v) and were
thawed (cell lysis) upon use. Membrane pellets were puriﬁed from
lysed RBCs through repeated washings in cold PBS and centrifu-
gation at 13,000 rpm for 10 min  at 4 ◦C. Supernatants containing
cytosolic proteins, mainly hemoglobin, were discarded. The mem-
brane pellets were then solubilized with 50 l STET lysis buffer
(50 mM Tris (pH 7.6), 150 mM NaCl, 2 mM EDTA, 1% Triton-X) on ice
for 30 min. Solubilized membrane extracts were ﬁnally centrifuged
(13,000 rpm; 10 min; 4 ◦C) and the supernatant was  transferred to
a new tube and used for Western immunoblotting.
2.4. Western Immunoblotting
Protein concentrations from membrane-enriched erythrocyte
extracts were determined using the Bradford method (Bio-Rad,
Hercules, CA, USA). Forty micrograms of protein was run on 12%
sodium dodecyl sulfate-polyacrylamide gels. Following transfer
to a nitrocellulose membrane, blots were probed with antibod-
ies directed against AS: Syn 1 (BD Biosciences, San Jose, CA, USA),
C-20 (Santa Cruz Biotechnology), and Syn 2.11 (Santa Cruz Biotech-
nology), and ERK (BD Biosciences, San Jose, CA, USA). Blots were
probed with horseradish peroxidase-conjugated secondary anti-
bodies and visualized with enhanced chemiluminescence substrate
(ECL) following exposure to Super RX ﬁlm (FUJI FILM, Europe GmbH,
Germany).
2.5. Band quantiﬁcation
The Gel analyzer software 1.0 (Biosure, Greece) was used to
quantify the intensity of the bands, following scanning of the
images with Adobe Photoshop 7.0. The ratio of monomeric AS to
ERK, used as loading control, was  ﬁrst assessed. In order to perform
the comparison across different Western blots, an internal control
was always included on each blot as the reference point regarding
the monomeric AS/ERK ratio.
Ratios of dimer to monomer of AS were assessed in a similar
fashion. Values were normalized using the same blood sample as
an internal control, the ratio of which was set as 1. Of note, the
absolute AS dimer to monomer ratio of the internal control sample
was similar across all blots (range from 0.19 to 0.36, mean = 0.29,
SEM = 0.02, n = 7), attesting to the reproducibility of this ratio across
blots.
2.6. Peptide competition
To test whether the Syn 1 monoclonal antibody and the C-20
polyclonal antibody react speciﬁcally with AS species, antibodies
diluted in PBS were incubated for 1 h at room temperature in the
presence of 10-fold molar excess of recombinant AS or 187-fold
molar excess of the blocking peptide sc-7011 P (Santa Cruz Biotech-
nology) respectively. Following a 10-fold dilution in the case of
the C-20 polyclonal antibody, the Syn 1-recombinant AS or the
C-20–peptide sc-7011 mixture were used at a 1:1000 dilution to
detect AS following SDS PAGE and immunoblotting.
2.7. Statistical analysis
Statistical analysis was  performed either via Student’s t-test or
with linear regression with the GraphPad Prism 4 program with
statistical signiﬁcance set at P < 0.05. Data were parametrically dis-
tributed, and similar results with linear regression analysis were
achieved using correlation analysis.
3. Results
3.1. AS species are readily detected in human erythrocytes
Initial attempts to detect AS by Western immunoblotting in bio-
logical material other than RBCs were unsuccessful, as AS was not
detected in cell lysates derived from cultured skin ﬁbroblasts, and
only a small amount was  detected in an isolated white blood cell
(WBC) preparation. However, since it was not clear to what extent
it was derived from contaminating erythrocytes and/or platelets
[1],  it was not pursued any further. Thus, and despite the fact that
other investigators have used ELISA to measure AS in peripheral
blood mononuclear cells (PBMCs) [2],  our investigation focused
only on RBCs. The ﬁrst step involved the detection of AS in RBCs
using Western immunoblotting as previously reported [1].  Typical
results of such experiments are shown in Fig. 1. A band migrating
at the level of monomeric AS, at around 17 kDa could invariably
be detected. In some samples, high molecular species (HMS), and
in particular a band migrating at the expected size for a dimer,
around 35 kDa, were also detected. This band migrated at the same
level on the blot using either one of the antibodies, and was also
detected using the human-speciﬁc 211 antibody (data not shown).
Such species were competed out when the antibodies were previ-
ously incubated either with an excess of the immunizing peptide
(the case for C-20), or human recombinant AS (in the case of Syn-1)
(Fig. 1).
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Fig. 1. Speciﬁcity of Syn-1 and C-20 antibodies to -synuclein species. Lysates from Gaucher erythrocytes were separated by SDS PAGE and immunoblotted with the C-20
polyclonal (A) or Syn 1 monoclonal (B) antibodies to -synuclein (AS). AS immunoreactivity was  diminished when antibodies were preincubated with molar excess of either
the  peptide to C-20 (A) or human recombinant AS (B).
3.2. Monomeric AS levels are not signiﬁcantly different between
GD and control RBCs
Since the C-20 antibody appeared to be more sensitive toward
the detection of AS (Fig. 1), and especially the presumed oligomeric
species, this antibody was used in all subsequent experiments. The
levels of monomeric AS across the two groups, GD and control
subjects, were initially investigated, using ERK as the loading con-
trol. As shown in Fig. 2A, there was considerable variability in AS
levels across samples, even within the same group, i.e. GD or con-
trols. Overall, statistical analysis showed no signiﬁcant difference
between monomeric AS levels in our two study groups (Fig. 2B),
i.e. no signiﬁcant correlation between monomeric AS levels and
GD status was found. Similar results were obtained when we used
beta-actin as a loading control (data not shown).
3.3. AS dimer to monomer ratio is higher in GD patients
compared to controls
Even from our initial experiments (see Figs. 1 and 2), it appeared
that AS oligomeric species might be more prominent in GD patients.
To assess this in a systematic fashion, we went on to compare the
dimer/monomer AS ratio in the two groups. Longer exposure times
were used in such Western immunoblotting experiments, so that
the dimer would be readily visible. As shown in Fig. 3, the initial
impression was conﬁrmed, as statistical analysis showed that the
dimer/monomer ratio was signiﬁcantly higher in the GD compared
to the control group.
3.4. AS monomer levels show no correlation to age
We also examined possible changes of monomeric AS levels
as a correlation of age. We  assessed each group separately; lin-
ear regression analysis of normalized protein loading data showed
no signiﬁcant age-related association in the levels of AS monomer
in either of the two groups (Fig. 4A). Assessment of all samples
together also failed to show any correlation of monomeric AS levels
with age (data not shown).
3.5. AS dimer to monomer ratio increases with age in the control,
but not in the GD group
We performed a similar linear regression analysis to assess
whether the dimer/monomer AS ratio changed with aging. We
observed a statistically signiﬁcant positive correlation of this ratio
with aging in the control, but not in the GD group (Fig. 4B). Inter-
estingly, the AS dimer/monomer ratio in the GD group differed
markedly from the control group in early and middle ages, but was
similar to that of the older control subjects (>70 years of age). There
was no correlation of the dimer/monomer ratio with age when all
samples were assessed together (data not shown).
4. Discussion
The genetic link of GD to PD is now widely accepted, yet the
molecular and biochemical underpinnings of this effect remain
unknown. Given the pivotal role of AS oligomerization and aggre-
gation in PD pathogenesis, we hypothesized that AS homeostasis
could somehow be affected in GD. Support for this idea is provided
Fig. 2. Monomeric AS levels in Gaucher and control samples. (A) Lysates from Gaucher (G), (G17 55 years old and G74 7 days old subjects) and control (ctl) (ctl67 4, ctl65 10
and  ctl62 38 years old subjects) erythrocytes were separated with SDS-PAGE, and immunoblotted with the C-20 polyclonal antibody to AS and the loading control ERK. Note
the  wide variability in monomeric AS levels and the faint, in this exposure, presence of the dimeric form. (B) The graph shows the normalized AS monomer to ERK ratio in
control  (black solid squares) and Gaucher (black solid triangles) samples respectively. Statistical analysis made via t test showed no signiﬁcant difference of AS monomer to
ERK  ratio between control (n = 32) and Gaucher samples (n = 27). P value =0.3698.
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Fig. 3. (A) AS dimer to monomer ratio in Gaucher and control samples. Lysates from Gaucher (G8 32, G47 71, and G43 4.5 years old subjects) and control (ctl62 38 and ctl59
27  years old subjects) erythrocytes were separated with SDS-PAGE and immunoblotted with the C-20 polyclonal antibody to AS. There is an apparent increase of the AS
dimer, but also of higher molecular weight species, in Gaucher compared to control samples. In the ﬁrst lane, a lysate derived from human neuroblastoma SH-SY5Y cells
inducibly expressing WT AS (wt) [24] is depicted for comparison. Note that both the monomer and the dimer in these samples migrate lower than the corresponding bands
in  the human erythrocytes. (B) The graph shows the normalized AS dimer to monomer ratio in control (black solid squares) and Gaucher (black solid triangles) samples
respectively. Statistical analysis made via t test showed a signiﬁcant increase for this ratio in Gaucher samples (n = 27), with a P value = 0.0135 compared to controls (n = 32).
by the presence of AS pathology in the brains of GD patients who
develop Parkinsonism [17,8,10], and by the increase of monomeric
and/or oligomeric AS in pharmacological or genetic cell culture and
in vivo models of GD [13,25,7,15]. To further explore this hypothesis
in human tissue material, we embarked on a study to systematically
assess AS in various accessible tissues using Western immunoblot.
The lack of signiﬁcant expression in other accessible tissues how-
ever has forced us to restrict our study to RBCs.
The main ﬁnding from our study is the signiﬁcantly increased
ratio of dimer/monomer of AS in RBCs in patients with GD com-
pared to age- and gender-matched controls. As this was not
accompanied by an increase of monomeric alpha-synuclein, it sug-
gests an increased tendency of conversion of the monomeric to
the dimeric form. There was the impression that higher molecu-
lar weight forms were also increased in the group of GD patients
(see for example Fig. 3), however because such bands were rather
broad and fuzzy they were not formally quantiﬁed. The AS dimer
is thought to be the limiting step toward oligomer formation [12].
Such ﬁndings suggest increased tendency of oligomerization of AS
in GD patients, which may  act as a risk factor for PD development.
Consistent with this idea, the major risk factor for PD development,
aging, was also associated with an increase of the dimer/monomer
ratio, but only in the group of controls. The lack of an association of
aging with this ratio in GD patients may  be due to the fact that in
this group blood was obtained for diagnostic purposes; therefore
in all cases it represents the subjects’ state at the time of diagnosis,
which may  be rather homogeneous regarding AS oligomerization
potential. Alternatively, this may  represent a state marker, which
cannot be increased above a certain threshold.
The fact that two risk factors for PD development, GD and aging,
are associated with increased tendency of AS to oligomerize in
RBCs provides important biological insights into PD pathogene-
sis, placing AS oligomerization, detectable in peripheral tissues, at
an early stage of the pathogenetic process. How can we  explain
the increased tendency of AS to oligomerize in GD RBCs and with
aging? Given the fact that we  are assessing AS in membrane-rich
fractions, it is tempting to speculate that alterations in membrane
composition, and in particular the lipid bilayer, may occur in these
two conditions, and may  lead to enhanced AS oligomerization.
Accumulation of glycosphingolipids, and in particular glucocere-
broside, as occurs in GD, may  lead to alterations in membrane lipid
trafﬁcking [9].  Erythrocytes, despite their lack of lysosomes, also
have increased levels of glucocerebroside [18], probably through
internalization of plasma lipoprotein-derived glucocerebroside [5].
Aging has also been associated with alterations of membrane-
associated cholesterol [14]. It is known that change of membrane
and lipid composition can profoundly inﬂuence AS oligomerization
behavior [20,23]. Another possibility is that in these two condi-
tions, aging and GD, there is increased oxidative stress that drives
conversion of monomeric AS to the dimeric and other oligomeric
forms. Indeed, both conditions have been associated with erythro-
cyte oxidative stress [4,16],  and in turn oxidative stress is known
Fig. 4. Correlation of AS monomer and AS dimer/monomer ratio with age. (A) The graph shows the AS monomer to ERK ratio with the corresponding age in Gaucher (open
white  squares, dotted line) and control (black solid triangles, black line) samples. We observed no signiﬁcant age-related difference in the AS monomer to ERK ratio neither in
the  Gaucher nor in the control group. Statistical analysis made through the GraphPad Prism Linear Regression program showed r2 = 0.004158 and P value = 0.7259 for control
group  (n = 32) and r2 = 0.001624 and P value = 0.8450 for Gaucher group (n = 27) respectively. (B) The graph shows the correlation of the AS dimer to monomer ratio with
the  corresponding age in Gaucher (white open squares, dotted line) and control (black solid triangles, black line) samples. We observed an age-related signiﬁcant increase
in  the AS dimer to monomer ratio for the control group, whereas there was  no signiﬁcant age-dependent correlation in the Gaucher group. Statistical analysis through the
GraphPad Prism Linear Regression program showed r2 = 0.2907 and P value = 0.0015 for control group (n = 32) and r2 = 0.01983 and P value = 0.4836 for Gaucher group (n = 27)
respectively.
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to enhance AS dimerization and oligomerization [12]. Of potential
relevance is a study providing evidence of increased nitrosylation
of AS in PBMCs of PD patients [19].
Our ﬁndings are based on a modest sample size and the study
had a retrospective design, analyzing for the most part material
that had already been obtained and preserved for other purposes.
Our work therefore needs replication in a larger prospective and
longitudinal study, where RBCs can also be obtained prior- and
post-enzymatic replacement therapy. It will also be very important
to include in such a study heterozygotes, carriers of GBA mutations.
The aging effect will also need to be validated in such a future study.
The AS oligomer/monomer ratio was recently reported to be ele-
vated in PD patients compared to controls in a study performed
in CSF [22]. It will be very important to examine whether the
dimer/monomer ratio in RBCs used here also differentiates PD
patients from controls, as would be expected if this ratio reﬂects
relative PD risk. Further work along these lines will be needed to
test the possibility that this ratio may  be a useful biomarker for dis-
ease risk, disease onset and/or progression. An advantage of such a
biomarker would be the ease of accessibility of the tissue and the
relative simplicity of the method employed.
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Abstract
To date, a plethora of studies have provided evidence favoring an association between Gaucher disease (GD) and
Parkinson’s disease (PD). GD, the most common lysosomal storage disorder, results from the diminished activity of the
lysosomal enzyme b-glucocerebrosidase (GCase), caused by mutations in the b-glucocerebrosidase gene (GBA). Alpha-
synuclein (ASYN), a presynaptic protein, has been strongly implicated in PD pathogenesis. ASYN may in part be degraded by
the lysosomes and may itself aberrantly impact lysosomal function. Therefore, a putative link between deficient GCase and
ASYN, involving lysosomal dysfunction, has been proposed to be responsible for the risk for PD conferred by GBA
mutations. In this current work, we aimed to investigate the effects of pharmacological inhibition of GCase on ASYN
accumulation/aggregation, as well as on lysosomal function, in differentiated SH-SY5Y cells and in primary neuronal
cultures. Following profound inhibition of the enzyme activity, we did not find significant alterations in ASYN levels, or any
changes in the clearance or formation of its oligomeric species. We further observed no significant impairment of the
lysosomal degradation machinery. These findings suggest that additional interaction pathways together with aberrant
GCase and ASYN must govern this complex relation between GD and PD.
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Introduction
Gaucher Disease (GD), is the most prevalent lysosomal storage
disorder (estimated incidence 1 in 40.000–60.000) that follows an
autosomal recessive trait. It is due to the diminished activity of the
enzyme b-glucocerebrosidase (GCase). As a consequence gluco-
sylceramide (GluCer) and, its deacylated form, glucosylsphingosine
(GlcSph), accumulate in practically every tissue examined,
including the brain. This accumulation is believed to lead to
cellular pathology, through a mechanism that is not completely
understood. The disease exhibits a remarkable heterogeneity that
has been observed in its clinical symptoms, even among twins
carrying identical mutations, suggesting the involvement of
additional modifiers [1,2]. Classically, GD is divided into three
clinical types, GD type 1, GD type 2 and GD type 3 depending on
the presence, degree and rate of progression of neurologic
involvement. GD 1, the most common type, is distinguished as
the non-neuronopathic type, a classification that has been
challenged due to its association with Parkinson’s Disease (PD)
and parkinsonism [3]. More specifically, genetic studies have
identified GBA mutations as one of the most common reported
risk factors for PD [4–12]. Many studies have attempted to shed
light on the complex relation between GD and PD. One candidate
culprit for this relation is alpha-synuclein (ASYN). Firstly, ASYN is
an abundant neuronal protein that has been linked to PD
pathogenesis. Intraneuronal inclusions, mainly consisting of ASYN
(Lewy bodies, Lewy neurites), are pathological hallmarks of PD
and other synucleinopathies. Secondly, ASYN degradation has
been proposed to take place in lysosomes, in part via chaperone-
mediated autophagy (CMA) [13–16]; therefore, potential lyso-
somal dysfunction in neuronal cells due to diminished GCase
activity could in time lead to ASYN accumulation and PD
pathology.
In support to the presence of an interaction (direct or indirect)
between ASYN and aberrant GCase, gain and/or loss-of-function
models have been proposed. Immunofluorescence studies in brain
samples from PD and/or Lewy body dementia individuals, along
with GD or GBA mutation carriers, have shown the presence of
GCase in LBs and LNs in most cases [17,18], suggesting a gain-of-
function mechanism via a direct interaction. In accordance with
the above, a recent study has demonstrated aggregation of ASYN
in brain samples from individuals with GBA mutations [19].
Another study revealed that the direct interaction between WT
GCase and ASYN under acidic conditions was stronger compared
to the interaction with mutant GCase [20]. Likewise, GBA
mutants were reported to promote ASYN accumulation whereas
pharmacological inhibition of GCase activity did not affect ASYN
levels in vitro [21]. On the other hand, other groups favor a positive
correlation between loss of GCase activity and ASYN accumula-
tion. Manning Bog et al [22] showed elevated ASYN levels
following pharmacological inhibition of GCase. In support of the
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notion of loss of function, in an extended study, Mazzulli et al [23]
demonstrated accumulation of toxic, soluble oligomeric interme-
diates of ASYN and impaired lysosomal function, both in primary
neuronal cultures, in which GBA had been lowered via RNAi, and
in human iPS neurons derived from a GBA mutation carrier.
Under the scope of this evidence, we undertook the present study
to further investigate the contribution of deficient GCase activity
to ASYN levels and lysosomal function in differentiated SH-SY5Y
cells, in a doxycycline-inducible Tet-Off system for ASYN, and in
primary neuronal cultures. We found that GCase deficiency was
not sufficient to either up-regulate ASYN or compromise the
lysosomal degradation machinery, suggesting the presence of
additional molecular mechanisms which, synergistically with
aberrant GCase activity, contribute to the pathogenesis of PD
and related synucleinopathies.
Figure 1. ASYN levels remain unchanged following GCase inhibition in differentiated SH-SY5Y cells. (A) Differentiated SH-SY5Y cells
were exposed to increasing doses of CBE (50, 100, 200 mM) for 72 h and 7 days respectively. Untreated cells served as control (ctl). Cell pellets were
assessed for GCase enzymatic activity at the aforementioned doses and time points. (B–C) Cell lysates were separated with SDS-PAGE and
immunoblotted with the C-20 polyclonal antibody to ASYN. ERK= loading control. (D–E) Graphs show quantification of ASYN immunoreactivity (vs
ERK) via densitometric analysis at 72 h and 7 day time point respectively. Statistical analysis made via One Way Anova showed no significant
difference in ASYN levels at the given doses and time points (n = 8).
doi:10.1371/journal.pone.0060674.g001
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Materials and Methods
Cell Culture
Neuroblastoma SH-SY5Y cells were cultured in RPMI 1640
plus L-glutamine (Sigma, St. Louis, MO, USA) supplemented with
10% heat-inactivated FBS and 1% penicillin/streptomycin (com-
plete medium). The stable inducible Tet-Off SH-SY5Y neuro-
blastoma cell line overexpressing WT ASYN described in [14,24]
was also cultured in the above complete medium in the presence
(WT+dox) or in the absence (WT – dox) of doxycycline (2 mg/mL)
(dox, Clontech). Differentiation of SH-SY5Y cells was with all-
trans Retinoic Acid (RA, 20 mM, Sigma). With the particular SH-
SY5Y line we are working with, there is full neuronal differen-
tiation, as assessed by neuronal markers, 5 days after RA
application [24]. For pharmacological studies Conduritol B-
Epoxide (CBE, Sigma), 3-Methyladenine (3MA, Sigma-Aldrich),
Bafilomycin (Baf, Sigma-Aldrich), NH4Cl (Sigma-Aldrich) and
rapamycin (rap, Sigma-Aldrich) were added at indicated time
points and concentrations. In particular, the CBE inhibitor was
replenished every other day together with the change of the
medium.
Primary Culture
Cultures of Wistar rat (embryonic day 18) cortical neurons were
prepared as previously described [25,26]. 1.56106 cells were
plated onto poly-D-lysine-coated six-well dishes. Cells were
maintained in Neurobasal medium (Gibco, Rockville, MD,
USA; Invitrogen, Carlsbad, CA, USA), with B27 serum-free
supplement (Gibco; Invitrogen), L-glutamine (0,5 mM), and
penicillin/streptomycin (1%). More than 98% of the cells cultured
under these conditions represent post-mitotic neurons [27]. All
efforts were made to minimize animal suffering and to reduce the
number of the animals used, according to the European
Communities Council Directive (86/609/EEC) guidelines for
the care and use of laboratory animals. All animal experiments
were approved by the Institutional Animal Care and Use
Committee of Biomedical Research Foundation of the Academy
of Athens.
Assay of GCase Activity
Cell pellets from differentiated SH-SY5Y cells or rat embryonic
cortical cultures treated with or without CBE were homogenized
in water by sonication. GCase activity was determined in whole
cell homogenates using the artificial fluorogenic substrate 4-
methylumbelliferyl b-D-glucopyranoside in the absence of tauro-
cholate. The reaction mixture contained 5 mmol/L substrate in
citrate phosphate buffer pH:4,5. The reaction was stopped after
30 min incubation at 37uC by the addition of 0,25 mol/L glycine-
NaOH, pH:10,4 [28].
Figure 2. LC3 II levels slightly increase following GCase inhibition in differentiated SH-SY5Y cells. (A–B) Differentiated SH-SY5Y cells
were exposed to increasing doses of CBE (50, 100, 200 mM) for 72 h and 7 days respectively. Untreated cells served as control (ctl). Cells were lysed,
separated with SDS-PAGE and immunoblotted with the LC3 polyclonal antibody. ERK= loading control. (C–D) Graphs show quantification of LC3 II
immunoreactivity (vs. ERK) via densitometric analysis at 72 h and 7 day time point respectively. Statistical analysis made via One Way Anova showed a
significant increase in LC3 II levels for the 100 mM dose at the 7 day time point only, compared to ctl cultures (P,0,05; n = 8).
doi:10.1371/journal.pone.0060674.g002
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Fractionation Assay
Stable inducible Tet-Off SH-SY5Y neuroblastoma cell lines
overexpressing WT ASYN [14,29] were cultured in the presence
(+) or absence (2) of dox (2 mg/mL) for 7 days. Subsequently, cells
were differentiated for 5 days and then were exposed for various
periods of time to CBE (200 mM), a pharmacological GCase
inhibitor, either in the presence or absence of dox. Untreated cells
were also used (ctl). Following this, cells were lysed in mild lysis
buffer (50 mM Tris, pH 7,6, 1 mM EDTA, PH 8,0) and protease
inhibitors. Lysates were passed through an insulin syringe and
centrifuged at 6006g for 5 min at 4uC. Supernatant was
transferred to a new tube and centrifuged at 100.0006g for 2 h
at 4uC. The resultant supernatant represents the cytosolic fraction.
The pellet was washed 65 with solution: 50 mM Tris, pH 7,6,
1 M NaCl, 1 mM EDTA, PH 8,0 and centrifuged at 10.000 X g
for 5 min at 4uC. Finally the pellet was resuspended in STET lysis
buffer (50 mM Tris, pH 7,6, 150 mM NaCl, 1% Triton X-100,
2 mM EDTA) with protease inhibitors. This fraction represents
the membrane-associated, Triton X-100 soluble fraction [30].
Intracellular Protein Degradation
Total protein degradation in differentiated SH-SY5Y cultured
cells was measured by pulse-chase experiments [13,14,29,31] with
modifications. Briefly, differentiated SH-SY5Y cells were exposed
to CBE (200 mM) at day 5 of differentiation for 5 days. Untreated
cells were used as well as controls. Following this treatment, cells
were labeled with [3H] leucine (2 mCi/ml) (leucine, L-3,4,5;
PerkinElmer Life Sciences) at 37uC for 48 h, in the presence or
absence of CBE. The cultures were then extensively washed with
medium and returned in starvation medium (0,5% FBS) contain-
ing 2,8 mM of unlabeled excess leucine for 6 h. This medium
containing mainly short lived proteins was removed and replaced
with complete fresh medium containing the general lysosomal
inhibitor Baf (500 nM)/NH4Cl (20 mM) or the inhibitor of
macroautophagy 3MA (10 mM) in the presence or absence of
CBE (200 mM), as above. At this concentration 3MA is known to
completely inhibit macroautophagy [32,33] and in our hands it
abolishes the rapamycin-induced induction of LC3 II (Figure S1).
Aliquots of the medium were taken at 14 h and proteins in the
medium were precipitated with 20% trichloroacetic acid for
20 min on ice and centrifuged (10,0006g, 10 min, 4uC).
Radioactivity in the supernatant (representing degraded proteins)
and pellet (representing undegraded proteins) was measured in a
liquid scintillation counter (Wallac T414, PerkinElmer Life
Sciences). At the same time point, cells were also harvested and
lysed with 0.1% NaOH. Proteolysis was expressed as the
percentage of the initial total acid precipitable radioactivity
(protein) in the cell lysates transformed to acid-soluble radioactivity
(amino acids and small peptides) in the medium during the
incubation. Baf or NH4Cl-inhibited degradation represented total
lysosomal degradation, whereas 3MA-inhibited proteolysis repre-
sented macroautophagic degradation. Relative CMA-dependent
degradation was calculated as total lysosomal minus macroauto-
phagic-dependent degradation [14], as microautophagy is not
thought to play a significant role in bulk lysosomal protein
degradation. In addition CMA activity is routinely measured in
this fashion in our laboratory and others [13,14;29]. Such activity
is drastically and commensurately altered with molecular manip-
ulation of LAMP-2A expression [14; Xilouri et al., manuscript
submitted], confirming that it reflects CMA-related activity. We
cannot exclude the possibility that this measurement includes a
small component of microautophagy.
Western Immunoblotting
Cultured cells (differentiated neuroblastoma SH-SY5Y cells or
differentiated WT ASYN 6 dox cells or embryonic rat cortical
neurons), were washed twice in cold PBS and then harvested in
STET lysis buffer (50 mM Tris, pH 7,6, 150 mM NaCl, 1%
Triton X-100, 2 mM EDTA) with protease inhibitors. Lysates
were centrifuged at 10.0006g for 10 min at 4uC. Protein
concentrations were determined using the Bradford method
(Bio-Rad, Hercules, CA, USA). Twenty to thirty micrograms of
lysates were mixed with 4x Laemmli buffer prior to running on
10% (for LAMP-2A, Hsc70), 12% (for ASYN) or 15% (for LC3)
SDS–polyacrylamide gels. Following transfer to a nitrocellulose
membrane, blots were probed with the following antibodies:
polyclonal ASYN C-20 (Santa Cruz Biotechnology), polyclonal
LC3 (Molecular Probes), polyclonal p62 (Molecular and Biological
Laboratories), polyclonal rat LAMP-2A (Zymed, Invitrogen),
polyclonal human LAMP-2A (Abcam), polyclonal Hsc70 (Abcam),
polyclonal ERK (BD Biosciences, San Jose, CA, USA), and
monoclonal b-actin (Santa Cruz Biotechnology). Blots were
probed with horseradish peroxidase-conjugated secondary anti-
bodies and visualized with enhanced chemiluminescence substrate
(ECL) following exposure to Super RX film (FUJI FILM, Europe
GmbH, Germany). After scanning the images with Adobe
Photoshop 7,0, Gel analyzer software 1,0 (Biosure, Greece) was
used to quantify the intensity of the bands.
Statistical Analysis
Statistical analysis was performed using One-way ANOVA with
a post hoc Tukey’s. Values of p,0,05 were considered significant.
Figure 3. Lysosomal activity is not compromised following
GCase inhibition in differentiated SH-SY5Y cells. Differentiated
SH-SY5Y cells were treated or not (control cells) with CBE (200 mm) for 5
days. Following this, cells were radiolabelled with [3H] leucine
supplemented with either 3MA (10 mM) or Baf (500 nM) and then
assayed for long-lived protein degradation as described analytically in
‘‘Materials and Methods’’. Untreated cells were also used as control (ctl).
Values are the mean 6SE of two independent experiments that were
represented in triplicate per condition. Statistical analysis made via One
Way Anova revealed no difference in the activity of the different
lysosomal pathways between CBE-treated and control cells.
doi:10.1371/journal.pone.0060674.g003
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All statistical analyses were performed using the GRAPHPAD
PRISM 4 suite of software (GraphPad Software, Inc., San Diego,
CA, USA).
Figure 4. ASYN levels remain unchanged following GCase inhibition in rat embryonic cortical cultures. (A) Rat cortical neuron cultures
were prepared from embryonic day 18 (E18) rat foetuses and were exposed at the 6th day of culture to increasing doses of CBE (100, 200 mM) for 72 h
and 7 days respectively. Untreated cells served as control (ctl). Cell pellets were assessed for GCase enzymatic activity at the aforementioned doses
and time points. (B) Cell lysates were separated with SDS-PAGE and immunoblotted with the C-20 polyclonal antibody to ASYN. ERK= loading
control. (C) Graph shows quantification of ASYN immunoreactivity (vs ERK) via densitometric analysis at the 7 and 10 day time points respectively.
Statistical analysis made via One Way Anova showed no significant difference in ASYN levels at the given doses and time points (n = 6 samples/2
different culture preparations with 3 independent biological samples per condition).
doi:10.1371/journal.pone.0060674.g004
Figure 5. LC3 II shows no change following GCase inhibition in rat embryonic cortical cultures. (A) Cultured cortical neurons (E18) were
exposed to increasing doses of CBE (100, 200 mM) for 7 and 10 days respectively. Untreated cells served as control (ctl). Cells were lysed, separated
with SDS-PAGE and immunoblotted with the LC3 polyclonal antibody. ERK= loading control. (B) Graphs show quantification of LC3 II
immunoreactivity (vs. ERK) via densitometric analysis at the 7 and 10 day time points respectively. Statistical analysis made via One Way Anova
showed no difference in the LC3 II levels for the corresponding doses and time points of CBE in comparison to the control samples (n = 6 samples/2
different culture preparations with 3 independent biological samples per condition).
doi:10.1371/journal.pone.0060674.g005
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Results
ASYN Levels Show No Change after CBE Treatment in
Differentiated SH-SY5Y Cells
Previous data have shown that both pharmacological and
molecular inhibition of GCase activity can lead to increased
ASYN levels in in vitro systems [22,23]. To analyze the effect of
GCase inhibition upon ASYN levels we inhibited GCase activity
by the use of the specific inhibitor CBE. We used a well-
established cell line available in our laboratory, the neuroblastoma
SH-SY5Y cells. These cells assume a neuron-like phenotype upon
differentiation and express both ASYN and GCase. The first step
was to assay GCase activity in these cells cultured in the presence
of the CBE inhibitor for various periods of time (72 h, 7 days) and
at various doses of the inhibitor (50, 100, 200 mM). We observed a
dramatic inhibition of GCase enzymatic activity, even at the lower
dose of 50 mM, following a 72 h exposure to CBE (, 95%)
(Figure 1A). We then evaluated ASYN levels by Western
immunoblot analysis under these conditions. No changes in
ASYN levels were observed even at the higher dose and exposure
time of CBE (200 mM, 7 days) (Figure 1B–E). Similar results were
obtained in non-differentiated SH-SY5Y cells (data not shown).
These data demonstrate that inhibition of the GCase is not
sufficient to alter ASYN levels at the given time points in neuronal
SH-SY5Y cells.
Inhibition of GCase Activity does not Compromise
Lysosomal Function in Differentiated SH-SY5Y Cells
As inhibition of GCase activity appeared to not affect ASYN
levels in differentiated SH-SY5Y cells at the given doses and time
points, we next examined whether GCase inhibition could affect
lysosomal function.
Lysosomal function has been found to be compromised upon
partial depletion of the lysosomal form of GCase and in GD iPS
neurons in vitro [23]. In a first level, we aimed to assess changes in
LC3 II levels (an autophagosome marker per se) in differentiated
SH-SY5Y cells. Increases in the conversion of LC3 I to LC3 II are
a strong indication of accumulation of autophagosomes, which
could occur either due to induction of macroautophagy or to
inhibition of lysosomal function downstream of autophagosome
formation [34]. To test this, we used the well-established general
lysosomal inhibitor bafilomycin (Baf) which inhibits lysosomal
acidification and prevents fusion of autophagosomes with
lysosomes, thus leading to accumulation of autophagosomes and
LC3 II (Figure S2). LC3 II levels were evaluated by Western blot
analysis in differentiated SH-SY5Y cells upon treatment with CBE
at different time points (72 h, 7 days) and doses (50, 100, 200 mM).
We observed a trend for a slight increase of the LC3 II protein at
all time-points and doses tested; however, this reached statistical
significance only for the dose of 100 mM at 7 days (Figure 2). We
also examined the levels of CMA markers, the lysosome-associated
membrane protein type 2A (LAMP-2A) and the lysosomal Heat
shock cognate protein of 70 kDa (Hsc70) [35–37] in the presence
Figure 6. GCase inhibition does not affect ASYN-specific HMW species in differentiated WT ASYN cells. A stable inducible Tet-Off SH-
SY5Y neuroblastoma cell line overexpressing WT ASYN was used in this assay. Initially cells were cultured in the presence (+) or absence (2) of dox
(2 mg/mL) for 7 days. Subsequently cells were differentiated for 5 days and then were exposed to CBE (200 mM) at different conditions. Untreated cells
were also used (ctl). WT (+) 7 d: differentiated WT ASYN cells expressing basal levels of ASYN in the presence of dox for 7 days, WT (2) 7 d:
differentiated WT ASYN overexpressing cells in the absence of dox, treated with CBE, or not (ctl) for 7 days. WT (2_+) 72 h: differentiated WT ASYN
overexpressing cells were switched to +dox conditions for 72 h along with the presence or not of CBE, WT (2_+) 7 d: differentiated WT ASYN
overexpressing cells were switched to +dox conditions for 7 days, along with the presence or not of CBE. WT (+_2) 7 d: differentiated WT ASYN cells
expressing basal levels of ASYN were switched to -dox conditions for 7 days, along with the presence or not of CBE. Cell lysates were separated with
SDS-PAGE and immunoblotted with the C-20 polyclonal antibody to ASYN. b-actin = loading control. At no condition was there any difference in the
presence or relative amount of ASYN monomers or ASYN-specific High Molecular Weight (HMW) species between the CBE and control-treated cells in
the cytosol (A) and the membrane-associated, Triton X-100 soluble fraction (B) respectively. A doublet that is also present in the+dox conditions
represents no specific immunolabeling (designated with an asterisk).
doi:10.1371/journal.pone.0060674.g006
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of the CBE inhibitor. We detected no alterations in the levels of
the aforementioned proteins (Figure S3A).
Next, in order to examine lysosomal function per se, we
measured the proteolysis of long-lived proteins in these cells with
or without CBE treatment. This is a well-established method to
monitor deviations in the lysosomal degradation capacity. Cells
were radiolabelled with [3H] leucine in a pulse-chase experiment
and then treated with the general lysosomal inhibitor bafilomycin
(Baf) or the macroautophagy inhibitor 3 methyladenine (3MA)
respectively. Untreated cells served as controls. These experiments
revealed no alterations in the lysosomal degradation pathways,
including macroautophagy (Figure 3). To further assess the
possibility of subtle dysfunction of lysosomes, we examined the
levels of p62, a sensitive indicator of macroautophagic failure [38];
levels of p62 were unaltered in these experiments with CBE
application (Figure S4), further reinforcing the idea that profound
GCase inhibition fails to lead to significant lysosomal/autophagic
dysfunction.
ASYN Levels Show No Change after CBE Treatment in
Embryonic Rat Cortical Cultures
Given the lack of change of ASYN levels with CBE treatment in
differentiated SH-SY5Y cells, we wished to investigate whether we
could detect any changes in primary neuron cell cultures. We used
embryonic (E18) rat cortical cultures as they represent a
homogenous source of near-pure post-mitotic neurons. Again,
we measured GCase activity in these cultures upon treatment with
CBE at different time points (72 h, 7 days) and doses (100,
200 mM). We observed strong inhibition of GCase activity in this
cell culture system as well, even at the lower dose of 100 mM, at
72 h following exposure to CBE; this inhibition was more
dramatic at the highest dose of 200 mM at 7 days (95%)
(Figure 4A). ASYN levels showed no change upon treatment with
the CBE inhibitor (100, 200 mM) at 7 and 10 days respectively
(Figure 4B–C), similarly to differentiated SH-SY5Y cells. These
results suggest that GCase inhibition does not affect ASYN levels,
at least in cultured neuronal cells, and over the relatively short
time frames utilized in this study.
Macroautophagy and CMA Markers Show No Alteration
after CBE Treatment in Embryonic Rat Cortical Cultures
Following the same strategy as for SH-SY5Y neuroblastoma
cells, we next assessed the effect of GCase inhibition on LC3 II
levels in embryonic rat cortical cultures. The ability to detect
accumulation of autophagosomes in this primary neuron culture
system was verified by the use of the general lysosomal inhibitor
ammonium chloride (NH4Cl) (Figure S2). LC3 II levels were then
analyzed by Western blot upon application of the CBE inhibitor
(100, 200 mM) at 7 and 10 days respectively. No alteration in LC3
II levels was observed in any of the given time points (Figure 5).
CMA markers were also assessed revealing once again no
alterations (Figure S3B). Given these results and the fact that no
significant lysosomal impairment was evident in the differentiated
SH-SY5Y cells upon CBE exposure, we did not further assess
proteolysis of long-lived proteins in these cultures.
GCase Inhibition does not Affect The Formation or
Clearance of ASYN Oligomers
As GCase inhibition did not appear to increase the monomeric
levels of ASYN, we next assessed the effects of such inhibition on
ASYN oligomers. Others have presented data suggesting that
GCase deficiency can influence the aggregation of ASYN in vitro
by stabilizing oligomeric intermediates [23]. For this, we used a
doxycycline inducible Tet- Off system for ASYN. In the absence of
doxycycline ASYN is overexpressed and creates oligomeric species
(Off system), whereas in the presence of doxycycline ASYN is
expressed at basal levels. ASYN monomeric and oligomeric levels
were assessed in the presence or absence of CBE in this inducible
system via Western blot analysis at different stages of the formation
or clearance of these species. We were not able to detect
alterations in ASYN oligomeric or monomeric species upon
treatment with CBE (Figure 6). Of note, ASYN was not detectable
in the SDS or urea-soluble fraction in these cells (data not shown)
and this is consistent with the fact that we do not detect aggregated
ASYN by immunostaining in these cultures. These results support
the notion that profound GCase inhibition is not sufficient to
influence ASYN in neuronal cell cultures, at least within the time
frame employed in the current experiments.
Discussion
A variety of genetic, pathological and clinical studies have
suggested a potential biological link between Type 1 Gaucher
(GD) and Parkinson’s disease (PD). Interestingly, this link has been
proposed to be attributed, at least to an extent, to the interplay
between GCase and ASYN [17–20,23]. Gain-of-function, loss-of-
function and prion theories have been proposed to date, describing
either a direct or an indirect interaction between GCase and
ASYN, but all with significant limitations [18–23,39–43]. In the
present study, we demonstrate that profound deficiency of GCase
activity via pharmacological inhibition was not sufficient, within
the time frame examined, to alter ASYN levels, neither in
neuronally differentiated SH-SY5Y cells, nor in primary cortical
neuronal cultures. In support of the above results, fractionation
studies in a doxycycline inducible Tet-Off system for ASYN
revealed again no changes in the clearance or formation of
oligomeric forms of ASYN following GCase inhibition. Further,
GCase inhibition did not appear to significantly compromise
lysosomal function in the above cell culture models. We observed
only a slight increase of the LC3 II protein levels at one specific
time-point and no distortion in any of the lysosomal degradation
pathways, including macroautophagy.
Taken together, our results demonstrate that GCase deficiency
is not sufficient to alter ASYN levels (monomeric or oligomeric) in
differentiated SH-SY5Y cells and rat cortical neuronal cultures.
Our findings thus contrast with a study showing that loss of GCase
activity through a similar pharmacological approach led to
enhanced ASYN levels in neuroblastoma cells [22]. Mazzulli
et al. [23] showed that significant, but partial, reduction of the
levels of the GCase protein was sufficient to induce protein levels
of ASYN, but this study is not directly comparable to ours, as in
our experiments GCase protein is still present, but dysfunctional
due to the pharmacological inhibition. There are certainly
limitations inherent to the approach we have used, and in
particular the use of cell systems (cell lines or primary cultures) and
the short time frames of monitoring for an effect, which could
potentially mask the outcome of an interaction between loss-of-
function of GCase and ASYN, which otherwise might have been
obvious in longer-term in vivo settings. Our findings are more in
accord with those of Cullen et al. [21], who did not find alterations
in ASYN levels following profound chemical inhibition of GCase
activity by CBE in cell lines. In the current work, we have
extended these findings by assessing lysosomal function in the face
of GCase inhibition. Our results indicate no significant impair-
ment of the lysosomal degradation machinery. Mazzulli et al. [23]
in contrast, found that loss of GCase protein levels and resultant
loss of activity was associated with lysosomal dysfunction, and
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posited that such lysosomal dysfunction led to secondary ASYN
accumulation. Methodological differences, in particular in the cell
types tested, may account for the observed discrepancies.
Alternatively, loss of GCase protein levels may have other effects
on lysosomal function, independent of the known GCase
enzymatic activity.
Our results suggest that the scenario of a direct sequence of
events of GCase inhibition leading to lysosomal dysfunction, and
this in turn leading to ASYN accumulation, is unlikely. It could be
instead that the link of GBA mutations to ASYN accumulation in
PD involves gain-of-function mechanisms, rather than loss-of-
function, whereby GBA mutations could potentially result in an
unstable or misfolded protein, which in turn could contribute to
the enhanced accumulation and aggregation of ASYN. In
addition, subsequent substrate accumulation could synergistically
add to the pathology of ASYN. This would be in accord with the
data of Cullen et al. [21], who found enhanced levels of ASYN in
situations where mutant GBA was overexpressed, without loss of
the enzymatic activity. Alternatively, more prolonged GCase
inhibition may be needed to lead to ASYN accumulation and/or
aggregation. This could occur secondary to the accumulation of
GCase substrates, as suggested by our finding that ASYN has an
increased tendency to oligomerize in erythrocyte membranes of
GD patients, compared to controls [44]; it has been demonstrated
that glucosylceramide (GluCer), a GCase substrate, accumulates in
GD erythrocyte membranes [45], and we have suggested that such
accumulation may underlie the increased oligomerization of
ASYN [44]. Another explanation could be that the interaction
between aberrant GCase and ASYN is in fact indirect and that
contribution of other gene modifiers is pivotal for the development
of the disease. This would account for the discrepancies observed
across studies, and also explain why only a fraction of carriers and
GD patients develop PD.
Concluding, to date, the contribution of an association between
GCase deficiency and ASYN to PD and related disorders remains
elusive. Our study questions a simplistic model in which GCase
inhibition leads to ASYN accumulation/aggregation via lysosomal
dysfunction, as neither of these phenomena occur in neuronal cells
exposed to profound GCase inhibition. A future challenge will be
to unmask other risk factors that, together with aberrant GCase,
synergistically add to the pathology of the disease, thus providing
new insights for therapeutic intervention.
Supporting Information
Figure S1 Complete inhibition of the rapamycin-in-
duced induction of LC3 II with 3MA in cortical neuron
cultures. Rat embryonic cortical cultures (E18) on their 7th day
of culture were exposed either to the macroautophagy inhibitor
3MA (10 mM) or the mTOR inhibitor rapamycin (activator of
macroautophagy) (500 nM) (rap) or in 3MA together with
rapamycin (rap+3MA). Untreated cells served as control (ctl).
24 h later the cells were harvested for SDS-PAGE analysis against
the polyclonal LC3 antibody. ERK= loading control. (A)
Increased levels of the LC3 II protein were found in the presence
of rapamycin, whereas in the presence of the rapamycin together
with 3MA the LC3 II levels decreased, reaching the levels of the
3MA-alone treated cells. (B) Statistical analysis made via One Way
Anova showed significant difference between 3MA vs ctl
(*P,0,05), 3MA vs rap (##p,0,001) and rap+3MA vs rap
(*P,0,01).
(TIF)
Figure S2 Induction of autophagic vacuoles in differen-
tiated SH-SY5Y cells and cortical neuron cultures.
Differentiated SH-SY5Y cells or rat embryonic cortical cultures
(E18) on their 6th day of culture were exposed to the general
lysosomal inhibitor bafilomycin (Baf) (500 nM) or ammonium
chloride (NH4Cl) (20 mM) respectively overnight. Untreated cells
served as control (ctl). Cells were lysed, separated with SDS-PAGE
and immunoblotted with an LC3 polyclonal antibody. ERK= -
loading control. Increase in the conversion of the LC3 I to LC3 II
was evident in both differentiated SH-SY5Y cells and cultured
cortical neuron cultures.
(TIF)
Figure S3 No alteration in LAMP-2A and Hsc70 levels in
differentiated SH-SY5Y cells and cortical neuron cul-
tures. Differentiated SH-SY5Y cells or rat cultured cortical
neurons (E18) on their 6th day of culture, were exposed to
increasing doses of CBE (50, 100, 200 mM) for 7 days. Untreated
cells served as control (ctl). Cells were lysed, separated with SDS-
PAGE and immunoblotted with a LAMP-2A (human or rat) and
Hsc70 polyclonal antibody. ERK= loading control. No significant
alterations in the LAMP-2A and Hsc70 levels were evident either
in the differentiated SH-SY5Y cells (A) or primary cortical neurons
(B). The band corresponding to LAMP-2A protein is indicated by
an arrow. Similar results were achieved in one or two other
independent experiments in the differentiated SH-SY5Y cells and
primary cortical cultures respectively.
(TIF)
Figure S4 No alteration in p62 levels in differentiated
SH-SY5Y cells. Differentiated SH-SY5Y cells were exposed to
increasing doses of CBE (50, 100, 200 mM) for 72 h and 7 days
respectively. Untreated cells served as control (ctl). Cells were
lysed, separated with SDS-PAGE and immunoblotted with a p62
polyclonal antibody ERK= loading control. No significant
differences in p62 levels were detected at the given doses and
time points (representative of 4 experiments).
(TIF)
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